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FOREWORD 
This toxicological profile is prepared in accordance with guidelines developed by the Agency for
Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health
effects information for the hazardous substance described therein.  Each peer-reviewed profile identifies
and reviews the key literature that describes a hazardous substance’s toxicologic properties.  Other
pertinent literature is also presented, but is described in less detail than the key studies.  The profile is not
intended to be an exhaustive document; however, more comprehensive sources of specialty information
are referenced.
The focus of the profiles is on health and toxicologic information; therefore, each toxicological
profile begins with a public health statement that describes, in nontechnical language, a substance’s
relevant toxicological properties.  Following the public health statement is information concerning levels
of significant human exposure and, where known, significant health effects.  The adequacy of information
to determine a substance’s health effects is described in a health effects summary.  Data needs that are of
significance to protection of public health are identified by ATSDR and EPA.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and
epidemiologic evaluations on a hazardous substance to ascertain the levels of significant
human exposure for the substance and the associated acute, subacute, and chronic health
effects;
(B) A determination of whether adequate information on the health effects of each substance is
available or in the process of development to determine levels of exposure that present a
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels
of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal,
State, and local levels; interested private sector organizations and groups; and members of the public.  We
plan to revise these documents in response to public comments and as additional data become available. 
Therefore, we encourage comments that will make the toxicological profile series of the greatest use.
Comments should be sent to: 
Agency for Toxic Substances and Disease Registry
Division of Toxicology
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of
available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances will find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1:  Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and
assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type of
health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of
exposure (acute, intermediate, and chronic). In addition, both human and animal studies are
reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in
the clinical setting.  Please refer to the Public Health Statement to identify
general health effects observed following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health
issues:
Section 1.7 How Can (Chemical X) Affect Children?
Section 1.8 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center 
Phone:  1-888-42-ATSDR or (404) 498-0110  Fax:    (404) 498-0057
E-mail:  atsdric@cdc.gov  Internet:  http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an
exposure history and how to conduct one are described, and an example of a thorough exposure
history is provided. Other case studies of interest include Reproductive and Developmental
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide
Toxicity; and numerous chemical-specific case studies.
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene
(prehospital) and hospital medical management of patients exposed during a hazardous materials incident. 
Volumes I and II are planning guides to assist first responders and hospital emergency department
personnel in planning for incidents that involve hazardous materials.  Volume III—Medical Management
Guidelines for Acute Chemical Exposures—is a guide for health care professionals treating patients
exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease,
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-
3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and
safety in the workplace, recommends standards to the Occupational Safety and Health
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue,
SW, Washington, DC 20201 • Phone: 800-356-4674 or  NIOSH Technical Information Branch,
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998
• Phone: 800-35-NIOSH.
 The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on
human health and well-being.  Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive,
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics
in the United States to provide expertise in occupational and environmental issues.  Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 •   Phone: 202-347-4976 •
FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and
environmental medicine.  Contact:  ACOEM, 55 West Seegers Road, Arlington Heights, IL
60005 • Phone: 847-818-1800 • FAX: 847-818-9266.
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ATSDR, Division of Toxicology, Atlanta, GA
Gary Diamond, Ph.D.
Richard Amata, Ph.D.
Stephen G. Swarts, Ph.D.
Syracuse Research Corporation, North Syracuse, NY
THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review.  The Health Effects Review Committee examines the health effects
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2. Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to
substance-specific minimal risk levels (MRLs), reviews the health effects database of each
profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review.  The Research Implementation Branch reviews data needs sections to assure
consistency across profiles and adherence to instructions in the Guidance.
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PEER REVIEW
A peer review panel was assembled for iodine.  The panel consisted of the following members: 
1. Dr. Raymond Lloyd, Professor Emeritus of Radiobiology, University of Utah, 729 Arapeen Dr.,
Salt Lake City, UT 84108-1218;
2. Dr. Kiyohiko Mabichi, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD
20852;
3. Dr. Marvin Rallison, Professor Emeritus of Pediatric Endocrinology and Metabolism, University of
Utah School of Medicine, 1706 Oakridge Dr., Salt Lake City, UT 84106;
4. Dr. Noel R. Rose, Professor of Molecular Medicine, Johns Hopkins University, 615 North Wolfe
St., Baltimore, MD 21205; 
5. Dr. Roy E. Shore, Professor and Director, Division of Epidemiology and Biostatistics, New York
University School of Medicine, 650 First Ave., New York, NY 10016-3240
These experts collectively have knowledge of iodine’s physical and chemical properties, toxicokinetics,
key health end points, mechanisms of action, human and animal exposure, and quantification of risk to
humans.  All reviewers were selected in conformity with the conditions for peer review specified in
Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as
amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.  A list of databases reviewed and
a list of unpublished documents cited are also included in the administrative record.
The citation of the peer review panel should not be understood to imply its approval of the profile's final
content.  The responsibility for the content of this profile lies with the ATSDR.
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1.  PUBLIC HEALTH STATEMENT
This public health statement tells you about iodine and the effects of exposure.  
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in
the nation.  These sites make up the National Priorities List (NPL) and are the sites targeted for
long-term federal cleanup activities.  Iodine has been found in at least 8 sites. Radioactive iodine
has been found at 8 sites, including iodine 129 (129I) in at least 2 sites, and iodine 131 (131I) in at
least 6 sites of the 1,585 current or former NPL sites.  However, the total number of NPL sites
evaluated for iodine is not known.  As more sites are evaluated, the sites at which iodine is found
may increase.  This information is important because exposure to iodine may harm you and
because these sites may be sources of exposure.
When a substance is released from a large area, such as an industrial plant, or from a container,
such as a drum or bottle, it enters the environment.  This release does not always lead to
exposure.  You are exposed to a substance only when you come in contact with it. You may be
exposed by breathing, eating, or drinking the substance, or by skin contact.  You can be exposed
to some forms of radiation by being near a radioactive substance.
If you are exposed to either radioactive or stable iodine, many factors determine whether you’ll
be harmed.  These factors include the dose (how much), the duration (how long), and how you
come in contact with it.  You must also consider the other chemicals you’re exposed to and your
age, sex, diet, family traits, lifestyle, and state of health.
1.1 WHAT IS IODINE?
Iodine is a naturally occurring element that is essential for the good health of people and
animals.  Iodine is found in small amounts in sea water and in certain rocks and sediments. 
Iodine occurs in many different forms that can be blue, brown, yellow, red, white, or colorless. 
Most forms of iodine easily dissolve in water or alcohol.  Iodine has many uses.  Its most
important use is as a disinfectant for cleaning surfaces and storage containers.  Iodine is also
used in skin soaps and bandages, and for purifying water.  Iodine is used in medicines.  Iodine is
added to food, such as table salt, to ensure that all people in the United States have enough
iodine in their bodies to form essential thyroid hormones.  Iodine is put into animal feeds for the
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same reason.  Iodine is used in the chemical industry for making inks and coloring agents,
chemicals used in photography, and in making batteries, fuels, and lubricants.  Radioactive
iodine also occurs naturally.  Radioactive iodine is used in medical tests and to treat certain
diseases, such as over activity or cancer of the thyroid gland.
1.2 WHAT HAPPENS TO IODINE WHEN IT ENTERS THE ENVIRONMENT?
The oceans are the most important source of natural iodine in the air, water, and soil.  Iodine in
the oceans enters the air from sea spray or as iodine gases.  Once in the air, iodine can combine
with water or with particles in the air and can enter the soil and surface water, or land on
vegetation when these particles fall to the ground or when it rains.  Iodine can remain in soil for
a long time because it combines with organic material in the soil.  It can also be taken up by
plants that grow in the soil.  Cows or other animals that eat these plants will take up the iodine in
the plants.  Iodine that enters surface water can reenter the air as iodine gases.  Iodine can enter
the air when coal or fuel oil is burned for energy; however, the amount of iodine that enters the
air from these activities is very small compared to the amount that comes from the oceans.  
Radioactive iodine also forms naturally from chemical reactions high in the atmosphere.  Most
radioactive forms of iodine change very quickly (seconds to days) to stable elements that are not
radioactive.  However, one form, 129I, changes very slowly (millions of years), and its levels
build up in the environment.  Small amounts of radioactive iodine, including 129I and 131I, can
also enter the air from nuclear power plants, which form radioiodine from uranium and
plutonium.  Larger amounts of radioactive iodine have been released to the air from accidents at
nuclear power plants and from explosions of nuclear bombs. 
1.3 HOW MIGHT I BE EXPOSED TO IODINE?
Iodine is a natural and necessary part of the food that you eat and the water that you drink.  In the
United States, most table salt contains iodine.  Iodine is put into table salt to make sure that
everyone has enough iodine in their bodies to form essential thyroid hormones.  In the past,
people in some areas of the United States did not get enough iodine in their diets.  Iodine is in
some breads because it is added to flour to condition bread dough for baking.  Iodine is also in
cow and goat milk.  Iodine gets into milk when cows or goats eat iodine that is in their food and
water.  Iodine can also get into milk when iodine is used to clean milking machines and milk
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storage containers, and to clean the animals’ udders at dairy farms and dairies.  Iodine is in ocean
fish, shellfish, and certain plants that grow in the ocean (kelp).  This is because there is iodine in
sea water and some sea plants and animals concentrate iodine in their tissues.  Iodine can also be
in the air.  Iodine is in sea spray and mist, which are tiny drops of seawater.  Iodine is in
cleansers and medicines that are used to clean and bandage skin wounds (tincture of iodine). 
You can be exposed to these if they are placed on your skin.  Some medicines have iodine in
them.  Iodine is used to treat water to make it safe for drinking.  You can buy iodine water
purifying tablets that you add directly to water.  You can also buy water treatment cartridges for
your home that have iodine in them.  Some iodine will get into the water that you drink if you
use these tablets or cartridges.
People are almost never exposed to radioactive iodine, unless they work in a place where
radioactive iodine is used or if they are given radioactive iodine by their doctors.  Radioactive
iodine is used in certain medical tests and treatments.  You might have these tests if your doctor
needs to look for problems in your thyroid gland or if your doctor needs to treat you for a
problem with your thyroid gland.  In the past, people were exposed to radioactive iodine released
from nuclear bomb tests, after accidental explosions and fires at nuclear power plants, or from
facilities that processed or used nuclear fuel for power plants. 
1.4 HOW CAN IODINE ENTER AND LEAVE MY BODY?
Most of the iodine that enters your body comes from the food that you eat.  A smaller amount
comes from the water that you drink.  Iodine will enter your body if it is in the air that you
breathe.  Some forms of iodine can enter your body when placed on the skin.  Iodine can also be
injected into your blood by your doctor for special medical tests or treatments.  Iodine that enters
your body quickly goes into your thyroid gland, a small important organ in your neck.  Iodine is
used in the thyroid gland to make hormones that are needed for growth and health.  Almost all of
the iodine in your body is in your thyroid gland.  Iodine that does not go into your thyroid gland
leaves the body in your urine, in a few weeks to months.  Iodine that leaves your body each day
is usually replaced by the iodine that you eat in your food, so that the amount of iodine in your
body is just enough to keep you healthy.  Small amounts of iodine can also leave your body in
sweat or in breast milk.
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1.5 HOW CAN IODINE AFFECT MY HEALTH?
Iodine is needed for your thyroid gland to produce thyroid hormones.  You and your thyroid
gland are healthy when there is just enough iodine in your body, about 10–15 milligrams so that
just the right amount of thyroid hormones are produced.  This amount would look like much less
than a pinch of table salt if placed in your hand.  This amount of iodine is in most people when
they eat the foods that people normally eat in the United States.  Your thyroid gland can become
unhealthy if more or less than this amount of iodine is in your body.  An unhealthy thyroid gland
can affect your entire body.  If the thyroid gland cannot make enough hormone, then you would
have to be given thyroid hormone in pills.  If your thyroid gland makes too much hormone, then
you would have to be given drugs to make your thyroid make less hormone.  Radioactive iodine
can also be unhealthy for your thyroid gland.  If too much radioactive iodine enters your body,
the radioactive iodine will destroy your thyroid gland so that the gland will stop making
hormones.  Too much radioactive iodine in your body can also cause thyroid nodules or cancer.  
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people
who have been harmed, scientists use many tests.  
One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and
released by the body.  In the case of a radioactive chemical, it is also important to gather
information concerning the radiation dose and dose rate to the body.  For some chemicals,
animal testing may be necessary.  Animal testing may also be used to identify health effects such
as cancer or birth defects.  Without laboratory animals, scientists would lose a basic method to
get information needed to make wise decisions to protect public health.  Scientists have the
responsibility to treat research animals with care and compassion.  Laws today protect the
welfare of research animals, and scientists must comply with strict animal care guidelines.
1.6 HOW CAN IODINE AFFECT CHILDREN?
This section discusses potential health effects from exposures during the period from conception
to maturity at 18 years of age in humans. 
Babies and children need iodine to form thyroid hormones, which are important for growth and
health.  If infants and children do not have enough iodine in their bodies, their thyroid glands
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will not produce enough thyroid hormone and they will not grow normally.  If they have too
much iodine in their bodies, they will develop enlarged thyroid gland (goiter), which also do not
produce enough thyroid hormone for normal growth.  We also need just the right amount of
iodine from our mothers before we are born.  Too much iodine from the mother can cause a
baby’s thyroid gland to be so large that it makes breathing difficult or impossible.  Not enough
iodine from the mother can cause a baby to not produce enough thyroid hormone, which can
affect growth and mental development of the baby.  Radioactive iodine in food can be more
harmful to babies and children than to adults.  When radioactive iodine is in the air, it can get
onto the grass and water that the cows eat and drink.  Infants and children drink a lot more milk
than most adults.  So, if there is radioactive iodine in the milk that a child or infant drinks, more
iodine will enter the thyroid gland of the child than of an adult who drinks less milk.  And,
because the thyroid gland of a child or infant is smaller than that of an adult, the child’s thyroid
gland will receive a higher radiation dose than the adult.  Children are more sensitive to the
harmful toxic effects of iodine and radioactive iodine than adults because their thyroid glands are
still growing and the thyroid gland tissues are more easily harmed by radioactive iodine, and
because children need a healthy thyroid gland for normal growth.
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO IODINE?
If your doctor finds that you have been exposed to significant amounts of iodine, ask whether
your children might also be exposed.  Your doctor might need to ask your state health
department to investigate.
We all are exposed to iodine in the food that we eat and in the water that we drink.  Iodine is
needed for your good health.  We do not want to prevent exposure to iodine, but we do want to
try to prevent exposure to too much iodine.  This is not likely to happen from eating a normal
diet in the United States or from drinking water or breathing air.  It could happen if you were
careless about storing soaps or cleansers or medicines that have iodine in them.  For example, a
child could swallow medicines that contain iodine.  People are almost never exposed to
radioactive iodine, unless they work in a place where radioactive iodine is used or if they are
given radioactive iodine by their doctors for certain medical tests or treatments. 
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1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
EXPOSED TO IODINE?
Most physicians do not test for iodine in their offices, but can collect samples and send them to
special laboratories.  They can also feel the thyroid for lumps that may have been caused by
disease or past exposure to radioactive iodine, but the physical examination of the neck or tests
for iodine do not always reveal the cause of the problem.  Every person's body contains a small
amount of iodine, but normally not radioactive iodine (such as 131I).  Iodine can be measured in
the blood, urine, and saliva.  The amount is normally measured by its mass (in grams).  If the
iodine is radioactive, it can be measured by its mass or by its radiation emissions.  These
emissions are used to tell the amount of radioactive iodine (in Becquerels or curies) and the
radiation dose that it gives to your body (in Sieverts or rem).  Radiation detectors can measure
radioactive iodine inside your body using the radiation coming from the thyroid gland in your
neck.  This is useful only if you recently inhaled or ingested some, or if your physician recently
gave you some for medical purposes.  Your body quickly eliminates iodine and radioactive
iodine, so tests should be done shortly after exposure.
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health. 
Regulations can be enforced by law.  Federal agencies that develop regulations for toxic
substances include the Environmental Protection Agency (EPA), the Occupational Safety and
Health Administration (OSHA), the Food and Drug Administration (FDA), and the Nuclear
Regulatory Commission (NRC).  
Recommendations provide valuable guidelines to protect public health but cannot be enforced by
law.  Federal organizations that develop recommendations for toxic substances include the
Agency for Toxic Substances and Disease Registry (ATSDR), the National Institute for
Occupational Safety and Health (NIOSH), and the FDA.
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or
food that are usually based on levels that affect animals; then they are adjusted to help protect
people.  Sometimes these not-to-exceed levels differ among federal organizations because of
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different exposure times (an 8-hour workday or a 24-hour day), the use of different animal
studies, or other factors.
Recommendations and regulations are also periodically updated as more information becomes
available.  For the most current information, check with the federal agency or organization that
provides it.  Some regulations and recommendations for iodine include the following:
The National Research Council has established a Recommended Dietary Allowance for iodine of
150 µg/day, with additional allowances of 25 µg/day during pregnancy and 50 µg/day during
nursing.  The EPA has established regulations that limit releases of certain forms of radioactive
iodine to the environment and limits for requiring that industries report releases of certain forms
of radioactive iodine.  NIOSH has established recommendations for limits of worker exposures
to iodine and radioactive iodine.  The Nuclear Regulatory Commission, the National Council of
Radiation Protection and Measurement (NRCP), and the International Commission of
Radiological Protection (ICRP) have established recommended limits for worker exposures to
radioactive iodine and for releases of radioactive iodine to the environment.
1.10 WHERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or
environmental quality department, your regional Nuclear Regulatory Commission office, or
Agency for Toxic Substances and Disease Registry
Division of Toxicology
1600 Clifton Road NE, Mailstop E-29
Atlanta, GA 30333
* Information line and technical assistance
Phone: 1-888-42-ATSDR (1-888-422-8737)
Fax: 1-404-498-0057
ATSDR can also tell you the location of occupational and environmental health clinics.  These
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to
hazardous substances.
IODINE 8
1.  PUBLIC HEALTH STATEMENT
***DRAFT FOR PUBLIC COMMENT***
* To order toxicological profiles, contact
National Technical Information Service
5285 Port Royal Road
Springfield, VA 22161
Phone: 1-800-553-6847 or 1-703-605-6000
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2.  RELEVANCE TO PUBLIC HEALTH
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO IODINE IN THE UNITED
STATES
Iodine is an essential nutrient.  Adequate intakes of iodine are required for the production of thyroid
hormones.  The term iodine excess is used in this profile to refer to increases in intake relative to
estimated physiological requirements.  As a reference point, the chronic dietary intake of iodine in U.S.
populations has been estimated to range from approximately 150 to 950 µg/day.  Estimates for various
populations have ranged from <50 µg/day in iodine-deficient regions to >10 mg/day in populations that
regularly ingest seaweeds containing a high iodine content.  The National Research Council
Recommended Dietary Allowance (RDA) for iodine is 150 µg/day (2.1 µg/kg/day for a 70-kg adult), with
additional allowances of 25 and 50 µg/day during pregnancy and lactation, respectively.
The diet is the major source of iodine intake in the U.S. population.  Iodine enters the human diet from a
variety of natural sources, including mineral dissolution and atmospheric transport and deposition of
seawater aerosols to surface water, vegetation, and soil.  Major food categories that contribute to dietary
iodine include marine produce (e.g., fish and shellfish) and milk.  Cows and goats absorb iodine from
ingested vegetation and water, when iodine is either deposited on the vegetation or in water or when the
iodine is taken up by vegetation grown in soils containing iodine.  The absorbed iodine is excreted into
their milk; goat milk typically has higher concentrations of iodine than cow milk for equal deposition on
feed.  Additional sources of iodine in milk derive from the use of iodine disinfectants on cows, milking
machines, and other milk processing equipment, as well as from supplementation of dairy feed with
iodine-containing compounds.  Breast milk is the primary source of iodine intake in nursing infants. 
Commercial infant formula preparations are fortified with sufficient iodine to support infant health,
growth, and development.  Cow milk is a significant source of iodine intake in children.  Iodine is also
intentionally added to the U.S. diet as iodized table salt and as iodine-containing bread dough oxidizers. 
Other sources of intake derive from the use of iodine-containing topical disinfectants (e.g., povidone-
iodine), iodine-containing diagnostic and therapeutic agents, dietary supplements, and water purifiers
containing iodine.
Thirty-five isotopes of iodine are recognized (108I through 142I).  Only one isotope is stable (127I); the
remaining are radioactive.  Most of these have radioactive half-lives of minutes or less.  Twelve have
half-lives that exceed 1 hour, and five have half-lives that exceed 1 day (124I, 125I, 126I, 129I, and 131I).  Three
isotopes (125I, 129I, and 131I) are of particular interest with respect to human exposures because 125I and 131I
are used medically and all three are sufficiently long-lived to be transported to human receptors after their
release into the environment.  The U.S. population has been exposed to radioiodine in the general
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environment as a result of atmospheric fallout of radioiodine released from uncontained and/or
uncontrolled nuclear reactions.  Historically, these have included surface or atmospheric detonation of
nuclear bombs, routine and accidental releases from nuclear power plants and nuclear fuel reprocessing
facilities, and from hospitals and medical research facilities.  Estimates have been made of radiation doses
to the U.S. population attributable to nuclear bomb tests conducted in the during the 1950s and 1960s at
the Nevada Test Site; however, dose estimates for global fallout have not been completed.  Geographic-
specific geometric mean lifetime doses are estimated to have ranged from 0.19 to 43 cGy (rad) for people
born on January 1, 1952 who consumed milk only from commercial retail sources, 0.7–55 cGy (rad) for
people who consumed milk only from home-reared cows, and 6.4–330 cGy (rad) for people who
consumed milk only from home-reared goats.  Additional information is available on global doses from
nuclear bomb tests, and doses from nuclear fuel processing, and medical uses can be found in
UNSCEAR.
Individuals in the United States can also be exposed to radioiodine, primarily 123I and 131I, as a result of
clinical procedures in which radioiodine compounds are administered to detect abnormalities of the
thyroid gland or to destroy the thyroid gland to treat thyrotoxicosis or thyroid gland tumors.  Diagnostic
uses of radioiodine typically result in exposures by the oral or intravenous routes to 0.1–0.4 mCi
(4–15 MBq) of 123I or 0.005–0.01 mCi (0.2–0.4 MBq) of 131I.  These exposures correspond to approximate
thyroid radiation doses of 1–5 rad (cGy) and 6–13 rad (cGy) for 123I and 131I, respectively.  Cytotoxic
doses of 131I are delivered for ablative treatment of hyperthyroidism or thyrotoxicosis, exposures typically
range from 5 to 15 mCi (185–555 MBq), which correspond to thyroid radiation doses of
5,000–10,000 rad (50–100 Gy).  Higher exposures are used in the ablative treatment of thyroid gland
cancer; 25–250 mCi (925–9,250 MBq), which correspond to thyroid radiation doses of
10,000–30,000 rad (100–300 Gy).
2.2 SUMMARY OF HEALTH EFFECTS
An extensive amount of literature is available on the effects of iodine on human physiology and health. 
The intense interest in iodine derives from early recognition of the necessity of appropriate amounts of
iodine for maintenance of normal function of the thyroid gland and of awareness of diseases of the
thyroid gland that are caused or affected by iodine intake.  The prevalence of thyrotoxicosis (the clinical
outcome of uncontrolled hyperthyroidism) has been estimated to be approximately 0.5%, and that of
hypothyroidism is of a similar magnitude.  Research directed at understanding the epidemiology,
pathophysiology, and therapeutic strategies for these relatively common diseases have given way to a
fairly comprehensive, although not complete, understanding of the role of iodine in thyroid gland
physiology and the related health consequences and risks associated with excessive or inadequate iodine
intake.  The development of radiologic strategies for treating thyrotoxicosis, as well as studies of the
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thyroid gland as a target for internal exposures to atmospheric radioactive fallout, have further
complemented our understanding of iodine toxicity as it relates to exposures to radioactive isotopes of
iodine.  
This profile does not attempt to summarize in detail all of the studies relevant to iodine toxicity, as to do
so would require several volumes.  Instead, the focus is on literature that identifies the lowest observable
exposure levels associated with iodine toxicity in humans.  Where applicable, relevant studies in animals
are summarized, particularly when such studies have identified potential targets of toxicity not already
documented in humans or for which adequate dose-response information does not exist for humans.  This
strategy leads to a focus on the thyroid gland as the primary and most sensitive target of iodine for both
chemical and radiologic toxicity.  This is not surprising given that avid uptake of absorbed iodine by the
thyroid gland results in approximately 90% of the body iodine content residing in the thyroid gland (see
Section 3.3, Toxicokinetics).  Adverse effects on a wide variety of other organ systems can result from
disorders of the thyroid gland, including disturbances of the skin, cardiovascular system, pulmonary
system, kidneys, gastrointestinal tract, liver, blood, neuromuscular system, central nervous system,
skeleton, male and female reproductive systems, and numerous endocrine organs, including the pituitary
and adrenal glands.  Although these secondary effects are noted in the profile, they are not discussed in
detail and the reader is referred to authoritative references on these subjects for further information.  
An important consideration in interpreting the iodine toxicology literature is that the effect of an increase
in iodine intake will depend, in part, on the preexisting background dietary intake and the associated
physiological adaptations to background intake.  The response to an upward excursion in intake may be
quite different in individuals who have adapted to either low dietary or high dietary intake.  Examples of
this are described in appropriate sections of this report (e.g., Section 3.2.2.2).  In this profile, the term
molecular iodine is used to refer to I2; the term iodide is used to refer to the anion, I-, the term iodate is
used to refer to the anion IO3-, and the term iodine is used to refer to the element in any form, usually
when the form was not specified in the literature being summarized, or where the form is not relevant to
the discussion.  From a physiological perspective, regardless of the form of iodine that is absorbed after
an exposure, iodide is the form of iodine that is taken up into the thyroid gland, and effects from
exposures to iodine ultimately derive from exposure of the gland to iodide.  A more important
toxicological distinction is that, unlike iodide, molecular iodine (I2) is a relatively strong oxidizing agent
and has the potential to produce injuries related to redox reactions with proteins.  This is the primary basis
for the use of I2 as a topical antiseptic and antimicrobial disinfectant for drinking water.
The health effects of exposure to radioiodine derive from the emission of beta and gamma radiation.
Radioiodine that is absorbed into the body quickly distributes to the thyroid gland and, as a result, the
tissues that receive the highest radiation doses are the thyroid gland and surrounding tissues (e.g.,
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parathyroid gland).  Tissues other than the thyroid gland can accumulate radioiodine, including salivary
glands, gastric mucosa, choroid plexus, mammary glands, placenta, and sweat gland.  Although these
tissues may also receive a radiation dose from internal radioiodine, the thyroid gland receives a higher
radiation dose.  The radiation dose to the thyroid gland from absorbed radioiodine varies with isotope and
its radiation emission properties (e.g., type of radiation, energy of emission, effective radioactive half-
life).  A comparison of the doses delivered to the thyroid gland from a few of the isotopes of iodine are
compared in Table 2-1.  The highest total doses are achieved with 131I, whereas the highest dose rates
(rad/hour) are delivered from 132I.
Endocrine Effects.    The principle direct effects of excessive iodine ingestion on the endocrine system
are on the thyroid gland and regulation of thyroid hormone production and secretion.  Adverse effects on
the pituitary and adrenal glands derive secondarily from disorders of the thyroid gland.  Effects of iodine
on the thyroid gland can be classified into three types: hypothyroidism, hyperthyroidism, and thyroiditis. 
Hypothyroidism refers to the diminished production of thyroid hormone leading to clinical manifestations
of thyroid insufficiency.  This can occur with or without goiter, a functional hypertrophy of the gland that
occurs in response to thyroid stimulating hormone (TSH) and suppressed thyroid hormone production. 
Typical biomarkers of hypothyroidism are a depression in the circulating levels of thyroxine (T4) and/or
triiodothyronine (T3) below their normal ranges.  This is usually, but not always, accompanied by an
elevation of TSH (also known as thyrotropin) above the normal range.  Hyperthyroidism is an excessive
production and/or secretion of thyroid hormones.  The clinical manifestation of abnormally elevated
circulating levels of T4 and/or T3 is thyrotoxicosis.  Thyroiditis refers to an inflammation of the gland,
which is often secondary to thyroid gland autoimmunity.  The above three types of effects of iodine can
occur in children and adults, in fetuses exposed in utero, or in infants exposed during lactation.  The
primary effect of iodide excess in the fetus is goiter formation secondary to a suppression of thyroid
hormone production and an elevation in TSH levels.
Measurements of serum levels of thyroid hormones and TSH are often used as biomarkers of
hypothyroidism and hyperthyroidism in toxicology and epidemiology studies.  In interpreting this
literature in terms of human health risks, a distinction must be made between outcomes that have a high
potential for producing clinical manifestations and those outcomes that are not clinically significant.  In
this profile, an observed decrease in circulating T4 or T3 levels or an increase in serum TSH level, within
their respective normal ranges is referred to as subclinical hypothyroidism.  Similarly, the term subclinical
hyperthyroidism refers to a condition in which the circulating levels of T4 or T3 are elevated within their
normal ranges.  Typical normal ranges for these hormone levels are discussed in Section 3.8.2
An acute iodide excess can cause a decrease in thyroid hormone production in the thyroid gland; this
effect is referred to as the Wolff-Chaikoff effect.  In most people, this is followed by a return to normal 
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rate of 10 rad
from 1 mCi in
the thyroid
(rad/hour)
123I 77 13 0.1 76 3.7
125I 73 866 0.01 3,747 3.0
131I 94 177 0.4 5,627 22
132I 90 2.3 1.7 199 59
133I 96 20 1.3 1,355 46
135I 90 6.7 1.1 434 45
a from Maxon and Saenger 2000
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levels of production, referred to as escape from the Wolff-Chaikoff effect, without clinically significant a
change in circulating hormone levels.  Escape is thought to be the result of down regulation of the iodine
transport mechanism in the thyroid gland (see Section 3.4.3.2 for further details on the Wolff-Chaikoff
effect).  An acute or chronic excess of iodide can also decrease circulating T4 and T3 levels and induce a
hypothyroid state.  These effects are thought to involve the inhibition of the release of T4 from the thyroid
gland and/or inhibition of extrathyroidal production of T3.  Most iodine-induced hypothyroidism is
transient, although T4 replacement may be required in some patients.  Hypothyroidism is thought to occur
primarily in susceptible individuals who fail to escape from the inhibitory effect of large doses of iodide
that produce the Wolff-Chaikoff effect.  Susceptible individuals includes fetuses and newborn infants,
patients who have autoimmune thyroiditis, patients with Graves’ disease previously treated with iodine or
antithyroid drugs, women who have had postpartum thyroiditis, or those who have had subacute
thyroiditis.  Spontaneous recovery usually occurs within 2–3 weeks, although some individual may
develop permanent thyroiditis.
Several studies have examined the acute and intermediate-duration effects of increased intake of iodine on
thyroid hormone status of adults.  Acute iodine exposures (1,500 µg/day) have been shown to produce
reversible thyroid gland hypertrophy, in addition to suppression of hormone production.  The results of
epidemiological studies suggest that chronic exposure to excess iodine can result in or contribute to
hypothyroidism, with or without goiter, in children (1,150 µg/day, 29 µg/kg/day) and elderly adults
(160–800 µg/day, 4–12 µg/kg/day).  Several studies have found an increased prevalence of
hypothyroidism in residents of areas of Japan where dietary iodine intake is extraordinarily high as a
result of consumption of seaweeds with a high iodine content (13 mg/day, 0.22 mg/kg/day).  Populations
that are iodine deficient and, in particular, those that include people who have goiter, appear to be
particularly sensitive to an increase in their iodine intake.  For example, iodine supplementation
(200–400 µg/day, 3–6 µg/kg/day) for treatment of endemic goiter has been associated with thyroid
dysfunction, including thyroid autoimmunity.
People who have autoimmune thyroid disease may be at increased risk of developing thyroid dysfunction
when exposed to excess iodide.  Euthyroid patients who were diagnosed with Hashimoto’s thyroiditis and
who were positive for antithyroid (thyroid peroxidase) antibodies developed subclinical hypothyroidism
after oral doses of 375 µg/day (4.5 µg/kg/day) for 6 months or clinical hypothyroidism after exposures to
180 mg I/day (2.6 mg/kg/day) for 6 weeks, more than 1,000 times the RDA.  In general, iodine excess
accelerates autoimmune thyroiditis in autoimmune-prone individuals, whereas iodine deficiency
attenuates thryoiditis.
The clinical case literature demonstrates that doses of iodide exceeding 200 mg/day (2.8 mg/kg/day)
given to a mother during pregnancy can result in congenital goiter and hypothyroidism in the newborn
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infant.  An iodine-deficient status of the mother can lead to goiter in the fetus and neurodevelopmental
impairment of the fetus.  Adequate iodine supplementation early in pregnancy can correct the deficiency
and prevent maternal and neonatal goiter formation.  Thyroid dysfunction was not detected in newborns
of mothers who received oral doses of 3–4 µg/kg/day during pregnancy for the purpose of correcting or
preventing potential iodine deficiency and for the management of Graves’ disease during pregnancy
(Graves’ disease is a hyperthyroid state in which autoantibodies to the TSH receptor are produced and act
on the TSH receptor to stimulate the gland to produce thyroid hormones).
Oral exposure to excess iodide can, under certain circumstances, induce hyperthyroidism and
thyrotoxicosis.  The epidemiological and clinical literature suggest that hyperthyroidism occurs most
often in people who have a previous history of iodine deficiency, goiter, or thyroid diseases such as
postpartum thyroiditis or Graves’ disease.  What has been referred to as an epidemic of hyperthyroidism
occurred in the midwestern United States between the years 1926 and 1928.  Clinical records suggest that
the incidence of mortality from hyperthyroidism increased substantially during this period; for example,
in Detroit, mortality from hyperthyroidism increased from approximately 2–4 deaths per 100,000 to
approximately 11 deaths per 100,000.  Although there is considerable debate about the origins of the
epidemic, the advent of aggressive supplementation of the diet with iodide in midwestern endemic goiter
areas has been implicated as a contributing factor.  More recent and more rigorous epidemiologic designs
have been applied to several populations in which dietary iodide was supplemented as a prophylaxis for
iodine deficiency and goiter.  These studies confirm that iodide supplementation of iodide-deficient diets,
to achieve intakes in the range of 3–7 µg/kg/day, does indeed result in a detectable increase in incidence
of hyperthyroidism.  Cases of iodine-induced hyperthyroidism in people who were euthyroid and without
apparent thyroid disease have also been reported; however, only a few have provided dose information,
suggesting effects after oral doses of 3–1,440 mg/day (0.05–23 mg/kg/day) for 6 months.
Extensive clinical use of radioiodine, principally 123I,  124I, 125I, and 131I, for diagnostic purposes and for
treatment of thyrotoxicosis has provided a wealth of information on the effects of relatively high acute
exposures on thyroid gland function.  Radioiodine is cytotoxic to the thyroid gland at high radiation doses
and produces hypothyroidism when doses to the thyroid gland exceed 25 Gy (2,500 rad).  Thyroid gland
doses of approximately 300 Gy (30,000 rad) can completely ablate the thyroid gland and result in
hypothyroidism.  This dose is achieved with an acute exposure of approximately 25–250 mCi
(0.9–9 GBq).  Such high dosages are used to ablate thyroid remnants after surgery for thyroid cancer. 
Cytotoxic doses of 131I can also produce dysfunction of the parathyroid gland, which can receive a
radiation dose from β emission of 131I in the adjacent thyroid gland.
Clinical cases have been reported in which congenital hypothyroidism occurred in newborn infants after
maternal exposures to high doses of 131I for treatment of thyroid gland tumors.  However, the complex
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clinical picture and pharmacotherapy of the mothers for their thyroid condition during pregnancy makes
direct associations between the radioiodine exposure and clinical outcomes of the newborn unclear. 
Exposure in these case ranged from 11 to 77 mCi (407–2,850 MBq).  Two studies that reviewed the
thyroid status of larger sets of infants (37 or 73) born to patients who received 131I for ablative treatment
of thyroid cancer 2–10 years (mean, 5.3 years) prior to pregnancy (i.e., exposure occurred before
conception and fetal development) found no thyroid gland disorders.  The maternal 131I exposures ranged
from 1 to 17 GBq (50–400 mCi); the mean exposure was 3.5–4.4 GBq (100–120 mCi).
A large amount of epidemiological literature exists on the health outcomes in populations who were
exposed to environmental releases of radioiodine.  These include (1) releases from explosions of nuclear
bombs such as the Marshall Islands BRAVO test, the largest U.S. detonation (15 megaton), and from the
Nevada Test Site; (2) accidental releases from nuclear power plants such as the Chernobyl explosion and
fire; and (3) releases from nuclear fuel production facilities such as the Hanford Nuclear Site (Table 2-2). 
In general, releases of these types result in mixed exposures to a variety of radioisotopes and to radiation
doses from both external and internal exposure.  However, doses from radioiodine that are significant to
health derive largely from internal exposure as a result of uptake of radioiodine into the thyroid gland (see
Section 3.4.2.2).  The relative contribution of the inhalation and oral pathways can be expected to vary
depending on the duration of the release and the duration of human access and contact to the sites of
contamination.  In the so-called BRAVO cohort, which has been studied extensively (see Section 3.3.1
for a more detailed discussion), inhalation may have been a more significant contributor to the internal
radioiodine dose because the subjects comprising the cohort were evacuated from the site of major
contamination within 2 days after the release of radioiodine to the atmosphere; this would have limited
their dietary exposures.  Nevertheless, estimates of inhalation intakes of airborne radioactivity amounted
to <1% of the total intake estimated based on measurements of 131I in urine, suggesting a substantial
contribution from other routes.  In nursing infants, exposure would have continued from ingestion of
contaminated breast milk.  The Chernobyl cohorts had access to contaminated areas and contaminated
foods (e.g., locally harvested produce and goat and cow milk) for weeks to months after the accident. 
The thyroid radiation doses in this population are thought to have been dominated by the oral exposure
pathway.  Epidemiological studies of the Nevada Test Site detonations and releases from the Hanford
Nuclear Site have focused on subjects who were potentially exposed through the dietary pathway as a
result of repeated releases during periods of 7 or 13 years, respectively.  
Radiation doses to the thyroid gland (external and internal) in the most highly exposed individuals after
the Marshall Islands BRAVO test is estimated to have ranged from 0.3 to 20 Gy (30–2,000 rad).  External
radiation is estimated to have contributed approximately 4–16% or 10–50% of total thyroid dose,
depending on the location of the individual with respect to the blast.  Thyroid gland outcomes have been
assessed periodically since the BRAVO test in 1954.  Cases of thyroid gland disorders began to be 
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Table 2-2.  Releases from Radioiodine-producing Events
Source 131I Released (PBq)a Reference
All nuclear bomb tests 650,000 Gonzalez 1998
Nevada Test Site nuclear bomb tests 5,500 NCI 1997
Chernobyl power plant accident 3,200 UNSCEAR 2000
Hanford Nuclear Site nuclear fuel processing-
related releases
27 CDC 1999
Three Mile Island power plant accident 0.0004–0.0011 NRC 1995
a1 PBq=27,000 Ci
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detected in the exposed population in 1964, 10 years after the BRAVO test, particularly in exposed
children; these included cases of apparent growth retardation, myxedema (typical of hypothyroidism), and
thyroid gland neoplasms.  Collectively, the various health assessments and studies of the so-called
BRAVO cohort have revealed dose-related abnormally high elevations in serum concentrations of TSH,
characteristic of hypothyroidism.  Among exposed children who were 1-year-old at the time of the
BRAVO test and who received an estimated thyroid radiation dose exceeding 1,500 rad (or 15 Gy), 83%
had serum concentrations of TSH >5 mU/L; thyroid nodularity was found in 67–81% of the most highly
exposed group, and thyroid cancer was discovered in 6% of the most an apparent highly exposed group.
The 1986 explosion and fire at the nuclear power plant at Chernobyl in the Ukraine resulted in the release
of airborne radionuclides to the surrounding regions and contamination of soil, food, and surface water. 
Several different exposure populations have been characterized that vary considerably in exposure levels
and radiation doses received.  These include emergency response workers who received the highest acute
radiation doses, early evacuees from areas near the reactor (generally within 30 km of the reactor), and
people who continued to inhabit contaminated areas outside the evacuation zone.  The radiation exposures
to the general population (i.e., evacuees and people who continued to inhabit contaminated areas) were
attributed largely to isotopes of cesium (e.g., 137Cs), which accounted for approximately 90–98% of the
external radiation dose.  However, radioiodine is estimated to have contributed approximately 50% of the
total lifetime committed effective radiation dose for children born in the region in 1986, and
approximately 80% of the radiation dose received during the first year after the release.  Estimates of
thyroid radiation doses to the general population suggest that doses were highest in children who were
younger than 1 year of age at the time of the release.  The highest estimated doses were received within
the 30-km evacuation zone; median doses ranged from 2.3 Gy (250 rad) at age <1 year to 0.4 Gy (40 rad)
in adolescents and adults.  Estimated median doses received in populations residing 100–200 km from the
plant (e.g., Mogilev region) were <0.3 Gy (30 rad) for all age groups.  Thyroid screening programs and
epidemiological studies conducted after the Chernobyl accident have revealed a dose-related elevated
prevalence of thyroid nodules and thyroid cancer in children of the Belarus and Ukraine regions, apparent
approximately 4 years after the Chernobyl accident.  These effects have been associated with thyroid
radiation doses of 0.3–1 Gy (30–100 rad).  In both Belarus and the Ukraine, the highest rates of childhood
thyroid cancer have occurred in areas where exposure to other industrial contaminants are likely to have
occurred and where there is evidence for widespread iodine deficiency.  These factors may have affected
the early appearance of thyroid cancer after the accident, when vigorous public health screening programs
for thyroid abnormalities were initiated.  The incidence of thyroid cancer prior to the accident in these
areas was poorly documented.
IODINE 19
2.  RELEVANCE TO PUBLIC HEALTH
***DRAFT FOR PUBLIC COMMENT***
Immunological and Lymphoreticular Effects.    Excess iodide intake may be a contributing factor
in the development of autoimmune thyroiditis in susceptible individuals, which can result in
hypothyroidism or hyperthyroidism (associated with Graves’ disease).  Autoimmune thyroiditis is an
inflammation of the thyroid gland that can lead to fibrosis of the gland, follicular degeneration, follicular
hyperplasia, and hypothyroidism.  IgG autoantibodies to thyroglobulin and thyroid peroxidase are a
consistent feature of the disorder.  Iodine appears to play an important role in autoimmune response, as
human lymphocytes recognize and proliferate in response to iodinated human thyroglobulin, but not
iodine-free thyroglobulin.  In general, iodine excess accelerates autoimmune thyroiditis in autoimmune-
prone individuals, whereas iodine deficiency attenuates thryoiditis.  Several studies have been conducted
of people who reside in endemic goiter areas and who received iodide supplementation.  These studies
suggest that iodine intakes of 230–420 µg I/day (3.3–6.0 µg/kg/day total intake) for 12 months can induce
thyroid autoimmunity.  However, other studies have not found increases in autoimmunity associated with
iodine supplementation at doses of 1,150 µg/day (29 µg/kg/day).  Studies using rats have shown that
doses of 70–95 mg I/kg/day (in drinking water) for 8–12 weeks may increase the incidence of
autoimmune thyroiditis in inbred strains of rats that develop spontaneous thyroid autoimmunity.
Larger scale assessments of thyroid autoimmunity have been conducted in the Marshall Islands, where
exposures to 131I occurred as a result of fallout and contamination from test detonations of thermonuclear
devises during the period 1946–1958.  These studies have not revealed an elevated prevalence of thyroid
autoimmunity relative to other populations.  Studies of populations in the Belarus and Ukraine suggest a
possible contribution of radioiodine exposure to an increased prevalence of thyroid autoimmunity
following the Chernobyl accident.  Cases of autoimmune hyperthyroidism, with serum antibodies to the
TSH receptor, have occurred after exposures to higher levels of  131I for ablative treatment of
hyperthyroidism.  No relationship was found between the prevalence or incidence of autoimmune
thyroiditis and exposure to radioiodine associated with bomb tests at the Nevada Test Site.
Oral exposure to excess iodide can produce allergic reactions in sensitive subjects.  The reactions include
urticaria (hives), acneiform skin lesions (ioderma), and fevers.  Cases of more serious reactions involve
angioedema (localized edema), vasculitis, peritonitis and pneumonitis, and complement activation.  Both
humoral and cell-mediated immune responses are thought to be involved.  In general, reactions to iodide
have occurred in association with repeated oral doses of iodide 300–1,600 mg I/day (5–23 mg/kg/day). 
However, in many of these cases, preexisting disease and related drug therapy may have contributed to
the reaction to the iodine; thus, the dose-response relationship for ioderma in healthy people remains
highly uncertain.  
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Gastrointestinal Effects.    Ablative treatment of thyroid cancers with 131I has been associated with
inflamation of the salivary glands (sialadentitis) in humans.  Salivary glands express a transport protein,
the sodium-iodine symport (NIS), which is also present in the thyroid gland, where it functions to
transport iodide into the gland for hormone synthesis.  Salivary glands can accumulate iodide in saliva at
concentrations considerably above that in serum (see Sections 3.4.2.2 and 3.5.1).  Exposures in reported
cases of 131I-induced sialadentitis ranged from 100 to 300 mCi (3.7–11 GBq).  Sialadentitis usually
occurred within a few days or weeks of exposure and had a duration of several weeks to 2–3 years.
Neurological Effects.    Exposure to excess iodine has been shown to produce subclinical
hypothyroidism, which in certain individuals sensitive individuals, may take the form of hypothyroidism.  
Sensitive populations include fetuses, newborn infants, and individuals who have thyroiditis or Graves’
disease, many of whom have abnormal autoimmune disorders (see Section 3.2.2.2, Endocrine Effects). 
Of  these iodine-induced forms of hypothyroidism, that occurring in the fetus or newborn infant has the
greatest potential for producing neurological effects.  This is because thyroid hormones are essential to
the development of the neuromuscular system and brain.  An iodine-induced hypothyroid state can result
in delayed or deficient brain and neuromuscular development of the newborn.  Iodine-induced
hypothyroidism in an older child or adult would be expected to have little or no deleterious effects on the
neuromuscular system.  Exposure of a fetus to large amounts of radioiodine would result in thyroid tissue
ablation and in similar delayed brain and neuromuscular development, if the hypothyroid state was not
corrected (e.g., with hormone replacement therapy) after birth.
Exposure to excess iodine can also produce hyperthyroidism in sensitive individuals (see Section 3.2.2.2,
Endocrine Effects).  These include people who are initially iodine deficient, those who have thyroid
disease, including Graves’ disease, who have been treated with antithyroid drugs, people who have has
postpartum thyroiditis, and those who have developed thyrotoxicosis from amiodarone or inteferon-alpha
treatments.  Patients who develop thyrotoxicosis may experience neuromuscular disorders, including
myopathy, periodic paralysis, myasthenia gravis, peripheral neuropathy, tremor, and chorea.
Developmental Effects.    Although iodine excess may result in hypothyroidism, iodine deficiency is
far more likely to cause prenatal and postnatal hypothyroidism and be associated with neurologic injury
leading to cretinism, a developmental effect (see Section 3.2.2.2, Endocrine Effects).  Thyroid hormone
deficiency from any cause at critical times of development may result in severe mental retardation,
neurologic abnormalities, growth retardation, or abnormal pubertal development.  
Congenital hypothyroidism secondary to thyroid ablation has been reported subsequent to maternal
exposure to ablative doses of 131I.  In one case, an infant became hypothyroid after his mother received
99 mCi (3.7 GBq) of 131I during her sixth week of pregnancy.  Growth retardation was also observed in
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some children who were exposed to radioiodine in the Marshall Island BRAVO cohort, early after the
bomb test.  Studies are suggestive of possible extra-thyroidal developmental effects of radioiodine
following maternal exposures to ablative doses of 131I received 2–10 years prior to pregnancy.  Observed
outcomes that may or may not have been related to the 131I exposures included low birth weights with
subsequent normal growth patterns, tetrology of Fallot (pulmonic stenosis, atrial septal defect, and right
ventricular hypertrophy), hypoparathyroidism, Down’s syndrome, and cardiac anomalies.  The maternal
131I exposures ranged from 1 to 17 GBq (20–460 mCi).  Studies of pregnancy outcomes in Belarus and
Ukraine populations after the Chernobyl accident are suggestive of possible developmental effects related
to radiation exposures. 
Exposure to excess iodine can also produce hyperthyroidism in sensitive individuals (see Section 3.2.2.2,
Endocrine Effects).  Growth acceleration occurs in childhood hyperthyroidism, from any cause, which is
thought to be related to changes in pituitary regulation of growth. 
Reproductive Effects.    Exposure to excess iodine may produce hypothyroidism or hyperthyroidism
(see Section 3.2.2.2, Endocrine Effects) and could cause disruption of reproductive function, secondary to
thyroid gland dysfunction.  Hypothyroidism can produce changes in the menstrual cycle in humans,
including menorrhagia (excessive uterine bleeding) and anovulation (no ovulation).  Spontaneous
abortions, stillbirths, and premature births have also been associated with hypothyroidism.  Reproductive
impairments associated with hyperthyroidism include amenorrhea and alterations in gonadotropin release
and sex hormone-binding globulin (SHBG), and associated changes in the levels and metabolism of
steroid hormones in both females and males.
Clinical follow-up studies of pregnancies in patients who received 131I (1–17 GBq, 20–460 mCi) for
ablative treatment of thyroid cancer 2–10 years (mean, 5.3 years) prior to pregnancy have not shown
evidence of effects on reproductive success.  However, clinical cases of impaired testicular function
following exposures to 131I for ablative treatment of thyroid cancer in men have been reported.  Observed
effects included low sperm counts, azospermia (absence of spermatozoa), and elevated serum
concentrations of follicle stimulating hormone (FSH), which persisted for more than 2 years.  Exposures
to radioiodine ranged from 30 to 1,335 mCi (1.1–49.5 GBq).  In Belarus and Ukraine populations after
the Chernobyl accident, pregnant women who resided in heavily exposed areas (including exposures to
other industrial contaminants) appeared to be at risk for development of toxemia, renal insufficiency, and
anemia.
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Cancer.    The relationship between iodide intake and thyroid cancer has been examined in several
large-scale epidemiology studies.  The results of these studies suggest that increased iodide intake may be
a risk factor for thyroid cancer in certain populations, particularly in populations in iodine-deficient,
endemic goiter regions.  Not all studies have found an increased risk of cancer; however, a recurrent
observation is an apparent shift in the histopathology toward a higher prevalence of papillary cancer after
increased iodine intake in otherwise iodine-deficient populations.  Two studies found a significant excess
of thyroid gland cancer in populations from endemic goiter regions whose diets were supplemented to
achieve approximate iodine intakes of 3.5 µg/kg/day.
The thyroid gland receives the highest radiation dose of any organ or tissue following internal exposure to
radioiodine (see Section 3.4.2.2, Toxicokinetics), and therefore, cancer of the thyroid gland is a major
cancer concern associated with radioiodine exposures.  Cancer morbidity and mortality among
populations who received exposures to radioiodine have been examined in several large-scale
epidemiology studies.  In general, these studies fall into several categories that can be distinguished by
the sources of exposure and estimated radiation doses to the thyroid gland and include (see Table 3-3):
(1) high exposures and doses (10–20 mCi, 370–740 MBq; >10,000 rad, >100 Gy) achieved when 131I is
administered to treat hyperthyroidism (higher exposures are used in treatment of thyroid cancer);
(2) lower exposures and doses (40–70 µCi, 1.5–2.6 MBq; 80–130 rad, cGy) associated with clinical
administration of 131I for diagnosis of thyroid gland disorders; (3) doses from exposures to fallout from
nuclear bomb tests (BRAVO test, 300–2,000 rad, cGy;  Nevada Test Site, 1–40 rad, cGy); (4) doses from
exposures to releases from nuclear power plant accidents (Chernobyl, 1–200 rad, cGy), and (5) exposures
from operational releases from nuclear fuel processing plants (Hanford Nuclear Site, 0.0001–284 rad,
cGy).  
The relatively high and acutely cytotoxic radiation doses to the thyroid gland that are achieved in the
treatment of thyroid gland disorders, and the related outcomes on the thyroid, are virtually irrelevant to
predicting outcomes from the much lower environmental exposures that occur in most U.S. populations. 
Nevertheless, these studies have revealed that, even at high exposures (3–27 mCi, 111–999 MBq) and
thyroid gland doses (60 Gy, 6,000 rad), significant risks for cancers in organs other than the thyroid gland
have not been consistently detected when the study designs control for other treatments administered to
the patients.  Studies of diagnostic doses of radioiodine have not consistently revealed significant risks of
thyroid or other cancers; those that have, however, found significantly elevated risks only in patients who
were administered the radioiodine for diagnosing a suspected thyroid gland tumor.  In general, studies of
the outcomes of medical uses of radioiodine involve subjects who were exposed as adults.  Studies of
thyroid cancers and external radiation exposure have found a strong age dependence between thyroid
radiation dose and thyroid cancer.  Risk is substantially greater for radiation doses received prior to age
15 years when compared to risks for doses received at older ages.  This same general trend in age-
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dependence would be expected for internal exposures to radioiodine, thus, studies of adult exposures to
radioiodine may not be directly applicable to predicting outcomes from exposures to children.  Studies of
populations potentially exposed to radioiodine (0.09–3.2 Gy, 9–325 rad) as a result of nuclear bomb tests
at the Nevada Test Site are suggestive, but not conclusive, of a possible association between radioiodine
exposures and thyroid cancer.  The National Research Council concluded that, because of uncertainties
related to dose reconstruction and epidemiological analyses of the Nevada Test Site experience, the
currently available information is not adequate to determine the extent to which the bomb tests in Nevada
increased the incidence of thyroid cancer.  A case-control study of thyroid cancers among children in
Belarus provides reasonably strong evidence for the contribution of higher level radioiodine exposure and
thyroid cancers diagnosed after the Chernobyl accident.
Breast cancer is also a concern with exposures to high levels of radioiodine after ablative therapy for
hyperthyroidism because the breast expresses NIS and can transport and accumulate iodide (see
Sections 3.4.4.2 and 3.5.1, Distribution).  However, the epidemiological literature to date has not
implicated such exposures as a significant risk factor for breast cancer.
2.3 MINIMAL RISK LEVELS
Inhalation MRLs
C An MRL could not be derived for iodine because of a lack of information on dose-response
relationships for the inhalation pathway. 
Oral MRLs
C An MRL of 0.01 mg/kg/day has been derived for acute-duration oral exposure (1–14 days) to
iodine.
The acute-duration MRL is based on a no-observed-adverse-effect-level (NOAEL) of 0.024 mg/kg/day in
healthy adult humans.  Although the NOAEL is derived from acute studies of health adults, supporting
studies indicate that the NOAEL would be applicable to children and elderly adults.  On this basis, an
uncertainty factor is not needed adjust the NOAEL to account for human variability in sensitivity.
Although elevated serum concentrations of TSH and decreased serum concentrations of thyroid hormone
(T4 and T3) in healthy adults who had no history of thyroid disease or detectable antithyroid antibodies,
hormone levels were within the normal range for healthy adults.  Furthermore, the hormone levels
reverted to pretreatment levels when the iodine dosage was withdrawn. 
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Healthy euthyroid adults (9 males, 9 females) who had no history of thyroid disease or detectable
antithyroid antibodies received daily oral doses of 250, 500, or 1,500 µg I/day as sodium iodide for
14 days.  Based on 24-hour urinary excretion of iodide prior to the iodide supplement, the background
iodine intake was estimated to be approximately 200 µg/day; thus, the total iodide intake was
approximately 450, 700, or 1,700 µg I/day (approximately 0.0064, 0.01, or 0.024 mg/kg/day, assuming a
70-kg body weight).  Subjects who received 1,700 µg/day (0.024 mg/kg/day) had significantly depressed
(5–10%) serum concentrations of TT4, FT4, and TT3 compared to pretreatment levels, and serum TSH
concentrations were significantly elevated (47%) compared to pretreatment values.  Hormone levels were
within the normal range during treatment.  In this same study, nine females received daily doses of 250 or
500 µg I/day for 14 days (total intake was approximately 450 or 700 µg/day; 0.0064 or 0.010 mg/kg/day)
and there were no significant changes in serum hormone concentrations. 
In similar type of study, healthy, euthyroid, adult males (n=10) received daily oral doses of 500, 1,500, or
4,500 µg I/day (as sodium iodide) for 14 days.  Based on 24-hour urinary excretion of iodide prior to the
iodide supplement of 250–320 µg/day, the total estimated intakes were 300, 800, 1,800, or 4,800 µg/day
or approximately 0.004, 0.011, 0.026, or 0.069 mg/kg/day.  There were no effects on serum thyroid
hormone or TSH concentrations at the 800 µg/day intake (0.011 mg/kg/day); however, intakes of 1,800 or
4,800 µg I/day (0.026 or 0.064 mg/kg/day) produced small (10%) but significant, transient decreases in
serum TT4 and FT4 concentrations and an increase (48%) in serum TSH concentration, relative to the
pretreatment values. 
Although the acute NOAEL is derived from acute studies of health adults, supporting studies indicate that
the NOAEL would be applicable to children and elderly adults.  On this basis, an uncertainty factor is not
needed adjust the NOAEL to account for human variability in sensitivity.  In the Chow et al. study,
30 healthy elderly adult females, without evidence of thyroid peroxidase antibodies (TPA), received daily
doses of 500 µg I/day (as potassium iodide) for 14 or 28 days.  Serum concentrations of FT4 were
significantly decreased and serum TSH concentrations were significantly elevated in the women who
received the iodide supplements, relative to a placebo control group.  On average, the magnitude of the
changes did not produce clinically significant depression in thyroid hormone levels; however, five
subjects had serum TSH concentrations that exceeded 5 mU/L.  The subjects had a lower dietary iodine
intake than those in the Gardner et al. study, approximately 72–100 µg/day, based on urinary iodide
measurements.  Therefore, the total iodide intake was approximately 600 µg/day or 0.0086 mg/kg/day,
essentially the same as the acute NOAEL in healthy adults based on Gardner et al. and Paul et al.
In the Boyages et al. study, thyroid status was compared in groups of children, ages 7–15 years, who
resided in two areas of China where drinking water iodide concentrations were either 462 µg/L (n=120)
or 54 µg/L (n=51).  Although the subjects were all euthyroid with normal values for serum thyroid
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hormones and TSH concentrations, TSH concentrations were significantly higher in the high iodine
group.  The prevalence and severity of goiter in the population were evaluated, the latter based on a goiter
severity classification scale (Grade 0, no visible goiter; Grade 1, palpable goiter that is not visible when
the neck is not extended; Grade 2, palpable and visible goiter when the neck is not extended).  The high
iodide group had a 65% prevalence of goiter and a 15% prevalence of Grade 2 goiter compared to 15%
for goiter and 0% for Grade 2 goiter in the low iodine group.  Urinary iodine was 1,236 µg I/g creatinine
in the high iodine group and 428 µg I/g creatinine in the low iodine group.  Assuming a body weight of
40 kg and lean body mass of 85% of body weight, the above urinary iodine/creatinine ratios are
approximately equivalent to iodine excretion rates, or steady state ingestion rates of
1,150 (0.029 mg/kg/day) and 400 µg/day (0.01 mg/kg/day) in the high and low iodide groups,
respectively.  The NOAEL of 0.01 mg/kg/day from this study is the same as the acute NOAEL based on
Gardner et al. and Paul et al.
The MRL is higher than the National Research Council RDA of 150 µg/day (0.0021 mg/kg/day for a
70-kg adult), with additional allowances of 25 µg/day (0.0025 mg/kg/day) and 50 µg/day
(0.0029 mg/kg/day) during pregnancy and lactation, respectively. 
C An MRL of 0.01 mg/kg/day has been derived for chronic-duration (>364 days) oral exposure to
iodine.
The chronic-duration MRL is based on a NOAEL of 0.01 mg/kg/day and a lowest-observed-adverse-
effect level (LOAEL) of 0.029 mg/kg/day for subclinical hypothyroidism in healthy human children.  An
uncertainty factor is not needed adjust the NOAEL to account for human variability in sensitivity because
the NOAEL is based on a sensitive end point in children, a sensitive subpopulation.  Supporting studies
indicate that the NOAEL would be applicable to elderly adults who may represent another sensitive
subpopulation.  The chronic MRL was based on a chronic human study; however, since the chronic MRL
is the same as the acute MRL (0.01 mg/kg/day), it is also applicable to intermediate-duration exposures.
Although serum concentrations of TSH were elevated, they remained within the normal range for
children.  Thyroid gland enlargement, however, was observed in children who had no history of thyroid
disease or detectable antithyroid antibodies.  Hormone levels were within the normal range for healthy
children; therefore, these dosages did not induce clinical hypothyroidism.  The slight thyroid enlargement
can be considered a less-serious LOAEL, not indicative of functional impairment.  Thyroid status was
compared in groups of children, ages 7–15 years, who resided in two areas of China where drinking water
iodide concentrations were either 462 µg/L (n=120) or 54 µg/L (n=51).  Urinary iodine was 1,236 µg I/g
creatinine in the high iodine group and 428 µg I/g creatinine in the low iodine group.  Assuming a body
weight of 40 kg and lean body mass of 85% of body weight, the above urinary iodine/creatinine ratios are
approximately equivalent to iodine excretion rates, or steady state ingestion rates of
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1,150 (0.029 mg/kg/day) and 400 µg/day (0.010 mg/kg/day) in the high and low iodide groups,
respectively.  Although the subjects were all euthyroid with normal values for serum thyroid hormones
and TSH concentrations, TSH concentrations were significantly higher (33%) in the high iodine group. 
The high iodide group had a 65% prevalence of goiter and a 15% prevalence of Grade 2 goiter compared
to 15% for goiter and 0% for Grade 2 goiter in the low iodine group.  
Although the acute NOAEL is derived from acute studies of children, supporting studies indicate that the
NOAEL would be applicable to elderly adults.  On this basis, an uncertainty factor is not needed adjust
the NOAEL to account for human variability in sensitivity.  In the Chow et al. study, 30 healthy elderly
adult females, without evidence of TPA, received daily doses of 500 µg I/day (as potassium iodide) for
14 or 28 days.  Serum concentrations of FT4 were significantly decreased and serum TSH concentrations
were significantly elevated in the women who received the iodide supplements, relative to a placebo
control group.  On average, the magnitude of the changes did not produce clinically significant depression
in thyroid hormone levels; however, five subjects had serum TSH concentrations that exceeded 5 mU/L. 
The pre-existing dietary iodine intake was approximately 72–100 µg/day, based on urinary iodide
measurements.  Therefore, the total iodide intake was approximately 600 µg/day or 0.0086 mg/kg/day,
essentially the same as the acute NOAEL in healthy adults based on Boyages et al. and Li et al.
Szabolcs et al. studied elderly nursing home residents in the Carpathian Basin and revealed a prevalence
of hypothyroidism that increased with increasing iodine intake.  Subjects were from one of three regions
where, based on reported urinary iodine levels of 72, 100, or 513 µg I/g creatinine, the iodine intakes
were approximately 117, 163, or 834 µg/day (0.0017, 0.0023, or 0.012 mg/kg/day for low, n=119;
moderate, n=135; or high intake, n=92, respectively).  The prevalence of elevated serum TSH
concentrations together with serum FT4 concentrations below the normal range was 0.95, 1.5, and 7.6% in
the low, moderate, and high iodine groups, respectively.  If a prevalence of abnormal thyroid hormone
levels of <5% is considered a NOAEL, than this study supports a NOAEL in elderly adults that is slightly
below 0.012 mg/kg/day.  Linear interpolation of the dose-prevalence data reported above yields an
estimate of a 5% prevalence at an iodine intake of approximately 0.008 mg/kg/day.
The MRL is higher than the National Research Council RDA of iodine of 150 µg/day (0.0021 mg/kg/day
for a 70-kg adult), with additional allowances of 25 µg/day (0.0025 mg/kg/day) and 50 µg/day
(0.0029 mg/kg/day) during pregnancy and lactation, respectively. 
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3.  HEALTH EFFECTS
3.1 INTRODUCTION
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and
other interested individuals and groups with an overall perspective on the toxicology of iodine.  It
contains descriptions and evaluations of toxicological studies and epidemiological investigations and
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation,
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive,
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or
lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the
studies.  LOAELS have been classified into "less serious" or "serious" effects.  "Serious" effects are those
that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory
distress or death).  "Less serious" effects are those that are not expected to cause significant dysfunction
or death, or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is
considered to be important because it helps the users of the profiles to identify levels of exposure at which
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
the effects vary with dose and/or duration, and place into perspective the possible significance of these
effects to human health.  
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The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and
figures may differ depending on the user's perspective.  Public health officials and others concerned with
appropriate actions to take at hazardous waste sites may want information on levels of exposure
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of iodine are
indicated in Tables 3-1 and 3-2 and Figures 3-1 and 3-2. 
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been
made for iodine.  An MRL is defined as an estimate of daily human exposure to a substance that is likely
to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of
exposure.  MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of
effect or the most sensitive health effect(s) for a specific duration within a given route of exposure. 
MRLs are based on noncancerous health effects only and do not consider carcinogenic effects.  MRLs can
be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes. 
Appropriate methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990),
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic
bronchitis.  As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure
No studies were located on the toxicity of inhaled nonradioactive iodine.  Iodine is absorbed in humans
when I2 or methyl iodide vapors are inhaled (Black and Hounam 1968; Morgan and Morgan 1967;
Morgan et al. 1967a, 1967b, 1968).  Once absorbed, iodide would be expected to exert effects that are
similar to that of iodide absorbed after ingestion, including effects on the thyroid gland and thyroid
hormone status, sensitivity reactions, and cancer (see Section 3.2.2).  Iodine (I2) is a strong oxidizing
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agent; therefore, exposure to high air concentrations of I2 vapor could potentially produce upper
respiratory tract irritation and possibly oxidative injury.
A large amount of epidemiological literature exists on the heath outcomes in populations exposed to
radioiodine as a result of releases from explosions of nuclear bombs (e.g., Marshall Islands, Nevada Test
Site), operational releases from nuclear fuel reprocessing facilities (e.g., Hanford Nuclear Site), and
accidental releases from nuclear power plants (e.g., Chernobyl).  Releases of these types resulted in mixed
exposures to a variety of radioisotopes, and radiation doses from both external and internal exposure. 
However, doses from radioiodine that are significant to health effects derive largely from internal
exposure to the thyroid gland as a result of absorption and uptake of radioiodine into the thyroid gland
(see Section 3.4.2.2).  Inhalation of airborne radioiodine is likely to have occurred after each of these
releases and prior to ground deposition of radioiodine.  However, the major contributors to thyroid
radiation dose in each of these incidents are thought to have been from ingestion of milk, vegetation, and
water contaminated from atmospheric deposition of radioiodine.  Ingestion of human breast milk is also
considered to have been a major contributor to doses received in nursing infants.  For example, it has
been estimated that, in seven Ukraine cities following releases of radioiodine from the Chernobyl nuclear
power plant, inhalation of 131I contributed between 2 and 13% of total absorbed radiation dose, whereas
the ingestion pathway contributed from 98 to 87% (IAEA 1991).  In the Marshall Islands, after the
BRAVO bomb test, the inhalation pathway is thought to have contributed <1% of the absorbed
radioiodine, with the ingestion pathway contributing 80–99%; dermal absorption of radioiodine may have
contributed as much as 20% (Lessard et al. 1985).  Because of the more substantial contribution of the
oral pathway to the absorbed thyroid radiation doses, health effects studies related to the Chernobyl
accident, the Marshall Islands, the Hanford Nuclear Site, and the Nevada Test Site are discussed in the
oral section of this profile (Section 3.2.2).  However, the effects observed that have been related to the
internal radiation dose to the thyroid gland are also directly relevant to inhalation exposures since inhaled
radioiodine absorbed from either the respiratory tract or gastrointestinal tract would be expected to
distribute to the thyroid gland (see Section 3.4.2.1, Toxicokinetics).
3.2.1.1 Death
Deaths related to thyroid cancers (or to other cancers or causes) following the Chernobyl accident are
being studied with well-controlled epidemiological designs, and possible associations between mortality
and radioiodine exposures may become evident once the dose reconstruction project, now underway, has
been completed.  Although radiation-related deaths were recorded among emergency response personnel
on site during the Chernobyl accident, these deaths were associated with external exposure to gamma
radiation from molten fuel areas and not with exposure to radioiodine. 
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3.2.1.2 Systemic Effects
All of the information on systemic effects of inhaled iodine in humans relates to endocrine effects from
exposures to radioiodine following the BRAVO nuclear bomb test in the Marshall Islands, the Chernobyl
accident, and radioiodine releases from the Hanford Nuclear Site.  Because oral ingestion of radioiodine
is thought to have been the major contributor to exposure, these studies are discussed in detail in
Section 3.2.2.  No information was located regarding respiratory, cardiovascular, gastrointestinal,
hematological, musculoskeletal, hepatic, renal, dermal, ocular, body weight, or other systemic effects of
inhalation exposure to iodine or radioiodine.  However, one epidemiological study has examined health
outcomes of infants of mothers who resided in the Belarus region before or after the Chernobyl accident
(Petrova et al. 1997).  The health outcomes observed in this study include respiratory, hematological,
renal, and dermal effects; however, their association to radioiodine exposure has not been established. 
This study is discussed in greater detail in the sections of reproductive and developmental effects
associated with oral exposures to radioiodine (Sections 3.3.1.5 and 3.3.1.6).
3.2.1.3 Immunological and Lymphoreticular Effects
All of the information on immunological effects of inhaled iodine in humans relates to thyroid gland
autoimmunity and exposures to radioiodine following the BRAVO nuclear bomb test in the Marshall
Islands, the Chernobyl accident, and releases of radioiodine from the Hanford Nuclear Site.  Because
exposures in these incidents are thought to have been largely from oral ingestion of radioiodine, these
studies are discussed in detail in Section 3.2.2.
3.2.1.4 Neurological Effects
No information was located on neurological effects of inhaled iodine.  Exposure to radioiodine at
sufficient doses to produce hypothyroidism could give rise to neurological manifestations of thyroid
gland dysfunction including impairments in neurological development and myopathy (Boyages 2000a,
2000b).  Congenital hypothyroidism can be associated with a severe impairment in neurological
development of the fetus termed cretinism, which usually occurs in areas of endemic iodine deficiency. 
This condition would be highly unlikely in iodine-induced hypothyroidism secondary to inhalation of
iodine.
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3.2.1.5 Reproductive Effects
No information was located regarding reproductive effects of inhalation exposure to iodine or
radioiodine.  However, a large-scale retrospective analysis was conducted to evaluate pregnancy health
and reproductive outcomes of women who were exposed to radiation resulting from releases from the
Chernobyl nuclear power plant, including a major contribution from 131I (Petrova et al. 1997).  Although
inhalation of radioiodine certainly occurred in this population, internal radiation doses resulting from this
incident are thought to have been largely from oral ingestion of radioiodine (IAEA 1991).  The study is
summarized in greater detail in Section 3.3.1.5, which discusses the reproductive effects of oral exposures
to radioiodine.  
3.2.1.6 Developmental Effects
No information was located regarding developmental effects associated with inhalation exposure to iodine
or radioiodine other than those related to the thyroid gland (e.g., Marshall Islands,  Section 3.3.1.1,
Endocrine Effects).  However, one epidemiological study has examined health outcomes of infants of
mothers who resided in the Belarus region before or after the Chernobyl accident (Petrova et al. 1997). 
Exposures resulting from this incident are thought to have been largely from oral ingestion of radioiodine
(IAEA 1991) and, therefore, a summary of this study can be found in Section 3.3.1.6 on the
developmental effects of oral exposures to radioiodine.
3.2.1.7 Cancer
No information was located on carcinogenicity of inhaled stable iodine.  Thyroid cancers have been
associated with exposures to radioiodine following the BRAVO nuclear bomb test in the Marshall Islands
and the Chernobyl accident.  Thyroid cancers have also been studied in populations exposed to
radioiodine released from nuclear bomb tests at the Nevada Test Site, and from operational releases of
radioiodine from the Hanford Nuclear Site.  Although the inhalation of radioiodine occurred in these
incidents, oral ingestion of radioiodine is thought to have been the major contributor to thyroid radiation
doses.  Summaries of these studies can be found in Section 3.3.1.7 on cancer effects of oral exposures to
radioiodine. 
3.2.2  Oral Exposure
The section that follows provides background information relevant to the various study summaries that
are presented subsequently.  A description of the approaches used to calculate doses of stable iodine is
provided.  Also provided is background information on the exposure scenarios from the major 
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radioiodine-releasing events for which health effects studies have been reported.  The actual study
summaries follow.  For each category of health effect, studies of oral exposures to stable iodine are
presented first, followed by summaries of studies of radioiodine exposures.  
Stable Iodine.  A large number of human experimental, clinical, and epidemiological studies on the
effects of excess iodine on human health have been reported.  The key studies that provide information on
exposures associated with effects are summarized in this section of the profile.  Oral iodine intakes were
not directly assessed in many studies with sufficient accuracy to define dose-response relationships;
however, measurements of urinary iodide provide a basis for estimating intakes in some of the studies
(Konno et al. 1993b).  Rather than describing the basis for estimating intakes from urinary iodine data in
each of the study descriptions that follow, the general approach used is described here.  If a 24-hour
urinary iodide measurement was provided that could be regarded as a steady state value (relatively
constant intake for at least 6 months), the intake was assumed to be equivalent to the 24-hour excretion
rate.  This assumption is consistent with information available on the toxicokinetics of iodide that
indicates nearly complete absorption of ingested iodide and that urinary excretion accounts for >97% of
the absorbed dose (see Sections 3.4.1.2 and 3.4.4.2).  The assumption is also supported by studies in
which 24-hour urinary iodide was measured before and after supplementation.  For example, 31 patients
received oral supplements of 382 µg I/day for 6 months.  Prior to the supplementation, the mean 24-hour
urinary iodide excretion rate was 36 µg/day (range, 13–69), whereas after 6 months of iodide
supplementation, the mean 24-hour urinary iodide excretion rate was 415 µg/day (Kahaly et al. 1998). 
The difference between these two values, 379 µg/day, is nearly identical to the supplemental dose of
382 µg/day.
If a urine iodide concentration was provided for a morning sample that included overnight bladder urine,
the measured concentration was assumed to represent the 24-hour average concentration and iodide intake
was calculated as:
Equation (1)IntakeI U I 1.4= ⋅
where UI is the measured urinary iodine concentration and 1.4 is the average urine volume (L/day) for a
70-kg adult (ICRP 1981).  Equation 1 is in reasonable agreement with observed relationships between
morning bladder urine iodide concentrations and 24-hour iodide excretion rates (Konno et al. 1993b;
Nagata et al. 1998).  Urine iodide concentration from untimed (spot) samples, other than morning samples
that included overnight bladder urine, were considered too uncertain to derive intake estimates, unless
paired urinary creatinine concentrations or a urinary iodide:creatinine ratio (µg I:g creatinine) was
reported.  Urinary iodide:creatinine ratios were converted to estimated iodide intake as follows, assuming
a constant relationship between urinary creatinine excretion rate and lean body mass.  The rate of
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creatinine excretion (e.g., ECr , g creatinine/day) was calculated from the relationship between lean body
mass (LBM) and ECr:
Equation (2)LBM ECr= ⋅ +0 0272 8 58. .
where the constants 0.0272 and 8.58 are the weighted arithmetic mean of estimates of these variables
from eight studies reported in Forbes and Bruining (1976).  Lean body mass was calculated as follows
(ICRP 1981):
Equation (3)LBM BW males= ⋅088. ,
LBM BW females= ⋅ 0 85. ,
where BW is the reported or assumed body weight for males (75 kg) and females (65 kg) (EPA 1997f).  A
mean value of 60 kg (females, 55 kg; males, 65 kg) was assumed for body weights of adult populations of
the Asian Pacific countries (e.g., Japan, China, Marshall Islands).  Iodide intake was calculated as:
 Equation (4)Intake U EI I Cr Cr= ⋅/
where UI/Cr is the urinary iodide:creatinine ratio (µg I/g creatinine).  This approach yields relationships
between 24-hour urinary iodide excretion rates and the urinary iodide:creatinine ratios that are in
reasonable agreement with observations (Konno et al. 1993b).
Radioactive Iodine.  A discussion of the relevant biokinetics of radioiodine is provided in Sections 3.4.
Marshall Islands BRAVO Test.  Several epidemiological studies have examined thyroid gland disorders
in residents of the Marshall Islands who were exposed to radioiodine from atmospheric fallout after an
atmospheric nuclear bomb test (the so-called BRAVO test).  Residents of islands near and downwind
from the test site on Bikini Atoll (e.g., Ailingnae, Rongelap, Utirik) were exposed to both internal
radionuclides and external gamma radiation from fallout during the 2 days prior to their evacuation.  The
estimated cumulative gamma radiation dose on these islands ranged from 69 to 175 rad (0.7–1.75 Gy) or
approximately 10–50% of the estimated thyroid dose (Conard 1984).  Later estimates suggest that
external radiation contributed approximately 4–16% of total thyroid dose (Hamilton et al. 1987).  Internal
exposures, resulting primarily from radioiodine, were much higher.  Although inhalation of airborne
radioiodine probably occurred during the fallout period immediately after the blast, ingestion of deposited
radioiodine on locally harvested foods and surface water during the subsequent 2 days prior to evacuation
IODINE 34
3.  HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
is thought to be the major contributor to the internal exposures (Lessard et al. 1985).  Nursing infants
would also have received internal exposures from ingestion of radioiodine in breast milk.  Estimated total
absorbed doses to the thyroid gland (external and internal) were 3.3–20 Gy (330–2,000 rad) on Rongelap
(highest doses in children), 1.3–4.5 Gy (130–450 rad) on Ailingnae, and 0.3–0.95 Gy (30–95 rad) on
Utirik (Conard 1984).  Estimates of the internal radiation dose to the thyroid remain uncertain as they
were based primarily on measurements of radioiodine (principally 131I) in a pooled urine sample, collected
15 days after exposure, from a subset of exposed people.  Although these measurements allowed back
extrapolation of the initial internal 131I exposures, shorter-lived radioiodine species (132I, 133I, 135I) could
not be detected in the urine sample.  These isotopes are thought to have contributed 2–3 times the thyroid
radiation dose of 131I (Conard 1984).  It is generally agreed that external radiation exposures resulted
nearly entirely from fallout and deposits of radionuclide-containing materials on the skin, rather than from
direct photon irradiation from the blast, as the exposed populations were approximately 100–320 miles
from the detonation site.  In this respect, the Marshall Island exposures are very different from the
Hiroshima and Nagasaki exposures, which are characterized by acute (single dose) exposure to mostly
gamma radiation (with a small neutron contribution in Hiroshima).  Numerous bomb tests were conducted
in the Marshall Islands during the period 1946–1958.  Comparisons of 137Cs in soils in the Marshall
Islands with estimates of global fallout in the mid-Pacific region suggest contamination from local
activities over much of the Marshall Islands (i.e., local 137Cs:global 137Cs ratio>1) with particularly high
local:global 137Cs ratios (>10) on the islands of Bikini (test site), Enewatak (test site), Rongelap, and
Utirik (Takahashi et al. 1997).
Chernobyl Accident.  In 1986, a chemical explosion and fire at the nuclear power plant in Chernobyl in
the Ukraine was caused by the uncontrolled release of stored energy in graphite moderator blocks; this
resulted in the release of airborne radionuclides to the surrounding regions and contamination of soil and
locally grown foods.  The external radiation exposures were contributed largely by isotopes of cesium
(e.g., 137Cs), which accounted for approximately 90–98% of the external radiation dose (Mould 2000;
UNSCEAR 2000; Vargo 2000).  Radioiodine is estimated to have contributed approximately 50% of the
internal committed radiation dose for children born in 1986 in the region and approximately 80% of the
total radiation dose received during the first year after the release (Vargo 2000).  Estimates of thyroid
radiation doses have been derived from external thyroid gland scans that measure radiation (most gamma)
from radioiodine in the thyroid.  These measurements suggest that radioiodine doses to the thyroid gland
were highest in children <1 year of age at the time of the release, and were highest in locations nearest to
the nuclear plant where contaminated food was not quarantined.  The highest estimated doses were
received within 30 km of the Chernobyl plant; median doses ranged from 2.3 Gy (250 rad) at age <1 year
to 0.4 Gy (40 rad) in adolescents and adults (UNSCEAR 2000).  Estimated median doses received in
populations residing 100–200 km from the plant (e.g., Mogilev region) were <0.3 Gy (30 rad) for all age
groups (UNSCEAR 2000).  Although inhalation of airborne radioiodine is likely to have occurred after
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the accident, the major contributors to the absorbed thyroid radiation dose are thought to have been from
ingestion of milk, vegetation, and water contaminated from atmospheric deposition of radioiodine. 
Ingestion of human breast milk is also considered to have been a major contributor to doses received in
utero and in nursing infants.  For example, it has been estimated that, in seven Ukraine cities, ingestion of
131I contributed between 87 and 98% of total absorbed radiation dose (IAEA 1991).  Estimated doses in
Finland were significantly lower than on comparably contaminated areas in Belarus because of the control
exercises to quarantine contaminated food until radioiodine levels had sufficiently decayed.  Endemic
goiter in the Belarus population (Gembicki et al. 1997) and differences in the extent of use of stable
iodine to mitigate the thyroid dose may have also contributed to the differences in the thyroid doses
observed in Belarus compared to similarly contaminated areas of Finland. 
Thyroid dose estimates, particularly peak dose rates, are largely based on extrapolations from thyroid
gland 131I measurements made within 1 to several weeks after the major release from the Chernobyl plant
and ground monitoring of atmospheric deposition of radioiodine.  One set of measurements of thyroid
gland radioactivity came from postmortem measurements of thyroid glands from 416 people collected
over the period from May 3 (8 days after the initial release) to August 4, 1986 (Beno et al. 1991).  Back
extrapolation of thyroid gland activities and consideration of temporal trends in both the thyroid gland
data and atmospheric deposition allowed the estimation of transfer coefficients relating atmospheric
deposition of radioiodine (kBq/m2) and thyroid dose (µSv); the coefficients were 641 µSv/kBq-m2 in
exposed children and 221 µSv/kBq-m2 in exposed adults (Beno et al. 1992).  Based on this approach,
thyroid radiation doses may have ranged from 0.12 to 24 Sv (12–2,400 rem) in children and from 0.04 to
8 Sv (4–800 rem) in adults.  In Gomel, where the highest incidence of thyroid cancer in children has been
reported, the transfer coefficients yield estimated doses of 1.2–12.3 Sv (120–1,230 rem) in children
(Bleuer et al. 1997; Drobyshevskaya et al. 1996).  Various other approaches have been used to estimate
thyroid doses associated with the Chernobyl.  In the Ukraine, most of these rely on exposure estimates
based on measured ratios of long-lived isotopes of iodine (e.g., 129I) and assumed relationships between
radioiodine and 137Cs air levels and/or deposition, and models of indirect pathways, including milk
ingestion (IIyin et al. 1990; Likhtarev et al. 1995).  Estimates of absorbed thyroid doses from 131I based on
137Cs deposition densities in seven Ukraine cities ranged from 80 to 240 cGy (rad) in infants, 64–190 cGy
(rad) in children, and 19–57 cGy (rad) in adults (IAEA 1991).  In estimates of lifetime radiation doses,
almost all of the radiation exposure was received in the first 3 months after the accident, during which
time, the 131I activity decreased to <0.1% of the initial values.  The continued 129I exposure can be
considered minimal, although it will persist for several decades for some populations because of
environmental contamination and its longer decay half-life.  
Nevada Test Site.  During the period 1951–1958, 119 atmospheric nuclear bomb tests were conducted at
the Nevada Test Site (NTS) in southern Nevada (NCI 1997).  These tests were followed by nine surface
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detonations during the period 1962–1968 and approximately 809 below-ground tests, of which 38 were
determined to have resulted in off-site releases of radioactive materials.  A dose estimation methodology
was developed by the National Cancer Institute (NCI 1997), which has enabled estimates of population
radiation doses to the thyroid gland from direct and indirect (e.g., ingestion of cow milk) exposures to 131I
resulting from the NTS activities for the purpose of health assessments and epidemiologic investigations
(Gilbert et al. 1998; Kerber et al. 1993).  Geographic-specific geometric mean lifetime doses are
estimated to have ranged from 0.19 to 43 cGy (rad) for people born on January 1, 1952 who consumed
milk only from commercial retail sources, 0.7–55 cGy (rad) for people who consumed milk only from
home-reared cows, and 6.4–330 cGy (rad) for people who consumed milk only from home-reared goats
(NCI 1997; NRC 1999).  A discussion of the uncertainties and limitations of these population dose
estimates for use in epidemiology studies and risk assessment can be found in a review of the NCI (1997)
dose estimations conducted by the Institute of Medicine and the National Research Council (NRC 1999).
Hanford Nuclear Site.  The Hanford Nuclear Site in southeastern Washington reprocessed uranium to
produce plutonium.  Radioiodine was released to the atmosphere during the early years of operation of the
facility.  Approximately 740,000 Ci (27 PBq) of 131I was estimated to have been released to the
atmosphere during the period 1944–1957 (CDC 1999; at the time this profile was developed, a draft
report of this study was available from the Fred Hutchinson Cancer Research Center web site
(http://www.fhcrc.org/science/phs/htds/); however, a final published report was not available).  Thyroid
radiation doses have been estimated using a dosimetry model developed in the Hanford Environmental
Dose Reconstruction Project.  The estimated mean thyroid radiation dose in a population of 3,190 people
who resided near the facility was 182 mGy (±227, standard deviation [SD]) (18.2±22.7 rad), and the
range was 0.0008–2,842 mGy (0.00008–284 rad).  Doses varied geographically, with the highest doses
received by people who lived near and downwind from the site.
3.2.2.1 Death
Two recent reviews of the clinical case literature note that deaths have occurred after ingestion of iodine
preparations (FDA 1989b, 1990b).  A review of medical records from the New York City Medical
Examiners Office revealed that, in a period of 6 years, there were 18 deaths from attempted suicides in
which adults ingested iodine tinctures (Finkelstein and Jacobi 1937).  Tinctures of iodine contain a
mixture of molecular iodine (I2) and sodium triiodide (NaI3) and have iodine concentrations of
approximately 40 mg/mL.  Doses of iodine from ingestion of the tinctures ranged from 1,200 to 9,500 mg
(17–120 mg/kg), and deaths usually occurred within 48 hours of the dose.  In one case, an adult male
ingested 15 g of iodine as a potassium iodide solution and survived the episode; 18 hours after the dose, 
his serum iodide concentration was 2.95 mg/mL (Tresch et al. 1974).  Symptoms of toxicity that have
been observed in lethal or near-lethal poisonings have included abdominal cramps, bloody diarrhea and
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gastrointestinal ulceration, edema of the face and neck, pneumonitis, hemolytic anemia, metabolic
acidosis, fatty degeneration of the liver, and renal failure (Clark 1981; Dyck et al. 1979; Finkelstein and
Jacobi 1937; Tresch et al. 1974).  
Two cases of infant deaths were reported in which death was from complications related to compression
of the trachea by a goiterous thyroid gland; the mothers had ingested potassium iodide during their
pregnancies at doses of approximately 850 and 1,180 mg I/day (12 and 17 mg/kg/day) (Galina et al.
1962).
Although radiation-related deaths were recorded among emergency response personnel on site during the
Chernobyl accident, these deaths were associated with exposure to gamma radiation from molten fuel
areas and not with exposure to radioiodine.  External, but not internal exposure to radiation from a variety
of radionuclides caused these deaths.  Approximately 134 cases of acute radiation sickness (ARS) were
recorded, mainly in plant workers and firemen, of which 120 deaths were later attributed to radiation. 
Symptoms included skin burns, epithelial injuries, and bone marrow suppression, which are typical of
ARS.  Thyroid disorders, which would have been indicative of radioiodine toxicity, were not reported and
would have been inconsequential had they occurred in context with the extreme health consequences
associated with ARS.  Deaths related to thyroid cancers (or to other cancers or causes) following the
accident are being studied with well controlled epidemiological designs, and possible associations
between mortality and radioiodine exposures may become evident once the dose reconstruction project,
now underway, has been completed.
The LOAEL values in humans for exposures by the oral route are presented in Table 3-1 and plotted in
Figure 3-1.
3.2.2.2 Systemic Effects
Systemic effects of oral iodine exposure, other than after massive acute iodine overload such as in cases
of attempted suicides (see Section 3.2.2.1), are on the thyroid gland and are discussed in the section on
Endocrine Effects.  As noted in the introduction to this chapter of the profile, adverse effects on a wide
variety of other organ systems can result from iodine-induced disorders of the thyroid gland, including
disturbances of the skin, cardiovascular system, pulmonary system, kidneys, gastrointestinal tract, liver,
blood, neuromuscular system, central nervous system, skeleton, male and female reproductive systems,
and numerous endocrine organs, including the pituitary and adrenal glands.  The reader is referred to
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The major systemic effects of exposures to radioiodine are on the thyroid gland; however, other systemic
effects have been observed, including inflamation of the salivary glands (sialadentitis), following
relatively high exposures to radioiodine such as those used for ablative treatment of thyroid cancers. 
The highest NOAEL values and all reliable LOAEL values in each duration category for systemic
(endocrine) effects from exposures by the oral route are presented in Table 3-1 and plotted in Figure 3-1.
Gastrointestinal Effects.    Ablative treatment of thyroid cancers with 131I has been associated with
inflamation of the salivary glands (sialadentitis) in humans (Allweiss et al. 1984; Bohuslavizki et al.
1996, 1998a and b, 1999; Mandel and Mandel 1999).  Salivary glands express a transport protein, the
sodium-iodine symport (NIS), which is also present in the thyroid gland where it functions to transport
iodide into the gland for hormone synthesis.  Salivary glands can accumulate iodide in saliva at
concentrations considerably above that in serum (see Sections 3.4.2.2 and 3.5.1).  The range of
administered radioiodine in these cases was 100–300 mCi (3.7–11 GBq).  Sialadentitis usually occurred
within a few days or weeks of exposure and had a duration of several weeks to 2–3 years.
Endocrine Effects.    
Endocrine Effects of Stable Iodine
The principal direct effects of excessive iodine ingestion on the endocrine system are on the thyroid gland
and regulation of thyroid hormone production and secretion.  Adverse effects on the pituitary and adrenal
glands derive secondarily from disorders of the thyroid gland.  Effects on the thyroid gland can be
classified into three types: hypothyroidism, hyperthyroidism, and thyroiditis.  Hypothyroidism refers to
the diminished production of thyroid hormone leading to clinical manifestations of thyroid insufficiency
and can occur with or without goiter, a functional hypertrophy of the gland in response to suppressed
hormone production.  Typical biomarkers of hypothyroidism are a depression in the circulating levels of
thyroxine (T4) and/or triiodothyronine (T3) below their normal ranges.  This is usually, but not always,
accompanied by an elevation of thyroid stimulating hormone (TSH, also know as thyrotropin) above the
normal range.  Hyperthyroidism is an excessive production and/or secretion of thyroid hormones.  The
clinical manifestation of abnormally elevated circulating levels of T4 and/or T3 is thyrotoxicosis. 
Thyroiditis refers to an inflammation of the gland, which is often secondary to thyroid gland
autoimmunity.  The above three types of effects can occur in children and adults, in fetuses exposed in
utero, or in infants during lactation.  
Measurements of serum levels of thyroid hormones and TSH are often used as biomarkers of
hypothyroidism and hyperthyroidism in toxicology and epidemiology studies.  In interpreting this
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literature in terms of human health risks, a distinction must be made between outcomes that have a high
potential for producing clinical manifestations from those outcomes that are not clinically significant.  In
this profile, an observed decrease in circulating T4 or T3 levels or an increase in serum TSH level, within
their respective normal ranges, is referred to as subclinical hypothyroidism.  Similarly, the term
subclinical hyperthyroidism refers to a condition in which the circulating levels of T4 or T3 are elevated
within their normal ranges.  Typical normal ranges for these hormone levels are discussed in Section 3.8.2
Hypothyroidism.
An acute iodide excess (above the preexisting dietary intake) decreases the production of thyroid
hormones (organification of iodide) in the thyroid gland; this effect is referred to as the Wolff-Chaikoff
effect (Wolff et al. 1949).  In most people, this is followed by a return to normal levels of hormone
synthesis, referred to as escape from the Wolff-Chaikoff effect, without a change in circulating hormone
levels.  Escape is thought to be the result of down regulation of the iodine transport mechanism in the
thyroid gland (see Section 3.4.3.2 for further details on the Wolff-Chaikoff effect).  An acute or chronic
excess of iodide can also decrease circulating T4 and T3 levels and induce a hypothyroid state.  These
effects are thought to involve the inhibition of the release of T4 from the thyroid gland and/or inhibition of
extrathyroidal production of T3.  Most iodine-induced hypothyroidism is transient, although T4
replacement may be required in some patients.  Hypothyroidism is thought to occur primarily in
susceptible individuals who fail to escape from the inhibitory effect of large doses of iodide that produce
the Wolff-Chaikoff effect.  Susceptible individuals include fetuses and newborn infants, patients who
have autoimmune thyroiditis, patients with Graves’ disease previously treated with iodine or antithyroid
drugs, women who have had postpartum thyroiditis, or those who have had subacute thyroiditis. 
Spontaneous recovery usually occurs within 2–3 weeks, although some individuals may develop
permanent thyroiditis (Markou et al. 2001).
Several studies have examined the acute effects of increased intakes of iodine on thyroid hormone status
of adults (Chow et al. 1991; Gardner et al. 1988; Georgitis et al. 1993; Namba et al. 1993; Paul et al.
1988; Robison et al. 1998).  The results of these studies suggest that acute (14 days) increases in iodine
intake of 1,500 µg/day (21 µg/kg/day) above the preexisting dietary intake can be tolerated without
producing a clinically adverse change in thyroid hormone levels, although such doses may produce a
reversible depression in serum T4 concentration and an elevation in serum TSH concentration, both within
the normal range of values for healthy individuals.  Changes in thyroid hormone levels within normal
ranges are not considered to be clinically adverse; however, they are indicative of a suppressing effect on
thyroid hormone production that, if persistent, could result in thyroid gland enlargement and other
clinically significant complications.  The above conclusions apply to healthy adults who have no prior
history of thyroid disease, no detectable antithyroid antibodies, and no prior history of chronic deficiency
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or excessive iodine intakes (Gardner et al. 1988; Paul et al. 1988).  One study found that subclinical
hypothyroidism was induced by an acute increase of 500 µg/day (7 µg/kg/day) in elderly adults (Chow et
al. 1991), suggesting the possibility that elderly adults may be less tolerant of an iodide excess than
younger adults.  Based on estimates of the background dietary intakes of the subjects in these studies, in
most cases estimated from measurements of urinary iodide excretion, the total iodide intakes (including
background dietary intake) that produced subclinical hypothyroidism were approximately 1,700 µg/day
or approximately 24 µg/kg/day (Gardner et al. 1988; Paul et al. 1988).  Acute intakes of approximately
700 µg/day or approximately 10 µg/kg/day had no detectable effect of thyroid hormone status in healthy
individuals (Gardner et al. 1988; Paul et al. 1988).  One study found no evidence for disturbances in
thyroid hormone status in healthy adults who received doses of 300 µg/kg/day (approximately
20 mg/day) for 14 days (Robison et al. 1998).  This suggests that, at least under certain conditions,
exposure levels >10–24 µg/kg/day may be tolerated in some people.  Brief summaries of the relevant
studies that provide information on oral exposures to iodine that suppress the thyroid gland are provided
below.
Healthy euthyroid adults (9 males, 9 females) who had no history of thyroid disease or detectable
antithyroid antibodies received daily oral doses of 1,500 µg I/day as sodium iodide for 14 days (Paul et al.
1988).  Based on 24-hour urinary excretion of iodide prior to the iodide supplement, the background
iodine intake was estimated to be approximately 200 µg/day; thus, the total iodide intake was
approximately 1,700 µg I/day (approximately 24 µg/kg/day, assuming a 70-kg body weight).  Serum
concentrations of TT4, FT4, and TT3 were significantly depressed (5–10%) compared to pretreatment
levels and serum TSH concentrations were significantly elevated (47%) compared to pretreatment values. 
Hormone levels were within the normal range during treatment and, therefore, the subjects were not
clinically hypothyroid.  In this same study, nine females received daily doses of 250 or 500 µg I/day for
14 days (total intake was approximately 450 or 700 µg/day [8 or 10 µg/kg/day] and there were no
significant changes in serum hormone concentrations [some of these women participated in the higher
dose study 1 year earlier]). 
In a similar type of study, healthy, euthyroid, adult males (n=10) received daily oral doses of 500 µg I/day
(as sodium iodide) for 14 days; there were no effects on serum thyroid hormone or TSH concentrations;
however, dosages of 1,500 or 4,500 µg I/day (7 or 64 µg/kg/day) produced small (10%) but significant,
transient decreases in serum TT4 and FT4 concentrations and an increase (48%) in serum TSH
concentration, relative to the pretreatment values (Gardner et al. 1988).  Urinary iodide excretion prior to
the dose ranged from 250 to 320 µg/day, suggesting that the background dietary intake was
approximately in this same range (see Sections 3.3.1.2 and 3.3.4.2).  The magnitude of the changes at the
higher iodide dosages yielded hormone concentrations that were within the normal range and, thus, would
not represent a clinically significant thyroid suppression.  This suggests that an acute oral intake of
500 µg/day above a preexisting dietary intake, or approximately 800 µg I/day total (11 µg/kg/day), is
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tolerated without thyroid gland suppression in healthy adult males, and intakes as high as 4,800 µg I/day
(69 µg/kg/day) may be tolerated in some people without clinically adverse effects.  
In a similar type of study, 30 healthy elderly adult females, without evidence of thyroid peroxidase
antibodies (TPA), received daily doses of 500 µg I/day (as potassium iodide) for 14 or 28 days (Chow et
al. 1991).  Serum concentrations of FT4 were significantly decreased (change from pretreatment level,
approximately -1 pmol/L) and serum TSH concentrations were significantly increased (change from
pretreatment level approximately +0.6 mI/L) in the women who received the iodide supplements, relative
to a placebo control group.  On average, the magnitude of the changes did not produce clinically
significant depression in thyroid hormone levels; however, five subjects had serum TSH concentrations
that exceeded 5 mU/L, typically considered the high end of the normal range.  The subjects had a lower
dietary iodine intake than those in the Gardner et al. (1988) study; approximately 72–100 µg/day, based
on urinary iodide measurements.  Therefore, the total iodide intake was approximately 600 µg/day
(9 µg/kg/day).
Higher acute iodine exposures have been shown to produce reversible thyroid gland hypertrophy, in
addition to hormone suppression.  The effects of tetraglycine hydroperiodide, an iodine compound used to
purify drinking water, was examined in an acute experimental study (Georgitis et al. 1993).  When
dissolved in water, tetraglycine hydroperiodide releases I2 and iodide (as a reduction product).  Seven
healthy adults, who had no history of thyroid disease, ingested 227 mL (8 ounces) of a flavored drink into
which tetraglycine hydroperiodide had been dissolved; the dosage was 32 mg/day of iodine for
7 consecutive days (460 µg/kg/day).  Seven age-, weight-, and height-matched controls received water
without added iodine.  A statistically significant decrease in serum concentration of T4 and T3 (14–15%)
and a significant increase in TSH concentration (50%) occurred in the treatment group during the
treatment, relative to their pretreatment values, whereas no change occurred in the control subjects.  Two
subjects in the treatment group had T4 concentrations below approximately 60 nmol/L and two subjects
had TSH concentrations that were between 4.5 and 6 mU/L, which would be indicative of mild clinical
hypothyroidism (it is not clear from the report if these were the same two subjects).  In a more extensive
study of similar design, eight healthy euthyroid adults (seven males, one female), who were negative for
thyroid antimicrosomal antibody, ingested approximately 32 mg iodine/day (460 µg/kg/day) as
tetraglycine hydroperoxide dissolved in juice or water, for 90 days (LeMar et al. 1995).  The mean
pretreatment 24-hour urinary iodide excretion rate was 276 µg/day.  Thyroid gland volumes increased
significantly during the treatment, with a peak volume 37% above the pretreatment volume and reverted
to pretreatment volumes 7 months after the iodine dosing was discontinued.  Serum TSH concentrations
increased significantly during the treatment, with one subject having a 3-fold increase to a value of
6.1 mU/L; this subject also had the highest thyroid volume during the treatment period.  None of the
subjects developed clinical hypothyroidism. 
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Daily doses of 27 mg I/day (390 µg/kg/day), as licorice lecithin-bound iodide, given for 28 days to
10 healthy, euthyroid adult males who were TPA negative resulted in a statistically significant, 15%
increase in thyroid gland volume, compared to pretreatment values (Namba et al. 1993).  Serum
concentrations of FT4 and T3 were decreased, and serum TSH and thyroglobulin (Tg) concentrations were
significantly elevated, although the treatment values were within the normal ranges.  All values, including
thyroid gland volume returned to normal within 28 days after the last iodide supplement.  In a clinical
study of 22 hypothyroid adults from Japan who consumed an estimated 1–43 mg I/day
(17–720 µg/kg/day, from consumption of seaweed), 12 patients reverted to a euthyroid state after 3 weeks
of voluntary dietary iodine restriction (Tajiri et al. 1986).  When seven of these patients who converted to
a euthyroid state after dietary restriction received supplements of 25 mg I/day (420 µg/kg/day) as Lugol’s
solution (a mixture of 50 mg/mL I2 and 100 mg/mL potassium iodide KI) for 2–4 weeks, all reverted to a
hypothyroid state (serum TSH concentrations >5 mU/L).  In this same study, 11 healthy euthyroid adults
(8 females, 3 males) received 25 mg I/day for 14 days (420 µg/kg/day).  The mean serum TSH
concentrations significantly increased (40%) during the treatment compared to their pretreatment values;
however, their TSH concentrations during treatment (3.9 mU/L) did not exceed the normal range
(<5 mM/L).
In contrast to the results of the above studies, no clinical abnormalities in thyroid hormone status occurred
when healthy, euthyroid, adult males (n=6 or 7), who had no history of thyroid-related illness, ingested
daily oral doses of 300 or 1,000 µg I/kg/day as either I2 or sodium iodide for 14 days (Robison et al.
1998).  Based on measurements of urinary iodide excretion rates, the pretreatment iodide intakes were
approximately 100 µg/day.  The high dosage (1,000 µg I/kg/day) produced a small but statistically
significant increase in serum TSH concentrations compared to a sodium chloride control group; the TSH
concentrations in the control group did not exceed the normal range (<5 mU/L) and reverted to control
levels within 10 days after the iodine supplementation was ended.  Serum TT4 and TT3 were not
significantly different in the treatment groups, compared to the control group. 
In a more remarkable, intermediate-duration experimental study, four healthy adults (three males, one
female) received a daily oral dose of approximately 1,000 mg I/day as a saturated solution of potassium
iodide (30 drops/day, approximately 36 mg I/drop, 15 mg I/kg/day) for 11 weeks (Jubiz et al. 1977).  A
small, statistically significant decrease in the mean serum concentration of T4 occurred (pretreatment,
8.8 µg/dL; treatment minimum 7.6 g/dL) and an increase in TSH concentration (pretreatment, 7.3 mU/L;
treatment maximum, 13.5 mU/L).  The above changes were no longer evident within 1 week after the
treatment was discontinued.  In a similar study, eight euthyroid adults (seven male, one female), who
were hepatitis patients, received daily oral doses of approximately 360 mg I/day (5 mg/kg/day) as a
saturated solution of potassium iodide (10 drops/day, approximately 36 mg I/drop) for 60 days (Minelli et
al. 1999).  A small statistically significant decrease in the mean serum concentration of T4 (pretreatment,
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13.8 pmol/L; treatment minimum 13.2 pmol/L) and an increase in TSH concentration (pretreatment,
0.6 mU/L; treatment maximum, 1.7 mU/L) occurred.  Two patients were reported to have developed
transient elevated serum TSH concentrations during the iodide treatment, with normal concentrations of
FT4 and FT3.  There were no incidences of clinical hypothyroidism or hyperthyroidism.  A nearly
identical result was reported for eight euthyroid hepatitis patients who had previously received
recombinant interferon-alpha therapy (but who did not develop thyroid dysfunction during therapy) and
who subsequently received daily doses of approximately 360 mg I/day (5 mg/kg/day) as a saturated
solution of potassium iodide for 60 days (Minelli et al. 1997).  As part of the study reported by Jubiz et al.
(1977), 13 patients with obstructive pulmonary disease who were receiving 1,000–2,000 mg I/day
(14–28 mg/kg/day) as a saturated potassium iodide solution for periods of 1 month to 8 years exhibited
unambiguous symptoms of hypothyroidism, including thyroid gland enlargement, depressed serum
concentrations of T4 (mean 2–2.7 µg/dL), and elevated serum TSH concentrations (20–35 mU/L).  Serum
T4 and TSH levels returned to normal in all but one of the patients within 1 month after the iodide dosage
was discontinued. 
The results of several epidemiological studies suggest that chronic exposure to excess iodine can result in
or contribute to hypothyroidism.  Thyroid status was compared in groups of children, ages 7–15 years,
who resided in two areas of China where drinking water iodide concentrations were either 462 µg/L
(n=120) or 54 µg/L (n=51) (Boyages et al. 1989; Li et al. 1987).  Although the subjects were all euthyroid
with normal values for serum thyroid hormones and TSH concentrations, TSH concentrations were
significantly higher in the high iodine group.  The prevalence and severity of goiter in the population
were evaluated, the latter based on a goiter severity classification scale (Grade 0, no visible goiter;
Grade 1, palpable goiter that is not visible when the neck is not extended; Grade 2, palpable and visible
goiter when the neck is not extended).  The high iodide group had a 65% prevalence of goiter compared
to 15% in the low iodine group.  The prevalence of more severe, Grade 2 goiter, was also higher in the
high iodide group (15%) compared to the low iodide group (0%).  Urinary iodine was 1,236 µg I/g
creatinine in the high iodine group and 428 µg I/g creatinine in the low iodine group.  Assuming a body
weight of 40 kg and lean body mass of 85% of body weight, the above urinary iodine/creatinine ratios are
approximately equivalent to iodine excretion rates or steady state ingestion rates of 1,150 µg/day
(29 µg/kg/day) and 400 µg/day (10 µg/kg/day) in the high and low iodide groups, respectively. 
A survey of a group of Peace Corps volunteers revealed a high prevalence of goiter among volunteers
who drank water from iodine filters (Khan et al. 1998).  Of 96 volunteers surveyed, 44 (46%) had
enlarged thyroid glands, 33 (34%) had elevated serum TSH concentrations ($4.2 mU/L), and 4 (4%) had
depressed serum TSH concentrations (#0.4 mU/L).  The mean iodide concentration in filtered drinking
water was 10 mg I/L, which corresponded to a daily intake of iodide from drinking water of 50–90 mg
I/day (0.7–1.3 mg/kg/day, based on a reported daily water consumption of 5–9 L/day).  This estimate was
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consistent with measured mean urinary iodide concentration of 11 mg/L, which corresponds to
approximately 55–99 mg I/day excreted or ingested, assuming daily urine volumes similar to water
consumption.
In a study of elderly adults, thyroid status was compared in 423 residents (ages 66–70 years) of Jutland,
Denmark who had iodine intakes of 40–60 µg/day (0.7 µg/kg/day) and 100 residents of Iceland who had
intakes of 300–350 µg/day (5 µg/kg/day) (Laurberg et al. 1998).  Subjects from the high iodine intake
region had a significantly higher prevalence (18%) of serum TSH levels above the high end of the normal
range (>4 mU/L) compared to subjects from the low iodine region (3.8%).  The prevalence of serum TSH
concentrations above 10 mU/L was 4.0% in the high iodine region and 0.9% in the low iodine region. 
Females in both regions had a significantly higher prevalence of elevated TSH concentrations than males. 
Serum concentrations of T4 were not depressed, even in subjects with TSH concentrations that exceeded
10 mU/L.  Thus, although the subjects appeared to be euthyroid, the higher iodine intakes were associated
with a subclinical suppression of the thyroid gland as indicated by a high prevalence of elevated serum
TSH concentrations.  A study of elderly nursing home residents in the Carpathian Basin also revealed a
prevalence of hypothyroidism that increased with increasing iodine intake (Szabolcs et al. 1997). 
Subjects were from one of three regions where, based on reported urinary iodine levels of 72, 100, or
513 µg I/g creatinine, the iodine intakes were approximately 117, 163, or 834 µg/day (1.7, 2.3, or
12 µg/kg/day for low, n=119; moderate, n=135; or high intake, n=92, respectively).  The prevalence of 
serum TSH concentrations above the normal range was 4.2, 10.4, and 23.9% in the low, moderate, and
high iodine groups, respectively.  The prevalence of elevated serum TSH concentrations together with
serum FT4 concentrations below the normal range was 0.95, 1.5, and 7.6% in the low, moderate, and high
iodine groups, respectively.
Several studies have found increased prevalence of hypothyroidism in residents of areas of Japan where
dietary iodine intake is high as a result of consumption of seaweeds containing a high iodine
concentration.  In one study, urinary iodide and serum TSH concentrations were measured in a group of
1,061 adult residents of five coastal areas of Japan and in 4,100 residents of two inland areas (Konno et
al. 1993a, 1994).  The subjects were classified as having high or normal iodine intakes based on whether
their urinary iodide concentrations were less than or greater than the high end of the normal range,
75 µmol/L (9,500 µg/L).  The urine samples were not timed and urinary creatinine concentrations were
not reported; therefore, only rough estimates of the rate of urinary excretion of iodide (µg/day) and iodide
intake can be made.  The report indicates that the urine samples were collected in the morning and
included night urine (i.e., urine voided on awakening).  If it is assumed that the concentrations of iodide
in the morning urine samples reflect the concentration for a 24-hour sample and that the 24-hour urine
volume is approximately 1.4 L (ICRP 1981), then the 24-hour excretion and intake rates in the high
iodine group may have been approximately 13.3 mg/day (0.22 mg/kg/day, assuming a body weight of
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60 kg).  Even if the morning urine samples were relatively concentrated compared to the 24-hour average,
the above urine iodide concentrations suggest an iodide intake of several mg/day.  This is consistent with
other reported estimates that range from 1 to 5 mg/day in Japan among consumers of seaweed
(Pennington 1990b).  Examples of much higher intakes (25–40 mg/day, 0.4–0.7 mg/kg/day) have been
reported in hypothyroid patients who consume seaweed (Tajiri et al. 1986).  The prevalences of elevated
serum TSH concentrations (>5 mU/L) and urine iodide concentrations (>9,500 µg/L) were both
significantly higher in the costal regions compared to the inland regions (Konno et al. 1994).  Serum TSH
concentrations were positively correlated with the urine iodide concentrations, and the prevalence of
elevated serum TSH concentrations in the seven areas correlated positively with the prevalence of high
urinary iodide concentrations.  There were no significant correlations or associations with urine iodide
and suppressed concentrations of serum TSH (<0.15 mU/L) or with the presence of thyroid antibodies. 
A study of iodine supplementation for treatment of endemic goiter provides additional evidence that
increases in iodine intake can induce thyroid dysfunction, including thyroid autoimmunity.  Otherwise
healthy adults who had goiter but no evidence of clinical hypothyroidism or hyperthyroidism or
antithyroid antibodies received either a placebo (16 females, 15 males) or 200 mg I/day (3 µg/kg/day total
intake) (16 females, 15 males) as potassium iodide for 12 months (Kahaly et al. 1997).  A significant
decrease in thyroid volume occurred in the treated group relative to the control group.  Three subjects in
the treatment group (9.7%, two females and one male) developed elevated levels of thyroglobulin and
thyroid microsomal antibodies compared to none in the control group.  Two of these subjects developed
hypothyroidism and one subject developed hyperthyroidism; all three subjects reverted to normal thyroid
hormone status when the iodide supplementation was discontinued.  In a similar study, 31 adult euthyroid
patients from an endemic goiter region who had goiter received 500 µg/day potassium iodide (382 mg
I/day, 5 mg I/kg/ day based on reported median body weight of 75 kg) for 6 months, and 31 patients
received 0.125 mg T4/day (Kahaly et al. 1998).  Based on reported measurements of 24-hour urine iodide
excretion, the preexisting iodide intake was approximately 40 µg/day (range, 13–77, 0.6 µg/kg/day); thus,
the total intake during treatment was approximately 420 mg I/day (6 µg/kg/day).  After 6 months of
iodide supplementation, the mean 24-hour urinary iodide excretion rate was 415 µg/day, which is
consistent with the estimate of a total iodide intake of approximately 420 µg/day.  Six of the patients who
received iodide (19%) developed high titres of thyroglobulin and thyroid microsomal antibodies,
compared to none in the T4 group.  Four of the high antibody patients became hypothyroid and two
patients became hyperthyroid.  The thyroid hormone status reverted to normal and antibody titres
decreased during a 6-month period following the treatment in which the patients received a placebo.
People who have autoimmune thyroid disease may be at increased risk of developing thyroid dysfunction
when exposed to excess iodide.  Euthyroid patients (37 females, 3 males), who were diagnosed with
Hashimoto’s thyroiditis and who were positive for antithyroid (thyroid peroxidase) antibodies, received
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an oral dose of 250 µg potassium iodide (190 µg I/day) for 4 months; a similar group of thyroiditis
patients (41 females, 2 males) served as controls (Reinhardt et al. 1998).  Based on urinary iodide
measurements of 72 µg I/g creatinine before the iodide supplementation, the preexisting iodide intake was
approximately 125 µg/day, for a total iodide dosage of 375 µg/day (4.5 µg/kg/day) in the treatment group. 
Seven patients in the treatment group developed elevated serum TSH concentration (>4 mU/L) and one
patient developed overt clinical hypothyroidism with a TSH concentration of 43.3 mU/L and a serum FT4
concentration of 7 pmol/L.  One patient in the treatment group became clinically hyperthyroid with a
serum FT4 concentration of 30 pmol/L and TSH concentration of <1 mU/L.  One patient in the control
group developed mild subclinical hypothyroidism.  After the iodine supplementation was discontinued,
three of the seven hypothyroid patients in the treatment group reverted to normal thyroid.  An additional
patient in the treatment group became hypothyroid, requiring T4 supplements.  The patient who became
hyperthyroid while in the treatment group reverted to normal thyroid status after the iodide supplements
were discontinued.  In a smaller clinical study, four of seven euthyroid patients with Hashimoto’s
thyroiditis who received 180 mg I/day (2.6 mg/kg/day) as a saturated potassium iodide solution for
6 weeks developed hypothyroidism, which reverted to normal after the iodide supplementation was
discontinued (Braverman et al. 1971a).
Maternal exposures to excess iodine during pregnancy have been shown to produce goiter and
hypothyroidism in neonates.  In general, clinical cases have involved maternal exposures to several
hundred mg I/day during pregnancy.  For example, in one clinical case, hypothyroidism and life-
threatening goiter occurred in an infant born to a woman who consumed approximately 200 mg I/day
(2.9 mg/kg/day), as sodium iodide, for 2 years, including during pregnancy (Iancu et al. 1974).  The
infant was treated with levothyroxine and reverted to a normal gland and hormone status within 3 weeks
after birth, without further hormone therapy.  In another case, a woman ingested approximately
260–390 mg I/day (4.6 mg/kg/day) during pregnancy and her infant developed goiter in utero, which was
successfully treated in utero with levothyroxine; the thyroid gland and hormone status of the infant was
normal at birth (Vicens-Colvet et al. 1998).  Coakley et al. (1989) reported, as part of the results of a
screening program for congenital hypothyroidism, two cases in which women ingested iodide during
pregnancy and gave birth to infants who had a transient goiter.  In one case, the estimated total dose
iodide dose was approximately 38.3 g I, of which approximately 15.3 g was ingested during the last
month of pregnancy.  These doses are equivalent to an average daily total dose of approximately 96 mg
I/day during the first 8 months and 510 mg I/day (7.3 mg/kg/day) during the last month of pregnancy. 
Penfold et al. (1978) reported two cases, one of goiter without hypothyroidism in an infant born to a
mother who ingested approximately 380 mg I/day (5.4 mg/kg/day) as potassium iodide during the last
trimester of pregnancy, and the other case of goiter with hypothyroidism in an infant born to a mother
who had ingested approximately 460 mg I/day (6.6 mg/kg/day) as potassium iodide during the last
4 months of pregnancy.  In both cases, hypothyroidism and/or goiter were temporary and did not require
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thyroid hormone therapy.  Hassan et al. (1968) reported three cases of neonatal goiter and
hypothyroidism.  In each case, the mother had ingested daily doses of potassium iodide during pregnancy;
approximate doses were 450, 688, and 765 mg I/day (6–11 mg/kg/day).  The goiter and hypothyroidism
reversed with temporary thyroid hormone therapy.  Martin and Rento (1962) reported two cases of goiter
and severe but reversible hypothyroidism in infants born to mothers who ingested potassium iodide
during pregnancy; the approximate dosages were 920 and 1,530 mg I/day (13 and 22 mg/kg/day).  In two
cases, infants died with complications related to a goiterous thyroid gland compression of the trachea; the
mothers had ingested potassium iodide during their pregnancies at doses of approximately 850 and
1,180 mg I/day (12 and 17 mg/kg/day) (Galina et al. 1962).
The above clinical cases demonstrate that doses of iodide exceeding 200 mg/day (2.8 mg/kg/day) during
pregnancy can result in congenital goiter and hypothyroidism.  There is also a large clinical experience
with the lower doses of iodide supplementation given during pregnancy for the purpose of correcting or
preventing potential iodine deficiency and for the management of Graves’ disease during pregnancy.  In a
study of 35 women with Graves’ disease who received 6–40 mg iodide (0.1–0.7 mg/kg/day, assuming a
60-kg body weight) as potassium iodide during pregnancy, 2 of 35 infants had serum TSH concentrations
above normal at birth (>20 mU/L) and none had FT4 concentrations below normal at birth (<10 pmol/L;
7 ng/L), suggesting that this level of iodide supplementation did not induce a hypothyroid state in the
newborn, but did produce a subclinical change in TSH levels in some infants (Momotani et al. 1992).  In
a study of iodide supplementation during pregnancy in an iodide-deficient area of Denmark, 28 women
received daily doses of 200 µg I/day from the 17th–18th week of pregnancy through the first 12 months
after delivery and 26 women received no supplementation (Pedersen et al. 1993).  Pretreatment urinary
iodide levels were 51 and 55 µg/L, respectively, in the two groups, suggesting a preexisting dietary iodine
intake of approximately 75 µg/day (assuming that the urine iodide concentration reflected the 24-hour
average and that urine volume was approximately 1.4 L/day) and a total iodide intake of 275 µg/day
(4 µg/kg/day).  There were no statistically significant differences in serum TT4, FT4, T3, or TSH
concentrations in the infants in the two groups at birth, and there were no abnormal values for the
hormones in any of the infants.  In a similar type of study, 38 pregnant women from a potentially iodine-
deficient region of Germany received daily doses of 230 µg I/day as potassium iodide during pregnancy
and lactation and 70 women received no supplementation.  Pretreatment urinary iodide levels were 53 µg
I/g creatinine (median), suggesting a preexisting iodide intake of approximately 90 µg/day (Liesenkötter
et al. 1996) and a total intake of 320 µg/day (5 µg/kg/day).  Thyroid gland volumes were significantly
decreased in infants from the supplemented group, compared to the control group (median control,
1.5 mL; median treated, 0.7 mL).  One infant (1/38, 2.6%) from the supplemented group was classified as
having an enlarged gland (>1.5 mL) compared to 14 (14/70, 20%) from the control group.  The report
indicates that “no hypothyroidism or hyperthyroidism was observed in the mothers or newborns”,
although the end points evaluated, other than serum TSH, were not indicated.  
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Iodized oil has been used to supplement intakes in populations that are iodine deficient and live in areas
where supplementation with iodized table salt or drinking water is not practical.  Iodized oil (ethiodiol)
consists of a mixture of covalently iodinated fatty acids of poppy seed oil; the iodine content is
approximately 38% by weight.  Iodine in iodized oil is taken up in adipose tissue and has a much longer
retention time in the body than iodide salts; thus, epidemiological studies of iodized oil cannot be directly
compared to those of iodide.  Nevertheless, the studies provide some useful information on oral exposures
to iodine that are tolerated during pregnancy without apparent adverse consequences to the fetal or
neonatal thyroid.  Delange (1996) reviewed epidemiological studies in which iodized oil was
administered just prior to and/or during pregnancy to prevent maternal and neonatal hypothyroidism.  A
study of an iodine-deficient population in Algeria (with a 53% prevalence of goiter and 1% prevalence of
congenital cretinism) compared thyroid status in infants born to mothers who received a placebo or a
single oral dose of 240 mg I (3.4 mg/kg), as iodized oil, either 1–3 months prior to conception, during the
first month of pregnancy, or during the third month of pregnancy.  Neonatal serum concentrations of TSH
were significantly lower in the treated groups compared to controls (treated, 4.6–4.9 mU/L; placebo,
12.4 mU/L) and serum T4 concentrations were significantly higher compared to controls (treated,
10.4–11 µg/dL; placebo, 6.7 µg/dL).  The incidence of infant hypothyroidism was 0 in 554 infants; the
incidence in the placebo control was 2 in 982 (0.2%).  A similar outcome occurred in a population from
an iodine-deficient region of Malawi (59% prevalence of goiter, 1% incidence of cretinism), where
pregnant women received either a placebo or an oral dose of 240 mg I as iodized oil (Delange 1996).  
Hyperthyroidism.
Oral exposure to excess iodide can, under certain circumstances, induce hyperthyroidism and
thyrotoxicosis.  The epidemiological and clinical literature suggest that this disorder occurs most often in
people who have a previous history of iodine deficiency, goiter, or thyroid diseases including postpartum
thyroiditis or Graves’ disease (Braverman and Roti 1996; Fradkin and Wolff 1983; Leger et al. 1984;
Paschke et al. 1994).  Cases of iodine-induced hyperthyroidism in people who were euthyroid and
without apparent thyroid disease have been reported (Rajatanavin et al. 1984; Savoie et al. 1975; Shilo
and Hirsch 1986); however, only a few have provided dose information.  In one case, a 72-year-old
female without apparent preexisting thyroid disease developed clinical hyperthyroidism after ingesting
approximately 2.8–4.2 mg iodine/day (0.05 mg/kg/day) in the form of sea-kelp tablets; her thyroid status
reverted to normal within 6 months after she stopped taking the tablets (Shilo and Hirsch 1986).  In
another case, a 15-year-old male developed hyperthyroidism and thyrotoxicosis after receiving 1,440 mg
I/day (23 mg/kg/day) as a saturated solution of potassium iodide for 4 months (Ahmed et al. 1974).  The
thyroid status reverted to normal within 6 months after the potassium iodide was discontinued.
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In a clinical study, eight healthy adult euthyroid females, who had nontoxic goiter, received oral doses of
180 mg I/day (2.6 mg/kg/day) as a saturated potassium iodide solution for 10–18 weeks (Vagenakis et al.
1972).  Four of the eight patients developed clinical hyperthyroidism and thyrotoxicosis.  Two patients
developed thyrotoxicosis within 7–10 weeks after supplementation began, which became more serious
after supplementation was discontinued.  One patient developed clinical hyperthyroidism after 10 weeks
of supplementation and then became overtly thyrotoxic after the iodide supplementation was stopped.  A
fourth patient developed subclinical hyperthyroidism during iodide treatment and became clinically
hyperthyroid with thyrotoxicosis after supplementation was stopped.
What has been referred to as an epidemic of hyperthyroidism occurred in the midwestern United States
between the years 1926 and 1928 (Kohn 1975, 1976).  Clinical records suggest that the incidence of
mortality from hyperthyroidism increased in Detroit during this period from approximately 2–4 deaths per
100,000 to approximately 11 deaths per 100,000 at the peak of the epidemic.  Although there is
considerable debate about the origins of the epidemic, the advent of aggressive supplementation of the
diet with iodide in midwestern endemic goiter areas has been implicated as a contributing factor.  More
recent and more rigorous epidemiologic designs have been applied to several populations in which dietary
iodide was supplemented as a prophylaxis for iodine deficiency and goiter (Lind et al. 1998; Stanbury et
al. 1998).  These studies confirm that iodide supplementation of iodide-deficient diets does indeed result
in a detectable increase in incidence of hyperthyroidism.
In an epidemiology study conducted in Austria, the annual incidence of hyperthyroidism was evaluated in
patients examined at nuclear medicine centers (where all thyroid examinations are conducted in Austria)
before and after an upward adjustment was made in the use of iodized table salt in 1991 (Mostbeck et al.
1998).  The mean urinary iodide concentration before the adjustment was 42–78 µg I/g creatinine and
after the adjustment was 120–140 µg I/g creatinine; these are approximately equivalent to 77–146 µg/day
(1.1–2.1 µg/kg/day) and 225–263 µg/day (3.2–3.8 µg/kg/day), respectively.  The analysis included
392,820 patients examined between 1987 and 1995 in 19 nuclear medicine centers.  A significant relative
risk of hyperthyroidism, both for Graves’ disease and intrinsic thyroid autonomy, was found when the
annual incidences of each in the postadjustment period (1991–1995) were compared to the preadjustment
period (1987–1989).  The highest relative risks were for Graves’ disease which were 2.19 (2.01–2.38,
95% confidence interval [CI]) for overt clinical disease and 2.47 (2.04–3.00) for subclinical disease.  A
regression analysis of the pre- and postadjustment incidences found a significant increasing trend for
hyperthyroidism of both types in the postadjustment period and no trend in the preadjustment period. 
When the postadjustment incidence data were stratified by time periods 1990–1992 or 1993–1995, and by
sex and age, higher relative risks were evident for intrinsic thyroid autonomy among males compared to
females and in subjects older than 50 years compared to younger than 50 years.  The incidence for
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hyperthyroidism (all forms of overt or subclinical) was 70.1 per 100,000 in the preadjustment period and
reached a peak of 108.4 per 100,000 in 1992, after the adjustment.
Data collected on the incidence of hyperthyroidism in Tasmania also show that a 2- to 4-fold increase in
hyperthyroidism cases occurred within a few months after diets were supplemented with iodide for
preventing endemic goiter from iodide deficiency (Connolly et al. 1970).  The approximate supplemental
dose was 80–200 µg/day from the addition to potassium iodide to bread.  Mean 24-hour urinary iodide
excretion rates suggested a total postsupplementation iodide intake of approximately 230 µg/day (range,
94–398, 3.3 µg/kg/day), some of which may have came from sources other than supplemented bread
(Connolly 1971a, 1971b).  The highest incidence of hyperthyroidism after the iodine supplementation
began occurred in people over 50 years of age (Stewart 1975; Stewart and Vidor 1976).
A large multinational epidemiological study was conducted in Africa to evaluate the effectiveness and
possible adverse consequences of the introduction of iodized salt into diets of populations residing in
iodine-deficient and endemic goiter regions of Africa (DeLange et al. 1999).  In each study area, urine
and table salt were collected from a group of 100–400 randomly-selected children, ages 6–14 years. 
Health care facilities were surveyed for information on thyroid disease in each area.  In Zimbabwe, the
incidence of hyperthyroidism increased by a factor of 2.6 within 18 months after the widespread
introduction of iodized salt into the diet (from 2.8 in 100,000 to 7.4 in 100,000).  Females accounted for
90% of the cases, with the highest incidence in the age group 60–69 years.  The most common disorders
were toxic nodular goiter (58%) and Graves’ disease (27%) (Todd et al. 1995).  Urinary iodide
concentrations in children increased by a factor of 5–10 over this time period.  Urine samples were
reported as “casual samples” and, thus, there is a large uncertainty in translating the concentrations into
intakes.  Median urine iodide concentrations ranged from 290 to 560 µg/L.  Reported estimates of iodide
intake from salt and seafood were 500 µg/day (7.1 µg/kg/day) and 15–100 µg/day (0.7 µg/kg/day),
respectively.  Increased numbers of cases of thyrotoxicosis along with an increase in urinary iodide levels
(from 16 to 240 µg/L) occurred after iodized salt was introduced into the diet of an iodine-deficient
population in the Kivu region of Zaire (Bourdoux et al. 1996).  
An epidemiological study in Switzerland examined the incidence of hyperthyroidism before and after the
iodine content of salt was increased from 7.5 to 15 mg/kg (Baltisberger et al. 1995; Bürgi et al. 1998). 
The study population included 109,000 people.  The mean urinary iodide concentration was 90 µg I/g
creatinine before the supplementation and 150 µg I/g creatinine after the supplementation.  This is
equivalent to an increase in intake from approximately 170 to 280 µg I/day (4 µg/kg/day), assuming a
body weight of 70 kg.  During the first year after supplementation began, the combined annual incidence
of hyperthyroidism diagnosed as either Graves’ disease or toxic nodular goiter increased by 27% (from
62.3/100,000 to approximately 80/100,000).  Subsequent to this increase, the incidence of
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hyperthyroidism steadily declined to 44% of the presupplementation rates, with most of the decrease
resulting from a decline in incidence of toxic nodular goiter.
In an experimental study, adults with goiter who lived in an iodine-deficient region of Sudan received a
single oral dose of 200, 400, or 800 mg iodine (3–11 mg/kg/day) as iodine oil (37–41 subjects per dose
group) and their thyroid status was evaluated for a period of 12 months (Elnagar et al. 1995). 
Approximately half of the subjects were clinically hypothyroid with serum T4 concentrations <50 nmol/L
and TSH concentrations >4 mU/L.  One week after the iodine oil was administered, there was a dose-
related increase in the incidence of serum TSH concentrations; 1 in 41 (2.5%) in the low-dose group, 3 in
37 (8.1%) in the middle-dose group, and 10 in 39 (25.6%) in the high-dose group, although the number of
subjects exceeding 4 mU/L was not dose-related.  One subject in the low-dose group and three subjects in
the high-dose group became hyperthyroid during the observation period.  One of the high-dose subjects
remained hyperthyroid 1 year after the dose of iodine oil.
Effects of Radioiodine on the Thyroid Gland.
Extensive clinical use of radioiodine, principally 123I and 131I, for diagnostic purposes and for treatment of
thyroxicosis has provided a wealth of information on the effects of relatively high acute exposures on
thyroid gland function.  Radioiodine is cytotoxic to the thyroid gland and produces hypothyroidism at
absorbed effective doses to the thyroid gland exceeding 2,500 rad (25 Gy).  Thyroid gland doses of
approximately 30,000 rad (300 Gy) can completely ablate the thyroid gland.  This dose is achieved with
an acute exposure of approximately 25–250 mCi (0.9–9 GBq) (Maxon and Saenger 2000).  Doses this
high are administered for the treatment of thyroid cancer.  Smaller doses are generally used in the
treatment of  hyperthyroidism (10–20 mCi, 370–740 MBq; 5,000–12,000 rad, 50–120 Gy).  Diagnostic
uses of radioiodine involve much smaller exposures and doses, typically 0.1–0.4 mCi (4–15 MBq) of 123I
or 0.005–0.01 mCi 131I (0.2–0.4 MBq).  These exposures correspond to approximate thyroid radiation
doses of 1–5 rad (1–5 cGy) and 6–13 rad (6–13 cGy) for 123I and 131I, respectively (McDougall and
Cavalieri 2000).  
Several epidemiological studies have examined the relationship between oral exposure to 131I and thyroid
gland nodularity.  Thyroid nodules are irregular growths of the thyroid gland tissue that can be benign or
cancerous.  Nodules can be detected by physical palpation of the gland or by various imaging techniques. 
Palpation detects only larger (>1 cm) nodules, whereas ultrasound can detect nodules that are not palpable
(e.g., 10 mm or less).  The complete description of  a study by Kerber et al. (1993) is provided in
Section 3.2.2.7, as it primarily relates to thyroid neoplasms.  The study reported no difference in
prevalence of thyroid nodularity detected by physical examination in a cohort living near the NTS when
compared to a nonexposed cohort living remote from the NTS.  However, when the thyroid radiation dose
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from 131I was calculated for each subject in each location, there was a correlation between radiation dose
and formation of neoplasia of the thyroid, but not to nonneoplastic nodules (Kerber et al. 1993).  The Hall
et al. (1996a) study evaluated 1,005 women for thyroid nodularity who had been exposed to diagnostic
levels of 131I during the period 1952–1977 and whose diagnosis for thyroid abnormalities were negative. 
The subjects were evaluated for palpable thyroid nodules during the period 1991–1992.  A comparison
group consisted of 248 women who attended a mammography screening clinic with no prior history of
exposure to 131I or thyroid disease.  The average total administered 131I activity was 0.95 MBq (26 µCi). 
Absorbed radiation doses to the thyroid gland were estimated based on the administered activity and
dosimetry tables from International Commission on Radiological Protection (ICRP 1988).  The average
dose was 0.54 Gy (54 rad) (10th–90th percentiles, 0.02–1.45 Gy; 2–145 rad).  Thyroid nodules were
detected in 107 of 1,005 (10.6%) exposed women and 29 of 248 (11.7%) nonexposed women.  The
relative risk (RR, based on odds ratios [ORs]) for thyroid nodularity for women exposed to 131I was
0.9 (95% CI, 0.6–1.4) and was not statistically significant.  A linear quadratic excess relative risk model
revealed a statistically significant dose trend for thyroid nodularity (excess RR, 0.9/Gy).  Hall et al.
(1996a) suggest as an explanation for the lack of a significant RR for thyroid nodularity that the
nonexposed control group was self-selected (i.e., the subjects voluntarily sought mammographic
screening) and, therefore, may not have been an appropriate control group for comparison to the group of
women who received radioiodine. 
Clinical cases have been reported in which congenital hypothyroidism occurred after maternal exposures
to high doses of 131I for treatment of thyroid gland tumors (Green et al. 1971; Hamill et al. 1961; Jafek et
al. 1974; Russell et al. 1957).  However, the complex clinical picture and pharmacotherapy of the mothers
for their thyroid condition during pregnancy makes direct associations between the radioiodine exposure
and the clinical outcomes of the newborns highly uncertain.  Exposures in these case ranged from 11 to
77 mCi (0.4–2.8 GBq).  Effects on the fetal and newborn thyroid would be expected if mothers received
ablative doses of 131I during pregnancy after approximately 12 weeks of gestation, when the fetal thyroid
begins to take up iodide.  A study of 73 infants and children born to 70 patients who received 131I for
ablative treatment of thyroid cancer 2–10 years (mean, 5.3 years) prior to pregnancy found no thyroid
gland disorders (Casara et al. 1993).  The maternal 131I exposures ranged from 1.85 to 16.55 GBq
(50–400 mCi); the mean exposure was 4.40 GBq (120 mCi).  A similar finding was reported in a study of
37 patients (47 infants) who received 131I,  1–60 months prior to conception (mean, 16.5 months);
exposures ranged from 1.1 to 13.1 GBq (30–350 mCi), with a mean exposure of 3.67 GBq (100 mCi)
(Lin et al. 1998). 
Marshall Islands.  Shortly after the BRAVO test, residents on three of the Marshall Islands were
identified as having been exposed to external gamma radiation during the 2 days prior to their evacuation
(Conard 1984): 64 residents of Rongelap (1.90 Gy, 190 rad), 18 residents of Ailingnae (1.10 Gy, 110 rad)
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and 150 residents of Utirik  (0.11 Gy, 11 rad).  Estimated total absorbed doses to the thyroid gland
(external and internal) were 3.3–20 Gy (300–2,000 rad) on Rongelap (highest doses in children),
1.3–4.5 Gy (130–450 rad) on Ailingnae, and 0.3–0.95 Gy (30–95 rad) on Utirik (Conard 1984).  As part
of a medical evaluation program, these individuals, the so-called BRAVO cohort, were evaluated
periodically for health consequences of their exposures.  Evidence of acute radiation sickness was
prevalent early after exposures, including nausea and vomiting, hematological suppression, and dermal
radiation burns.  Cases of thyroid gland disorders began to be detected in the exposed population in 1964,
10 years after the exposure, particularly in exposed children; these included cases of apparent growth
retardation, myxedema, and thyroid gland neoplasms (Conard et al. 1970).  In 1981, when the children
from Rongelap island were screened, it was discovered that 83% of the children who were <1 year of age
at the time of the BRAVO test were found to have evidence of hypothyroidism (i.e., a serum
concentration of TSH >5mU/L).  This group of children had received an estimated thyroid dose
exceeding 1,500 rad (15 Gy).  Prevalence and thyroid radiation dose decreased with exposure age: 25%
for ages 2–10 years (800–1,500 rad, 8–15 Gy) and 9% for ages $10 years (335–800 rad, 3.35–8.00 Gy). 
Prevalences in the exposed groups from Ailignae were 8% for exposure ages >10 years (135–190 rad,
1.35–1.90 Gy) and 1% on Utirik (30–60 rad, 0.3–0.6 Gy).  These prevalences are consistent with the
apparent dose-response relationship for the Rongelap group.  In an unexposed group (Rongelap residents
who were not on the island at the time of the BRAVO test), the prevalence was 0.3–0.4% (Conard 1984). 
At about the same time, in 1964, cases of palpable thyroid gland nodules began to be identified in health
screening programs (Conard 1984).  The prevalence of thyroid nodularity had an age/dose profile similar
to that of thyroid hypofunction (i.e., elevated serum TSH).  In 1981, thyroid nodules were found in
67–81% Rongelap residents exposed before the age of 10 years and in 13% of those exposed after
10 years.  Prevalence in the Ailingnae populations was 29% in the population of children exposed before
age 10 years and 33% in the population exposed after age 10 years.  In the Utirik population, the
prevalence of thyroid nodules was 8% in the population of children exposed before age 10 years and 12%
in the population exposed after age 10 years.  The prevalence of thyroid gland carcinoma, mainly
papillary carcinomas, also appeared to be elevated in the exposed Rongelap population (6%) compared to
the unexposed group (1%).  In 1994, thyroid ultrasound examinations were performed on 117 of the
original exposure group, 47 from Rongelap, and 70 for Utirik, and 47 residents of Rongelap who were on
Majuro at the time of the BRAVO test, approximately 480 miles south of the test site on Bikini Atoll
(Howard et al. 1997).  Over the period 1965–1990, the case rate for thyroid nodules was approximately
3–8% per year in the exposed groups and approximately 3 times greater in females than in males. 
However, the 1994 ultrasound evaluations found relatively high, but not significantly different
prevalences of thyroid nodules in exposed (12–33%) and nonexposed (25%) groups or between males and
females (Howard et al. 1997).  The differences in the outcomes in 1994 and earlier may reflect the age
differences at the time of examination, or possibly that palpation detects only larger (>1 cm) nodules,
whereas ultrasound can detect nodules that are not palpable (e.g., 10 mm or less).  Ultrasound is more
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likely to detect clinically insignificant nodules that are actually normal variants of thyroid tissue.  Another
possible contributor to the differences between outcomes is that earlier studies may have been biased by
greater screening/surveillance intensity given to the high-dose groups, whereas the Howard et al. (1997)
study was a more systematic comparison across the dose range and used a more objective ultrasound
criteria for diagnosing nodularity.  Thyroid nodule incidence is highly susceptible to surveillance effects
and these studies were not adequately controlled for such effects.  A possibly related observation is an
apparent high prevalence of iodine deficiency in the Marshall Islands, which may have contributed to a
high background prevalence of nodular goiter (Hermus and Huysmans 2000; Takahashi et al. 1999). 
A retrospective cohort study reexamined the prevalence of thyroid gland nodularity reported in the 1980s
among residents of the Marshall Islands who were potentially exposed to 131I from atmospheric fallout
from the BRAVO test in 1954 (Hamilton et al. 1987).  This study included residents on islands located
112–589 miles from the test site.  The cohort consisted of 7,266 people known to have been residents on
the islands (or in utero) in 1954 at the time of the BRAVO test.  Each subject was examined for palpable
thyroid nodules during the period 1983–1985.  The examiners were blind to the estimated thyroid
radiation dose received by each subject.  Radiation doses to the thyroid gland were estimated to have been
21 Gy (2,100 rad) for residents of Rongelap (120 miles from the test site) and 2.80 Gy (280 rad) for
residents of Utirik (321 miles).  Residents of 12 other islands, who historically were thought not to have
received exposures to radioiodine based on location (distance and/or position with respect to prevailing
winds), were included in the study.  The age-adjusted prevalence of thyroid nodularity was 37% among
residents of Rongelap Island and 10.3% for Utrik Island.  Prevalence among residents of the other
12 islands ranged from 0.8 to 10.2% and there were no statistically significant differences in prevalence
among these 12 less-exposed islands.  A prevalence of 2.45% was assumed for nonexposed populations,
based on observed prevalence in the two most southern islands (Ebon and Mili), for the purpose of
calculating ORs.  A logistic regression model yielded a statistically significant effect of sex on OR for
thyroid nodularity, with an OR 3.7 times higher in females.  The model also yielded a significant trend for
decreasing prevalence of thyroid nodularity with both distance and direction from the test site, with
prevalence decreasing 3-fold per 100 miles (OR, 0.3 per 100 miles) from the site and 2-fold for every
10 degrees east or west of the site (OR, 0.59 per 10 degrees).  The risk estimate for thyroid nodularity
among the Marshall Islanders was 1,100 excess cases/Gy/year of exposure per 1 million people
(0.0011/person-Gy/year, 0.000011/person-rad/year). 
A large-scale screening program for thyroid disease was conducted in the Marshall Islands during the
period 1993–1997 (Fujimori et al. 1996; Takahashi et al. 1997, 1999).  Results of screening of
1,322 residents of Ebeye (in the Kwajalein Atoll, approximately 190 miles from Bikini Atoll) are reported
in Takahashi et al. (1997).  Evaluations included neck palpation, thyroid ultrasound, and fine needle
aspiration biopsy if warranted (results on diagnoses relevant to thyroid cancer are discussed in
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Section 3.2.1.7).  The examiners were blind to the estimated thyroid radiation dose received by each
subject.  Among 815 subjects born before 1954, the date of the BRAVO test, 266 (32.6%) were diagnosed
with thyroid nodules, 132 (16.2%) were palpable.  The prevalence of thyroid nodules (palpable and
detected by ultrasound) was higher in females than males; however, as was observed in the Hamilton et
al. (1987) study, the difference was significant only for palpable nodules (palpable: females 17.7%, males
9.3%; total nodules: females 35.9%, males 21.0%).  In either case, nodule prevalence was 2–3 times
higher among groups born during the bomb testing period (before 1958) than after the testing ended.  A
logistic regression model applied to the nodule prevalence data revealed significant effects of sex, age,
and distance from Bikini Atoll on nodule prevalence (Takahashi et al. 1997).  A more recent report on the
screening program described the results of thyroid palpation and ultrasound (7,721 subjects), tests of
thyroid hormone (1,050 subjects), and iodine status (urinary iodide, 309 subjects) (Takahashi et al. 1999). 
The study group included 5,263 residents of Majuro (approximately 480 miles from Bikini Atoll),
1,610 residents from Ebeye Island (192 miles) and 348 residents from Mejit (398 miles).  Of the
7,221 subjects examined in the study (1993–1997), 4,766 (66%) were of an age to have potential
exposures to radioactive fallout from bomb tests.  The prevalence of thyroid nodules (palpable and
detected by ultrasound) was approximately 3 times higher in females than males; among females, the
prevalence was highest (13%, 407 of 3,151) among women born before 1959, the date of the last bomb
tests.  Thyroid hormone tests (T4, T3, and TSH) revealed no evidence of an unusual prevalence of thyroid
gland dysfunction.  Measurements of urinary iodide levels suggested mild to severe iodine deficiency in
the population; approximately 21% of the adult subjects had urinary iodides in the range of 22–45 nmol
I/mmol creatinine (25–50 µg I/g creatinine).  This corresponds to a urinary excretion rate and iodine
intake rate of approximately 40–80 µg I/day (based on an assumed body weight of 60 kg).  Thyroid
volumes were compared in subjects who had nodules and were iodine deficient with subjects who were
iodine sufficient and who did not have nodules.  Although there was no apparent indication of excessive
prevalence of thyroid enlargement in either the iodine-deficient or -sufficient groups, subjects who had
the largest thyroid volumes tended to fall in the deficient-nodular group.  Thyroid nodularity occurs in
populations that have experienced prolonged iodine deficiency, although it is usually associated with
goiter (Hermus and Huysmans 2000).  The observation of a high prevalence of iodine deficiency in the
Marshall Island population may be an important confounding variable in many of the epidemiology
studies that have attempted to explore relationships between thyroid nodularity and radiation dose in the
Marshall Island populations.
Chernobyl Accident.  Subsequent to the release of radioactive materials from the Chernobyl power plant
in 1986, an increased prevalence of thyroid nodules in children of the Belarus region was reported
(Astakhova et al. 1996).  An analysis of the results of ultrasound screening of 20,785 people in Belarus
conducted during the period 1990–1995 revealed a prevalence of thyroid gland nodules that ranged from
4 to 22 per 1,000.  Prevalence was highest (16–22 per 1,000) among residents from districts in which
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thyroid radiation doses were estimated to have been above 1 Gy (1.3–1.6 Gy, 130–160 rad).  Verified
diagnoses from patients who were referred for further examination revealed a prevalence of thyroid
cancer of 2.5–6.2 per 1,000, or approximately 13–50% of nodule cases, among cases from districts where
thyroid radiation doses were estimated to have been above 1 Gy (1.3–1.6 Gy, 130–160 rad) (see
Section 3.2.1.7 for further discussion of thyroid cancer related to the Chernobyl release).  Nodular goiter
was diagnosed in 5–22% of the thyroid nodule cases, and 7–64% of the nodule cases were diagnosed as
benign cysts.  In districts in which thyroid doses were estimated to have been <0.1 Gy, no thyroid cancers
were diagnosed in the nodule cases; approximately 75–100% were diagnosed as cysts.  Dietary iodine
status was assessed from measurements of urinary iodine (Astakhova et al. 1996).  Urinary iodide levels
varied across regions in Belarus.  Approximately 30–80% (mean 61%) of children and adolescents had
overnight urinary iodine concentrations <100 µg/L, 10–50% (mean 26%) had concentrations <50 µg/L,
and 0–25% (mean 9%) had concentrations <20 µg/L.  These results suggest a substantial prevalence (on
average 26 and 50% in some districts) of dietary iodine intakes below 50–70 µg/day (assuming a daily
urine output of 1–1.4 L in children and adolescents).  The results of other thyroid screening programs
(e.g., the Chernobyl Sasakawa Health and Medical Cooperation Project) also suggest a high prevalence of
goiter among people born in Belarus between the years 1976 and 1986, which would be consistent with a
high prevalence of iodine deficiency in the population (UNSCEAR 2000).  Therefore, iodine deficiency
may have contributed to the observed thyroid nodularity and also a confounding variable in susceptibility
to thyroid cancer (Gembicki et al. 1997).
Hanford Nuclear Site.  The CDC (1999) has conducted a follow-up prevalence study of thyroid disease in
populations who resided near the Hanford Nuclear Site in southeastern Washington during the period
1944–1957.  As noted previously, at the time this profile was developed, a draft report of this study was
available from the Fred Hutchinson Cancer Research Center web site (http://www.fhcrc.org/science/
phs/htds/); however, a final published report was not available.  The study included 3,441 subjects who
were born during the period 1940–1946 in counties surrounding the Hanford Nuclear Site.  Thyroid
disease was assessed from a clinical evaluation of each subject, which included assessments of ultrasound
or palpable thyroid nodules, thyroid hormone status, and thyroid autoimmunity and parathyroid hormone
status.  Historical information on thyroid disease and information on radiation exposures were obtained
by interviews and, when possible, review of medical records of participants.  Thyroid radiation doses
were estimated using a dosimetry model developed in the Hanford Environmental Dose Reconstruction
Project.  Information on residence history and relevant food consumption patterns (e.g., milk
consumption, breast feeding, consumption of locally harvested produce) for each study participant was
obtained by interview.  The estimated mean thyroid radiation dose, based in 3,190 participants, was
182 mGy (±227, SD) (18.2±22.7 rad) and the range was 0.0008–2,842 mGy (0.00008–284 rad).  An
indication that the statistical power of the study was appreciably limited by the low distribution of thyroid
doses is the fact that only 29 (0.8%) of the study population had estimated thyroid doses >1 Gy (100 rad)
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and only 8 (0.3%) had doses >2 Gy.  Doses varied geographically, with the highest doses received by
people who lived near and downwind from the site.  Health outcomes investigated included thyroid
carcinoma, thyroid nodules, hypothyroidism, and hyperthyroidism (serum TSH levels), including Graves’
disease, thyroid autoimmunity (serum antimicrosomal antibodies and antithyroid peroxidase), goiter, and
hyperparathyroidism.  Dose-response relationships were assessed using a linear regression model with
adjustments for the following confounding and effect modifying variables: sex, age of first exposure, age
of evaluation, ethnicity, smoking, and potential exposures from Nevada Test Site releases.  Estimated
dose coefficients were: thyroid carcinoma, not reported (linear model did not converge on maximum
likelihood estimate); thyroid nodules, -0.014±0.011 per Gy (p=0.85); hypothyroidism, 0.003±0.02 per Gy
(p=0.4); hyperthyroidism -0.008±0.015 per Gy (p=0.69); thyroid autoimmunity, -0.007±0.028 per Gy
(p=0.6); goiter, not reported (linear model did not converge on maximum likelihood estimate);
hyperparathyroidism, 0.000±0.006 per Gy (p=0.5).  Alternatives to the linear model including linear
quadratic and logistic models were also explored.  Incidence of thyroid disease was found to be unrelated
to thyroid radioiodine dose for all outcomes evaluated. 
Effects of Radioiodine on the Parathyroid Gland
Cases of hypo- and hyperparathyroidism have been reported in patients who received 131I treatments for
ablative therapy of thyroid cancer or hyperthyroidism.  The parathyroid gland is in close proximity to the
thyroid gland.  Although in most people, the parathyroid and thyroid glands are separated by more than
1 cm, in approximately 20% of people, the parathyroid gland is located within the thyroid gland capsule
(Glazebrook 1987).  The latter configuration would result in irradiation of the parathyroid gland with
β emission from 131I concentrated in the thyroid gland; β emission from 131I has a tissue penetration
distance of approximately 0.5–2 mm (Esselstyn et al. 1982).  Cases of parathyroid dysfunction have been
reported after exposures to 131I ranging from 4 to 30 mCi (0.15–1.1 GBq) (Better et al. 1969; Burch and
Posillico 1983; Eipe et al. 1968; Esselstyn et al. 1982; Fjälling et al. 1983; Freeman et al. 1969;
Glazebrook 1987; Jialal et al. 1980; Rosen et al. 1984).  A clinical follow-up study evaluated serum
calcium status of 125 patients (106 females, 19 males) who received 131I for treatment of hyperthyroidism
during the period 1951–1960.  The follow-up assessments occurred 16–26 years (mean, 21 years) after
exposure to 131I (Fälling et al. 1983).  A group of age- and sex-matched healthy subjects who had no
history of irradiation to the head or neck region served as a control group.  Exposures to 131I ranged from
75 to 1,400 MBq (2–38 mCi).  These corresponded to radiation doses to the parathyroid of 2–5 Gy in
subjects whose parathyroid gland was 0.2 cm from the surface of the thyroid gland and 3–7.5 Gy in
subjects whose parathyroid gland was at the surface of the thyroid gland.  Two patients and two control
subjects were found to have hypercalcemia and verified hyperparathyroidism (the exact basis for the
verification was not reported).  The 131I exposures of the two patients were 140 and 450 MBq (3.8 and
12 mCi), respectively.
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Hanford Nuclear Site.  Hyperparathyroidism was assessed as part of the CDC (1999) study of health
outcomes related to radioiodine releases from the Hanford Nuclear Site.  The study included
3,441 subjects who were born during the period 1940–1946 in counties surrounding the site.  Parathyroid
hormone status was assessed from measurements of serum parathyroid hormone.  Historical information
on parathyroid disease was obtained by interviews and, when possible, review of medical records of
participants.  The estimated mean thyroid radiation dose, based on 3,190 participants, was 182 mGy
(±227, SD) (18.2±22.7 rad) and the range was 0.0008–2,842 mGy (0.00008–284 rad).  Dose-response
relationships were assessed using a linear regression model with adjustments for the following
confounding and effect modifying variables: sex, age of first exposure, age of evaluation, ethnicity,
smoking, and potential exposures from Nevada Test Site releases.  Alternatives to the linear model
including linear quadratic and logistic models were also explored.  Incidence of hyperparathyroidism was
found to be unrelated to thyroid radioiodine dose.
3.2.2.3 Immunological and Lymphoreticular Effects
Immunological and Lymphoreticular Effects of Stable Iodine
Information on immunological effects of oral exposure to iodine in humans relates to thyroid gland
autoimmunity or immune reactions (e.g., ioderma).  The highest NOAEL values and all reliable LOAEL
values in each duration category for immunological and lymphoreticular effects from exposures by the
oral route are presented in Table 3-1 and plotted in Figure 3-1.
Excess iodide intake may be contributing factor in the development of autoimmune thyroiditis in people
who are susceptible (Brown and Bagchi 1992; Foley 1992; Rose et al. 1997; Safran et al. 1987). 
Autoimmune thyroiditis is an inflammation of the thyroid gland that can lead to fibrosis of the gland,
follicular degeneration, follicular hyperplasia, and hypothyroidism (Weetman 2000).  IgG autoantibodies
to thyroglobulin and thyroid peroxidase are consistent features of the disorder.  Iodine appears to play an
important role in autoimmune response as human lymphocytes recognize and proliferate in response to
iodinated human thyroglobulin, but not iodine-free thyroglobulin (Rose et al. 1997).
Evidence for iodide inducing autoimmune thyroiditis in humans is incomplete.  Several studies have been
conducted of people who reside in endemic goiter areas and who received iodide supplementation.  In one
study, otherwise healthy adults who had goiter, but no evidence of clinical hypothyroidism or
hyperthyroidism or antithyroid antibodies, received either an oral placebo (16 females, 15 males) or
200 mg I/day (3 µg/kg/day total intake) (16 females, 15 males) as potassium iodide for 12 months
(Kahaly et al. 1997).  Three subjects in the treatment group (9.7%, two females and one male) developed
elevated levels of thyroglobulin and thyroid microsomal antibodies compared to none in the control
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group.  Two of these subjects developed hypothyroidism and one subject developed hyperthyroidism; all
three subjects reverted to normal thyroid hormone status when the iodide supplementation was
discontinued.  In a similar study, 31 adult euthyroid patients from an endemic goiter region who had
goiter received either 500 µg/day potassium iodide (382 mg I/day, 5.1 mg I /kg/day based on reported
median body weight of 75 kg) for 6 months, and 31 patients received 0.125 mg T4/day (Kahaly et al.
1998).  Based on reported measurements of 24-hour urine iodide excretion, the preexisting iodide intake
was approximately 40 µg/day (range, 13–77, 0.6 µg/kg/day); thus, the total intake during treatment was
approximately 420 mg I/day (6 µg/kg/day).  After 6 months of iodide supplementation, the mean 24-hour
urinary iodide excretion rate was 415 µg/day, which is consistent with the estimate of a total iodide intake
of approximately 420 µg/day.  Six of the patients who received iodide (19%) developed high titres of
thyroglobulin and thyroid microsomal antibodies, compared to none in the T4 group.  Four of the high
antibody patients became hypothyroid and two patients became hyperthyroid.  The thyroid hormone
status reverted to normal and antibody titres decreased during a 6-month period following the treatment in
which the patients received a placebo.  A comparison of autoantibody titres of 27 adult patients who were
diagnosed with iodide-induced goiter and/or hypothyroidism with 55 healthy adults revealed a
significantly greater incidence of antibodies to thyroglobulin in the goiter patients (13 of 27, 48%) than in
the healthy controls (9 of 55, 16%) (Hall et al. 1966).  Iodide doses in the goiter group varied from 24 to
3,728 mg I/day (0.3–53 mg/kg/day).  Koutras (1996) reported that 30% of a group of goiter patients
developed thyroid autoimmunity several weeks after receiving 150 or 300 µg/day potassium iodide
(115 or 130 µg I/day, 1.6–1.9 µg/kg/day); further details of the study were not provided. 
Other studies have not found increases in autoimmunity associated with iodine supplementation.  For
example, thyroid status was compared in groups of children, ages 7–15 years, who resided in two areas of
China where drinking water iodide concentrations were either 462 µg/L (n=120) or 54 µg/L (n=51)
(Boyages et al. 1989; Li et al. 1987).  Although the subjects were all euthyroid with normal values for
serum thyroid hormones and TSH concentrations, TSH concentrations were significantly higher in the
high iodine group.  The high iodide group had a 65% prevalence of goiter and a 15% prevalence of
Grade 2 goiter compared to 15% for goiter and 0% for Grade 2 goiter in the low iodine group.  There
were no differences in the serum titres of either thyroglobulin or thyroid peroxidase antibodies between
the high and low iodine groups.  Urinary iodine was 1,236 µg I/g creatinine in the high iodine group and
428 µg I/g creatinine in the low iodine group.  Assuming a body weight of 40 kg and lean body mass of
85% of body weight, the above urinary iodine/creatinine ratios are approximately equivalent to iodine
excretion rates, or steady state ingestion rates of 1,150 µg/day (29 µg/kg/day) and 400 µg/day
(10 µg/kg/day) in the high and low iodide groups, respectively. 
The effects of iodide on the development of autoimmune thyroiditis has been examined in animal models. 
In general, iodine does not induce autoimmune thyroiditis in outbred strains of rats; however, a
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susceptible inbred strain, the BB/Wor rat, has a high incidence of spontaneous autoimmune thyroiditis
and does respond to iodide with an increased incidence of thyroid autoimmunity (Allen et al. 1986).  This
can be detected histologically as a lymphocytic infiltration of the gland (lymphocytic thyroiditis)
accompanied by increased serum titres of antibodies to thyroglobulin, and increased serum TSH
concentrations, indicating thyroid gland suppression (Allen and Braverman 1990).  Weanling BB/Wor
rats that were exposed to 0.05% iodide in drinking water for 8 weeks (approximately 85 mg/kg/day) had a
significantly higher incidence of lymphocytic thyroiditis (27 of 35, 77%) compared to a control group
(11 of 36, 30%) that received tap water.  Similarly exposed outbred strains did not have an increase in
lymphocytic thyroiditis.  The spontaneous incidence of lymphocytic thyroiditis in the Buffalo strain rat (a
Sprague-Dawley strain) is increased after neonatal thymectomy (Noble et al. 1976).  In thymectomized
Buffalo rats, 12 weeks of exposure to 0.05% iodide in drinking water (approximately 70 mg/kg/day)
resulted in a significant increase in the incidence of lymphocytic thyroiditis (73%) compared to a control
group that received tap water (31%) (Allen and Braverman 1990).  The treatment group also had
significantly higher serum TSH concentrations and significantly higher serum titres of antithyroglobulin
antibody.  In both of the above two studies, intake from food (Purina chow) was approximately
0.05 mg/kg/day. 
Oral exposure to excess iodide can produce allergic reactions in sensitive subjects.  The reactions include
urticaria, acneiform skin lesions, and fevers (Kurtz and Aber 1982; Rosenberg et al. 1972; Stone 1985). 
There were also cases of more serious reactions involving angioedema (localized edema), vasculitis,
peritonitis and pneumonitis, and complement activation (Curd et al. 1979; Eeckhout et al. 1987).  Both
humoral and cell-mediated immune response are thought to be involved (Curd et al. 1979; Rosenberg et
al. 1972; Stone 1985).  In general, reactions to iodide have occurred in association with repeated doses
exceeding 300 mg I/day. 
Oral exposure to excess iodide can produce skin lesions, referred to as ioderma, which are thought be a
form of cell-mediated hypersensitivity (Rosenberg et al. 1972; Stone 1985).  The dermal lesions appear to
be unrelated to thyroid gland function.  Characteristic symptoms include acneiform pustules, which can
coalesce to form vegetative nodular lesions on the face, extremities, trunk, and mucous membranes.  The
lesions regress and heal when the excess iodide intake is discontinued.  The clinical literature includes
cases of ioderma that occurred subsequent to oral doses of iodide 300–1,000 mg I/day (5–14 mg/kg/day)
(Baumgartner 1976; Khan et al. 1973; Kincaid et al. 1981; Kint and Van Herpe 1977; Peña-Penabad et al.
1993; Rosenberg et al. 1972; Shelly 1967; Soria et al. 1990).  However, in many of these cases,
preexisting disease and related drug therapy may have contributed to the reaction to the iodine; thus, the
dose-response relationship for ioderma in healthy people remains highly uncertain.  A typical regimen in
the case literature was potassium iodide co-administered with theophylline and phenobarbitol for
treatment of obstructive lung disease.  In at least two cases, transient dermal lesions typical of ioderma
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were elicited by a single oral dose of 360 or 500 mg iodide (5.1 or 7.1 mg/kg/day), as potassium iodide
and similar lesions were induced in these same patients by oral doses of aspirin, suggesting a possible
cross sensitivity (Shelly 1967).  In a more typical case, an adult male developed vegetative dermal lesions
of the face, scalp, and trunk 5 days after receiving approximately 300 mg I/day (5.1 mg/kg/day) as
potassium iodide (390 mg/day), along with penicillin for an acute respiratory tract infection (Soria et al.
1990).  The lesions healed within 4 weeks after the potassium iodide was discontinued.  Another adult
male developed a vegetative dermal lesion of the neck and trunk after receiving approximately 600 mg
I/day (10 mg/kg/day) as potassium iodide (720 mg/day) along with theophylline for obstructive
pulmonary disease for 8 months (Soria et al. 1990).  The lesions regressed within 3 weeks after the
potassium iodide was discontinued and returned when an oral provocation dose of potassium iodide was
administered.  Another case of ioderma occurred in an adult female who received oral doses of
approximately 740 mg I/day (11 mg/kg/day) as potassium iodide (970 mg/day) for 6 months, as part of a
treatment for obstructive lung disease (Kincaid et al. 1981).  Other drugs included in the patient’s
treatment were ephedrine, theophylline, and phenobarbitol.  The lesions occurred on the face and
conjunctiva of the eye, and healed several weeks after the potassium iodide was discontinued.  A similar
case occurred in an adult woman, similarly treated for 1 year with 990 mg I/day (14 mg/kg/day) as
potassium iodide (1,300 mg/day) for asthma (along with ephedrine, theophylline, and phenobarbitol)
(Rosenberg et al. 1972).  The vegetative lesions occurred on her face and arms and healed within 3 weeks
after the potassium iodide was discontinued.  In a more complex case, an adult female who was being
treated for a variety of disorders, including polyarteritis nodosa, for which she was receiving
cyclophosphamide and prednisone, and pneumonia, for which she was receiving an expectorant
containing potassium iodide, developed vegetating dermal lesions on her face (Soria et al. 1990).  The
lesions healed within 1 month after the iodide expectorant was discontinued.  She received vidarabine
during this period, as the dermal lesions were, at that time, suspected of being a herpes simplex infection. 
One week after receiving approximately 400 mg I/day (6 mg/kg/day) as potassium iodide (520 mg/day),
similar lesions of the skin and oral mucosa developed.  The lesions healed within 3 weeks after the
potassium iodide was discontinued. 
Oral exposures to iodide can induce fevers that are thought to have an immunological basis.  The fevers
do not appear to be related to thyroid function.  Reported clinical cases have almost always involved a
preexisting disease, usually pneumonia or obstructive lung disease in which potassium iodide was
administered along with other drugs, including antibiotics, barbiturates, and methylxanthines; thus, the
dose-response relationship for healthy people is highly uncertain.  In one case, recurrent fevers occurred
in an adult male who was receiving oral doses of approximately 1,080 mg I/day (15 mg/kg/day) as a
potassium iodide solution (assumed, but not specified in the case report, to be a saturated solution) for
approximately 15 years (Kurtz and Aber 1982).  The fevers stopped within 2 weeks after the potassium
iodide was discontinued.  In another case, an adult male developed a fever 8 days after the start of a daily
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regimen of approximately 1,440 mg I/day as a saturated solution of potassium iodide for treatment of a
respiratory illness; the fever stopped within 3 days after the potassium iodide was discontinued (Horn and
Kabins 1972).  In another case, an adult female developed a fever after a dosage of approximately
1,620 mg I/day (23 mg/kg/day) as a saturated potassium iodide solution along with ampicillin to treat
pneumonia (Horn and Kabins 1972).  The fever stopped within 36 hours after the potassium iodide was
discontinued; at the same time, a regimen of diazepam, secobarbitol, and glycerol guaiacolate was
administered.  The fever returned when a challenge dose of potassium iodide was administered.  A fourth
case involved an adult female diabetic patient who received 1,080 mg I/day (15 mg/kg/day) as a saturated
potassium iodide solution along with antibiotics, cortisone, and aminophylline for pneumonia (Horn and
Kabins 1972).  Four days after the potassium iodide treatments began, the patient developed a fever,
which stopped when the potassium iodide was discontinued.
Cases of autoimmune hyperthyroidism after exposures to 131I for ablative treatment of hyperthyroidism
have been reported.  In three cases, thyrotoxicosis developed with serum antibodies to TSH receptor
developed 3–6 months after the patients received oral treatments with 40–86 mCi 131I (1.5–3.2 GBq) for
reduction of nontoxic goiter that was compressing the trachea (Huysmans et al. 1997a).  Prior to the 131I
treatments, the patients were euthyroid and had no detectable TSH antibodies.
Immunological and Lymphoreticular Effects of Radioiodine
Marshall Islands.  Large scale assessments of thyroid autoimmunity have been conducted in the Marshall
Islands, where exposures to 131I occurred as a result of fallout and contamination from test detonations of
nuclear bombs during the period 1946–1958 (see Section 3.2.1.2, Endocrine, for a more complete
description of these studies).  In a thyroid screening program conducted during the period 1993–1997,
7,721 subjects were evaluated for various end points of thyroid size, nodularity, and function (Fujimori et
al. 1996, Takahashi et al. 1997, 1999).  Antithyroglobulin antibodies in serum were detected in 67 of
2,700 (2.5%) subjects examined (Fujimori et al. 1996).  This prevalence is unremarkable compared to that
found in other populations, (10% in healthy adults, Marcocci and Chiovata 2000; Takahashi et al. 1999).
Chernobyl Accident.  A study that compared thyroid cancers in Belarus and Ukraine diagnosed after the
Chernobyl releases with those diagnosed in Italy and France during the same time period found that the
Belarus-Ukraine cases had a higher incidence of thyroid autoimmunity (i.e., elevated antithyroid
peroxidase and thyroglobulin antibodies) than the Italy-France cases (Pacini et al. 1997).  It is unclear to
what extent the autoimmunity may be related to the exposures to radioiodine.  Serum antithyroglobulin
antibody titres were measured in 53 children ages 7–14 years (in 1993–1994) who received 0.4–3.2 Gy
(40–320 rad) as a result of the Chernobyl release (Chernyshov et al. 1998).  Antibody titres were detected
in 80.6% of exposed children compared to 16.7% of a reference group that had no estimated exposure to
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131I, and there was a significant positive correlation between antibody titre and estimated thyroid 131I dose. 
These results suggest a possible contribution of thyroid radioiodine exposure to thyroid autoimmunity. 
Other screening programs conducted in Belarus have not found relationships between thyroid
autoimmunity and radiation exposure, as assessed by 137Cs soil levels or body 137Cs levels (UNSCEAR
2000).
Hanford Nuclear Site.  Thyroid autoimmunity was assessed as part of the CDC (1999) study of health
outcomes related to radioiodine releases from the Hanford Nuclear Site.  The study included
3,441 subjects who were born during the period 1940–1946 in counties surrounding the site.  Thyroid
autoimmunity was assessed from measurements of serum antimicrosomal antibody and antithyroid
peroxidase.  Historical information on thyroid disease, including autoimmunity and related disorders (e.g.,
Graves’ disease), was obtained by interviews and, when possible, review of medical records of
participants.  The estimated mean thyroid radiation dose, based on 3,190 participants, was 182 mGy
(±227, SD) (18.2±22.7 rad) and the range was 0.0008–2,842 mGy (0.00008–284 rad).  Dose-response
relationships were assessed using a linear regression model with adjustments for the following
confounding and effect modifying variables: sex, age of first exposure, age of evaluation, ethnicity,
smoking, and potential exposures from Nevada Test Site releases.  Alternatives to the linear model
including linear quadratic and logistic models were also explored.  Incidence of thyroid autoimmunity
was found to be unrelated to thyroid radioiodine dose.
3.2.2.4 Neurological Effects
Exposure to excess iodine has been shown to produce subclinical hypothyroidism, which in certain
sensitive individuals, may take the form of hypothyroidism.   Sensitive populations include fetuses,
newborn infants, and individuals who have thyroiditis or Graves’ disease, many of whom have abnormal
autoimmune disorders (see Section 3.2.2.2, Endocrine Effects).  Of these iodine-induced forms of
hypothyroidism, that occurring in the fetus or newborn infant has the greatest potential for producing
neurological effects.  This is because thyroid hormones are essential to the development of the
neuromuscular system and brain.  An iodine-induced hypothyroid state can result in delayed or deficient
brain and neuromuscular development of the newborn (Boyages 2000b)  Iodine-induced hypothyroidism
in an older child or adult would be expected to have little or no deleterious effects on the neuromuscular
system.  Exposure of a fetus to large amounts of radioiodine would result in thyroid tissue ablation and in
similar delayed brain and neuromuscular development, if the hypothyroid state was not corrected (e.g.,
with hormone replacement therapy) after birth.  An example is a case of severe hypothyroidism with
neurological sequellae that developed at age 8 months in an infant whose mother received 99 mCi
(3.7 GBq) of 131I during her sixth week of pregnancy (Goh 1981).
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Exposure to excess iodine can also produce hyperthyroidism in sensitive individuals (see Section 3.2.2.2,
Endocrine Effects).  These include people who are initially iodine deficient, those who have thyroid
disease, including Graves’ disease, who have been treated with antithyroid drugs, people who have has
postpartum thyroiditis, and those who have developed thyrotoxicosis from amiodarone or inteferon-alpha
treatments (Roti and Uberti 2001).  Patients who develop thyrotoxicosis may experience neuromuscular
disorders, including myopathy, periodic paralysis, myasthenia gravis, peripheral neuropathy, tremor, and
chorea (Boyages 2000a) 
3.2.2.5 Reproductive Effects
Reproductive Effects of Stable Iodine
Oral exposure to excess iodine may produce hypothyroidism or hyperthyroidism (see Section 3.2.2.2,
Endocrine Effects) and may cause disruption of reproductive function secondary to thyroid gland
dysfunction.  Hypothyroidism can produce changes in the menstrual cycle in humans, including
menorrhagia (excessive uterine bleeding) and anovulation (no ovulation).  Abortions, stillbirths, and
premature births have also been associated with hypothyroidism (Loncope 2000a).  Reproductive
impairments associated with hyperthyroidism include amenorrhea, and alterations in gonadotropin
release, sex hormone-binding globulin (SHBG), and associated changes in the levels and metabolism of
steroid hormones in both females and males (Longcope 2000b).
A clinical study of the outcomes of 70 pregnancies in patients who received 131I for ablative treatment of
thyroid cancer 2–10 years (mean, 5.3 years) prior to pregnancy revealed only two spontaneous abortions
(Casara et al. 1993).  The maternal 131I exposures ranged from 1.85 to 16.55 GBq (50–400 mCi); the mean
exposure was 4.40 GBq (120 mCi).  Maternal gonadal radiation doses ranged from 11 to 20 cGy
(11–20 rad).  In a similar study, 37 patients who received 131I  prior to conception (mean, 16.5 months
prior to conception; range 1–60 months); exposures ranged from 1.1 to 13.1 GBq (30–350 mCi) with a
mean exposure of 3.67 GBq (100 mCi) (Lin et al. 1998); of 58 pregnancies reported, there were
8 spontaneous abortions and 2 threatened abortions.  In a retrospective review of pregnancy outcomes of
154 women who received ablative 131I therapy for thyroid cancer, two cases of infertility occurred in
35 patients who attempted to conceive (Smith et al. 1994).  The 131I exposure range was 77–250 mCi
(2.8–9.2 GBq) with a mean exposure of 148 mCi (5.5 GBq).  The above studies did not have control
comparison groups.
Clinical cases of impaired testicular function have been reported following oral exposures to 131I for
ablative treatment of thyroid cancer (Ahmed and Shalet 1985; Handelsman and Turtle 1983; Pacini et al.
1994).  Effects observed included low sperm counts, azospermia (absence of spermatozoa), and elevated
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serum concentrations of follicle stimulating hormone (FSH), which persisted for more than 2 years of
follow-up.  Exposures to radioiodine ranged from 50 to 540 mCi (1.8–20 GBq).  A study of 103 patients
who received 131I treatments for thyroid cancer found low sperm counts and elevated serum FSH
concentrations when patients were examined 10–243 months after treatment (mean, 94 months) (Pacini et
al. 1994).  Exposures to radioiodine ranged from 30 to 1,335 mCi (1.1–49.5 GBq) with a mean exposure
of 167 mCi (6.2 GBq).
Reproductive Effects of Radioactive Iodine
A large-scale retrospective analysis was conducted to evaluate pregnancy health and reproductive
outcomes of women who were exposed to radiation resulting from releases from the Chernobyl nuclear
power plant, including a major contribution from 131I (Petrova et al. 1997).  Interpretation of the results of
this study, in terms of the contribution of radioiodine to the outcomes, is highly uncertain, as other factors
could have affected the outcomes, including exposure to other forms of radiation, nutrition, or other
chemical exposures.  Nevertheless, because it is one of the only large-scale epidemiological studies that
has focused on reproductive and developmental outcomes, and because of the substantial contribution that
radioiodine made to radiation exposures after the Chernobyl releases, a brief description of the study is
presented here.  In the retrospective analysis, clinical records on 755,297 pregnancies that occurred in
Belarus during the period 1982–1990 were evaluated.  Approximately half of the women resided in
Gomel and Mogilev, two districts that were relatively heavily contaminated with radioiodine and other
radionuclides, and approximately half of the women lived in two relatively lightly contaminated areas,
Brest and Vitebsk.  Three categories of outcomes were evaluated: pregnancy outcome, including
stillbirths, low birth weight, and neonatal or postneonatal mortality; maternal morbidity; and infant health,
including intrauterine hypoxia, perinatal infection, respiratory disorders, and congenital anomalies. 
Annual incidence of maternal anemia, renal insufficiency (elevated serum BUN and creatinine), and
toxemia appeared to increase more sharply in the heavily contaminated districts after 1986, the year of the
Chernobyl releases (a statistical analysis of trend was not reported).  Incidence of congenital
abnormalities and neonatal respiratory disorders also appeared to increase more sharply in the heavily
contaminated districts after 1986 (no statistical analysis of trend was reported).  Fetal death rates appeared
to increase or not decline in contaminated districts to the same extent as in less contaminated districts.  
A cohort study was conducted as part of this retrospective analysis (Petrova et al. 1997).  Health records
on 757 infants and their mothers who resided in radiation-contaminated or relatively uncontaminated
areas of Belarus were analyzed.  The prevalence of maternal toxemia was 4–5 times greater among
women who resided in contaminated areas (25–30%) compared to women from the control areas.  The
prevalence of atopic dermatitis in infants who resided in contaminated areas was approximately 2 times
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higher (approximately 40%) compared to infants from control areas.  The prevalence of anemia (low
blood hemoglobin levels) was 6–7 times higher in infants from contaminated areas (18–20%). 
Conclusions regarding relationships between pregnancy outcomes and exposure to radioiodine cannot be
drawn from the results of these studies.  A controlled epidemiological design (e.g., case-control) would be
needed to further explore whether such a relationship might exist.
The highest NOAEL values and all reliable LOAEL values in each duration category for reproductive
effects from exposures by the oral route are presented in Table 3-1 and plotted in Figure 3-1.
3.2.2.6 Developmental Effects
Exposure to excess iodine may produce hypothyroidism and hyperthyroidism (see Section 3.2.2.2,
Endocrine Effects), which could give rise to developmental defects secondary to thyroid gland
dysfunction (Boyages 2000a, 2000b).  Hypothyroidism may be associated with impairment in
neurological development of the fetus or growth retardation (Boyages 2000a, 2000b; Snyder 2000a). 
Martin and Rento (1962) reported two cases of goiter and severe transient hypothyroidism, without
neurological sequellae in infants born to mothers who ingested potassium iodide during pregnancy; the
approximate dosages were 920 and 1,530 mg I/day (13 and 22 mg/kg/day).  Growth acceleration may
occur in childhood hyperthyroidism, which is thought to be related to accelerated pituitary growth
hormone turnover or a direct effect of thyroid hormone on bone maturation and growth (Snyder 2000b). 
A clinical study of the outcomes of 70 pregnancies in patients who received 131I for ablative treatment of
thyroid cancer 2–10 years (mean, 5.3 years) prior to pregnancy revealed only two spontaneous abortions
(Casara et al. 1993).  Of 73 infants born to the patients, one was diagnosed with tetrology of Fallot’s
(pulmonic stenosis, atrial septal defect, and right ventricular hypertrophy) and the two other infants had
low birth weights with subsequent normal growth rates.  The maternal 131I exposures ranged from 1.85 to
16.55 GBq (50–400 mCi); the mean exposure was 4.40 GBq (120 mCi).  Maternal gonadal radiation
doses ranged from 11 to 20 cGy (11–20 rad).  A similar study was reported of 37 patients who received
131I 1–60 months prior to conception (mean, 16.5 months); exposures ranged from 1.1 to 13.1 GBq
(30–350 mCi) with a mean exposure to 3.67 GBq (100 mCi) (Lin et al. 1998); of 58 pregnancies reported,
there were 8 spontaneous abortions and 2 threatened abortions.  Birth weights of newborns of women
who received 131I were not different from newborns of maternal age-matched controls who did not receive
131I and who were not thyroid cancer patients.  A retrospective review of pregnancy outcomes of women
who received ablative 131I therapy for thyroid cancer found 3 spontaneous abortions and 4 premature
deliveries out of 67 pregnancies in 32 patients (Smith et al. 1994).  Two infants were born within 1 year
of the maternal 131I therapy and both died of congenital abnormalities; severe hypoparathyroidism and
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hypothyroidism in one case, and Down’s syndrome and cardiac anomalies in the second case.  The 131I
exposure range was 77–250 mCi (2.8–9.2 GBq) with a mean exposure of 148 mCi (5.5 GBq).  Goh
(1981) reported a case of cretinism that developed at age 8 months in an infant whose mother received
99 mCi (3.7 GBq) of 131I during her sixth week of pregnancy.
One epidemiological study has examined health outcomes of infants of mothers who resided in the
Belarus region before or after the Chernobyl accident (Petrova et al. 1997).  Interpretation of the results of
this study, in terms of the contribution of radioiodine to the outcomes, is highly uncertain, as other factors
could have affected the outcomes, including exposure to other forms of radiation, nutrition, or other
chemical exposures.  Nevertheless, because it is the only epidemiological study that has focused on
reproductive and developmental outcomes, and because of the substantial contribution that radioiodine
made to radiation exposures after the Chernobyl releases, a brief description of the study is presented
here.  As part of a retrospective cohort study, health records were analyzed on 757 infants and their
mothers who resided in heavily radiation-contaminated areas of Belarus resulting from radionuclide
releases from the Chernobyl nuclear power plant or relatively uncontaminated areas (Petrova et al. 1997). 
Prevalence of atopic dermatitis in infants who resided in contaminated areas was approximately 2 times
higher (approximately 40%) compared to infants from control areas.  The prevalence of anemia (low
blood hemoglobin levels) was 6–7 times higher in infants from contaminated areas (18–20%). 
Interpretation of the results of this study, in terms of the contribution of radioiodine, to the outcomes, is
highly uncertain, as other factors could have affected the outcomes, including exposure to other forms of
radiation, nutrition, or other chemical exposures. 
The highest NOAEL values and all reliable LOAEL values in each duration category for developmental
effects from exposures by the oral route are presented in Table 3-1 and plotted in Figure 3-1.
3.2.2.7 Cancer
Cancer effect levels (CELs) for iodine exposures by the oral route are presented in Table 3-2 and plotted
in Figure 3-2.
Stable Iodine and Cancer
The relationship between iodide intake and thyroid cancer has been examined in several large-scale
epidemiology studies.  The results of these studies suggest that increased iodide intake may be a risk
factor for thyroid cancer in certain populations, in particular, populations residing in iodine deficient,
endemic goiter regions (Franceschi 1998; Franceschi and Dal Maso 1999).  Not all studies have found
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towards a higher prevalence of papillary cancers, relative to follicular cancers, after increased iodine
intake in otherwise iodine-deficient populations (Bakiri et al. 1998; Belfiore et al. 1987; Kolonel et al.
1990; Pettersson et al. 1991, 1996).  Two studies found a significant excess of thyroid gland cancer in
populations from endemic goiter regions whose diets were supplemented to achieve approximate iodine
intakes of 3.5 µg/kg/day (Bacher-Stier et al. 1997; Harach and Williams 1995).
A case control study of residents of Hawaii examined dietary habits, including iodine intake and other
variables in 191 cases of thyroid cancer and 441 age- and sex-matched controls, diagnosed during the
period 1980–1987 (Kolonel et al. 1990).  Female cases had significantly higher dietary iodine intakes
than controls, although the group mean differences were not substantial; cases, 394 µg I/day
(5.6 µg/kg/day); controls, 326 µg I/day (4.7 µg/kg/day).  When cases and controls were classified
according to dietary iodine intake (quartile), the ORs for thyroid cancer in females increased with
increasing iodine intake; however, ORs were not statistically significant and there were no significant
trends in the OR with increasing iodine intake.  Other variables for which ORs were statistically
significant included miscarriage (2.4), use of fertility drugs (4.2), and the combination of either of the
former characteristics with an iodine intake exceeding 300 µg I/day or 4.3 µg/kg/day (4.8 or 7.3,
respectively), or seafood intake exceeding 27 g/day (3.0 or 6.9, respectively).
A cohort study compared thyroid cancer rates in iodine sufficient and iodine deficient regions of Sweden
during the period 1958–1981 (Pettersson et al. 1991, 1996).  Iodine deficient regions were defined as
having had a goiter prevalence that was >33% in females and >15% in males, based on a 1930 survey.  In
Sweden, dietary iodine intake has increased over the study period as a result of dietary supplementation,
which began in 1936 and was subsequently increased in 1966 and 1971 (Pettersson et a. 1996).  Thus,
iodine deficiency, even in the previously deficient regions has diminished.  A multivariate model that
included sex, age, dates of diagnosis, and region (i.e., iodine deficient or sufficient) as variables was
applied to a sample of 5,838 thyroid cancer cases to estimate adjusted RR for thyroid cancer, where RR
was the ratio of the adjusted cancer incidence rates for iodine deficient:iodine sufficient regions.  The RR
for papillary thyroid cancer was 0.8 (95% CI, 0.73–0.88), suggesting lower risk in the iodine deficient
regions, relative to the iodine sufficient regions.  The RR for follicular thyroid cancer was 1.98 (1.60–2.4)
in males and 1.17 (1.04–1.32) in females, suggesting a 1.2- to 2-fold higher risk for follicular cancer in
populations living in the iodine deficient regions, relative to iodine sufficient regions.  Analysis of
incidence of thyroid cancer as a function of dates of diagnosis revealed a significant trend for increasing
follicular cancers in the iodine deficient areas, but not in the iodine sufficient areas.  A significant trend
for increasing papillary cancers was evident in both the iodine sufficient and deficient regions. 
A cohort study examined the prevalence of thyroid cancer during the period 1979–1985 in populations
living in iodine deficient and sufficient areas of Sicily (Belfiore et al. 1987).  Mean urinary iodine
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excretion rate in the deficient regions was approximately 19–43 µg I/day (0.3–0.6 µg/kg/day) and, in the
iodine sufficient regions, was approximately 114 µg I/day (1.6 µg/kg/day); the intakes in the two regions
would be expected to be similar to urinary excretion rates.  Randomly selected subjects from both regions
were subjected to radioiodine thyroid scans to determine the presence of cold thyroid gland nodules,
indicative of a possible tumor with suppressed iodine uptake.  The prevalence of cold nodules in the
iodine deficient region was significantly greater (72 of 1,683, 4.3% ) than in the control group (21 of
1,253, 1.7%).  In the second phase of this study, all patients who had cold nodules in the two study areas,
911 patients from the iodine-deficient region, and 2,537 patients from the iodine-sufficient region, were
biopsied.  The prevalence of thyroid cancer among patients who had one or more cold nodules was higher
in the iodine sufficient region (5.48%) than in the deficient region (2.96%).  The prevalence of papillary
tumors, relative to that of follicular tumors, was higher in the iodine sufficient region (3.8) than in the
deficient region (1.0).  When the thyroid cancer prevalence among patients with cold nodules was
adjusted for the estimated prevalence of cold nodules in the two regions, the estimated prevalence of
thyroid cancer in the iodine deficient region was significantly higher (127 in 100,000) than in the
sufficient region (93 in 100,000). 
Epidemiological studies suggest that the incidence of thyroid cancer may increase in endemic goiter
regions after supplementation of the diet with iodine.  In Austria, iodized salt was introduced into the diet
in 1963 and then increased further in 1991.  The mean urinary iodide concentration before the adjustment
was 42–78 µgI/g creatinine and after the adjustment was 120–140 µgI/g creatinine; these are
approximately equivalent to 77–146 µg/day (1–2 µg/kg/day) and 225–263 µg/day (3–4 µg/kg/day),
respectively (Bacher-Stier et al. 1997; Mostbeck et al. 1998).  A retrospective analysis of medical records
in the Tyrol region of Austria (1,063,395 inhabitants) concluded that the incidence of thyroid cancer
increased from 3.1 per 100,000 year for the period 1960–1970 to 7.8 for the period 1990–1994 (Bacher-
Stier et al. 1997).  The prevalence of papillary tumors appeared to increase relative to that of follicular
tumors after supplementation; the ratio of papillary:follicular tumors was 0.6 before supplementation and
1.5 after supplementation.  Improved diagnosis may have contributed to the increased incidence.  In
support of this, a trend was observed towards increased prevalence of less advanced tumor stages in
439 patients for which complete medical records were available.  The authors reported that “no excessive
natural radiation has been found in Tyrol”.
A retrospective analysis of 1,000 consecutive patient records from endocrine wards in Algiers, recorded
during the period 1967–1991, revealed significantly greater prevalence of differentiated follicular thyroid
tumors in patients who resided in an endemic goiter region (53.6%; n=581) than in nonendemic regions
(44.0%; n=236) (Bakiri et al. 1998).  The prevalence of follicular tumors was significantly greater than
that of papillary tumors in the endemic areas, whereas follicular tumors were less prevalent than papillary
tumors in the nonendemic region.  The ratio of papillary:follicular tumors was 1.2 in the endemic region
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and 0.8 in the nonendemic region.  The mean urinary iodide concentration in the goiter endemic area was
<50 µg I/g creatinine and was >80 µg I/g creatinine in the nonendemic region; these are approximately
equivalent to <95 µg/day (1.2 µg/kg/day) and >150 µg/day (2.1 µg/kg/day), respectively. 
A retrospective analysis of 144 cases of thyroid cancer in the Salta region of Argentina, diagnosed during
the period 1960–1980, found that the prevalence of papillary tumors appeared to increase relative to that
of follicular tumors after dietary iodine supplementation was initiated as prophylaxis for goiter; the ratio
of papillary:follicular tumors was 1.8 before supplementation and 3.0 after supplementation (Harach and
Williams 1995; Harach et al. 1985).  The mean urinary iodide concentration before the supplementation
was 9 µg I/g creatinine and after the supplementation was 110–150 µg I/g creatinine; these are
approximately equivalent to 17 µg I/day (0.2 µg/kg/day) and 205–280 µg I/day (3–4 µg/kg/day),
respectively. 
Radioiodine and Cancer
The thyroid gland receives the highest radiation dose of any organ or tissue following an internal exposure
to radioiodine (see Section 3.3, Toxicokinetics) and, therefore, cancer of the thyroid gland is the major
health concern associated with radioiodine exposures.  Cancer morbidity and mortality among populations
who received exposures to radioiodine have been examined in several large-scale epidemiology studies.  In
general, these studies fall into several categories that can be distinguished by the sources of exposure and
estimated radiation doses to the thyroid gland and include (Table 3-3): (1) extremely high exposures and
doses (10–20 mCi, 370–740 MBq; >10,000 rad, >100 Gy) achieved when 131I is administered to treat
hyperthyroidism (even higher doses are used to treat thyroid cancer); (2) lower exposures and doses
(40–70 µCi, 1.5–2.6 MBq; 80–130 rad, cGy) associated with clinical administration of 131I for diagnosis of
thyroid gland disorders; (3) doses from exposures to fallout from nuclear bomb tests (BRAVO test,
300–2,000 rad, cGy; Nevada Test Site, 1–40 rad, cGy); (4) doses from exposures to releases from nuclear
power plant accidents (Chernobyl, 10–500 rad, cGy); and (5) exposures from operational releases from
nuclear fuel processing plants (Hanford Nuclear Site, 0.0001–284 rad, cGy).  As a point of reference, the
dose-response relationship for thyroid cancer and external radiation appears to extend down to thyroid
doses of 0.1 Gy (10 rad) and predicts an excess relative risk (ERR) of 7/Gy for ages <15 years at exposure
(Ron et al. 1995).  Studies of thyroid cancers and external radiation exposure have found a strong age
dependence between thyroid radiation dose and thyroid cancer.  Risk is substantially greater for radiation
doses received prior to age 15 years when compared to risks for doses received at older ages (Ron et al.
1995).  This same general trend in age-dependence would be expected for internal exposures to
radioiodine; thus, studies of adult exposures to radioiodine may not be directly applicable to predicting
outcomes from exposures to children.  The relatively high and acutely cytotoxic radiation doses to the
thyroid gland that are achieved in the treatment of thyroid gland disorders, and outcomes on the thyroid, 
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radiation dose (cGy)a Referenceb
Radioiodine therapy for
hyperthyroidism
>5,000c Holm et al. 1991; Ron et al. 1998
Clinical diagnosis of thyroid
gland disorders
80–130c Hall et al. 1996b
Marshall Islands BRAVO test 280–2,100c Hamilton et al. 1987; Lessard et
al. 1985
Chernobyl power plant accident <1–200d Astrakova et al. 1998
Nevada Test Site nuclear bomb
tests
1–30c Gilbert et al. 1998; Kerber et al.
1993; Rallison 1996
Hanford Nuclear Site releases <1–50d CDC 1999
a1 cGy=1 rad 
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are virtually irrelevant to predicting outcomes from the much lower environmental exposures that occur in
most U.S. populations.  This is in part because cell killing effects decrease the number of viable cells that
might otherwise be transformed by radiation-associated mutagenesis.  Uncertainties in estimating thyroid
doses are also greater in persons who have thyroid abnormalities because of the nonuniform distribution of
radioiodine in the thyroid gland (NCRP 1985).  Nevertheless, high-dose studies are summarized because
they provide useful information about the magnitude of radioiodine exposures that would present an
elevated risk for extrathyroidal cancers.  Although not specified in most of these studies, it is likely that
radioiodine was administered as a single dose by the oral route as either potassium or sodium iodide, as
these are the common clinical practices.  However, it is also possible that some patients received the
radioiodine by injection.  Since absorption of an oral dose of iodide is nearly complete, this is unlikely to
be a significant issue in interpreting the outcomes of the studies, except in considering the radiation dose to
the gastrointestinal tract.
Breast cancer is also a concern with exposures to high levels of radioiodine after ablative therapy for
hyperthyroidism because breast expresses NIS and can transport and accumulate iodide (see
Sections 3.4.4.2 and 3.5.1, Distribution).  However, the epidemiological literature to date has not
implicated such exposures as a significant risk factor for breast cancer (Goldman et al. 1988; Green et al.
1995). 
Therapeutic Doses of Radioiodine
A retrospective cohort study conducted in Sweden examined cancer incidence among 10,552 patients
(85% females; age 13–74 years) who received 131I therapy for treatment of Graves’ disease (51%) or toxic
nodular goiter (42%) (Holm et al. 1991).  The mean total activity administered was 506 MBq (13.7 mCi);
however, this varied with the objectives of the therapy; 360 MBq (9.7 mCi) for treatment of Graves’
disease and 700 MBq (18.9 mCi) for toxic nodular goiter.  The distribution of the administered activity in
the study population was as follows: 30% <220 MBq (5.9 mCi), mean, 150 MBq (4.1 mCi); 38%
221–480 MBq (6–13 mCi), mean 315 MBq (8.5 mCi); and 32% >480 MBq (13 mCi), mean 1,063 MBq
(28.7 mCi).  Cancers that occurred from 1 year after treatment (on or after 1958) until either the death of
the patient or the end of the calendar year 1985 were considered in the analysis.  Expected numbers of
cancers were estimated from data from the Swedish Cancer Register for the period 1958–1985.  Standard
incidence ratios (SIR, observed/expected cancers) were significantly elevated for cancers of the lung (1.32,
95% CI 1.07–1.59) and kidney (1.39, 1.07–1.76).  Among toxic nodular goiter patients, who received, on
average, twice the dose as Graves’ disease patients, the SIR was also significantly elevated for liver cancer
(2.14, 1.20–3.52).  Among 10-year survivors, significantly elevated SIRs included stomach (1.33,
1.01–1.71), kidney (1.51, 1.06–2.08), and brain (1.63, 1.10–2.32).  Doses to specific organs were
estimated for each patient based on the administered activity and dosimetry tables developed by the ICRP
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(1988).  Estimated average radiation doses to these tissues were: thyroid gland, >10,000 cGy
(>10,000 rad); stomach, 25 cGy (25 rad); lung, 7 cGy (7 rad); kidney, 5 cGy (5 rad); liver, 5 cGy (5 rad);
and brain, not reported.  There were no significant dose trends.  Notably, SIRs for thyroid cancer were not
significantly elevated (SIR 1.29, 0.76–2.03).  Some of the patients in this study received treatments other
than 131I for thyroid disorders, including antithyroid drugs (14%), surgery (3%), and/or thyroid hormone
supplements (2%).  Cancer mortality was examined in the same cohort (Hall et al. 1992a).  Standard
mortality ratios (SMRs) were calculated based on data from the Swedish Cause-of-Death Registry.  SMRs
were significantly elevated for all cancers (1.14, 1.04–1.24), digestive tract cancers (1.28, 1.16–1.45), and
respiratory tract cancers (1.31, 1.01–1.66) among patients who had greater than a 10-year follow up from
the date of their exposure to 131I, and for thyroid gland cancer during the first year (11.45, 2.8–33.72). 
There were no significant dose trends, although the SMR for thyroid gland cancer was approximately
4 times higher in patents who received >480 MBq (13 mCi) than in patients who received <221 MBq
(6 mCi).
A retrospective cohort study examined cancer mortality in 35,593 patients (79% females; mean age,
46 years, 3% younger than 20 years) treated for hyperthyroidism (91% Graves’ disease, 8% toxic nodular
goiter) in 25 U.S. hospitals and 1 British hospital (Ron et al. 1998).  The mean total activity administered
was 10.4 mCi (385 MBq; 5th–95th percentile, 3–27 mCi, 111–999 MBq).  The mean total administered
activity was 10.0 mCi (370 MBq) for treatment of Graves’ disease and 17.0 mCi (629 MBq) for toxic
nodular goiter.  Cancers that occurred between the first visit of the patient to the clinic during the
enrollment period (1946–1964) until either the death of the patient or the end of the calendar year 1990
were considered in the analysis.  Estimates of expected numbers of cancer deaths were based on U.S.
national mortality rates for the period 1958–1985.  This study, unlike those of Holm et al. (1991) and Hall
et al. (1992a), stratified patients into various categories of treatment, distinguishing patients who received
surgical treatments (22% of study population) that would have decreased their thyroid gland mass, and
possibly the risks of thyroid cancer.  SMRs (observed/expected deaths) were calculated for various
treatments (131I, surgery, antithyroid drugs, or combinations).  Radiation doses to specific organs were
estimated for each patient based on the administered activity and dosimetry tables developed by the ICRP
(1988).  The study identified 2,960 cancer deaths, 29 of which were classified as thyroid cancers.  Among
patients who received only 131I as treatment, SMRs were significantly elevated for the entire observation
period (maximum 44 years) only for thyroid cancer, 4.91 (95% CI, 2.45–8.79).  A similar outcome was
found for patients who received 131I along with any other form of treatment.  SMRs were significantly
elevated among these patients only for thyroid cancer, 3.94 (2.52–5.86) with the highest SMR during the
first 4 years after exposure (12.32, 6.38–21.61).  The estimated thyroid dose was 50–70 Gy
(5,000–7,000 rad).  When cancer mortality of toxic nodular goiter patients who received 131I treatment was
evaluated separately, SMRs for cancers of the esophagus (4.06, 1.10–10.45) and uterus (2.05, 1.02–3.67)
were significantly elevated, in addition to thyroid cancer (18.88, 7.58–38.98).  Estimated doses to the
IODINE 88
3.  HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
nonthyroid tissues was less than 100 mGy (100 rad).  However, in Graves’ patients who received 131I
treatment, SMRs were significantly elevated only for thyroid cancer (2.84, 1.62–4.61).  There were no
significant dose trends for cancer in thyroid or other organs, although the SMR for patients who received
$15 mCi (555 MBq) was 2.28 times higher (7.05) than in patients who received <7 mCi (3.01), when all
patients who received 131I treatments were considered.  Unlike the Holm et al. (1991) and Hall et al.
(1992a) studies, the Ron et al. (1998) study found a significantly elevated risk for thyroid cancer among
patients who received 131I treatment; however, it did not find elevated risks for other organs.  Potential
contributors to this difference in outcomes may be: (1) the larger size of the cohort in the Ron et al. (1998)
study (35,593 compared to 10,646); (2) a larger fraction of the study population in the Hall et al. (1992a)
study that received higher activities of 131I for toxic nodular goiter (42% compared to 8%); and (3)
stratification of the patients in the Ron et al. (1998) study into treatment categories that so that patients
who received only 131I or 131I in combination with other treatments could be assessed independently.  Much
of the apparent excess risk for thyroid cancer deaths observed in the Ron et al. (1998) study occurred
during the first 0–4 years after 131I treatment, which would suggest a remarkably short latency for a
radiation-induced cancer, or possibly other factors that contributed to the outcome.  Although a larger
fraction of the study population in the Hall et al. (1992a) study received higher activities of 131I for toxic
nodular goiter (42%) compared to (8%) in the Ron et al. (1998) study, this does not explain the difference
in thyroid cancer outcomes since the Ron et al. (1998) study found higher risks for thyroid cancer among
patients who received higher exposures to 131I for treatment of toxic nodular goiter. 
A follow-up cohort study was conducted of cancer morbidity and mortality among 1,762 women who
received ablative 131I therapy for hyperthyroidism during the period 1946–1964 (Goldman et al. 1988). 
The follow-up period was 17 years.  SMRs and SIRs were estimated based on age-, date-, sex-, and race-
specific mortality incidence and mortality of the United States or Massachusetts population.  The cohort
was stratified into treatment categories that included only 131I or 131I in addition to other therapies for
hyperthyroidism.  SIRs in the 131I-only group were not significantly elevated for any cancer type or group. 
SMRs in the 131I-only group were significantly elevated for cancers of all causes (SMR, 1.2, 1.1–1.4, 95%
CI, 10 cases).  There were no significant radiation dose trends.  Exposures ranged from 0.1 to >10 mCi
(4–370 MBq).
Diagnostic Doses of Radioiodine
A retrospective cohort study examined thyroid cancer incidence among 34,104 patients (80% females,
1–75 years of age) in Sweden who received 131I for diagnosis of thyroid disorders during the period
1950–1969.  The follow-up period was from 1958 to 1990 (Hall et al. 1996b).  A total of 2,408 patients
(7%) were exposed before 20 years of age and 316 patients were exposed before 10 years of age (1%). 
The diagnostic test was for a suspected thyroid tumor in 10,785 (32%) patients and for hypothyroidism,
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hyperthyroidism, or other reasons in 23,319 (68%) patients.  The follow-up period ranged from 5 to
39 years after exposure (thyroid cancers detected within 5 years of the diagnostic test were excluded on the
basis that they may have been related to cancer present at the time of the diagnostic test).  The mean total
activity administered was 2.4 MBq (65 µCi) for patients suspected of having a thyroid gland tumor and
1.6 MBq (43 µCi) for other patients.  Radiation doses to the thyroid gland were estimated for each patient
based on the administered activity and dosimetry tables developed by the ICRP (1988).  The mean
absorbed dose was 1.3 Gy (130 rad) for suspected thyroid tumor patients and 0.8 Gy (80 rad) for other
patients.  SIRs were calculated based on sex-, age-, and date-adjusted cancer incidence rates based on the
Swedish Cancer Registry.  Sixty-seven thyroid tumors were identified during the period of the study, of
which 42 (63%) were in patients who received 131I for diagnosis of a suspected thyroid gland tumor.  SIRs
were significantly elevated only in the latter group (2.86, 95% CI 2.06–3.86), but not in patients tested for
other suspected thyroid disorders.  There were no significant dose trends for thyroid cancer in either group.
The incidence of cancer in extrathyroidal organs was examined in this same cohort (Holm et al. 1989).  At
that time, the cohort consisted of 35,074 patients, 31% of whom received 131I for diagnosis of a suspected
thyroid gland tumor, 42% for suspected hyperthyroidism, 16% for suspected hypothyroidism, and 8% for
other reasons (the basis for the diagnostic procedure could not be determined for 3% of the patients).  The
mean total activity administered was 52 µCi (range 1–960 µCi) (1.9 MBq, 0.04–36 MBq).  The mean total
administered activity was 71 µCi (2.6 MBq) for patients suspected of having a thyroid tumor, 48 µCi
(1.8 MBq) for diagnostic tests for hyperthyroidism, and 40 µCi (1.5 MBq) for other diagnostic purposes. 
SIRs were significantly elevated for cancers of the endocrine organs other than thyroid gland (1.93,
1.62–2.29), lymphomas (1.24, 1.03–1.48), and leukemias (1.34, 1.11–1.60).  The SIR for nervous system
cancers was 1.19 (1.00–1.41).  The SIR for thyroid cancer was significantly elevated only in the 5–9-year
period of follow-up.  There were no significant dose trends.  In this study, unlike the Hall et al. (1996b)
study, SIRs were calculated for all patients, regardless of the intended purpose of the diagnostic test,
including patients who were administered 131I for the diagnosis of suspected thyroid tumors.
A prospective study examined thyroid outcomes of children and adolescents (<20 years old) who received
diagnostic doses of 131I during the period 1946–1967 (Hamilton et al. 1987).  Study groups consisted of
3,503 subjects who received diagnostic 131I, 2,495 control subjects who did not receive 131I and who were
matched with the exposed subjects by sex-, age-, and diagnostic-test date, and a group of 1,070 siblings of
the control group.  The follow-up period was from entry into the study until 1986.  Participants were
surveyed with a questionnaire to identify those who had thyroid or neck surgery during the study period,
and pathology reports and specimens were retrieved and reviewed by a panel of pathologists; neoplasms
were classified and the results were compared with hospital pathology reports.  Dose to the thyroid gland
was estimated for each exposed subject based on the reported activity administered, percent thyroid
uptake, and thyroid weight estimated from published thyroid growth tables.  The median total absorbed
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dose was 20–40 rad (0.2–0.4 Gy) (95th percentile, 200–330 rads 2–3 Gy).  The survey response rate was
63%.  A total of 34 surgeries were reported, of which 19 were on subjects who did not have any thyroid
disorder diagnosed at the time of entry into the study; 16 of these subjects had confirmed thyroid tumors;
10 benign, 8 of which occurred in the exposed group, and 6 malignant tumors, 5 of which occurred in the
exposed group.  Although these results are suggestive of a possible effect of 131I exposure on thyroid tumor
incidence, the differences between the exposed and control groups were not statistically significant.  Shore
(1992) reviewed the results of the Hamilton et al. (1987) study and calculated a relative risk for thyroid
cancer of 2.9 (90% CI, 0.6–15) based on the internal comparison of the exposed and unexposed groups in
the Hamilton et al. (1987).  Based on the Surveillance, Epidemiology and End Results (SEER) cancer data
for 1973–1981 (U.S. DHHS 1985), 3.7 thyroid cancers would have been expected in the Hamilton et al.
(1987) study, compared to the 4 observed during the period of 5 or more years after the diagnostic test
(one of the cancers reported in the Hamilton et al. (1987) study occurred with a latency of 2 years), which,
according to Shore (1992), indicates a SIR of 1.1, (95% CI, 0.3–2.6). 
Marshall Islands Nuclear Bomb Test BRAVO.  Several epidemiological studies have examined thyroid
gland disorders in residents of the Marshall Islands who were exposed to radioiodine from atmospheric
fallout resulting from nuclear bomb tests (including the so-called BRAVO test).  A more complete
discussion of these studies are presented in Section 3.2.1.2 (Endocrine), as the studies provide dose-
response information on thyroid disorders other than cancer.  However, cancer outcomes have been
examined in what has become known as the BRAVO cohort, as well as in larger samples of the Marshall
Island population.  Almost all that is known about radioiodine doses to the thyroid from the BRAVO test
exposures derive from a few urinary measurements collected 15 days after the exposures.  These have been
estimated to have been (external and internal): 3.3–20 Gy (300–2,000 rad) on Rongelap (highest doses in
children), 1.3–4.5 Gy (130–450 rad) on Ailingnae, and 0.3–0.95 Gy (30–95 rad) on Utirik (Conard 1984). 
The BRAVO test was not the only potential source of radioiodine exposure in the Marshall Island
population, as numerous bomb tests were conducted in the Marshall Islands during the period 1946–1958. 
Evidence for a higher prevalence of thyroid cancer among the original 250 people known to have been
heavily exposed as a result of the BRAVO incident has not been established; however, this may reflect the
small size of the cohort.  In 1982, a review of the diagnoses for thyroid nodules detected in 250 exposed
and 1,303 nonexposed Marshallanese revealed 9 definitive carcinomas (3.6%) and 7 adenomas (2.8%) in
the exposed group, and 6 carcinomas (0.5%) and 14 adenomas (1%) in the nonexposed comparison group
(Conard 1984).  Subsequent reviews of the thyroid pathology more or less agree with the conclusions of
Conard (1984), although differences in the composition of comparison group have contributed to slightly
different estimates of prevalence in the nonexposed population.  For example, Howard et al. (1997)
reported four cancers (1.8%) and one adenoma (0.4%) in a nonexposed comparison group.  Takahashi et
al. (1997) reviewed diagnoses of 22 cases of thyroid nodularity discovered in 1993 in an ultrasound
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screening program that evaluated 1,275 Marshall Island residents (mainly from Ebeye).  The prevalence of
thyroid cancer among patients referred for surgery-based thyroid gland ultrasound assessments suggested
an overall prevalence of thyroid cancer of approximately 1.2% (15/1,275) in the population evaluated, or a
12% prevalence (15/123) of thyroid cancer among those who had palpable nodules.  Several factors
confound attempts to associated thyroid cancers in the Marshall Islands population with radioiodine
exposures, including lack of definitive dosimetry, outside of the small BRAVO cohort.  Changes occurred
in diagnostic techniques used to detect thyroid nodules, which would direct further diagnostic attention; in
particular, the use of ultrasound for detecting small thyroid nodules began only in 1994.  More recent
studies have also suggested a relatively high prevalence of iodine deficiency in the Marshall Islands, which
may have affected background thyroid cancer prevalence (Takahashi et al. 1999).
The strengths of the Marshall Island studies summarized above include the relatively high range of thyroid
radiation doses and the multiple thyroid screenings that included, in the more recent studies, relatively
objective assessments of nodularity by ultrasound.  Limitations of the studies include: (1) large dose
uncertainties in terms of total thyroid dose; (2) further dose uncertainties in terms of the fraction of the
dose that was from 131I rather than from short-lived isotopes of iodine and gamma radiation; (3) no attempt
to estimate individual thyroid doses; (4) inequities between the exposed and unexposed populations in the
intensity of thyroid screening; (5) the relatively small number of exposed subjects in the BRAVO cohort;
(6) the potential confounding effects of prophylactic iodide administration to highly exposed subjects; and
(7) thyroid radiation dose estimates were not available for larger scale studies of populations in the
Marshall Islands.
 Nevada Test Site Nuclear Bomb Tests.  During the period 1951–1958, 119 atmospheric nuclear bomb
tests were conducted at the Nevada Test Site (NTS) in southern Nevada (NCI 1997).  These tests were
followed by nine surface detonations during the period 1962–1968 and approximately 809 below-ground
tests, of which 38 were determined to have resulted in off-site releases of radioactive materials.  A dose
estimation methodology was developed by the National Cancer Institute (NCI 1997), which has enabled
estimation of population radiation doses to the thyroid gland from direct and indirect (e.g., in utero,
ingestion of cow milk) exposures to 131I resulting from the NTS activities for the purpose of health
assessments and epidemiologic investigations (Gilbert et al. 1998; Kerber et al. 1993).  A discussion of the
uncertainties and limitations of these population dose estimates for use in epidemiology studies and risk
assessment can be found in a review of the NCI (1997) dose estimations conducted by the Institute of
Medicine and the National Research Council (NRC 1999).
A cohort study examined thyroid nodularity and performed diagnostic follow up in 2,678 adolescents (age
11–18 years) who resided in Utah or Nevada near the NTS during the early 1950s and in a comparison
population of 2,132 adolescents who lived in Arizona.  Examinations were conducted during the period
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1965–1970 (Rallison et al. 1974).  In a follow-up study conducted in 1985–1987, 1,962 of the original
Utah-Nevada group and 1,160 from the Arizona group were reexamined (Rallison et al. 1990). 
Radioiodine doses were estimated for each Utah-Nevada subject based on self-reported histories of
residence, local milk and leafy vegetable consumption, records of transport and deposition of radionuclides
at their town and/or county of residence, and age-specific transfer factors relating iodine ingestion with
iodine uptake in the thyroid gland (Kerber et al. 1993; Simon et al. 1990).  Mean thyroid dose estimates
were 150 mGy (15 rad) (maximum 4.6 Gy, 460 rad) in the Utah group, 50 mGy (5 rad) (maximum
0.84 Gy, 84 rad) in the Nevada group, and 13 mGy (1.3 rad) (maximum 0.45 Gy, 45 rad) in the Arizona
group (the group names refer to cohort designations used in the study, which were based on the place of
residence during the potential exposure period, and not necessarily where the entire radiation dose for each
individual was received).  In the 1965–1968 examinations, 76 of` 4,819 people examined had palpable
thyroid gland nodules, 22 of which were subsequently diagnosed as adenomas (20) or carcinomas (2).  The
prevalence of nodules was higher in the Utah-Nevada group (19.7/1,000) than in the Arizona group
(10.8/1,000).  Fifteen of the 22 neoplasms were found in the Utah-Nevada group (5.6/1,000) and 7 in the
Arizona group (3.3/1,000) (Rallison et al. 1974).  In 1985–1987, 125 new cases of thyroid nodularity were
identified, 65 of which were diagnosed as neoplasms and 5 of the latter were carcinomas.  Five carcinomas
were reported in the group during the interval between the two examinations.  Combining the results of the
first and second evaluations, including the five carcinomas observed during the interval, resulted in similar
prevalences in the two groups for nodules (Utah-Nevada 48.6/1,000, Arizona 36.6/1,000).  Prevalence of 
neoplasms were not disparate: Utah-Nevada, 2.8/1,000 and Arizona 4.8/1,000 (Rallison et al. 1990). 
Thyroid nodules were detected in 56 of 2,473 subjects; 38 of these lesions were diagnosed as
nonneoplastic (28 were colloid adenomas, the other 10 were miscellaneous nonneoplastic lesions), 11 were
benign adenomas (of these, 8 were follicular adenomas and there was one each of papillary, fetal, and
Hurthle cell adenomas), and 8 were papillary carcinomas (Rallison 1996).  Stratifying the outcomes by
estimated thyroid radiation dose revealed a significant dose trend for neoplasms, but not for all nodules or
for carcinomas alone.  The group that received a dose exceeding 0.25 Gy (25 rad) had a thyroid neoplasm
prevalence of 21–24/1,000, whereas groups that received <0.25 Gy had a prevalence of 4–5/1,000.  The
excess relative risk estimates per Gy were: neoplasms, 7.0 (lower 95% confidence limit [CL], 0.74,
p=0.019); nodules, 1.2 (95% CL<0, p=0.16); and carcinomas, 7.9 (95% CL<0, p=0.096) (Kerber et al.
1993).
In a large scale ecological study, mortality and incidence of thyroid cancer in 3,053 U.S. counties were
compared to estimated exposures to 131I from releases from the NTS (Gilbert et al. 1998).  Thyroid cancer
mortality data were obtained from the National Center for Health Statistics for 1957–1994 and thyroid
cancer incidence data from SEER for the period 1973–1994.  County-specific or state-specific cumulative
radiation doses were reconstructed based on NCI (1997) and were as follows (cGy, where 1cGy = 1 rad):
in utero, 4.3 cGy; 0–<1 year, 12.6 cGy; 1–4 years, 10.0 cGy; 5–9 years, 6.7 cGy; 10–14 years, 4.4 cGy;
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15–19 years, 3.1 cGy; $20 years, 1.1 cGy.  During the study period, there were 12,657 cases of thyroid
cancer and 4,602 thyroid cancer deaths.  Age-, calendar-, sex-, and count-specific mortality and incidence
rates in the U.S. were analyzed in relation to 131I dose estimates, taking into consideration geographic
location, age at exposure, and birth cohort.  There were no significant dose-related trends (linear excess
relative risk model) in either thyroid cancer mortality or incidence when all exposure age groups were
composited or when exposure age groups 1–5 years or 1–15 years were considered separately.  However,
when the exposure age group <1 year was analyzed, a dose trend was weakly suggested by highly positive
excess relative risks (ERR) for thyroid cancer deaths when doses were county-specific (ERR 10.6 per Gy,
95% CI -1.1–29, p=0.085) or state-specific (16.6 per Gy, -0.2–43, p=0.054), and for thyroid cancer
incidence when doses were county-specific (2.4 per Gy, -0.5–5.6).  These outcomes were strongly
influenced by two deaths and nine cases of thyroid cancer that occurred in individuals who received
estimated cumulative doses exceeding 9 cGy (9 rad) before they were 12 months of age.
The strengths of the NTS studies described above include the attempt to develop a systematic sampling
frame, the careful, multiple thyroid screenings (two or more times), the relatively high follow-up rate, and 
the extensive attempt to characterize individual 131I doses.  Limitations of the studies include: (1) the
substantial dose uncertainties, since no thyroid exposure measurements were available and individual milk
and vegetable consumption was recalled more than 30 years after the fact; (2) the food-consumption and
behavioral questionnaire was conducted after subjects knew their thyroid outcomes; (3) the modest sample
size and, therefore, small number of thyroid neoplasms found, which limited the statistical power and
precision; (4) the relatively low dose range also limited the statistical power and precision; (5) the
restriction of the thyroid examinations to palpation (no ultrasound); and (6) the fact that the thyroid
examinations were only partially blinded (i.e., examiners often knew the subject’s geographic region). 
Chernobyl Nuclear Power Plant Accident.  Clinical records from the Republics of Belarus and Ukraine
show an increase in the incidence of thyroid cancer in children and adolescents, which became apparent
approximately 4 years after the release of radioactive materials from the Chernobyl nuclear power plant in
April 1986 (Cherstvoy et al. 1996; Drobyshevskaya et al. 1996; Tronko et al. 1996).  Belarus recorded an
annual incidence of 0.09 cases per 100,000 in 1986 among children between the ages of 4 and 17 years and
2.46 per 100,000 in 1991, with the highest incidence in the Gomel oblast; from 0.24 cases per 100,000 in
1986 to 12.5 per 100,000 in 1991 (Drobyshevskaya et al. 1996).  In the Ukraine, annual incidence of
thyroid cancer in children and adolescents (under 19 years of age) increased from approximately 0.05 per
100,000 prior to 1986 to 0.43 per 100,000 in 1992 (Tronko et al. 1996).  In 1994, the incidence (per
100,000) was highest in regions nearest to Chernobyl: Chernihiv, 3.8; Zhytomyr, 1.6; and Kiev, 1 (Tronko
et al. 1996).  Although the available data strongly show that radiation exposure from the accident has led
to the excess risk of thyroid cancer, especially in persons exposed as children, there is also much
uncertainty in the radiation dose estimates.  The magnitude of the thyroid cancer risk associated with
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radioiodine is also highly uncertain because of factors that complicate the epidemiological picture,
including the contribution external exposure, the effect of the intensive screening for thyroid cancer that
followed the accident (Astakhova et al. 1998) on the baseline incidence of thyroid cancer, and the potential
effects of iodine deficiency and endemic goiter in the population (Gembicki et al. 1997). 
The relationship between childhood thyroid cancer and radiation exposure was examined in a case-control
study of children from Belarus (Astakhova et al. 1998).  Cases included all children under age 15 years at
the time of the accident who had confirmed pathology diagnoses of thyroid cancer during the period
1987–1992 and who could participate in the study (107 of 131 applicable cases in Minsk State Medical
Institute records).  Cases were matched with two control groups; one control group (Type 1) was randomly
selected from an area of Belarus thought to have relatively low or no exposures from the Chernobyl
accident (Brest, Grodno, and Vitebsk oblasts in north and west Belarus) but was otherwise matched with
cases for age, sex, and urban/rural residence.  A second control group (Type 2) was drawn from each
Belarus district, including the more heavily exposed oblasts near Chernobyl (Minsk, Mogilev, and Gomel),
in numbers proportional to the population census and was matched to cases by pathway to diagnosis, in
addition to age, sex, and urban/rural residence.  The objective of matching the pathway to diagnosis was to
control for screening intensity as a possible contributor to an increased incidence.  Diagnosis pathways
were classified into three elements: (1) systematic endocrine screening; (2) incidental finding during
physical examination not necessarily related to the Chernobyl releases; or (3) examination prompted by
referral because of a swelling of the neck or other symptoms of possible thyroid enlargement or nodularity. 
Average thyroid radiation doses were reconstructed based on thyroid gland 131I measurements made on
200,000 residents of Belarus, after the Chernobyl release, and estimates of cow milk contamination and
consumption for the area of residence of each case or control (vegetable and goat milk consumption was
not included in the exposure estimates).  If no cow milk consumption was thought to have occurred,
exposure was assumed to have occurred principally from inhalation.  Age-group thyroid doses were
constructed for each area of residence included in the study.  Mean (standard deviation) of thyroid doses in
the case group and controls were as follows: cases, 535 mGy (848) mGy; Type I controls, 188 mGy (386);
and Type II controls, 207 mGy (286).  For the purpose of estimating ORs, cases and controls were
stratified into three thyroid dose categories.  The resulting estimated dose distributions among thyroid
cancer cases were 64/107 (59.8%) in the <0.3 Gy dose category, 26/107 (24.3%) in the 0.3–0.99 Gy dose
category, and 17/107 (15.9%) in the $1 Gy dose category.  The corresponding distributions in Type
1 controls were 88/107 (82.2%) for <0.3 Gy, 15/107 (14.0%) for 0.3–0.99 Gy, and 4/107 (3.7%) $1 Gy. 
The corresponding OR for the $0.3 Gy category compared to <0.3 Gy was 3.11 (95% CI, 1.67–5.81) and
for the $1 Gy category compared to <0.3 Gy was 5.84 (1.96–17.3).  ORs were significant when Type 2
controls were the comparison group (controls for pathway to diagnosis).  For routine endocrine screening,
ORs were 2.08 (1.0–4.3) for comparison of the dose categories $0.3 Gy and <0.3 Gy, and 5.04 (1.5–16.7)
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when the dose category $1 Gy was compared to <0.3 Gy.  The OR for incidental findings was significant,
8.31 (1.1–58) when the dose category $0.3 Gy was compared to 0.3 Gy.  These results suggest that
radiation dose to the thyroid gland was a significant contributor to thyroid cancers diagnosed in children
who lived in Belarus during and after the Chernobyl releases and that this contribution is evident at doses
exceeding 0.3 Gy.
An analysis of 251 thyroid cancer cases in children (14 years or younger) from Belarus who were
diagnosed during the period 1986–1993 revealed a dose trend in incidence when the cases were organized
by districts that reflected their respective mean thyroid doses (Drobyshevskaya et al. 1996).  Incidence
ranged from 81 to 201 per 100,000 where estimated average thyroid doses were above 1 Gy (1.2–1.6 Gy,
120–160 rad), and 14–55 per 100,000 where doses were between 0.1 and 0.5 Gy (10–50 rad).  The highest
incidence occurred in Bragin where individual thyroid doses were estimated to have ranged from 0.8 to
20 Gy (560, 80–2,000 rad) (mean, 5.6 Gy, 560 rad).  Incidence was 9 per 100,000 in Braslav where the
lowest measurable thyroid doses were reported (mean, 0.005 Gy, 0.5 rad).  Children who were under
3 years old or in utero at the time of exposure accounted for 53% of thyroid cancer cases.  This age-group
was estimated to have received a thyroid radiation dose that was approximately 2–3 times that for older
children (approximately 1.4 Gy average dose).  However, 52% of the cancers were diagnosed in children
who received an estimated thyroid dose of <0.3 Gy and 84% in children who received doses <1 Gy. 
Children under 3 years old accounted for 38% of the cancer cases among children exposed to <0.3 Gy. 
These results suggest that young children were particularly susceptible to lower radiation doses. 
An analysis of 531 thyroid cancer cases in children and adolescents (under 18 years of age) from Ukraine
who were diagnosed during the period 1986–1994 revealed that 55% of the cases were under age 6 years
on the date of the Chernobyl release (Tronko et al. 1996).  The annual incidence of thyroid cancer in
children and adolescents (under 19 years of age) increased from approximately 0.05 per 100,000 prior to
1986 to 0.43 per 100,000 in 1992.  In 1994, the incidence (per 100,000) was highest in regions nearest to
Chernobyl: Chernihiv, 3.8; Zhytomyr, 1.6; and Kiev, 1 (Tronko et al. 1996).  Thyroid radiation doses were
estimated to have ranged from 0.01 to >1.5 Gy in the case group analyzed.  Approximately 20% of the
cases were estimated to have been exposed to 0.01–0.05 Gy (1–5 rad) and 80% to 0.1–0.3 Gy or less
(10–30 rad).  
Further evidence that the Chernobyl releases probably contributed to the observed increase in thyroid
cancer incidence comes from a study of the demographics and pathology of thyroid cancers in Belarus and
Ukraine with those diagnosed in Italy and France during the same time period (Pacini et al. 1997). 
Thyroid cancers cases in 472 children and adolescents <21 years of age diagnosed in Belarus and Ukraine
during the period 1986–1995 were evaluated.  These included approximately 98% of all childhood cases
reported during that period.  The comparison group consisted of 369 cases of the same age groups
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consecutively diagnosed at two clinics in Italy (n=219) and France (n=150).  The study revealed several
differences in the Belarus-Ukraine cases when compared with the Italy-France cases.  Most of the Belarus-
Ukraine cases were 5 years of age or less, whereas most of the Italy-France cases occurred after age
14 years.  The female:male ratio of the Italy-France cases was significantly higher (2.5) than the ratio in
the Belarus-Ukraine cases (1.6).  Most (94%) of the Belarus-Ukraine cases were papillary carcinomas with
follicular carcinomas accounting for only 5% of cases, whereas 82% of the Italy-France cases were
papillary and 15% were follicular carcinomas.  Cancers diagnosed in the Belarus-Ukraine group, typical of
thyroid cancer in early childhood, tended to be more invasive with extrathyroidal involvement more
frequently than in the Italy-France cases.  The Belarus-Ukraine cases also had a higher incidence of
thyroid autoimmunity (i.e., elevated antithyroid peroxidase and thyroglobulin antibodies) than the Italy-
France cases.  These results suggest different factors contributed to the Belarus-Ukraine and Italy-France
cases, radiation dose possibly being at least one factor. 
In both Belarus and the Ukraine, the highest rates of childhood thyroid cancer have occurred in areas
where exposure to other industrial contaminants are likely to have occurred and where there is evidence for
widespread iodine deficiency.  These factors may have affected the early appearance of thyroid cancer
after the accident, when vigorous public health screening programs for thyroid abnormalities were
initiated.  The incidence of thyroid cancer prior to the accident in these areas was poorly documented
(Nikiforov and Fagin 1998).
The strengths of the Chernobyl thyroid studies described above include: (1) the large number of children
who received substantial thyroid doses; (2) the studies included thyroid exposure measurements on more
than 100,000 children; (3) the generally high level of thyroid surveillance in the population after the
accident; and (4) that many children were screened with ultrasound, which provides relatively objective
evidence of thyroid nodularity; one study (Astakhova et al. 1996) attempted to control for the intensity of
thyroid surveillance.  Limitations of these studies include: (1) substantial dose uncertainties and use of
average doses in many of the studies rather than estimates of individual doses; (2) no thyroid dose
estimates for many of the thyroid cancer cases; (3) the presence of iodine deficiency in the study
populations may have affected both the thyroid radiation dose received from 131I as well as the likelihood
of a thyroid neoplasm; (4) greater intensity of thyroid screening and surveillance in the areas of highest
exposure than in areas of lower exposure; and (5) lack of rigorous epidemiologic study designs in many of
the studies (i.e., no systematic sampling design, no blinding of examiners with respect to likely thyroid
dose, and irregular variations in thyroid screening).
Hanford Nuclear Site Releases.  The CDC (1999) has conducted a follow-up prevalence study of thyroid
cancer in populations who resided near the Hanford Nuclear Site in southeastern Washington during the
period 1944–1957.  At the time this profile was developed, a draft report of this study was available from
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the Fred Hutchinson Cancer Research Center web site (http://www.fhcrc.org/science/phs/htds/); however,
a final published report was not available.  The study included 3,441 subjects who were born during the
period 1940–1946 in counties surrounding the Hanford Nuclear Site.  Thyroid disease was assessed from a
clinical evaluation of each subject, which included assessments of ultrasound or palpable thyroid nodules. 
Historical information on thyroid disease and information on radiation exposures were obtained by
interviews and, when possible, review of medical records of participants, including pathology slides to
confirm cancer diagnosis.  Thyroid radiation doses were estimated using a dosimetry model developed in
the Hanford Environmental Dose Reconstruction Project.  Information on residence history and relevant
food consumption patterns (e.g., milk consumption, breast feeding, consumption of locally harvested
produce) for each study participant was obtained by interview.  The estimated mean thyroid radiation dose,
based in 3,190 participants, was 182 mGy (±227, SD) (18.2±22.7 rad) and the range was
0.0008–2,842 mGy (0.00008–284 rad).  Doses varied geographically, with the highest doses received by
people who lived near and downwind from the site.  Dose-response relationships were assessed using a
linear regression model with adjustments for the following confounding and effect modifying variables:
sex, age of first exposure, age of evaluation, ethnicity, smoking, and potential exposures from Nevada Test
Site releases.  Alternatives to the linear model were also explored including linear quadratic and logistic
models.  Incidences of thyroid carcinoma or nodules were found to be unrelated to thyroid radioiodine
dose.  As noted above, a final report of conclusions has not been published and the study is currently under
review by the National Research Council.  Strengths of the Hanford study include: (1) the extremely
careful study design and methods; (2) the systematic sampling and high rates of subject location and
participation; (3) blinded thyroid assessments by multiple examiners, along with ultrasound which is a
more objective assessment of thyroid nodularity; and (4) extensive attempts to model thyroid radiation
doses in various locales, combined with self-reported or parent-reported estimates of milk and vegetable
consumption to estimate individual thyroid doses.  Limitations of the Hanford study include substantial
individual dose uncertainties, since no thyroid exposure measurements were available and individual milk
and vegetable consumption estimates were recalled 30–40 years after the exposure period studied; and
statistical power and precision were limited by the model’s sample size and relatively low dose range.
3.2.3  Dermal Exposure
3.2.3.1 Death
No information was located on deaths associated with dermal exposure to iodine.
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3.2.3.2 Systemic Effects
No information was located regarding respiratory, cardiovascular, gastrointestinal, hematological,
musculoskeletal, hepatic, renal, dermal, ocular, body weight, or other systemic effects of dermal exposure
to iodine or radioiodine  
Endocrine Effects.    Povidone-iodine is a complex of I2 and polyvinyl pyrrolidone and is widely used
as a topical antiseptic for mouth, skin, and vaginal infections, and surgical procedures.  Topical
preparations of povidone-iodine contain approximately 9–12% iodine, of which a small fraction is in free
solution (Lawrence 1998; Rodeheaver et al. 1982).  Dermal exposure to povidone-iodine has induced acute
toxicity in humans.  In one case, hyperthyroidism and thyrotoxicosis developed in an adult male who, for
6 months, received povidone-iodine skin washes to treat dermal ulcers but had no other history of excess
iodine intake or treatment with iodine-containing drugs (Shetty and Duthie 1990).  The patient had
elevated antithyroglobulin and thyroid peroxidase (thyroid microsomal) antibodies.  The disorder
eventually required therapy with propylthiouracil and radioiodine.  It is possible that the povidone-iodine
exposure may have aggravated a pre-existing autoimmune disorder in the patient rather than having been
the cause of the thyrotoxicosis.
Several cases of hypothyroidism induced by topical applications of povidone-iodine to wounds have been
described.  In one case, an adult female was exposed to approximately 22 mg iodine as povidone-iodine,
3 days/week for 22 months, when an open fistula was swabbed with povidone-iodine and packed with
iodoform impregnated gauze (Prager and Gardner 1979).  The patient developed clinical hypothyroidism
with thyroid enlargement and became euthyroid within 6 weeks after the iodine treatment of the wound
was discontinued.  In a study of 27 neurological ward patients who received topical povidone-iodine
treatments for various procedures and for periods of 3–133 months, serum iodide, T4, and FT4
concentrations were significantly higher than a group of 13 patients who did not receive povidone-iodine
treatments (Nobukini et al. 1997).  Eight of the 27 patients who received povidone-iodine treatments were
clinically hyperthyroid (serum FT4 concentration above the normal range) and 3 of 27 patients were
suspected of having subclinical hypothyroidism (serum TSH concentrations above the normal range). 
None of these patients had elevated antithyroglobulin or thyroid peroxidase antibodies, suggesting that
thyroid autoimmunity was not the cause of the apparent thyroid hormone disturbances.  Serum FT4
concentrations were significantly positively correlated with the duration of povidone-iodine exposure.
Povidone-iodine gels are used for vaginal lubrication during labor checks prior to delivery.  Use of
povidone-iodine gels has been associated with increased serum iodide concentrations as well as changes in
thyroid hormone status, indicative of subclinical thyroid gland suppression.  In a study of 18 women who
received intravaginal treatments with povidone-iodine gel during labor checks, serum iodide
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concentrations were significantly higher after the applications than before the applications (Jacobson et al.
1984).  Serum TSH concentrations were significantly elevated (5.9 mU/L) in the povidone-iodine group
compared to a group of 13 women who received vaginal lubricants that did not contain iodine (1.9 mU/L). 
There were no differences in the levels of T4 or T3 between the iodine and no-iodine groups.
Use of povidone-iodine for topical disinfection and surgical wound disinfection in infants has been shown
to induce hypothyroidism and hyperthyroidism.  In a prospective study, 17 premature infants (#36 weeks
gestation), who were euthyroid with no indications of thyroid disorders, received topical povidone-iodine
applications for various procedures beginning within 24 hours of birth (Brown et al. 1997).  Five of
17 (29%) of the infants had a significant decrease (<50% of pretreatment value) in their serum T4
concentrations compared to none of 14 control infants who received the same clinical procedures, but with
topical application of a noniodine disinfectant (chlorhexidine).  These five infants had serum T4
concentrations that were below 40 nmol/L (3.1 µg/dL) 4–6 days after exposure to povidone-iodine,
indicating a clinical hypothyroidism (60 nmol/L is low end of normal range), although their serum TSH
concentrations were not elevated (<20 mU/L, de Zegher et al. 1994; Momotani et al. 1992).  Their T4
status reverted to normal within 10–25 days after treatment.  There were no significant differences between
the treatment and control group mean values for serum T4 or TSH.  Iodide concentrations in random
untimed urine samples were approximately 24 times higher in the treatment group (1,800–3,600 µg/L) than
in the control group (90–150 µg/L), indicating absorption of some of the topically applied iodine.  In a
study of 30 intensive care ward infants who received frequent topical applications of povidone-iodine for
various procedures, five patients (20%) developed clinical hypothyroidism with serum T4 and T3
concentrations below the normal range, serum TSH concentrations above the normal range, and thyroid
gland enlargement (Chabrolle and Rossier 1978a, 1978b).  Urinary iodide excretion rates at the time of
treatment ranged from 2.9 to 4.8 mg I/day in four of the patients and was 0.14 mg I/day in one of the
patients, suggesting daily absorbed doses of iodine in this same range.  The thyroid hormone status
reverted to normal after the povidone-iodine treatments were discontinued.  A 30% incidence of
hypothyroidism was reported in 10 intensive care ward newborns who received topical povidone-iodine
applications for various procedures for >2 days in duration (l’Allemand et al. 1987).  A newborn infant
who received povidone-iodine irrigations of wound drains became clinically hyperthyroid without elevated
serum titres of antithyroglobulin or thyroid peroxidase (thyroid microsomal) antibodies (Bryant and
Zimmerman 1995).  The patient became euthyroid within 1 month after the povidone-iodine irrigations
were discontinued.  Thyroid status of four infants with spinal bifida who received daily povidone-iodine
antiseptic dressings were followed; two of the four patients became hypothyroid after 4 weeks of exposure
and required treatment with T4 (Barakat et al. 1994).  The patients became euthyroid within 9 months after
the povidone-iodine applications were discontinued.  In a study of 47 neonatal intensive care patients who
were exposed to topical povidone-iodine for varying lengths of time, no evidence was found of thyroid
suppression or hypothyroidism (Gordon et al. 1995).
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Topical application of povidone-iodine during labor has been found to produce thyroid gland suppression
in newborns.  In a study of 30 women who received topical povidone-iodine in preparation for a cesarean
section, newborn serum TSH concentrations (cord blood) were significantly higher than in newborns from
12 mothers who also underwent a cesarean section, but who were not exposed to povidone-iodine (Novaes
et al. 1994); however, the levels were not above the normal range for newborns (>20 mU/L, de Zegher et
al. 1994; Momotani et al 1992).  Serum concentrations of T4 and T3 were not different in the two groups of
newborns.  In a study of infants delivered by mothers who received intravaginal povidone-iodine during
labor checks, serum TSH concentrations were significantly higher and T4 and T3 concentrations were
significantly lower compared to 18 control infants delivered from mothers who were not exposed to
povidone-iodine during labor (l’Allemand et al. 1983).  Twenty percent of the infants from the treated
mothers had serum TSH concentrations above the normal range for newborn infants (>20 mU/L) and
serum T4 concentrations below the normal range (<7 µg/dL) and, thus, were clinically hypothyroid.  All
infants were euthyroid at 14 days after birth.
3.2.3.3 Immunological and Lymphoreticular Effects
 
Dermal exposures to povidone-iodine have produced localized and systemic allergic responses in humans. 
In one case, an adult male developed a reaction to application of povidone-iodine to an arm wound.  The
reaction consisted of itching of the extremities, urticaria, and angioedema (of the face), which were
ameliorated with antihistamine treatment (López Sáez et al. 1998).  A serum specific IgE assay detected
reactivity in the patient’s serum to various povidone-iodine and various other iodine preparations.  Several
case reports have been published that describe dermatitis in people who have been exposed to topical
applications of povidone-iodine and subsequently reacted to dermal challenge tests to povidone-iodine
(Okano 1989; Tosti et al. 1990).
Intravaginal applications of povidone-iodine have also induced allergic reactions in humans.  In one case,
an adult woman developed a bronchospastic reaction in response to application of povidone-iodine and an
iodine-containing contrast medium (Moneret-Vautrin et al. 1989).  The patient reacted in a dermal
challenge test to povidone-iodine, but not the contrast medium, and the patient’s serum tested positive for
histamine release and basophil degranulation in vitro.  In another case, anaphylaxis occurred in a patient
after an intravaginal application of povidone-iodine.  The patient reacted to povidone-iodine in a dermal
challenge test (Waran and Munsick 1995).
Although the above cases appear to implicate povidone-iodine as the causative agent in the allergic
responses reported, povidone itself, without iodine, has also been shown to produce allergic reactions and
anaphylaxis in humans and may have contributed to the reactions observed in some of these cases (Garijo
et al. 1996).
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3.2.3.4 Neurological Effects
No information was located on neurological effects associated with dermal exposure to iodine.  Dermal
exposure to excess iodine may produce mild transient hypothyroidism and hyperthyroidism (see
Section 3.2.3.2, Endocrine Effects), which could give rise to neurological manifestations of thyroid gland
dysfunction including impairments in neurological development and myopathies (Boyages 2000a, 2000b). 
However, based on the mild effects that have been observed in association with dermal exposures, such
severe neurological sequellae are not likely.
3.2.3.5 Reproductive Effects
No information was located on reproductive effects associated with dermal exposure to iodine.  Dermal
exposure to excess iodine may produce mild transient hypothyroidism and hyperthyroidism (see
Section 3.2.3.2, Endocrine Effects).  Either could give rise to disruption of reproductive systems secondary
to thyroid gland dysfunction; however, based on the mild effects that have been observed in association
with dermal exposures, significant disruptions of reproductive function are not likely.  Hypothyroidism can
produce changes in the menstrual cycle in humans, including menorrhagia (excessive uterine bleeding) and
anovulation (no ovulation).  Abortions, stillbirths, and premature births have also been associated with
hypothyroidism (Longcope 2000a).  Reproductive impairments associated with hyperthyroidism include
amenorrhea, and alterations in gonadotropin release, sex hormone-binding globulin (SHBG), and
associated changes in the levels and metabolism of steroid hormones in both females and males (Longcope
2000b).
3.2.3.6 Developmental Effects
No information was located on developmental effects associated with dermal exposure to iodine.  Dermal
exposure to excess iodine may produce mild transient hypothyroidism and hyperthyroidism (see
Section 3.2.3.2, Endocrine Effects).  Use of povidone-iodine for topical disinfection and surgical wound
disinfection in infants has been shown to induce hypothyroidism and hyperthyroidism, and topical
application of povidone-iodine during labor has been found to produce thyroid gland suppression in
newborns (see Section 3.2.3.2, Endocrine Effects).  Hypothyroidism or hyperthyroidism could give rise to
developmental effects secondary to thyroid gland dysfunction  (Boyages 2000a, 2000b).  Developmental
effects of hypothyroidism include severe impairment in neurological development of the fetus known as
cretinism, or growth retardation (Boyages 2000a, 2000b; Snyder 2000a).  Severe impairment of
neurological development or growth retardation are effects only seen with severe, long-standing thyroid
deficiency, not the transient form that has been associated with dermal iodine-induced hypothyroidism. 
Growth acceleration may occur in childhood hyperthyroidism, which is thought to be related to accelerated
IODINE 102
3.  HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
pituitary growth hormone turnover or a direct effect of thyroid hormone on bone maturation and growth
(Snyder 2000b).
3.2.3.7 Cancer
No information was located on cancer in association with dermal exposure to iodine.
3.2.4 External Exposure
No information was located on health effects associated with external exposure to radioiodine. 
3.2.4.1 Death
3.2.4.2 Systemic Effects





3.2.5 Other Routes of Exposure
3.3 GENOTOXICITY
Potassium iodide, I2, and povidone iodine (0.1–10 mg/mL) did not show mutagenic effects in L5178Y
mouse lymphoma cells or in transforming activity in Balb/c 3T3 cells grown in culture (Kessler et al.
1980; Merkle and Zeller 1979).  Potassium iodide and I2 did not produce lethal mutations in Drosophila
melanogaster when eggs were incubated in 0.38 mg/mL I2 or 0.75 mg/mL potassium iodide (Law 1938).  I2
did not show mutagenic activity in His+ revertant assay in Saccharomyces cerevisiae (Mehta and von
Borstel 1982a)  Iodide is a free-radical scavenger and has been shown to decrease hydrogen
peroxide-induced reversion in strain TA104 of Salmonella typhimurium (Han 1992).
Sodium iodate (NaIO3) was not mutagenic when tested in the bacterial Ames assay, mouse bone marrow
micronucleus test, or recessive lethal test in Drosophila melanogaster (Eckhardt et al. 1982).  Sodium
iodate does have radiosensitizing activity and has been shown to increase the number of gamma radiation-
induced single-strand DNA breaks in bacteria (Myers and Chetty 1973).  Iodate is more active 
radiosensitizing agent than is iodide (Kada 1970; Kada et al. 1970; Noguti et al. 1971)
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Chromosome aberrations (breakages, dicentrics, micronuclei) have been found in peripheral blood cells of
patients who received 131I ablative therapy for hyperthyroidism, in infants born to mothers who received
such therapy during pregnancy, and in children exposed to radioiodine released from the Chernobyl
nuclear power plant (Ardito et al. 1987; Baugnet-Mähieu et al. 1994; Boyd et al. 1974; Catena et al. 1994;
Goh 1981; Lehmann et al. 1996; Ramírez et al. 1997).  The range of 131I exposures in these cases was
15–200 mCi (0.6–7.4 GBq). 
A study of 21 patients who received various exposures to 131I for ablative treatment of thyroid carcinoma
found a significantly higher frequency of micronuclei in peripheral blood cells of patients compared to a
group of 93 healthy controls (Catena et al. 1994).  A significant exposure response relationship was
observed at exposures that ranged from 35 to 202 mCi (1.3–7.5 GBq).  A study of 10 patients who
received 131I for ablative treatment of thyroid carcinoma compared the outcomes of cytogenetic assessment
of peripheral blood lymphocytes before or 1 and 10 days after their 131I exposures (Baugnet-Mahieu et al.
1994).  The patients received two oral doses of 840 MBq (50 mCi) given on 2 consecutive days.  A small
but statistically significant increase in “abnormal cells” (2.69%) and dicentrics (1.91%) occurred after
exposure to 131I.  Cytogenetic assessments of peripheral blood lymphocytes of five patients who received
15–40 mCi (0.6–1.6 GBq) for treatment of hyperthyroidism and four control subjects revealed dicentrics
and rings in the treated patients, but no such abnormalities in the control subjects (Boyd et al. 1974).  An
increase in the frequency of micronuclei in peripheral blood lymphocytes was observed of 12 adult women
1 week after they received 100–150 mCi 131I (3.7–5.5 GBq) for treatment of thyroid cancer (Ramírez et al.
1997).  The frequency of chromosome translocations in thyroid tumor tissue was compared among groups
of patients who had tumors but no radiation history (n=24), patients who received 131I or external radiation
therapy (n=7), and children (n=40) who were residents of the Gomel, Brest, or Minsk regions of Belarus at
the time of the Chernobyl accident (Lehmann et al. 1996).  The frequency of translocations was highest in
the patients who received radiation therapy and lowest in the patients that had no history of exposure to
radiation.  Translocation frequencies among Belarussian children were lower than in the radiation therapy
patients and higher than the patients who had no radiation history.  The highest translocation frequencies
among Belarussian children were observed in children from the Gomel region where 131I exposures and
thyroid radiation doses are considered to have been the highest of the three regions studied.
Goh (1981) reported a case of cretinism that developed at age 8 months in an infant whose mother received
99 mCi (3.7 GBq) of 131I during her sixth week of pregnancy.  The infant was hypothyroid and had no
detectable thyroid gland function.  Cytogenetic studies conducted on peripheral blood lymphocytes
revealed chromosomal breakages in both the infant and mother.  
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Molecular iodine (I2) is absorbed when humans are exposed to I2 vapor.  In volunteers who inhaled
radioiodine I2 vapor, essentially all of the inhaled vapor was retained and cleared from the respiratory tract
with a half-time of approximately 10 minutes (Black and Hounam 1968; Morgan et al. 1968).  Much of the
clearance of the iodine from the respiratory tract was transferred to the gastrointestinal tract, suggesting
that the initial deposition was primarily in the conducting airways and subject to mucocilliary clearance
mechanisms.  Observations in humans of relatively rapid absorption of inhaled I2 are supported by studies
in mice, rats, dogs, and sheep (Bair et al. 1963; Willard and Bair 1961). 
Methyl iodide is also inhaled when humans are exposed to methyl iodide vapor.  In volunteers who inhaled
tracer concentrations of [132I]methyl iodide, approximately 70% of the inhaled iodine was retained with a
half-time in the respiratory tract of approximately 5 seconds, suggesting extremely rapid absorption at the
alveolar-blood interface (Morgan and Morgan 1967; Morgan et al. 1967a, 1967b).  
Studies of the absorption of inhaled inorganic iodide in humans are not available.  However, in monkeys
that inhaled particulate aerosols of radioiodine as sodium iodide (mass median diameter,
2.32 µm±1.15 SD), inhaled iodide was retained in the respiratory tract with a half-time of approximately
10 minutes (Perrault et al. 1967; Thieblemont et al. 1965).  In dogs and rats that were exposed to cesium
chloride aerosols containing 131I (mass median aerodynamic diameter, 1.4 µm±1.7 SD), iodine was retained
and rapidly cleared from the respiratory tract (McClellan and Rupprecht 1968; Thomas et al. 1970). 
Retention and relatively rapid absorption of iodine has also been observed in mice and sheep that inhaled
radioiodine as either sodium iodide or silver iodide particulate aerosols (mean count diameter, 0.25 µm)
(Bair et al. 1963; Willard and Bair 1961).
3.4.1.2 Oral Exposure
Gastrointestinal absorption of iodine is generally considered to be approximately 100% after an ingested
dose of water soluble iodide salts, such as potassium or sodium iodide.  This conclusion is based on several
types of observations made in human subjects who received oral doses of radioiodine compounds (the
reader should note that where the chemical form of the radioiodine compound was not reported, which is
the case for most of the radioiodine tracer studies described here, it is likely that it was sodium iodide, as
this is a common form supplied commercially for pharmaceutical use).  Fecal excretion of 131I was <1% of
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the dose in seven euthyroid adult subjects who ingested a single tracer dose of 131I, suggesting near
complete absorption of the ingested radioiodine (Fisher et al. 1965).  In the same study, 20 euthyroid
adults received daily oral doses of potassium iodide for 13 weeks (0.25 or 1.0 mg I/day).  Daily urinary
iodine excretion was approximately 80–90% of the estimated daily intake, also suggesting near complete
absorption.  Similarly, in an acute ingestion study of nine healthy subjects, urinary and thyroid radioiodine
accounted for 97% (±5, SD) of a single ingested tracer dose of radioiodine (131I or 132I), suggesting near
complete absorption of the tracer dose (Ramsden et al. 1967).  In this same study, two subjects ingested the
tracer dose together with a dose of 5 or 15 mg stable iodide (the chemical form of the stable iodide was not
specified, but presumably, it was either potassium or sodium iodide) and the recoveries of radioiodine in
thyroid and urine were 96 and 98%, respectively.  In one subject who ingested the tracer dose either after a
fast (duration not specified) or with a “full stomach”, the recoveries of radioiodine in thyroid and urine
were 97 and 98% under the two conditions (Ramsden et al. 1967).
Measurement of radioiodine uptake in the thyroid gland is also an indicator of absorption, although such
measurements alone do not allow an accurate quantitative estimate of absorption without other
assumptions about the pharmacokinetics of iodine.  Studies of iodine kinetics in subjects who received
intravenous injections of tracer doses of radioiodine have shown that the fraction of an injected dose that
accumulates in the thyroid is affected by many variables; however, it is relatively constant among
individuals who have the same iodine intake and whose thyroid glands are "normal" (see Section 3.4.2.2). 
This fraction has been shown to be similar (20–35%) when radioiodine (123I, 125I, or 131I) is administered to
adults by the intravenous or oral routes, suggesting extensive, if not complete, absorption of ingested
radioiodine (Bernard et al. 1970; Gaffney et al. 1962; Ghahremani et al. 1971; Oddie and Fisher 1967;
Pittman et al. 1969; Robertson et al. 1975; Sternthal et al. 1980; Van Dilla and Fulwyler 1963, 1964). 
Although the fraction of the oral dose of radioiodine taken up by the thyroid 1–2 days after an oral dose
may be slightly higher in females than males, there is no evidence that this difference results from
differences in absorption (Ghahremani et al. 1971; Quimby et al. 1950; Robertson et al. 1975).
Gastrointestinal absorption of iodine appears to be similar in children, adolescents, and adults, as assessed
from measurements of 24-hour thyroid uptakes of radioiodine administered orally (Cuddihy 1966; Oliner
et al. 1957; Van Dilla and Fulwyler 1963, 1964).  Absorption in infants, however, may be lower than in
children and adults.  Evidence for this comes from studies in which thyroid uptake of radioiodine was
measured in newborns who received tracer doses of radioiodine orally or by injection.  In general, injection
of the radioiodine intramuscularly or intravenously resulted in higher thyroid uptakes than when the
radioiodine was administered by gastric tube, suggesting incomplete absorption of the oral dose.  For
example, in 8 healthy newborn infants (<36 hours post natal) who each received a tracer dose of 131I by
gastric tube, the average peak thyroid uptake (30 hours after the dose) was approximately 50% of the dose
compared to an average of 70% (25 hours after the dose) in 17 infants who received the tracer dose as an
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intramuscular injection (Morrison et al. 1963).  The ratio of the thyroid uptakes after the oral and injected
iodine doses suggests a fractional oral absorption of approximately 70%.  In a study involving slightly
older newborns (72–96 hours old), 15 newborns each received a tracer dose of 131I by gastric tube and the
average 24-hour uptake of radioiodine in the thyroid was 20% (range, 6–35%) (Ogborn et al. 1960).  By
contrast, in a study of seven healthy infants (<3 days old), the mean thyroid uptake 24 hours after an
intramuscular tracer dose of 131I was 70% (range, 46–97) (van Middlesworth 1954).  In a study of
26 healthy newborns (<48 hours old) who each received an intravenous tracer dose of 131I, the mean
24-hour thyroid uptake was 62% (range, 35–88) (Fisher et al. 1962).  Some of the differences in the
thyroid uptakes observed in the above three studies may reflect differences in age, as thyroid uptake of
injected radioiodine appears to decrease substantially during the first postnatal week (see Section 3.4.2.2);
nevertheless, the studies suggest the possibility of lower absorption of iodine (30–70% of an oral dose)
during the first few postnatal days, which may extend to older ages of infancy.
Although ingested iodide appears to be nearly completely absorbed in children and adults (but not in
infants), other chemical forms of iodine appear to be less completely absorbed.  For example, iodine
compounds, such as I2 and iodates (e.g., NaIO3), may undergo reduction to iodide before being absorbed in
the small intestine and absorption may not be complete (Cohn 1932).  Iodine from the sodium salt of the
thyroid hormone thyroxine (T4) is absorbed when T4 is ingested.  In two adults who each received a single
oral dose of 80 µg [131I]-T4, the rate of fecal excretion of radioiodine was similar to that observed in three
subjects who received the same dose intravenously (10–15% of the dose), suggesting substantial
absorption from the gastrointestinal tract (Myant and Pochin 1950).  In this same study, the sum of urinary
excretion of radioiodine and thyroid uptake of radioiodine, 24 hours after the oral dose of [131I]-T4 was
approximately 25% of the dose, compared to an average of 33% (±7) in six subjects who received the
[131I]-T4 dose intravenously.  This observation is also consistent with substantial, if not complete,
absorption of T4 from the gastrointestinal tract (at least 75% of the dose). 
Iodine incorporated into bovine milk appears to be nearly completely absorbed when ingested.  Cuddihy
(1966) measured thyroid uptakes of radioiodine in euthyroid subjects who ingested radioiodine-
contaminated cow milk for 14 days.  The milk was collected from a cow that was fed 131I in feed
(endogenously incorporated).  Thyroid uptake 24 hours after the last milk dose was approximately 23% of
the dose.  Since this value is within the range of 20–35% observed when a tracer dose of 131I was
administered orally or intravenously, it suggests that iodine that is endogenously incorporated into cow
milk is extensively, if not completely, absorbed.  A slightly different observation leads to a similar
conclusion.  Comar et al. (1963) compared radioiodine uptakes in each of 11 healthy adults who ingested
131I in a capsule (containing an aqueous solution of radioiodine) or 131I endogenously incorporated into cow
milk.  The 24-hour thyroid uptakes were nearly identical under each dosing condition (means, 19 and 20%
of the dose) suggesting a similar absorbed fraction of the dose.  Pendelton et al. (1963) measured 131I in
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dairy cow milk from farms near the NTS, and in the thyroids or total bodies of families who lived on these
farms (measured from external thyroid or total body counting).  The average uptake of 131I in
24 individuals was 17% (range, 5–47%) which is similar to that observed after ingestion or injection of
radioiodine.  Assessments of gastrointestinal absorption of iodine in other foods are not available, although
Wayne et al. (1964) reported that radioiodine incorporated into watercress was completely absorbed when
ingested by an adult (no details provided).
Observations in humans that indicate extensive absorption of ingested inorganic iodine are supported by
experiments in animals.  Iodine is extensively absorbed in rats when it is ingested as either I2 or NaI. 
When fasted rats were administered oral gavage tracer doses of 131I as either I2 or NaI, 8–9% of the dose
was excreted in feces in 72 hours and 34–35% of the dose was excreted in the urine (Thrall and Bull
1990).  In the same study, similar results were obtained in rats that were allowed free access to food before
the oral radioiodine dose; 6–7% of the dose was excreted in feces in 78 hours and 22–29% was excreted in
urine (22% of the I2 dose and 29% of the NaI dose).  These results suggest that tracer doses of ingested
iodine from NaI and I2 are both nearly completely absorbed from the gastrointestinal tract in rats.  When
tracer levels of radioiodine (131I) were administered orally, intravenously, or subcutaneously to four sheep,
the peak thyroid uptake of radioiodine was similar, 17–19% of the dose (these values are not corrected for
radioactive decay of the 131I), suggesting extensive absorption from the oral route (Wood et al. 1963). 
Povidone-iodine is a complex of I2 and polyvinyl pyrrolidone that is widely used as topical antiseptic. 
Povidone-iodine preparations contain approximately 9–12% iodine, of which only a small fraction is free
in solution (Lawrence 1998; Rodeheaver et al. 1982).  Absorption of iodine ingested as povidone-iodine
has be studied in rats.  Rats that received single gavage doses of 125[I]I-povidone (dose not specified)
absorbed approximately 3% of the dose, as assessed by measurements of the radioiodine that was retained
in the gastrointestinal tract 24 hours after the dose (Abdullah and Said 1981).  In the same study,
absorption was approximately 10 or 5% when the povidone-iodine was administered in 10% ethanol
solution and 5% when administered as a 0.2% solution of benzalkonium chloride.
3.4.1.3 Dermal Exposure
Systemic iodine toxicity has occurred following dermal exposures to iodine compounds, suggesting that
these compounds of iodine are absorbed across the skin of humans (see Section 3.2.3).  Harrison (1963)
attempted to estimate absorption rates for solutions of potassium iodide or iodine (I2), and gaseous I2 in
humans.  Subjects received topical applications of 131I as potassium iodide or iodine (I2) and absorption
was estimated from measurements of the cumulative urinary excretion of radioactivity and the 24-hour
activity in the thyroid.  Three subjects received a topical application of tracer concentrations of [131I]KI on
a 12.5 cm2 area of the forearm.  The site was left uncovered and after 2 hours, all of the applied
IODINE 108
3.  HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
radioactivity could be detected on the skin and approximately 90% of the radioactivity could be recovered
from the skin by washing with soap and water.  Absorption was estimated to be approximately 0.1% of the
applied dose (range, 0.09–0.13) based on 3-day cumulative urine radioactivity.  Thyroid radioactivity
24-hours after the topical dose was below the limits of detection.  If it was assumed that the 24-hour
thyroid uptake was 30% of the absorbed dose and that the all of the absorbed activity that was not
recovered in urine was in the thyroid, absorption was approximately 0.16% in the three subjects (range,
0.13–0.19).  In two subjects in this same study who received a similar topical application of aqueous tracer
[131I]I2 along with 0.1 mg of [127I]I2 carrier, the absorption was estimated to be 0.06–0.09% of the applied
dose, with the higher estimate assuming thyroid uptake of 30% of the absorbed dose.  This study also
estimated iodine absorption after dermal exposure to [131I]I2 vapor.  When a 12.5 cm2 area of skin was
isolated and placed in contact with I2 vapor for 30 minutes or 2 hours, approximately 90% of the total
iodine content of the vapor was deposited on the skin.  Approximately 50% of the deposited dose could be
washed off with soap and water.  Absorption varied depending on the amount of [127I]I2 carrier in the vapor
(the concentration was not reported).  At the lowest carrier amount (approximately 0.8 mg applied to the
skin), absorption of 131I was 1.2% of the activity that was on the skin at the end of the 2-hour exposure. 
With exposure to 3–5 mg carrier, which produced visible irritation of the skin (reddening or blistering),
absorption was 27–78%.  These observations suggest that exposure to I2 vapors can result in deposition of
iodine onto the skin and that dermal irritation produced by I2, and possibly other irritants, may
substantially increase the absorption of iodine after dermal exposure to I2.  Dermal absorption of I2 vapor
was indicated an experimental study in which 131I was detected in the thyroid glands of seven male adult
volunteers who were exposed, whole body and without respiratory intake, to 131I2 vapor (the exposure
appears to have been to tracer levels) for up to 4 hours (Gorodinskiy et al. 1979).
Povidone-iodine, a complex with iodine and polyvinyl-pyrrolidone, and alcohol tinctures of iodine are
widely used as a topical antiseptic.  Iodine is absorbed to some extent when such preparations are applied
to the skin, although quantitative estimates of the amount absorbed are not available for humans.  Urinary
iodine excretion has been shown to increase following the topical application of povidone-iodine to the
hands and arms as part of a surgical scrub routine, indicating systemic absorption (Connolly and Shepard
1972).  Increases in iodine concentration in maternal urine and umbilical cord blood have been observed in
pregnant women who received dermal or vaginal applications of povidone-iodine prior to delivery for
disinfection of the skin and fetal scalp electrodes, suggesting that absorption of iodine occurs with these
uses of povidone-iodine as well (l’Allemand et al. 1983; Bachrach et al. 1984).  Thyroid enlargement,
hypothyroidism, and elevated urinary iodine excretion also have been observed in hospitalized infants who
received frequent topical antiseptic scrubs with iodine-alcohol preparations as part of preparations for
various clinical procedures (Brown et al. 1997; Chabrolle and Rossier 1978a, 1978b).
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Some quantitative information is also available on dermal absorption of iodine in animals.  When tracer
levels of radioiodine (131I) were applied to the shaved skin (50–100 cm2) of four sheep, the peak thyroid
uptake of radioiodine was 2–6% of the applied dose compared to 17–19% when the dose was given orally,
subcutaneously, or intravenously (these values are not corrected for radioactive decay of the 131I) (Wood et
al. 1963).  In a second study, two sheep received a tracer dose of radioiodine as either an oral dose or a
topical dose; the peak thyroid uptake was 9–14% of the dose at 48–96 hours after the topical dose,
compared to 30% at 48 hours after the oral dose (both values corrected for radioactive decay).  The report
of these studies does not specify whether the topical applications were occluded or whether the animals
were restrained in any way from ingesting the topically applied radioiodine (e.g., licking the site of
application).  If ingestion of the radioiodine did not occur, then these studies suggest substantial absorption
of topically applied iodine since, during the first 1–4 days after topical dosing, thyroid radioiodine uptake
was approximately 30–50% of that observed after oral dosing, and thyroid uptakes after oral and parenteral
dosing were similar.  
Additional evidence for dermal absorption of iodine comes from a study of pigs.  A solution (solvent not
specified) containing a mixture of 85% [131I]I2 and 15% [131I]NaI was applied to a 150 cm2 area of
abdominal skin on each of four immature pigs and allowed to dry on the skin; the site of application was
not covered and it is not clear if the site was accessible to licking and ingestion of the applied radioiodine
(Murray 1969).  Approximately 95% of the applied dose was removed from the skin by washing the site of
application 2 hours after the dosing.  Peak thyroid uptake of radioiodine was approximately 0.2% of the
dose, 1–2 days after dosing (the report does not indicate whether the radioiodine measurements were
corrected for radioactive decay).  In the same study, a 150 cm2 area of clipped flank skin on each of four
immature pigs was exposed for 25 minutes to a vapor of 131I containing 85% gaseous 131I, presumably
[131I]I2.  The exposed areas were not covered or washed subsequent to exposure.  Peak thyroid uptake of
radioiodine was approximately 0.3% of the applied dose 5–7 days after dosing.  The lower amount of
absorption of radioiodine in the pigs compared to the results obtained in sheep (Wood et al. 1963) cannot
be interpreted with the available information.  It may reflect species differences in skin permeability to
iodine, differences in the chemical form iodine applied to the skin (I2 or I-), or differences in the amounts
of topically-applied radioiodine that were ingested from licking the site of application.
Povidone-iodine, an ingredient of some iodine-based topical disinfectants, is absorbed across the skin of
dogs.  Topical application of povidone-iodine in dogs resulted in elevated serum iodide concentrations
within 2 hours after application; the amount of iodine absorbed was not determined in this study (Moody et
al. 1988).  Evidence for absorption of iodine from topically applied povidone-iodine is also provided by
experiments with rats and mice.  Topical application of povidone-iodine to 15–20 mm2 of the shaved skin
of either rats or mice 2 hours prior to an injection of radioiodine decreased radioiodine uptake in the
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thyroid by 90%, suggesting competition between the absorbed topically applied iodine and the injected
radioiodine for thyroid uptake (Furudate et al. 1997).
3.4.1.4 Other Routes of Exposure
Iodine is absorbed systemically after intravaginal applications of povidone-iodine.  Increases in iodine
concentration in maternal urine, umbilical cord blood, and breast milk, and in infant urine have been
observed following vaginal applications of povidone-iodine to pregnant women prior to delivery for
disinfection of fetal scalp electrodes (l’Allemand et al. 1983).
3.4.2 Distribution
3.4.2.1 Inhalation Exposure
The distribution of absorbed iodine is expected to be similar regardless of the route of exposure to
inorganic iodine.  This is supported by studies in which humans were exposed to tracer levels of [132I]CH3I
and approximately 20–30% of the iodine retained in the respiratory tract was distributed to the thyroid
gland and 30–60% was excreted in urine in approximately 10 hours; essentially identical results were
obtained when a tracer dose of 132[I]NaI was ingested (Morgan et al. 1967a, 1967b).  Similar results were
obtained when volunteers inhaled tracer levels of radioiodine as I2 (Black and Hounam 1968; Morgan et al.
1968).  The distribution of inhaled particulate aerosols of sodium iodide in monkeys also appears to be
similar to ingested iodide (Perrault et al. 1967; Thieblemont et al. 1965).  A complete discussion of the
distribution of iodine after oral exposures to inorganic iodine is presented in Section 3.4.2.2, and is
applicable to inhalation exposures. 
3.4.2.2 Oral Exposure
The human body contains approximately 10–15 mg of iodine, of which approximately 90% is in the
thyroid gland, which accumulates iodine in producing thyroid hormones for export to the blood and other
tissues (Cavalieri 1997; Stather and Greenhalgh 1983).  The concentration of iodine in serum is
approximately 50–100 µg/L under normal circumstances (Fisher et al. 1965).  Approximately 5% in serum
is in the inorganic form as iodide; the remaining 95% consists of various organic forms of iodine,
principally protein complexes of the thyroid hormones T4 and T3 (Fisher et al. 1965; Nagataki et al. 1967; 
Sternthal et al. 1980; Wagner et al. 1961).  
The tissue distribution of iodide and organic iodine are very different and are interrelated by metabolic
pathways that lead to the iodination and deiodination of proteins and thyroid hormones in the body (see
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Section 3.4.3.2).  Iodide is largely confined to the extracellular fluid compartment, with the exception of 
tissues that possess specialized transport mechanisms for accumulating iodide; these include the thyroid,
salivary glands, gastric mucosa, choroid plexus, mammary glands, placenta, and sweat glands (Brown-
Grant 1961) (see Section 3.4.1).  Serum concentrations of iodide, indicative of extracellular fluid
concentrations, normally range from 5 to 15 µg/L; this would suggest a total extracellular iodide content of
the human body of approximately 85–170 µg, assuming an extracellular fluid volume of approximately
17 L (Cavalieri 1997; Saller et al. 1998).
Iodide concentrations in the thyroid are usually 20–50 times that of serum (0.2–0.4 mg/dL, 15–30 nM);
however, concentrations in excess of 100 times that of blood occur when the gland is stimulated by
thyrotrophin (a TSH) and concentrations in excess of 400 times blood have been observed (Wolff 1964). 
Other tissues that can accumulate iodide to a concentration greater than that of blood or serum include the
salivary glands, gastric mucosa, choroid plexus, mammary glands, placenta, and sweat glands (Brown-
Grant 1961).  Iodide taken up by the thyroid gland is utilized in the production of thyroid hormones, which
are stored in the gland (see Section 3.4.3.2).  This organic fraction of the thyroid iodine content accounts
for approximately 90% of the iodine in the thyroid gland and includes iodinated tyrosine and tyrosine
residues that comprise the thyroid hormones, T4 and T3, and their various synthesis intermediates and
degradation products.
The thyroid hormones, T4 and T3, account for approximately 90–95 and 5% of the organic iodine in
plasma, respectively (Fisher et al. 1965; Sternthal et al. 1980).  Nearly all (>99%) of the T4 and T3 in
plasma is bound to protein.  The major binding protein for T4 and T3 is thyroxine-binding globulin (TBG),
which has a high affinity for both hormones (Table 3-4) (Larsen et al. 1998; Robbins 1996).  Other
proteins that bind thyroid hormones, with lower affinity, include transthyretin (thyroxine-binding
prealbumin), albumin, and various apoproteins of the high density lipoproteins HDL2 and HDL3 (3–6% of
plasma hormones).  The distribution of protein-bound thyroid hormones is largely confined to the plasma
space, whereas the free hormones distribute to the intracellular space of a wide variety of tissues where
they exert the metabolic effects attributed to thyroid hormones.  TBG and other binding proteins serve as
reservoirs for circulating thyroid hormones and contribute to the maintenance of relatively constant free
hormone concentrations in plasma.
Uptake of T4 and T3 into liver, skeletal muscle, and other tissues occurs by a saturable, energy-dependent
carrier transport system (see Section 3.5.1).  Lipoprotein transport mechanisms may also play a role in the
uptake of thyroid hormones into certain tissues (Robbins 1996).  Intracellular T4 and T3 exist as free
hormone and are bound to a variety of intracellular proteins.
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Molecular weight of complex (D) 54,000 54,000 (subunit)a 66,000
Plasma concentration (µmol/L) 0.27 4.6 640
T4 binding capacity (µg T4/dL) 21 350 50,000
Association constants (M-1)
T4 1x1010 7x107 7x105 
T3 5x108 1.4x107 1x105
Fraction of sites occupied by T4b 0.31 0.02 <0.001
Distribution volume (L) 7 5.7 7.8
Turnover rate (percent/day) 13 59 5
Distribution of thyronines
(percent/protein)
T4 68 11 20
T3 80 9 11
Source:  Larsen et al. 1998
aTransthyretin consists of four subunits (54 kD) complexed with retinol binding protein
bIn euthyroid state
T3 = 3,5,3N-triiodo-L-thyronine; T4 = 3,5,3N,5N-tetraiodo-L-thyronine (thyroxine)
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Maternal exposure to iodine results in exposure to the fetus.  Radioiodine accumulation in the fetal thyroid
commences in humans at approximately 70–80 days of gestation, and precedes the development of thyroid
follicles and follicle colloid, which are generally detectable at approximately 100–120 days of gestation
(Book and Goldman 1975; Evans et al. 1967).  Fetal iodide uptake activity increases with the development
of the fetal thyroid and reaches its peak at approximately 6 months of gestation, at which point, the highest
concentrations in thyroid are achieved, approximately 5% of the maternal dose/g fetal thyroid 
(approximately 1% of the maternal dose) (Aboul-Khair et al. 1966; Evans et al. 1967).  Fetal radioiodine
concentrations 1–2 days following a single maternal dose of radioiodine generally exceed the concurrent
maternal thyroid concentration by a factor of 2–8 with the highest fetal/maternal ratios occurring in at
approximately 6 months of gestation (Book and Goldman 1975).  Following long-term exposure, either
from ingestion of administered radioiodine or from exposure to radioactive fallout, the fetal/maternal ratio
for thyroid radioiodine concentration has been estimated to be approximately 2–3 (Beierwaltes et al. 1963;
Book and Goldman 1975; Eisenbud et al. 1963). 
Iodine uptake into the thyroid gland is highly sensitive to the iodide intake.  At very low intakes,
representing iodine deficiency (e.g., 20 µg/day), uptake of iodide into the thyroid gland is increased
(Delange and Ermans 1996).  This response is mediated by TSH, which stimulates iodide transport and
iodothyronine production in the thyroid gland (see Section 3.5.1).  At very high intakes of iodine,
representing an intake excess (e.g., >1 mg/day), iodine uptake into the thyroid gland decreases, primarily
as a result of decreased iodothyronine synthesis (Wolff-Chaikoff effect) and iodide transport into the gland 
(Nagataki and Yokoyama 1996; Saller et al. 1998).  The fraction of an ingested (or injected) tracer dose of
radioiodide that is present in the thyroid gland 24 hours after the dose has been measured in thousands of
patients who received radioiodine for treatment of various thyroid disorders or for the assessment of
thyroid function; these provide a comparative index of effects of various factors on the distribution of
absorbed iodide to the thyroid gland.  A single oral dose of 30 mg iodide (as sodium iodide) decreases the
24-hour thyroid uptake of radioiodine by approximately 90% in healthy adults (Ramsden et al. 1967;
Sternthal et al. 1980).  The inhibition of uptake was sustained with repeated oral doses of sodium iodide
for 12 days, with complete recovery to control (presodium iodide) uptake levels within 6 weeks after the
last sodium iodide dose (Sternthal et al. 1980) or within 8 days after a single dose (Ramsden et al. 1967). 
Repeated oral doses of 1.5–2.0 mg iodide/m3 of surface area produced an 80% decrease in thyroid uptake
in children (Saxena et al. 1962).
The National Cancer Institute (NCI 1997) has analyzed data on 24-hour thyroid uptakes of radioiodine
reported over the period from 1950 to 1980 and concluded that thyroid uptakes in adults have decreased in
the United States over time from approximately 20–40% of the dose in the 1950–1960 period to
approximately 15–20% currently (Cuddihy 1966; Dunning and Schwartz 1981; Kearns and Phillipsborn
1962; Kereiakes et al. 1972; Oddie and Fisher 1967; Oliner et al. 1957; Pittman et al. 1969; Van Dilla and
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Fulwyler 1964).  This decrease appears to be related to a concurrent increase in the average dietary intake
of iodide in the population from approximately 200 µg/day to approximately 800 µg/day (NCI 1997).
Twenty-four-hour radioiodine uptakes into the thyroid gland in males and females who experience similar
iodide intakes are similar, although uptakes in females, as a percentage of the dose, appear to be 10–30%
higher than in males (Ghahremani et al. 1971; Oddie et al. 1968a, 1970; Quimby et al. 1950; Robertson et
al. 1975).  Thyroid uptakes in newborns are 3–4 times greater during the first 10 days of postnatal life than
in adults, and decline to adult levels after approximately age 10–14 days (Fisher et al. 1962; Kearns and
Phillipsborn 1962; Morrison et al. 1963; Ogborn et al. 1960; Van Middlesworth 1954).
3.4.2.3 Dermal Exposure
The distribution of absorbed iodine is expected to be similar regardless of the route of exposure to
inorganic iodine.  A complete discussion of the distribution of iodine after oral exposures to inorganic
iodine is presented in Section 3.4.2.2, and is applicable to inhalation exposures.
3.4.2.4 Other Routes of Exposure
The distribution of absorbed iodine is expected to be similar regardless of the route of exposure to
inorganic iodine.  A complete discussion of the distribution of iodine after oral exposures to inorganic
iodine is presented in Section 3.4.2.2, and is applicable to inhalation exposures.
3.4.3 Metabolism
3.4.3.1 Inhalation Exposure
The metabolism of absorbed iodine is expected to be similar regardless of the route of exposure to
inorganic iodine.  Inhaled methyl iodide and I2 appear to undergo rapid conversion to iodide based on
nearly identical distribution and excretion kinetics of radioiodine when it is inhaled as either methyl iodide
or I2, or ingested as sodium iodide (Black and Hounam 1968; Morgan and Morgan 1967; Morgan et al.
1967a, 1967b, 1968).  A complete discussion of the metabolism of iodine after oral exposures to inorganic
iodine is presented in Section 3.4.3.2, and is applicable to inhalation exposures.
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3.4.3.2 Oral Exposure
Iodide in the thyroid gland is incorporated into a protein, thyroglobulin, as covalent complexes with
tyrosine residues (Figure 3-3).  The iodination of thyroglobulin is catalyzed by the enzyme thyroid
peroxidase, which resides predominantly in the apical membrane of thyroid follicle cells, with the active
sites of the enzyme facing the follicular lumen (see Section 3.4.1).  The iodination reactions occur at the
follicular cell-lumen interface and consist of the oxidation of iodide to form a reactive intermediate, the
formation of monoiodotyrosine and diiodotyrosine residues in thyroglobulin, and the coupling of the
iodinated tyrosine residues to form T4 (coupling of two diiodotyrosine residues) or T3 (coupling of a
monoiodotyrosine and diiodotyrosine residue) in thyroglobulin (Figure 3-4).  The T4/T3 ratio in the thyroid
is approximately 15:1; however, the relative amounts of T4 and T3 produced depend, in part, on the
availability of iodide.  Low levels of iodide result in a lower T4/T3 synthesis ratio (Taurog 1996).
Thyroglobulin is stored in the follicular lumen.  When the thyroid gland is stimulated to produce and
release thyroid hormones, thyroglobulin is transported into the follicular cells (Taurog 1996).  Uptake of
thyroglobulin occurs by endocytosis at the apical membrane, which is followed by fusion of endocytotic
vesicles with lysosomes.  Proteolytic enzymes in the lysosomes break down the thyroglobulin into
constituent amino acid residues, including T4, T3, monoiodotyrosine, and diiodotyrosine.  T4 and T3 are
exported to the blood, while monoiodotyrosine and diiodotyrosine residues are retained in the cell and
deiodinated, and the iodide is recycled into the follicular lumen where it is reincorporated into 
thyroglobulin.  Under circumstances of extreme stimulation of the thyroid gland, monoiodotyrosine,
diiodotyrosine, and iodide can be released into the blood from the gland along with T4 and T3.  Although
the T4/T3 ratio in thyroglobulin is approximately 15:1 in the iodide replete state, the hormone secretion
ratio is lower, approximately 10:1; thus, some T4 appears to undergo monodeiodination to T3 in the thyroid
gland. 
All of the major steps of thyroid hormone synthesis and release are stimulated by the pituitary hormone,
TSH, including uptake of iodine by the thyroid gland, iodination of thyroglobulin, endocytosis of
thyroglobulin from the follicle lumen, and proteolysis of thyroglobulin to release thyroid hormone for
export to blood (see Section 3.4.1).  Hormone synthesis is also responsive to serum iodide concentration. 
An acute exposure to high oral doses of iodide (e.g., >1 mg) inhibits the production of iodothyronine in the
thyroid gland; this effect is not dependent on changes in circulating TSH levels, and is referred to as the
Wolff-Chaikoff effect (Wolff and Chaikoff 1948).  The effect is temporary, and with repeated exposure to
high doses of iodide, the thyroid gland escapes from the Wolff-Chaikoff effect and hormone synthesis
resumes to normal levels (Wolff et al. 1949).  The mechanism for the Wolff-Chaikoff effect appears to 
involve inhibition of both iodide transport and iodination reactions, possibly through an inhibition of the
expression of NIS and thyroid peroxidase that is mediated by iodide or an iodinated metabolic intermediate 
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Figure 3-3.  Pathways Uptake and Metabolism of Iodide in the Thyroid Gland
The diagram depicts a single thyroid follicle cell, with the plasma side of the follicle on the left and the follicle lumen on the right.
Iodide uptake (a) occurs through a Na+/I- symporter in the basolateral membrane and efflux into the follicle lumen(b) is thought to
occur through an I- channel in the apical membrane.  Iodination occurs in the follicle lumen (c). The enzyme thyroid peroxidase
(TPO), depicted in the follicle lumen, is actually located in the apical membrane.  Deiodination of iodotyrosines (g) is catalyzed by a
microsomal enzyme, iodotyrosine dehalogenase (ITDH); monodeiodination of T4 (h) is catalyzed by the microsomal enzyme,
5’-diodinase. All steps in the uptake of iodine and synthesis of thyroid hormones (a - h) are stimulated by binding of thyroid stimulating
hormone (TSH) to a receptor in the basolateral membrane.  Abbreviations:  DIT, diiodotyrosine ;EOI, enzyme-linked species; HOI,
hypoidous acid; ITDH, iodotyrosine dehalogenase; MMI, methimazole; MIT, monoiodotyrosine; PTU, propylthiouracil; T3,
triiodothyronine; T4, thyronine; Tg, throglobulin;TPO, thyroid peroxidase; TSH, thyroid stimulating hormone.





















































Figure 3-4.  Thyroid Hormones and Metabolic Precursors
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(Eng et al. 1999; Uyttersprot et al. 1997).  Escape occurs when transport of iodide into the thyroid gland
and the thyroid iodide concentration are sufficiently depressed to release the gland from inhibition of
thyroid peroxidase, or other steps in the production of iodothyronines (Saller et al. 1998).
A variety of chemical inhibitors of iodine thyroid metabolism have been described (Figure 3-3, see
Section 2.9).
The major pathways of metabolism of iodine that occur outside of the thyroid gland involve the catabolism
of T4 and T3, and include deiodination reactions, ether bond cleavage of thyronine, oxidative deamination
and decarboxylation of the side chain of thyronine, and conjugation of the phenolic hydroxyl group on
thyronine with glucuronic acid and sulfate (Figure 3-5).  Deiodination products formed in peripheral
tissues are depicted in Figure 3-6.  The monodeiodination of T4 to T3 is the major source of production of
peripheral T3, which has a greater hormonal potency than T4, and together with the production of
3,3',5-triiodo-L-thyronine (reverse T3, rT3), account for approximately 80% of total T4 turnover in humans
(Engler and Burger 1984; Visser 1990).  Deiodination of T4 and T3 also functions to deactivate the thyroid
hormones.  Iodide released from the deiodination reactions is either taken up by the thyroid gland or
excreted in urine (see Section 3.3.4.2).  Deiodination is catalyzed by selenium-dependent deiodinase
enzymes (selenodiodinases) (see Section 3.5.1). 
Oxidative deamination and decarboxylation of the alanine side chain of the iodothyronines represents
approximately 2 and 14% of total of T4 and T3 turnover, respectively (Braverman et al. 1970; Gavin et al.
1980; Pittman et al. 1980; Visser 1990).  Enzymes that catalyze these reactions have not been well
characterized.  Activity has been demonstrated in homogenates of rat kidney and brain, and the metabolites
have been detected in a variety of tissues, including kidney, liver, and skeletal muscle (Engler and Burger
1984).  The products of side chain deamination and decarboxylation, the acetic acid analogues of the
iodothyronines, undergo deiodination and conjugation with glucuronic acid and sulfate (Engler and Burger
1984; Green and Ingbar 1961; Pittman et al. 1972).  
Sulfate conjugation of the phenolic group of iodothyronines occurs in the liver and probably in other
tissues.  In humans, the reaction in liver is catalyzed by phenolic arylsulfotransferase (Young 1990). 
Iodothyronines having one iodine moiety on the phenolic ring are preferentially sulfated (Sekura et al.
1981; Visser 1994).  The sulfated products undergo deiodination.  Although a minor metabolite of the
thyroid hormones under normal conditions, the sulfation pathway becomes more important when Type I

































































































Figure 3-5.  Pathways of Metabolism of Iodothyronines





































































Figure 3-6.  Major Deiodination Pathways of Thyroid Hormones in Peripheral Tissues
Source: Engler and Burger 1984
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Glucuronide conjugation of the phenolic hydroxyl group of the iodothyronines occurs in the liver and
probably other tissues.  The identity of the glucuronytransferase enzymes that participate in the
conjugation of iodothyronines has not been determined in humans; however, in rats, the activity has been
shown to occur for the microsomal bilirubin, p-nitrophenol, and androsterone uridine diphosphate
(UDP)-glucuronyltransferases (Visser et al. 1993).  The activity of the pathway is increased by a variety of
chemicals that induce microsomal enzymes, including benzopyrene, phenobarbital, 3-methylcholanthrene,
polychlorinated biphenyls (PCBs), and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Visser 1990). 
Ether bond cleavage is a minor pathway of metabolism of iodotyrosines under normal conditions;
however, it explains the observation of diiodotyrosine in serum of some patients who received high
dosages of  T4 or who had severe bacterial infections (Meinhold et al. 1981, 1987, 1991).  The reaction has
been observed in phagocytosing leukocytes, which would be abundant during bacterial infections
(Klebanoff and Green 1973).
3.4.3.3 Dermal Exposure
The metabolism of absorbed iodine is expected to be similar regardless of the route of exposure to
inorganic iodine.  A complete discussion of the metabolism of iodine after oral exposures to inorganic
iodine is presented in Section 3.4.3.2, and is applicable to dermal exposures.
3.4.4 Elimination and Excretion
3.4.4.1 Inhalation Exposure
The excretion of absorbed iodine is expected to be similar regardless of the route of exposure to inorganic
iodine.  This is supported by studies in which humans were exposed to tracer levels of radioiodine as either
I2 or methyl iodide, and in studies in which monkeys inhaled particulate aerosols of sodium iodide (Black
and Hounam 1968;  Morgan et al. 1967a, 1967b, 1968; Perrault et al. 1967; Thieblemont et al. 1965).  A
complete discussion of the metabolism of iodine after oral exposures to inorganic iodine is presented in
Section 3.4.3.2, and is applicable to dermal exposures.
3.4.4.2 Oral Exposure
Absorbed iodine is excreted primarily in the urine and feces, but is also excreted in breast milk, exhaled
air, sweat, and tears (Cavalieri 1997).  Urinary excretion normally accounts for >97% of the elimination of
absorbed iodine, while fecal excretion accounts for approximately 1–2% (Larsen et al. 1998).  Vadstrup
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(1993) summarized data on the renal plasma clearance of iodide in humans and concluded that urinary
excretion was approximately 20–30% of the glomerular filtration rate (see Section 3.5.1).
The glucuronide and sulfate conjugates of T4, T3, and metabolites are secreted into bile.  Estimates of the
magnitude of the biliary pathway have been obtained from analyses of bile samples collected from patients
who underwent surgical cholecystectomy; the total secretion of  T4 and metabolites was approximately
10–15% of the daily metabolic clearance of T4 (Langer et al. 1988; Myant 1956).  More extensive
quantitative information is available on the biliary secretion of iodothyronines conjugates in experimental
animals.  In rats, approximately 30% of T4 clearance is accounted for by the biliary secretion of the
glucuronide conjugate and 5% as the sulfate conjugate; once secreted, the conjugates undergo extensive
hydrolysis with reabsorption of the iodothyronine in the small intestine (Visser 1990).
Iodide is excreted in human breast milk (Dydek and Blue 1988; Hedrick et al. 1986; Lawes 1992; Morita
et al. 1998; Robinson et al. 1994; Rubow et al. 1994; Spencer et al. 1986).  The fraction of the absorbed
iodide dose excreted in breast milk varies with functional status of the thyroid gland.  A larger fraction of
the absorbed dose is excreted in breast milk in the hypothyroid state compared to the hyperthyroid state. 
In the hypothyroid state, uptake of absorbed iodide into the thyroid and incorporation into iodothyronines
is depressed, resulting in greater availability of the absorbed iodide for distribution to the mammary gland
and breast milk.  Several examples of this have been reported in the clinical case literature.  A woman who
was hyperthyroid and received an oral tracer dose of radioiodine as [123I]NaI during lactation excreted
approximately 2.5% of the dose in breast milk collected over a 5.5-day period (Morita et al. 1998).  The
peak excretion (48.5% of the dose) occurred in the first postdosing collection of breast milk, which
occurred 7 hours after the dose.  A similar result, approximately 2.6% of the oral dose excreted in breast
milk, was reported by Hedrick et al. (1986) for a hyperthyroid patient.  By contrast, a hypothyroid patient
excreted 25% of an oral dose of radioiodine (as [123I]NaI) in breast milk in 41 hours (Robinson et al. 1994).
Iodide is excreted in human tears.  In an adult patient (hypothyroid with thyroid hormone supplementation)
who received an oral tracer dose of 123I radioiodine, approximately 0.01% of the dose was recovered in
tears collected over a 4-hour period.  The peak activity in tears was observed 1 hour after the dose and
activity was present in tears 24 hours after the dose (Bakheet et al. 1998).
Iodide is excreted into saliva in humans; however, the quantitative contribution of this pathway to
excretion has not been reported, and is probably minimal, given the relatively small rate of production of
saliva under normal circumstances, most of which is ingested (Brown-Grant 1961; Wolff 1983).  
Iodide appears to be excreted into the intestine by a mechanism other than biliary secretion of
iodothyronine (and metabolic conjugates).  Evidence in support of this comes from observations of
IODINE 123
3.  HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
radioactivity in the colon of patients who have no functioning iodothyronine production and who received
doses of radioiodine.  Kinetic analyses of the fecal excretion of radioiodine in euthyroid subjects also
supports a direct blood-to-intestine excretion route for iodide (Hays 1993).  Further support for a possible
colonic excretory pathway in humans comes from experimental studies in cats and rats (Hays et al. 1992;
Pastan 1957).
3.4.4.3 Dermal Exposure
The excretion of absorbed iodine is expected to be similar regardless of the route of exposure to inorganic
iodine.  A complete discussion of the metabolism of iodine after oral exposures to inorganic iodine is
presented in Section 3.4.3.2, and is applicable to dermal exposures.
3.4.4.4 Other Routes of Exposure
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry models. 
PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to
quantitatively describe the relationship between target tissue dose and toxic end points.  
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to delineate
and characterize the relationships between: (1) the external/exposure concentration and target tissue dose
of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 1987; Andersen
and Krishnan 1994).  These models are biologically and mechanistically based and can be used to
extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from route to
route, between species, and between subpopulations within a species.  The biological basis of PBPK
models results in more meaningful extrapolations than those generated with the more conventional use of
uncertainty factors.  
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
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toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The
numerical estimates of these model parameters are incorporated within a set of differential and algebraic
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) is
adequately described, however, this simplification is desirable because data are often unavailable for many
biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in humans
who are exposed to environmental levels (for example, levels that might occur at hazardous waste sites)
based on the results of studies where doses were higher or were administered in different species. 
Figure 3-7 shows a conceptualized representation of a PBPK model.
The ICRP (1994b, 1996) developed a Human Respiratory Tract Model for Radiological Protection, which
contains respiratory tract deposition and clearance compartmental models for inhalation exposure that may
be applied to gases and vapors of iodine compounds and particulate aerosols of iodine.  The ICRP (1979,
1989) also developed a biokinetic model for human oral exposure that applies to iodine.  Several other
multicompartmental models of iodine pharmacokinetics have been described, two of which are also
described below because of either their extensive history of use in clinical applications of radioiodine
(Oddie et al. 1955) or their potential value in environmental risk assessment (Stather and Greenhalgh
1983).  The EPA (1998) has adopted the ICRP (1989, 1994a, 1995) models for assessment of radiologic
risks from iodine exposures.  The National Council on Radiation Protection and Measurement (NCRP) has
also developed a respiratory tract model for inhaled radionuclides (NCRP 1997).  At this time, the NCRP
recommends the use of the ICRP model for calculating exposures for radiation workers and the general
public.  Readers interested in this topic are referred to NCRP Report No. 125; Deposition, Retention and
Dosimetry of Inhaled Radioactive Substances (NCRP 1997).  In the appendix to the report, NCRP
provides the animal testing clearance data and equations fitting the data that supported the development of
the human model.
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Figure 3-7.  Conceptual Representation of a Physiologically 
Based Pharmacokinetic (PBPK) Model for a 
Hypothetical Chemical Substance
Source:  adapted from Krishnan et al. 1994
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK)
model for a hypothetical chemical substance.  The chemical substance is shown to be absorbed
via the skin, by inhalation, or by ingestion, metabolized in the liver, and excreted in the urine or by
exhalation.
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Human Respiratory Tract Model for Radiological Protection (ICRP 1994).    
Deposition.  The ICRP (1994) has developed a deposition model for behavior of aerosols and vapors in the
respiratory tract.  It was developed to estimate the fractions of radioactivity in breathing air that are
deposited in each anatomical region of the respiratory tract.  ICRP (1994b) provides inhalation dose
coefficients that can be used to estimate the committed equivalent and effective doses to organs and tissues
throughout the body based on a unit intake of radioactive material.  The model applies to three levels of
particle solubility, and a wide range of particle sizes (approximately 0.0005–100 µm in diameter) and
parameter values, and can be adjusted for various segments of the population (e.g., sex, age, level of
physical exertion).  This model also allows the evaluation of the bounds of uncertainty in deposition
estimates.  Uncertainties arise from natural biological variability among individuals and the need to
interpret some experimental evidence that remains inconclusive.  It is applicable to gases and vapors of
volatile iodine compounds (e.g., I2 and methyl iodide) and particulate aerosols containing iodine, but was
developed for a wide variety of radionuclides and their chemical forms.
The ICRP deposition model estimates the amount of inhaled material that initially enters each
compartment (see Figure 3-8).  The model was developed with 5 compartments:  (1) the anterior nasal
passages (ET1);  (2) all other extrathoracic airways (ET2) (posterior nasal passages, the naso- and
oropharynx, and the larynx); (3) the bronchi (BB); (4) the bronchioles (bb); and (5) the alveolar
interstitium (AI).  Particles deposited in each of the regions may be removed from each region and
redistributed either upward into the respiratory tree or to the lymphatic system and blood by different
particle removal mechanisms.
For extrathoracic deposition of particles, the model uses experimental data (where deposition is related to
particle size and airflow parameters) and scales deposition for women and children from adult male data. 
Similar to the extrathoracic region, experimental data served as the basis for lung (bronchi, bronchioles,
and alveoli) aerosol transport and deposition.  A theoretical model of gas transport and particle deposition
was used to interpret data and to predict deposition for compartments and subpopulations other than adult
males.  Table 3-5 provides reference respiratory values for the general Caucasian population under several
levels of activity.
Deposition of inhaled gases and vapors is modeled as a partitioning process that depends on the
physiological parameters noted above as well as the solubility and reactivity of compound in the
respiratory tract (Figure 3-9).  The ICRP (1994b) model defines three categories of solubility and
reactivity: SR-0, SR-1, and SR-2:
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Figure 3-8.  Respiratory Tract Compartments* 
in Which Particles May be Deposited
*Compartment numbers shown in lower right corners are used to define clearance pathways.  The clearance pathways























Table 3-5.  Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity
Activity: Resting (sleeping) Sitting awake Light exercise Heavy exercise



























3 months 0.04 0.09 38 N/A N/A N/A 0.07 0.19 48 N/A N/A N/A
1 year 0.07 0.15 34 0.1 0.22 36 0.13 0.35 46 N/A N/A N/A
5 years 0.17 0.24 23 0.21 0.32 25 0.24 0.57 39 N/A N/A N/A
10 years Male: 0.841 2.22 44
Both: 0.3 0.31 17 0.33 0.38 19 0.58 1.12 32
Female: 0.667 1.84 46
15 years Male: 0.500 0.42 14 0.533 0.48 15 1.0 1.38 23 1.352 2.92 36
Female: 0.417 0.35 14 0.417 0.40 16 0.903 1.30 24 1.127 2.57 38
Adult Male: 0.625 0.45 12 0.750 0.54 12 1.25 1.5 20 1.923 3.0 26
Female: 0.444 0.32 12 0.464 0.39 14 0.992 1.25 21 1.364 2.7 33
aSee Annexe B (ICRP 1994b) for data from which these reference values were derived
bVT = Tidal volume, B = ventilation rate, fR = respiration frequency.










































Figure 3-9.  Reaction of Gases or Vapors at Various Levels of the Gas-Blood Interface
Source:  ICRP 1994b
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• Type SR-0 compounds include insoluble and nonreactive gases (e.g., inert gases such as H2, He). 
These compounds do not significantly interact with the respiratory tract tissues and essentially all
compound inhaled is exhaled.  Radiation doses from inhalation of SR-0 compounds are assumed to
result from the irradiation of the respiratory tract from the air spaces.
• Type SR-1 compounds include soluble or reactive gases and vapors that are expected to be taken
up by the respiratory tract tissues and may deposit in any or all of the regions of the respiratory
tract, depending on the dynamics of the airways and properties of the surface mucous and airway
tissues, as well as the solubility and reactivity of the compound.  Molecular iodine (I2) and methyl
iodide are classified as SR-1 compounds (ICRP 1995).  Deposition of molecular iodine vapor is
assumed to occur in ET1 (10%), ET2 (40%), and BB (50%) regions of the respiratory tract, whereas
70% of inhaled methyl iodide is assumed to deposit uniformly in ET2 and deeper regions of the
respiratory tract (ICRP 1995).
• Type SR-2 compounds include soluble and reactive gases and vapors that are completely retained
in the extrathoracic regions of the respiratory tract.  SR-2 compounds include sulfur dioxide (SO2)
and hydrogen fluoride (HF).
Respiratory Tract Clearance.  This portion of the model identifies the principal clearance pathways within
the respiratory tract.  The model was developed to predict the retention of various radioactive materials. 
Figure 3-10 presents the compartmental model and is linked to the deposition model (see Figure 3-8) and
to reference values presented in Table 3-6.  Table 3-6 provides clearance rates and deposition fractions for
each compartment for insoluble particles.  The table provides rates of insoluble particle transport for each
of the compartments, expressed as a fraction per day and also as half-time.  ICRP (1994b) also developed
modifying factors for some of the parameters, such as age, smoking, and disease status.  Parameters of the
clearance model are based on human evidence for the most part, although particle retention in airway walls
is based on experimental data from animal experiments.
The clearance of particles from the respiratory tract is a dynamic process.  The rate of clearance generally
changes with time from each region and by each route.  Following deposition of large numbers of particles
(acute exposure), transport rates change as particles are cleared from the various regions.  Physical and
chemical properties of deposited material determine the rate of dissolution, and as particles dissolve,
absorption rates tend to change over time.  By creating a model with compartments of different clearance
rates within each region (e.g., BB1, BB2, BBseq), the ICRP model overcomes problems associated with
time-dependent functions.  Each compartment clears to other compartments by constant rates for each
pathway.
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Table 3-6.  Reference Values of Parameters for the Compartment Model 
to Represent Time-dependent Particle Transport 
from the Human Respiratory Tract
Part A
Clearance Rates for Insoluble Particles  
Pathway From To Rate (d-1) Half-timea
m1,4 AI1 bb1 0.02 35 days
m2,4 AI2 bb1 0.001 700 days
m3,4 AI3 bb1 0.0001 7,000 days
m3,10 AI3 LNTH 0.00002 — 
m4,7 bb1 BB1 2 8 hours
m5,7 bb2 BB1 0.03 23 days
m6,10 bbseq LNTH 0.01 70 days
m7,11 BB1 ET2 10 100 minutes
m8,11 BB2 ET2 0.03 23 days
m9,10 BBseq LNTH 0.01 70 days
m11,15 ET2 GI tract 100 10 minutes
m12,13 ETseq LNET 0.001 700 days
m14,16 ET1 Environment 1 17 hours
See next page for Part B
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Table 3-6.  Reference Values of Parameters for the Compartment Model 
to Represent Time-dependent Particle Transport 
from the Human Respiratory Tract (continued)
Part B
Partition of deposit in each region between compartmentsb
Region or deposition site Compartment













aThe half-times are approximate since the reference values are specified for the particle transport rates and are rounded in units of d-
1.  A half-time is not given for the transport rate from Al3 to LNTH, since this rate was chosen to direct the required amount of material
to the lymph nodes.  The clearance half-time of compartment Al3 is determined by the sum of the clearance rates from it.bSee paragraph 181, Chapter 5  (ICRP 1994) for default values used for relating fs to dae.cIt is assumed that fs is size-dependent.  For modeling purposes, fs is taken to be:
f for d m and
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0 5 2 50 63 2 5
. . /
. . /. ( / . )
ρ χ µ
ρ χ µρ χ
where 
fs = fraction subject to slow clearance
dae = aerodynamic particle diameter/(µm)
ρ = particle density (g/cm3)
χ = particle shape factor
AI = alveolar-interstitial region; BB = bronchial region; bb = bronchiolar region; BBseq = compartment representing prolonged retention
in airway walls of small fraction of particles deposited in the bronchial region; bbseq = compartment representing prolonged retention in
airway walls of small fraction of particles deposited in the bronchiolar region; d = day(s); ET = extrathoracic region; ETseq =
compartment representing prolonged retention in airway tissue of small fraction of particles deposited in the nasal passages; LNET =
lymphatics and lymph nodes that drain the extrathoracic region; LNTH = lymphatics and lymph nodes that drain the thoracic region
Source:  ICRP 1994b
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Figure 3-10.  Compartment Model to Represent Time-Dependent Particle
Transport in the Respiratory Tract
Source:  ICRP 1994b
See Table 3-6 for abbreviations, rates, half-lives, and fractions by compartment
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Particle transport from all regions is toward both the lymph nodes and the pharynx, and a majority of
deposited particles end up being swallowed.  In the front part of the nasal passages (ET1), nose blowing,
sneezing, and wiping remove most of the deposited particles.  Particles remain here for about a day.  For
particles with AMADs a few micrometers or greater, the ET1 compartment is probably the largest
deposition site.  A majority of particles deposited at the back of the nasal passages and in the larynx (ET2)
are removed quickly by the fluids that cover the airways.  In this region, particle clearance is completed
within 15 minutes. 
Ciliary action removes deposited particles from both the bronchi and bronchioles.  Though it is generally
thought that mucocilliary action rapidly transports most particles deposited here toward the pharynx, a
fraction of these particles are cleared more slowly.  Evidence for this is found in human studies.  For
humans, retention of particles deposited in the lungs (BB and bb) is apparently biphasic.  The “slow”
action of the cilia may remove as many as half of the bronchi- and bronchiole-deposited particles.  In
human bronchi and bronchiole regions, mucus moves more slowly the closer to the alveoli it is.  For the
faster compartment, it has been estimated that it takes about 2 days for particles to travel from the
bronchioles to the bronchi and 10 days from the bronchi to the pharynx.  The second (slower)
compartment is assumed to have approximately equal fractions deposited between BB2 and bb2, both with
clearance half-times estimated at 20 days.  Particle size is a primary determinant of the fraction deposited
in this slow thoracic compartment.  A small fraction of particles deposited in the BB and bb regions is
retained in the airway wall for even longer periods (BBseq and bbseq).
If particles reach and become deposited in the alveoli, they tend to stay imbedded in the fluid on the
alveolar surface or move into the lymph nodes.  The one mechanism by which particles are physically
resuspended and removed from the AI region is coughing.  For modeling purposes, the AI region is
divided into three subcompartments to represent different clearance rates, all of which are slow.
In the alveolar-interstitial region, human lung clearance has been measured.  The ICRP model uses two
half-times to represent clearance: about 30% of the particles have a 30-day half-time, and the remaining
70% are given a half-time of several hundred days.  Over time, AI particle transport falls and some
compounds have been found in lungs 10–50 years after exposure.
Absorption into Blood.  The ICRP model assumes that absorption into blood occurs at equivalent rates in
all parts of the respiratory tract, except in the anterior nasal passages (ET1), where no absorption occurs.  It
is essentially a 2-stage process, as shown in Figure 3-11.  First, there is a dissociation (dissolution) of
particles; then the dissolved molecules or ions diffuse across capillary walls and are taken up by the blood. 
Immediately following dissolution, rapid absorption is observed.  For some elements, rapid absorption
does not occur because of binding to respiratory-tract components.  In the absence of specific data for 
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Figure 3-11.  The Human Respiratory Tract Model:  Absorption into Blood
Source:  ICRP 1994b
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specific compounds, the model uses the following default absorption rate values for those specific
compounds that are classified as Types F (fast), M (medium), S (slow), and V (instantaneous): 
  C For Type F, there is rapid 100% absorption within 10 minutes of the material deposited in the BB,
bb, and AI regions, and 50% of material deposited in ET2.  Thus, for nose breathing, there is rapid
absorption of approximately 25% of the deposit in ET and 50% for mouth breathing.  Type F iodine
compounds include molecular iodine (I2) and particulate aerosols of silver iodide and sodium iodide.
  C For Type M, about 70% of the deposit in AI reaches the blood eventually.  There is rapid absorption
of about 10% of the deposit in BB and bb, and 5% of material deposited in ET2.  Thus, there is rapid
absorption of approximately 2.5% of the deposit in ET for nose breathing, and 5% for mouth
breathing.  ICRP (1995) does not identify any Type M iodine compounds.
  C For Type S, 0.1% is absorbed within 10 minutes and 99.9% is absorbed within 7,000 days, so there
is little absorption from ET, BB, or bb, and about 10% of the deposit in AI reaches the blood
eventually.  ICRP (1995) does not identify any Type S iodine compounds.
  C For Type V, complete absorption (100%) is considered to occur instantaneously.  Methyl iodide is
classified as a Type V compound (ICRP 1995).
ICRP (1989) Iodine Biokinetics Model    
Description of the model.     
ICRP (1989) developed a compartmental model of the kinetics of ingested iodine in humans with versions
that are applicable to infants, children, adolescents, and adults.  The model is a modification and expansion
of a similar model described in ICRP (1979).  Ingested iodine is assumed to be completely absorbed. 
Absorbed iodine is assumed to distribute to three compartments: blood, thyroid gland, and extrathyroid
tissues (Figure 3-12).  Of the iodine entering the transfer compartment, 30% is assumed to be transferred to
the thyroid gland; the remaining 70% is excreted in urine.  All iodine eliminated from the thyroid gland is
assumed to be transferred to the extrathyroidal tissues compartment as organic iodine (e.g.,
iodothyronines).  Twenty percent of the of iodine eliminated from extrathyroidal tissues is assumed to be
excreted in feces; the remaining 80% is transferred to blood.  Elimination half-times of iodine from blood,
thyroid and extrathyroidal tissues are age-dependent (Figure 3-12).  The modifications made in this model
from ICRP (1979) include: (1) 20%, rather than 10% of the of iodine eliminated from extrathyroidal
tissues is assumed to be excreted in feces; (2) age-dependent elimination half-times for iodine, which
allows the model to be applied to infants, children, adolescents, and adults; and (3) the extrathyroidal
iodine pool is assumed to be 0.1 of the thyroid pool and the thyroid iodine pool is allowed to be variable,
reflecting geographic variation or other sources of variation in intake. 
IODINE 137
3.  HEALTH EFFECTS










Figure 3-12.  ICRP (1989) Metabolic Model for Iodine

















3 months 1 30 20 0.25 11.2 1.12 15
1 year 1 30 20 0.25 15 1.5 20 
5 years 1 30 20 0.25 23 2.3 30
10 years 1 30 20 0.25 58 5.8 70
15 years 1 30 20 0.25 67 6.7 80
Adult 1 30 20 0.25 80 12 91
aln2/ki b2–16 days after uptake
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Validation of the model.     
The extent to which the ICRP model has been validated is not described in ICRP (1989).
Risk assessment.     
The model has been used to establish radiation dose equivalents (Sv/Bq) of ingested radioiodine (129I, 131I,
and 132I) for ages 3 months to 70 years (ICRP 1989).
Target tissues.     
The model is designed to calculate radioiodine intake limits based on radiation dose to all major organs,
including the thyroid gland.
Species extrapolation.     
The model is designed for applications to human dosimetry and cannot be applied to other species without
modification.
Interroute extrapolation.     
The model is designed to simulate oral exposures to radioiodine and cannot be applied to other routes of
exposure without modification.
NRPB-UK Model.    
Description of the model.     
The National Radiological Protection Board of the United Kingdom (NRPB-UK) developed a
compartmental model of ingested iodine in human adults and children (Stather and Greenhalgh 1983).  The
model has three compartments representing the thyroid gland, an inorganic iodide pool that includes all
inorganic iodide in the body with the exception of that in the thyroid gland, and an organic iodine pool,
exclusive of organic iodine in the thyroid gland (Figure 3-13).  Iodide that enters the gastrointestinal tract
from ingestion is assumed to be completely absorbed into the inorganic iodide pool.  Of the iodine entering
the inorganic iodide pool, 25% is transferred to the thyroid gland where it resides with an elimination half-
time of 79 days; the rest is excreted in urine.  The thyroid gland is assumed to have a steady state iodine
content of 8 mg.  All iodine eliminated from the thyroid gland is assumed to be transferred to the organic
iodine pool where it resides with an elimination half-time of 8 days.  Twenty percent of the iodine 
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Figure 3-13.  NRPB-UK (1989) Metabolic Model for Iodine
Source:  Stather and Greenhalgh 1983
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eliminated from the organic iodine pool is assumed to be excreted in feces; the remaining 80% enters the
inorganic iodide pool.
Models for 1-year-old infants and 10-year-old children are also described in Stather and Greenhalgh
(1983).  The models are essentially the same as the adult model with one change; the elimination half-time 
for iodine in the thyroid gland is assumed to be 17 days for 1-year-old infants and 72 days for 10-year-old
children.
Validation of the model.     
The extent to which the NRPB-UK model has been validated is not described in Stather and Greenhalgh
(1983).
Risk assessment.     
The model was developed for calculating radiation doses to populations in the United Kingdom following
release of iodine isotopes into the environment.  The extent to which the model has been used for this
purpose is not described in Stather and Greenhalgh (1983).
Target tissues.     
The model is designed to calculate intake and exposure limits, based on radiation dose to the thyroid gland.
Species extrapolation.     
The model is designed for applications to human dosimetry and cannot be applied to other species without
modification.
Interroute extrapolation.     
The model is designed to simulate oral exposures to radioiodine and cannot be applied to other routes of
exposure without modification.
Oddie et al. Model.
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Description of the model.     
Oddie et al. (1955) described a compartmental model of absorbed iodine human adults and infants (Fisher
et al. 1962) for predicting 24-hour radioiodine uptake by the thyroid gland in clinical procedures.  The
model has two compartments representing the thyroid gland and a central iodide pool that includes all
inorganic iodide in the body with the exception of that in the thyroid gland.  An organic iodine pool is not
included in the model.  Although this would preclude the model from accurately simulating radioiodide
levels in extrathyroidal tissues, including blood, it was not considered necessary for simulating the initial
uptake of iodide by the thyroid following a single dose of radioiodine, prior to significant release of
organic iodine from the thyroid gland.  Iodide that enters the inorganic iodide pool is assumed to be
transferred either to the thyroid gland, represented as a first order rate constant k1, or to the kidney for
urinary excretion, represented by a rate constant k2, usually corrected for loss of iodide in sweat, feces, and
uncollected urine (Oddie and Fisher 1967).  In a study of 20 healthy adults, k1 was estimated to be
60x10-5/minute in subjects who ingested a tracer dose of radioiodine (Fisher et al. 1965).  In this same
study, the value of k1 was 49x10-5 after 13 weeks of daily ingestion of 252 µg iodide/day and 35x10-5, after
13 weeks of daily ingestion of 1,000 µg iodide/day.  The estimate of k2 from this study was
300x10-5 minute-1.  Values for k1 estimated in various populations have ranged from 67 to
134x10-5 minute-1 (Oddie and Fisher 1967).  The volume of the iodide space was estimated to be 2.1 L
(Fisher et al. 1965).
The same model has been used to predict thyroid uptakes of iodine in infants.  Values for k1 and k2 were
estimated from studies in which 24-hour thyroid uptakes of iodine were measured in 26 euthyroid newborn
infants (Fisher et al. 1962).  The values for k1 and k2 were 2.4x10-3 minute-1 and 1.1x10-3 minute-1,
respectively.  The iodide space was estimated to be approximately 0.4 L in newborn infants.
Validation of the model.     
The model has been shown to predict 24-hour iodine uptakes in the thyroid in adults who received single
doses of radioiodine.  Predicted 24-hour thyroid uptakes of radioiodine were compared to observed
estimates in 1,573 euthyroid subjects reported from various studies; the difference between observed and
predicted estimated for 8 studies ranged from 0.7 to 2.1%, with the observed uptakes ranging from 21 to
37% (Oddie and Fisher 1967). 
Risk assessment.     
The model was developed for predicting the 24-hour uptake of radioiodine in the thyroid after single doses
of radioiodine are given in the clinical setting for assessing thyroid function.  It has been evaluated in
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terms of its predictive value in detecting abnormal thyroid conditions that affect iodide uptake into the
gland (Oddie et al. 1960).  The extent to which the model has been used for risk assessment could not be
ascertained from the available literature.
Target tissues.     
The model is designed to predict 24-hour uptakes of radioiodine into the thyroid gland.
Species extrapolation.     
The model is designed for applications to humans and cannot be applied to other species without
modification.
Interroute extrapolation.     
The model is designed to simulate oral ingestion or parenteral injection (e.g., intramuscular in infants) of
radioiodine and cannot be applied to other routes of exposure without modification.
3.5 MECHANISMS OF ACTION
3.5.1 Pharmacokinetic Mechanisms
Absorption.    The mechanism(s) by which iodide is absorbed from the gastrointestinal tract is not
known.  Based on studies conducted by Small et al. (1961), absorption appears to occur primarily in the
small intestine in humans.  This study measured iodine in the saliva of healthy human subjects who
ingested 0.25 g of potassium iodide (0.19 g iodide) togther with a radioopaque suspension of barium
sulfate that allowed the emptying of the stomach to be imaged with a fluoroscope.  In five subjects, iodine
was not detected in saliva until 2–3 minutes after the first appearance of the barium sulfate in the
duodenum; the actual time of appearance relative to the oral dose of iodide ranged from 15 to 40 minutes. 
An intravenous dose of probanthine, which delays gastric emptying time, given just prior to the oral dose
of potassium iodide, substantially delayed the time of appearance of iodine in saliva to 114–133 minutes;
however, in each of three subjects, iodine was detected in saliva 3–4 minutes after the first appearance of
the radioopaque marker in the duodenum.  When iodide was instilled directly into the duodenum together
with the radioopaque marker (two subjects), iodine was detected in saliva 3–4 minutes after the dose was
administered.  These observations suggest that the absorption of iodide in humans occurs primarily in the
small intestine and that the stomach may play a minor role in iodide absorption.  The mechanisms by
which iodide is transported across the intestinal epithelium are not known.  Iodide may be transported by
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mechanisms that also transport chloride such as the Cl-/HCO3- antiport (Dalmark 1976; Lambert and Lowe
1978) or Cl- channels (Katayama and Widdicombe 1991). 
While the above studies implicate the small intestine as the major site of absorption of iodide in humans,
studies in rats and dogs indicate that 14–30% of an oral dose of iodide may be absorbed in the stomach in
these species (Small et al. 1961; Cohn 1932)
Distribution.    
Iodide Transport.  Uptake of iodide into the thyroid is facilitated by a membrane carrier in the basolateral
membrane of the thyroid follicle cell (Carrasco 1993; Levy et al. 1998a; Shen et al. 2001)  The carrier, or
NIS, catalyzes the simultaneous transfer Na+ and I- across the basolateral membrane (Chambard et al.
1983; Iff and Wilbrandt 1963; Nilsson et al. 1990).  The stoichiometry of transfer reaction is (2)Na+/(1)I-,
which confers to the NIS a net positive charge and, therefore, a sensitivity to transmembrane voltage
(Eskandari et al. 1997; O’Neill et al. 1987).  In the presence of an inward-directed electrochemical gradient
for Na+, the NIS can transfer I- into the cell against a pronounced outward-directed electrochemical
gradient for I- (Takasu et al. 1984; Williams 1969; Woodbury and Woodbury 1963).  This enables the
follicle cell to achieve intracellular/extracellular concentration ratios of 10–50 for iodide (Andros and
Wollman 1991; Bagchi and Fawcett 1973; Shimura et al. 1997; Vroye et al. 1998; Weiss et al. 1984a;
Wolff 1964). 
The NIS has been studied extensively in several in vitro preparations, including isolated plasma membrane
vesicles of mammalian thyroid (O’Neil et al. 1987), FRTL-5 cells, a cell line derived from normal rat
thyroid (Weiss et al. 1984a), Xenopus lavis oocytes transformed by intracellular injection of FRTL-5 RNA
to express NIS (Eskandari et al. 1997), and other mammalian cells cultures transformed to express NIS
(Levy et al. 1997; Nakamura et al. 1990; Smanik et al. 1996; Yoshida et al. 1997).  The apparent Km for I-
transport in cell systems is approximately 30–40 µM, which is considerably higher than the serum iodide
concentration of 0.04–0.08 µM (5–10 µg/L) (Eskandari et al. 1997; Weiss et al. 1984a).  The relatively
high Km enables the iodide transport rate to be highly sensitive to changes in plasma I- concentration. 
Iodide transport by the NIS is inhibited by other anions, most notably, thiocyanate (SCN-) and perchlorate
(ClO4-) (Carrasco 1993; Wolfe 1964).  Thiocyanate is one of several anions other than I- that can be
transported by the NIS, including SeCN-, NO3-, ClO3-, Br-, BF4-, IO4-, and BrO3- (Eskandari et al. 1997). 
Perchlorate, on the other hand, does not appear to be transported by NIS (Eskandari et al. 1997; Yoshida et
al. 1997).  Thus, thiocyanate and perchlorate, which both inhibit iodide uptake in thyroid in vivo, do so by
different mechanisms; thiocyanate is a competitive substrate for transport, whereas perchlorate appears to
block I- binding to the NIS.
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Synthesis of NIS is regulated by the pituitary hormone, TSH, which stimulates iodide uptake into the
thyroid.  The mechanism involves both increased transcription of the NIS gene and increased translation of
mRNA for NIS (Kogai et al. 1997; Levy et al. 1997; Ohno et al. 1999; Pekary et al. 1998).  Both responses
to TSH follow binding of TSH to a receptor on the basolateral membrane and activation of the enzyme
adenylate cyclase by GTP binding protein Gα (Akamizu et al. 1990; Chazenbalk et al. 1990; Kogai et al.
1997; Parmentier et al. 1989; Perret et al. 1990; Raspe and Dumont 1995).  In FRTL-5 cells grown in the
absence of TSH, NIS activity declines to a minimum level and can be restored by the addition of TSH to
the medium or by treating the cells with dibutryl-cAMP or other agents that increase the intracellular
concentration of cAMP (Pekary et al. 1998; Weiss et al. 1984a, 1984b).  Thus, the actions of TSH appear
to involve the activation of adenylate cyclase and subsequent increase in the intracellular concentration of
cAMP.  
Synthesis of NIS also appears to be regulated by plasma iodide concentration through a mechanism that
does not involve directly TSH.  In rats exposed to drinking water containing 500 mg/L I as sodium iodide,
expression of mRNA for the NIS in the thyroid decreased by 45% after 1 day of exposure and 60% after
6 days of exposure compared to controls that ingested water without added iodide.  Serum iodide
concentrations were 150–200-fold higher in the exposed rats compared to controls, whereas the serum
TSH concentrations were not different between control and treated groups (Eng et al. 1999).  A similar
observation was made in dogs made hypothyroid by treatment with propylthiouracil (an inhibitor of
iodination of thyroglobulin) and perchlorate (Uyttersprot et al. 1997).  The hypothyroid state elevated TSH
concentrations in serum; nevertheless, a single injection of 0.3 mg potassium iodide (0.23 mg I) resulted in
decreased expression of NIS in the thyroid within 24–48 hours after the dose, without a change in TSH
concentrations in serum.
The exact mechanisms by which the NIS gene transcription is regulated have not been determined.  The
gene in humans and rats has been sequenced, enabling studies of the mechanisms of gene transcription
regulation (Dai et al. 1996; Smanik et al. 1996).  The human gene resides on chromosome 19 (Smanik et
al. 1997).  Mutations in the gene sequence have been associated with hypothyroidism, goiter, and
abnormally low thyroid uptake of injected iodide (Fujiwara et al. 1997, 1998; Kosugi et al. 1998; Levy et
al. 1998c; Pohlenz and Refetoff 1999; Pohlenz et al. 1997).  The 5'-flanking region of the rat NIS gene has
been shown to contain one or more promoter regions; however, their role in regulation of the NIS
transcription is not completely understood (Endo et al. 1997; Ohno et al. 1999; Tong et al. 1997).  Ohno et
al. (1999) found evidence for a promoter region in the rat NIS gene that appears to be respond to a rise in
intracellular cAMP, most likely by binding a cAMP-inducible or cAMP-activated transcription factor.  A
promoter region in the rat NIS gene responsive to thyroid transcription factor 1 (TTF-1) has also been
described (Endo et al. 1997).  Tong et al. (1997) found evidence for a promoter region in the rat NIS gene
that could be suppressed in cell cultures that were transformed with the oncogene PTC1.  This may provide
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a mechanism for the decreased expression of the NIS gene in thyroid papillary carcinomas and the
decreased iodide uptake of some thyroid carcinomas (Smanik et al. 1996, 1997).
Several tissues in humans, other than thyroid, actively accumulate iodide; these include the mammary
gland, salivary glands, and stomach (Brown-Gant 1961; Wolff 1983).  These tissues can achieve
intracellular/extracellular and/or transepithelial concentration ratios for I- concentrations of 20–40. 
Transport of iodide in these tissues is inhibited by thiocyanate and perchlorate; however, transport activity
is not responsive to TSH.  Clinical cases of genetic absence or impaired iodide uptake in the thyroid
coupled with low uptakes in saliva and gastric fluid suggest an involvement of an NIS mechanism in these
tissues (Fujiwara et al. 1997, 1998; Kosugi et al. 1998; Leger et al. 1987; Pohlenz and Refetoff 1999;
Pohlenz et al. 1997; Wolff 1983).  Further evidence for extrathyroidal NIS comes from studies of
mammary gland.  The NIS gene is expressed in the mammary gland of both the human and the rat (Levy et
al. 1997; Smanik et al. 1997).  In the rat, expression of the NIS, or a structurally similar membrane protein,
increases during nursing and decreases after weaning (Levy et al. 1998a).
Studies in animals have revealed other tissues that actively secrete or accumulate iodide transport by a
mechanism that is inhibited by perchlorate and thiocyanate, suggestive of an active NIS.  These include,
choroid plexus, ciliary body of the eye, small intestine (ileum), ovary, placenta, and skin in mammals; and
avian salt gland in marine birds (Brown-Grant 1961).
Iodothyronine Transport.  Uptake of T4 and T3 into tissues occurs by a saturable, energy-dependent carrier
transport system.  Evidence for active transport derives from a variety of observations.  The rate of uptake
of T3 into the perfused rat liver is proportional to the concentration of free T3 in the perfusate and is not
related to the total concentration or bound concentration (Mendel et al. 1988).  The free cytosolic
concentration of T3 in the in vivo rat liver and heart muscle exceeds that of the simultaneous free
concentration in plasma, suggesting uptake of T3 into these tissues against a chemical gradient for T3
(Oppenheimer and Schwartz 1985).  T3 uptake into confluent cultures of human or rat hepatoma cells is
saturable, stereoselective for the active L enantiomer, temperature dependent, and inhibited by metabolic
and membrane transport inhibitors, including phloretin (Movius et al. 1989; Topliss et al. 1989). 
Saturable, stereoselective, temperature-dependent, and energy-dependent uptake of T3 and T4 has also been
observed in cultures of human fibroblasts and for T3 in in vitro preparations of rat skeletal muscle
(Centanni and Robbins 1987; Docter et al. 1987).
Metabolism.    
Iodination in the Thyroid Gland.  Iodination of thyroglobulin is catalyzed by thyroid peroxidase, a
hemoprotein in the apical (luminal) membrane of thyroid follicle cells (Dunn and Dunn 2001).  Thyroid
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peroxidase catalyzes both the iodination of tyrosine residues in thyroglobulin and the coupling of the
iodinated residues to form the thyroid hormones, T4 and T3, and diiodotyrosine.  The iodination reaction
involves the oxidation of iodide (I-) to a reactive species having a sufficiently high oxidation potential to
iodinate the aromatic ring of tyrosine.  The oxidizing agent in the reaction is hydrogen peroxide, which is
generated at the apical membrane of follicle cells by an NADPH oxidase (Deme et al. 1994; Dupuy et al.
1991).  Although the exact mechanism of the iodination reaction is not completely understood, three
species are suspected as being candidates for the reactive iodinating species: a free radical (I@), iodinium
(I+), or an enzyme-bound hypoiodite ([EOI]-) (Taurog 1996).  Human thyroglobulin contains 134 tyrosyl
residues, of which approximately 20 undergo iodination to yield approximately 2–4 molecules of T4 or T3
per molecule of thyroglobulin.  The coupling reaction occurs within thyroglobulin, rather than as a reaction
between free iodinated tyrosines.  In the formation of T4, two molecules of diiodotyrosine are coupled,
whereas the formation of T3 is a coupling of moniodityrosine and diiodotyrosine residues.  The reaction is
catalyzed by thyroid peroxidase with hydrogen peroxide serving as the oxidizing agent in the formation of
a reactive intermediate of the contributing diiodotyrosine residue, possibly a free radical species (Taurog et
al. 1994).  Specificity of iodination and coupling of tyrosine residues within thyroglobulin is conferred, in
part, by the specificity of thyroid peroxidase and, in part, by the structure of thyroglobulin (Taurog 1996).  
The gene for human thyroid peroxidase has been isolated and sequenced (Kimura et al. 1987; Libert et al.
1987; Magnusson et al. 1987).  Transcription of the gene is stimulated by TSH, possibly through a
mechanism involving cAMP (McLachlan and Rapoport 1992).
Diodination of Iodothyrones in Peripheral Tissues.  Deiodination serves both as an important mechanism
for the production of extrathyroidal T3 and for the deactivation of the thyroid hormones, T4 and T3.  The
deiodination reactions are catalyzed by selenium-dependent deiodinase enzymes (selenodeiodinases). 
Three selenodeiodinases have been described that differ in substrate preference, reaction products,
response to inhibitors (propylthiouracil, gold), and response to T3 (Table 3-7).  Full activity of each
enzyme requires selenocysteine in the amino acid sequence of the active site, which is the basis for
deiodination activity being responsive to nutritional selenium status (Larsen and Berry 1994; see
Section 3.9). 
Excretion.    
Urinary Excretion of Iodide.  Urinary excretion normally accounts for >97% of the elimination of
absorbed iodine.  The renal plasma clearance of iodine has been measured in human subjects during
continuous intravenous infusions of radioiodide (Bricker and Hlad 1955).  Under these conditions, only a
negligible amount of radioiodine in the plasma was associated with protein and >98% was ultrafilterable;
thus, the renal clearance of radioiodine can be assumed to reflect that of radioiodide (Bricker and Hlad 
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Table 3-7.  Properties of Human Iodothyronine Selenodeiodinases
Parameter Type 1 Type 2 Type 3
Physiological role Plasma T3 production,




Deactivate T3 and T4









Substrate preference rT3>>T4>T3 T4$rT3 T3>T4
Molecular weight (D)a 29,000 35,000 31,500






Deiodination site Outer and inner ring Outer ring Inner ring
Apparent Ki (M)
Propylthiouracil 2x10-7 4x10-3 10-3
Gold ~5x10-9 ~2x10-6 5x10-6
Response to T3 Increase Decrease Increase
Source:  Larsen et al. 1998
aMonomer
T3 = 3,5,3N-triiodo-L-thyronine; T4 = 3,5,3N,5N-tetraiodo-L-thyronine (thyroxine); rT3 = reverse T3
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1955; Walser and Rahill 1965).  Under steady-state conditions with respect to the serum radiodine
concentration, the renal plasma clearance of radioiodine was approximately 30% of the glomerular
filtration rate, suggesting that filtered iodide is reabsorbed in the renal tubule.  Measurements of the
steady- state renal clearance of radioiodide in dogs have provided additional evidence for tubular
reabsorption of iodide (Beyer et al. 1981; Walser and Rahill 1965).  The mechanism of renal tubular
reabsorption of iodide has not been elucidated, although studies to examine mechanisms have been largely
limited to clearance studies.  In humans, iodide clearance as a fraction of the glomerular filtration rate
(CI/GFR) increases in response to an acute increase in GFR and decreases in response to an acute decrease
in GFR; however, CI/GFR is relatively unaffected by large acute increases in the plasma concentration of
radioiodine at a constant GFR (Bricker and Hlad 1955).  This suggests a sensitivity of tubular reabsorption
to both filtered load of iodide and tubular flow rate.  CI/GFR can be increased to near unity during
mannitol-induced diuresis (Bricker and Hlad 1955).  Although the inability to detect an apparent saturation
of tubular reabsorption at high filtered loads of iodide, and the sensitivity of tubular reabsorption to tubular
flow rate, are consistent with a passive, paracellular, component to iodide reabsorption, these observations
do not rule out the existence of facilitated transport of iodide in the nephron.  In humans, CI/GFR, whole
body clearance of radioiodine is increased during diuresis induced by furosemide and hydrochlorothiazide,
two clinical diuretics that decrease sodium and chloride reabsorption in the in the loop of Henle and distal
convoluted tubule, suggesting the possibility of reabsorption of iodide in distal segments of the nephron
(Seabold et al. 1993).  This observation is further supported by steady-state clearance measurements in
dogs, in which CI/GFR was found to increase in response to hydrochlorothiazide-induced diuresis, and to
be lower, near that of CCl/GFR, in dogs that had been maintained on a sodium deprivation diet (Beyer et al.
1981; Walser and Rahill 1965).  The latter observation would suggest that adaptations to sodium
deprivation that result in greater reabsorption of sodium in the late distal nephron also give rise to
increased reabsorption of iodide. 
3.5.2 Mechanisms of Toxicity
The mechanism by which excess iodide produces hypothyroidism is not completely understood.  Iodide
excess inhibits the iodination of thyroglobulin in the thyroid gland and inhibits the release of T4 and T3
from the gland (Pisarev and Gärtner 2000).  Both effects could contribute to stimulation of release of TSH
from the pituitary gland and to the increase in serum concentration of TSH and hypertrophy of the thyroid
gland that has been shown to accompany iodide-induced thyroid gland suppression (see Section 3.2.2.2,
Endocrine).  The mechanism by which iodide suppresses iodination and thyroid hormone release appears
to involve inhibition of adenylate cyclase.  The stimulatory actions of TSH on the thyroid gland, which
include increased iodide transport, and increased iodination of thyroglobulin and production and release of
T4 and T3, occur in response to a rise in intracellular cAMP levels that follow binding of TSH to TSH
receptors on thyroid gland follicle cells.  Iodide inhibits adenylate cyclase in thyroid gland follicle cells
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and decreases the TSH-induced rise in intracellular cAMP.  However, the effect of iodide on adenylate
cyclase can be prevented by inhibitors of iodination, such as propylthiouracil.  This has led to the
suggestion that the ultimate active inhibitor is an endogenous iodinated species that is produced in a
reaction requiring thyroid peroxidase.  Candidates for the endogenous inhibitor are one or more iodinated
lipids (Filetti and Rapoport 1983; Pereira et al. 1990; Pisarev and Gärtner 2000).  The synthesis of NIS
also appears to be regulated by plasma iodide concentration, through a mechanism that does not directly
involve TSH.  In rats and dogs, expression of mRNA for the NIS in the thyroid decreased when serum
iodide concentrations were increased by ingestion or injection of iodide, even when serum TSH
concentrations were unchanged (Eng et al. 1999; Uyttersprot et al. 1997). 
Excess iodide intake may be a contributing factor in the development of autoimmune thyroiditis in people
who are susceptible (Brown and Bagchi 1992; Foley 1992; Rose et al. 1997; Safran et al. 1987).  In certain
inbred strains of rats and mice, exposure to iodide has been shown to increase the incidence of
lymphocytic thyroiditis (Allen and Braverman 1990; Allen et al. 1986; Noble et al. 1976; Rasooly et al.
1996).   The mechanism by which iodide stimulates autoimmunity is not completely understood.  In the
inbred mouse strain, NODh2h4, both CD4+ and CD8+ T cells are required for iodine-induced acceleration of
autoimmunity (Hutchings et al. 1999).  Highly iodinated thyroglobulin may be an antigen in susceptible
animals (or humans) (Rose et al. 1997; Saboori et al. 1998a, 1998b, 1999; Sundick et al. 1987).  Other
proposed mechanisms include effects of iodine on the regulation of major histocompatibility class I and
increased expression of thyroid gland TNF-α (Roti and Vagenakis 2000; Ruwhof and Drexhage 2001;
Verma et al. 2000).  Thyroid autoimmunity may produce hypothyroidism by stimulating thyroid cell
apoptosis (Huang and Kukes 1999; Phelps et al. 2000; Stassi et al. 2000).
Excess iodide can, under certain circumstances, induce hyperthyroidism and thyrotoxicosis; this has been
observed most often after iodine supplementation of iodine-deficient populations (Braverman and Roti
1996; Fradkin and Wolff 1983; Leger et al. 1984; Paschke et al. 1994).  The mechanism by which iodide
induces hyperthyroidism is not completely understood.  Chronic iodine deficiency results in thyroid gland
proliferation, which may increase the fixation of mutations in the gland and promote the development of
autonomous nodules, that are less responsive or unresponsive to regulation in response to serum TSH
concentrations.  Iodine excess, under these conditions, could result in increased and unregulated thyroid
hormone production (Corvilain et al. 1998; Dremier et al. 1996; Roti and Uberti, 2001).
3.5.3 Animal-to-Human Extrapolations
The principal health effects of iodine in humans have been characterized in experimental, clinical, and
epidemiological studies of humans.  Animal models remain useful for exploring mechanisms, and where
relevant, these studies have been described; for example, the use of inbred rat strains to study iodine-
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induced autoimmune thyroiditis (see Section 3.2.2.2, Endocrine).  The major features of the toxicokinetics
of iodine in humans, particularly following oral exposures, have been characterized in experimental and
clinical studies of humans.  A substantial amount of experience exists in the application of biomarkers for
assessing human exposures to iodine (e.g., urinary iodine excretion and thyroid scintillation scan) and
health effects in humans (e.g., serum thyroid hormone, TSH, and thyroid antibodies).  Thus, the
assessment of health effects and health risks associated with exposures to iodine or radioiodine can be
based soundly on human studies rather than on extrapolations from animal studies.
3.6 ENDOCRINE DISRUPTION
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones, or otherwise
interfere with the normal function of the endocrine system.  Chemicals with this type of activity are most
commonly referred to as endocrine disruptors.  Some scientists believe that chemicals with the ability to
disrupt the endocrine system are a potential threat to the health of humans, aquatic animals, and wildlife. 
Others believe that endocrine disrupting chemicals do not pose a significant health risk, particularly in
light of the fact that hormone mimics exist in the natural environment.  Examples of natural hormone
mimics are the isoflavinoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These
compounds are derived from plants and are similar in structure and action as endogenous estrogen.  While
there is some controversy over the public health significance of endocrine disrupting chemicals, it is
agreed that the potential exists for these compounds to affect the synthesis, secretion, transport, binding,
action, or elimination of natural hormones in the body that are responsible for the maintenance of
homeostasis, reproduction, development, and/or behavior (EPA 1997).  As a result, endocrine disruptors
may play a role in the disruption of sexual function, immune suppression, and neurobehavioral function. 
Endocrine disruption is also thought to be involved in the induction of breast, testicular, and prostate
cancers, as well as endometriosis (Berger 1994; Giwercman et al. 1993; Hoel et al. 1992).
Iodine is an endocrine disruptor in that the principal direct effects of excessive iodine ingestion are on the
thyroid gland and on the regulation of thyroid hormone production and secretion.  As discussed in
Section 3.2.2.2, Endocrine Effects, the effects of iodine on the thyroid gland include hypothyroidism,
hyperthyroidism, and thyroiditis.  The above three types of effects can occur in children and adults, and in
infants exposed in utero, or during lactation.  Adverse effects on the pituitary and adrenal glands derive
secondarily from disorders of the thyroid gland.  A wide variety of effects on other organ systems can
result from disorders of the thyroid gland, including disturbances of the skin, cardiovascular system,
pulmonary system, kidneys, gastrointestinal tract, liver, blood, neuromuscular system, central nervous
system, skeleton, male and female reproductive systems, and numerous endocrine organs, including the
pituitary and adrenal glands (Braverman and Utiger 2000).  
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3.7 CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  Relevant
animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the extent
of their exposure.  Exposures of children are discussed in Section 6.6 Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is a
difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less
susceptible than adults to health effects, and the relationship may change with developmental age
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are critical
periods of structural and functional development during both prenatal and postnatal life and a particular
structure or function will be most sensitive to disruption during its critical period(s).  Damage may not be
evident until a later stage of development.  There are often differences in pharmacokinetics and
metabolism between children and adults.  For example, absorption may be different in neonates because of
the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to body weight
(Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants and young
children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, infants have a
larger proportion of their bodies as extracellular water and their brains and livers are proportionately larger
(Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 1966; Widdowson and
Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 1985; Johanson 1980) and
probably an immature blood-testis barrier (Setchell and Waites 1975).  Many xenobiotic metabolizing
enzymes have distinctive developmental patterns.  At various stages of growth and development, levels of
particular enzymes may be higher or lower than those of adults, and sometimes unique enzymes may exist
at particular developmental stages (Komori et al. 1990; Leeder and Kearns 1997; NRC 1993; Vieira et al.
1996).  Whether differences in xenobiotic metabolism make the child more or less susceptible also
depends on whether the relevant enzymes are involved in activation of the parent compound to its toxic
form or in detoxification.  There may also be differences in excretion, particularly in newborns who all
have a low glomerular filtration rate and have not developed efficient tubular secretion and resorption
capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  Children and adults may differ in
their capacity to repair damage from chemical insults.  Children also have a longer remaining lifetime in
which to express damage from chemicals; this potential is particularly relevant to cancer.
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Certain characteristics of the developing human may increase exposure or susceptibility, whereas others
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
Children are highly vulnerable to radioiodine toxicity and related thyroid cancers (NRC 1999). 
Radioiodine is secreted into milk in humans, cows and goats, and infants and children ingest a larger
amount of milk per unit of body mass than adults; they also absorb ingested iodine as avidly as adults.  As
a result, children exposed to milk that has been contaminated with radioiodine may receive a larger internal
dose of radioiodine than similarly exposed adults.  This larger absorbed iodine dose per unit of body mass
is concentrated in a smaller thyroid mass in infants and children (Aboul-Khair et al. 1966; Kay et al. 1966;
Mochizuki et al. 1963), which can result in a higher radiation dose per unit of thyroid mass.  
In addition to a smaller thyroid mass, thyroid iodine uptakes, expressed as a fraction of absorbed dose, are
3–4 times higher during the first 10 days of postnatal life compared to adult uptakes and decline to adult
levels after approximately age 10–14 days (Fisher et al. 1962; Kearns and Phillipsborn 1962; Morrison et
al. 1963; Ogborn et al. 1960; Van Middlesworth 1954).  As a result, newborn infants will be particularly
vulnerable to high radiation doses from internal exposure to radioiodine.  NCI (1997) estimated that the
radiation dose (rad) to the thyroid gland resulting from ingestion of 1 µCi of 131I activity would increase
with decreasing age in children from approximately 1.5 rad/µCi in adults, to approximately 6.6 rad/µCi at
5 years, 12 rad at 1 year, and 33 rad in newborn infants.  Another important factor that contributes to
higher vulnerability of children is that children under 15 years of age appear to be more susceptible to
developing thyroid tumors from thyroid irradiation (Wong et al. 1996).  Studies of thyroid cancers and
external radiation exposure have found a strong age dependence between thyroid radiation dose and
thyroid cancer.  Risk is substantially greater for radiation doses received prior to age 15 years when
compared to risks for doses received at older ages (Ron et al. 1995).  An age-dependence has been found
for solid tumors of other organs and external radiation dose (Thompson et al. 1994).  This same general
trend in age-dependence would be expected for internal exposures to radioiodine; thus, studies of adult
exposures to radioiodine may not be directly applicable to predicting outcomes from exposures to children. 
 
Evidence for vulnerability of infants and children to radioiodine toxicity derive from studies of populations
that have been exposed to radioiodine fall-out as a result of thermonuclear bomb tests and nuclear reactor
accidents.  Several epidemiological studies have examined thyroid gland disorders in residents of the
Marshall Islands who were exposed to radioiodine from atmospheric fallout after an atmospheric nuclear
bomb test (so-called BRAVO test).  The exposures occurred as a result of an unexpected change in the
wind direction after the bomb detonation.  Residents of several islands near and downwind from the test
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site on Bikini Atoll (e.g., Ailingnae, Rongelap, Utirik) were exposed to both internal radioiodine and
external gamma radiation from fallout during the 2 days prior to their evacuation.  The estimated gamma
radiation dose on these islands ranged from 69 to 175 rad (0.7–1.75 Gy) or approximately 10–50% of the
estimated thyroid dose (Conard 1984; Hamilton et al. 1987; Howard et al. 1997; Takahashi et al. 1999). 
Cases of thyroid gland disorders began to be detected in the exposed population in approximately 10 years
after the exposure, particularly in persons who were exposed as children; these included cases of apparent
growth retardation, myxedema, and thyroid gland nodules and neoplasms (Conard et al. 1970).  In 1981,
health screening of children on Rongelap revealed an 83% prevalence of elevated serum concentrations of
TSH (>5 mU/L) among exposed children who were 1 year old or less at the time of the BRAVO test and
who received an estimated thyroid radiation dose exceeding 1,500 rad (15 Gy).  Prevalence decreased with
exposure age and/or thyroid dose: 25% for ages 2–10 years (800–1,500 rad, 8–15 Gy) and 9% for ages
$10 years (335–800 rad, 3.3–8 Gy).  A similar age-related prevalence of thyroid abnormalities occurred
after radioiodine release from the fire at the Chernobyl nuclear power plant in the Ukraine.  Clinical
records from the Republics of Belarus and Ukraine show an increase in the incidence of thyroid nodules
and thyroid cancers in children and adolescents, which became apparent approximately 4 years after the
release of radioactive materials from the Chernobyl nuclear power plant in April 1986 (Astakhova et al.
1998; Cherstvoy et al. 1996; Drobyshevskaya et al. 1996; Tronko et al. 1996).  A comparison of thyroid
cancers diagnosed in children in the Belarus-Ukraine region after the Chernobyl fire with thyroid cancers
diagnosed in children in France and Italy during the same period revealed a striking age difference (Pacini
et al. 1997).  Most the Belarus-Ukraine cancers were diagnosed at age 5 years or less, whereas most of the
cases in France and Italy were diagnosed after age 14 years.  This observation is consistent with a
radioiodine contribution to the Belarus-Ukraine cancers and a higher vulnerability of infants to radioiodine
toxicity. 
Nutritional factors can affect the toxicokinetics of iodine in children and adults.  The most important factor
is dietary iodine.  Chronic iodine deficiency triggers homeostatic mechanisms to increase iodide uptake
into the thyroid gland in order to sustain adequate thyroid hormone levels to regulate metabolism (Delange
and Ermans 1996).  These mechanisms include induction of iodide transport activity and iodination
activity in the thyroid gland, as well as hypertrophy of the gland (i.e., goiter).  As a result, exposures to
radioiodine that occur during a state of deficiency can be expected to result in a larger fraction of the
radioiodine dose being deposited in the thyroid gland, which could result in a higher radiation dose and
risk.
Another nutritional factor that could potentially affect iodine biokinetics in infants and children is
selenium deficiency.  Selenium is a cofactor in the iodothyronine deiodinases that are important for the
synthesis of the thyroid hormone, T3, in extrathyroidal tissues.  Iodine deficiency, in conjunction with
selenium deficiency, has been associated with goiter and cretinism, a developmental impairment related to
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prenatal hypothyroidism (Goyens et al. 1987; Vanderpas et al. 1990).  In this state, in which the thyroid
gland is responding to a deficiency in T3 production by increasing iodide transport and iodination activity
in the thyroid gland, infants and children (as well as adults) may experience a higher thyroid uptake of
absorbed iodine, and possibly a higher radiation dose to the thyroid when exposed to radioiodine.
As previously discussed in Section 3.4.2.2, exposure to iodine can begin in utero with maternal exposure
and, as a result, the fetus is vulnerable to the potential toxic effects of maternal iodine exposures that occur
during pregnancy.  Maternal exposures to excess iodine have been shown to produce thyroid enlargement
and hypothyroidism in neonates (Coakley et al. 1989; Hassan et al. 1968; Iancu et al. 1974; Martin and
Reno 1962; Penfold et al. 1978; Vicens-Colvet et al. 1998).  Deaths have occurred in neonates as a result
of tracheal compression from thyroid gland enlargement (Galina et al. 1962).  The vulnerability of the fetal
thyroid gland has a toxicokinetic basis.  Radioiodine uptake in the fetal thyroid commences in humans at
approximately 70–80 days of gestation and precedes the development of thyroid follicles and follicle
colloid, which are generally detectable at approximately 100–120 days of gestation (Book and Goldman
1975; Evans et al. 1967).  Fetal iodide uptake activity increases with the development of the fetal thyroid
and reaches its peak at approximately 6 months of gestation, at which point, the highest concentrations in
the thyroid are achieved, approximately 5% of the maternal dose/g fetal thyroid (approximately 1% of the
maternal dose) (Aboul-Khair et al. 1966; Evans et al. 1967).  Fetal radioiodine concentrations 1–2 days
following a single oral maternal dose of radioiodine generally exceed the concurrent maternal thyroid
concentration by a factor of 2–8, with the highest fetal/maternal ratios occurring at approximately
6 months of gestation (Book and Goldman 1975).  Following exposure to 131I from maternal ingestion of
medically administered radioiodine or from repeated exposure to radioactive fallout, the fetal/maternal
ratio for thyroid radioiodine concentration has been estimated to be approximately 2–3 (Beierwaltes et al.
1963; Book and Goldman 1975; Eisenbud et al. 1963).  
Dermal exposures to iodine, in particular topical antiseptics containing povidone-iodine, can expose the
fetus to iodine.  For example, increases in iodine concentration in maternal urine and umbilical cord blood
have been observed in pregnant women who received dermal or vaginal applications of povidone-iodine
prior to delivery for disinfection of the skin and fetal scalp electrodes, suggesting that absorption of iodine
occurs with these uses of povidone-iodine as well (l’Allemand et al. 1983; Bachrach et al. 1984). 
Consistent with this are observations that topical application of iodine preparations (i.e., povidone-iodine)
during labor has produced thyroid gland suppression in newborns (l’Allemand et al. 1983; Novaes et al.
1994).  Infants can also absorb iodine when such iodine preparations are applied topically.  Use of
povidone-iodine for topical and surgical wound disinfection in infants has been shown to induce transient
hypothyroidism or hyperthyroidism (Brown et al. 1997; Chabrolle and Rossier 1978a, 1978b).
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Nursing infants can be exposed to iodine in breast milk (Dydek and Blue 1988; Hedrick et al. 1986; Lawes
1992; Morita et al. 1998; Robinson et al. 1994; Rubow et al. 1994; Spencer et al. 1986).  The level of
exposure will depend not only on the maternal exposure, but also on the physiologic status of the maternal
thyroid.  A larger fraction of the absorbed dose is excreted in breast milk in the hypothyroid state
compared to the hyperthyroid state; in the hypothyroid state, excretion of radioiodine into breast milk can
be 10 times higher (e.g., 25% of the dose) than in euthyroid or hyperthyroid states (Hedrick et al. 1986;
Morita et al. 1998; Robinson et al. 1994).  
Iodine is not stored in skeletal tissue or fat to any significant degree and thus, mobilization of these tissues
during pregnancy, for production of the fetal skeleton or breast milk, would not be expected to contribute
to fetal or infant exposure.  There is no evidence that iodine metabolism would be appreciably different in
children compared to adults.  It is possible that the conjugation of iodothyronines with glucuronic acid
could be limited in newborns as a result of the normal development of glucuronyltransferase activity in the
newborn and infant; however, there is no evidence for an effect on iodine toxicokinetics.  In the Gunn rat,
which is a strain of rat that is deficient in glucuronyltransferase activity, glucuronic acid conjugates of
iodothyronines are formed and biliary excretion of iodothyronines is impaired; however, normal
circulating levels iodothyronine appear to be maintained (Curran and DeGroot 1991).  This would suggest
that the thyroid gland may not increase uptake of iodine in response to an impairment in glucuronyl-
transferase activity.
Models of the biokinetics of iodine in infants, children, adolescents, and adults have been developed by
ICRP (1989, 1994a, 1995).  Models have also been developed that predict, with reasonably high accuracy,
the accumulation of radioiodide in the thyroid gland of infants and children exposed to single doses of
radioiodine for clinical procedures (Fisher et al. 1962).
3.8 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples.  They have
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989).
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures
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from more than one source.  The substance being measured may be a metabolite of another xenobiotic
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as
copper, zinc, and selenium).  Biomarkers of exposure to iodine are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health impairment
or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of tissue
dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells),
as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. 
Note that these markers are not often substance specific.  They also may not be directly adverse, but can
indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused by iodine are
discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are
discussed in Section 3.10 “Populations That Are Unusually Susceptible”.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Iodine
Urinary iodine excretion provides a reliable biomarker of steady state iodine intake.  Under steady state
conditions, in which exposure to iodine has been reasonably constant for at least 6 months, daily iodine
will approximate the 24-hour urinary iodine excretion.  The basis for this relationship is that ingested
iodide is nearly completely absorbed in the gastrointestinal tract and that urine is the principal route of
excretion of the absorbed iodide (see Sections 3.3.1.2 and 3.3.4.2).  The use of urinary iodide as a
biomarker of iodide exposure is supported by studies in which 24-hour urinary iodide was measured before
and after supplementation.  For example, 31 patients received oral supplements of 382 µg I/day for
6 months.  Prior to the supplementation, the mean 24-hour urinary iodide excretion rate was 36 µg/day
(range, 13–69), whereas after 6 months of iodide supplementation, the mean 24-hour urinary iodide
excretion rate was 415 µg/day (Kahaly et al. 1998).  The difference between these two values, 379 µg/day,
is nearly identical to the supplemental dose of 382 µg/day. 
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Exposure to123I, 124I, and 131I can be detected directly from external measurements of gamma radiation
emanating from the thyroid gland.  The basis for this is that approximately 90% of the iodine in the body is
in the thyroid gland and absorbed iodine is rapidly taken up into the thyroid gland.  The measurement
procedure is known as a thyroid scintillation scan.  A scintillation detector device usually consists of a
shielded sodium iodide crystal connected to a collimator and spectrometer.  The detector is placed over the
thyroid gland and the spectrometer is tuned to collect gamma emissions having peak energies of the target
isotope (e.g., 0.159, 0.511, or 0.364 MeV for 123I, 124I,  or 131I, respectively).  Events are corrected for
attenuation by overlying tissue by counting a neck phantom containing a gamma source of known activity. 
Because of the relatively short radioactive decay half-times of 123I (13 hours), 124I (4.2 days), and 131I
(8 days), thyroid scans must be conducted soon after exposure in order to detect the iodine in the thyroid
gland.
3.8.2  Biomarkers Used to Characterize Effects Caused by Iodine
The thyroid gland is the primary and most sensitive target for both chemical and radioiodine toxicity.  As a
result, biomarkers of iodine effects are those that allow the detection of preclinical and clinical suppression
or stimulation of the thyroid gland.  Effects on the thyroid gland can be classified into five types: goiter,
hypothyroidism, hyperthyroidism, thyroiditis, and thyroid nodules.  Hypothyroidism refers to a state of
suppressed production and/or secretion of thyroid hormones and can occur with or without goiter, a
functional hypertrophy of the gland in response to suppressed hormone production.  The term clinical
hypothyroidism, regardless of the cause, refers to a condition in which the circulating levels of T4 and/or
T3 are depressed below their normal ranges and TSH is elevated above the normal range.  Typical normal
ranges are for hormone levels are shown in Table 3-8.  The term subclinical hypothyroidism refers to a
decrease in circulating T4 or T3 concentrations, usually accompanied by an increase in serum TSH
concentration, within their respective normal ranges.  Hyperthyroidism is an excessive production and/or
secretion of thyroid hormones.  The clinical manifestation of abnormally elevated circulating levels of T4
and/or T3 is thyrotoxicosis.  The terms subclinical and clinical hyperthyroidism refer to the conditions in
which the circulating levels of T4 or T3 are elevated within or above their normal ranges, respectively
(Table 3-8).  Thyroiditis refers to an inflammation of the gland, which is often secondary to thyroid gland
autoimmunity.  Thyroid autoimmunity can be detected as a presence of IgG antibodies to thyroglobulin
and thyroid peroxidase in serum antibodies (Table 3-8).  In addition to the above measurements, physical
examination and ultrasound can reveal nodules and other normal or abnormal variations in thyroid gland
structure.  Examples of the use of these measurements in assessing iodine-induced effects on the thyroid
gland are presented in Section 3.2 of the profile.
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Table 3-8.  Typical Reference Ranges for Serum Thyroid Hormones 




Total T4 4–11 µg/dL 60–140 nMa
Free T4 0.7–2.1 ng/dL 10–25 pMa
Total T3 75–175 ng/dL 1.1–2.7 nMa
Free T3 0.2–0.5 ng/dL 3–8 pM
Reverse T3 15–45 ng/dL 0.2–0.7 nM
TSH 0.3–4.0 mU/Lb,c 1–15 pM
Thyroid peroxidase antibodies (TPA) <10 IU/mL –
Thyroglobulin autoantibodies (Tg-ab) <10 IU/mL –
Source:  Stockigt (2000) and Marcocci and Chiovato (2000)
aChildren may be higher
bAssumes a biologic potency of 7–15 mU/mg
cHigher in neonates (de Zegher et al. 1994)
T3 = 3,5,3N-triiodo-L-thyronine; T4 = 3,5,3N,5N-tetraiodo-L-thyronine (thyroxine); TSH = thyroid stimulating hormone
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3.9 INTERACTIONS WITH OTHER CHEMICALS
Thiourelenes and Thionamides.  A variety of compounds that contain the thionamide chemical group have
been shown to increase the accumulation of iodide in the thyroid gland and to decrease the production of
iodothyronines (Green 1996): 
These include several drugs used in the treatment of thyrotoxicosis and other hyperthyroid states,
(carbimazole, methimazole, and propylthiouracil); as well as the antibiotic, ethionamide; the cancer 
chemotherapy agent, 6-mercaptopurine; and goitrin, a natural constituent of the plant genus Brassicae
(rutabaga, turnip, and cabbage).  The thionamides exert their effects by inhibiting the iodination of tyrosine
and monoiodotyrosine in the thyroid gland and the coupling of iodotyrosines to form iodothyronines.  The
mechanisms for these effects are not completely understood; however, at least two mechanisms are needed
to explain the reversible and irreversible inhibition of iodothyronine production that is characteristic of
these agents.  Thionamides agents may act reversibly by reducing  I+ or some other reactive intermediate of
iodine required in the iodination reaction, and also through a mechanism that involves a direct, irreversible
reaction with thyroid peroxidase.
Thiouracil and propylthiouracil, and related thiourylenes, are also inhibitors of iodthyronine deoidinase
(Leonard and Koehrle 1996).  The mechanism of inhibition involves the formation of a covalent complex
with deiodinase enzymes.  Inhibitory potency is highest for Type 1 deiodinase (Table 3-7).  The result of
inhibition is a decreased metabolic clearance of iodothyronines.
Analine Derivatives.  As a class, para-substituted aminobenzenes have activity similar to that of the
thionamides in that they increase the accumulation of iodide in the thyroid gland and decrease production
of iodothyronines, although possibly not through the same mechanisms (Green 1996).  The group includes
several drugs (and drug classes), amphenone B, carbutamide, amino-glutethimide, p-aminosalicylic acid,
and the sulfonamides.
Substituted Phenols.  Various substituted phenols that have hydroxyl groups in the meta positions have
been shown to increase thyroid iodide accumulation and to inhibit iodothyronine production in the thyroid. 
These include resorcinol, 2,4-dihydroxybenzoic acid, and 2,4-dihydroxyphenol.  These compounds exert
their activity by producing an irreversible inhibition of thyroid peroxidase (Green 1996).
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Hydroxypyridines.  Hydroxypyridines, including 3-hydroxypyridine and 3,4-dihydroxypyridine, have
been shown to increase thyroid iodide accumulation and to inhibit iodothyronine production in the thyroid
(Green 1996). 
Perchlorate and Related Complex Anions.  A variety of complex inorganic anions have been shown to
decrease the uptake of iodide in the thyroid gland.  When given at high enough dosages, these agents can
induce hypothyroidism and goiter (Green 1996).  The complex anions include, in order of potency:
perchlorate (ClO4-), perrhenate (ReO4-), pertechnetate (TcO4-), and tetrafluorborate (BF4-).  The mechanism
for their activity is competitive inhibition of the NIS (Carrasco 1993; Eskandari et al. 1997; Wolf 1964). 
These agents are also transported by the NIS and are accumulated in the gland.  They can also affect
accumulation and/or secretion of iodide in other tissues that have an active iodide transporter, including the
choroid plexus, gastric mucosa, mammary gland, placenta, salivary gland, and sweat gland (Brown-Gant
1961). 
Thiocyanate.  Thiocyanate (SCN-) is a potent inhibitor of iodide uptake in the thyroid gland and iodination
of thyroglobulin.  The mechanism for the effect on iodide uptake is primarily related to competitive
inhibition of iodide transport by the Na+/I- symport in thyroid gland; however, thiocyanate may also
accelerate iodide efflux from the thyroid by being a substrate with iodide for an anion exchange
mechanism on the basolateral membrane of thyroid follicle cells (Eskandari et al. 1997; Yoshida et al.
1997).  Thiocyanate inhibits iodination, apparently by its actions as a competitive oxidation substrate for
thyroid peroxidase (Virion et al. 1980).  Unlike other complex anion inhibitors of iodide transport,
thiocyanate is not accumulated in the thyroid gland.
Thiocyanate is a product of the metabolism of cyanide (ATSDR 1997) to which humans are exposed when
they smoke cigarettes, which has prompted interest in the potential effects of smoking on thyroid iodine
metabolism and thyroid disease (Bertelsen and Hegedus 1994).  Thiocyanate is a metabolite of
nitroprusside, a drug used in the treatment of acute hypertensive emergencies and cardiac failure. 
Impairment of thyroid function in patients on nitroprusside has been reported (Bodigheimer et al. 1979;
Nourok et al. 1964).
Microsomal Enzyme Inducers.  Agents that induce hepatic microsomal enzymes increase the activity of
phenolic glucuronyl transferases that catalyze the conjugation of iodothyronines with glucuronic acid
(Curran and DeGroot 1991; Visser 1990).  Induction of glucuronyltransferase increases the metabolic
clearance of iodothyronines and, if sufficiently accelerated, can stimulate thyroid stimulating hormone
release and goiter.  Such effects have been observed in rats and other experimental animal models in
response to exposures to 2,4-benzopyrene, chlordane, DDT and DDD, 3-methylcholanthrene, PCBs,
chlorinated dibenzodioxins (CDDs), and toxaphene.  A variety of drugs have also been shown to exert
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effects on glucruonide conjugation of iodothyronines, including the sedative, phenobarbitol; the
anticonvulsants, phenytoin and carbamazepine; and the antibiotic, rifampin.
Polychlorinated Biphenyls (PCBs).  Depending on dose and duration, PCBs can disrupt the production
and disposition of thyroid hormones at a variety of levels and thereby may potentially interact with iodine
in impairing the thyroid gland.  The major findings include (1) histological changes in the thyroid gland
indicative of both stimulation of the gland (e.g., similar to that induced by TSH or a hypothyroid state) and
disruption of the processing of follicular colloid needed for normal production and secretion thyroid
hormone; (2) depression of serum T4 and T3 levels, which may effectively create a hypothyroid state (in
some studies, low doses resulted in elevated serum T4 levels while depressed levels occurred at higher PCB
doses); (3) increased rates of elimination of T4 and T3  from serum; (4) increased activities of
T4-UDP-glucuronyl transferase (UDP-GT) in liver, which is an important metabolic elimination pathway
for T4 and T3; (5) decreased activity of iodothyronine sulfotransferases in the liver, which are also
important in the metabolic elimination of iodothyronines; (6) decreased activity of iodothyronine
deiodinases, including brain Type-2 deiodinase, which provide the major pathways for the production of
the active thyroid hormone, T3; and (7) decreased binding of T4 to transthyretin, an important transport
protein for both T4 and T3 (ATSDR 2000).
Selenium.  Selenium is essential for the activity of the glutathione peroxidases and iodothyronine
deiodinases.  In humans, concurrent selenium and iodine deficiency have been associated with goiter and
cretinism, a developmental impairment related to prenatal hypothyroidism (Goyens et al. 1987; Vanderpas
et al. 1990).  Supplementation of individuals deficient in both iodine and selenium with selenium produces
a further decrease in thyroid function, but if selenium supplementation is preceded by normalization of
iodine levels, normal thyroid function is restored (Contempré et al. 1991, 1992).  Selenium intake has been
reported to affect thyroid hormone levels in humans; these effects include decreases in serum T3 and T4
levels and increases in serum TSH levels, suggesting suppression of thyropid hormone production (Brätter
and Negretti De Brätter 1996; Duffield et al. 1999; Hagmar et al. 1998; Hawkes and Keim 1995).  In
experimental animals, selenium deficiency results in decreased metabolic clearance of iodothyronines and
decreased extrathyroidal production of T3, as a result of decreased iodothyronine deiodinase activity,
which can be restored to normal by selenium repletion (Arthur and Beckett 1994; Behne and
Kyriakopolous 1993).  Selenium deficiency also results in decreases in thyroid iodine concentrations.  The
latter effect is thought to involve direct and indirect effects on thyroid hormone production and secretion. 
The direct effect is thought to result from decreased activity of glutathione peroxidase in the thyroid and
increased availability of hydrogen peroxide for utilization in the production of iodothyronines in the
thyroid, which can then be exported from the gland.  The indirect effect may involve increased release of
TSH from the pituitary gland in response to a decrease in plasma concentration of T3, resulting from
inhibition of deiodination of T4.
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Amiodarone.  The more serious side effects of the use of the antiarrythmia drug, amiodarone, are effects
on the thyroid, including hypothyroidism, hyperthyroidism and thyroditis (Meier and Burger 1996). 
Although the exact mechanisms for these effects are not completely understood, amiodarone contains a
large quantity of iodine and has been shown to inhibit the deiodination of iodothyronines; in particular, the
production of T3 from T4, most likely as a result of inhibition of Type 1 deiodinase (Table 3-7).  A
metabolite of amiodarone, desethyamiodarone, has been shown to inhibit binding of T3 to thyroid hormone
receptors in a variety of tissues (Green 1996).  As a thyroid receptor antagonist, amiodarone (or its
metabolite) also stimulates the release of TSH from the pituitary gland.
Lithium.  Hypothyroidism and goiter have been associated with chronic therapy with lithium carbonate for
management of bipolar disease (Green 1996; Spaulding et al. 1972).  The mechanism for these effects is
not understood, although it has been suggested that lithium may inhibit the coupling reaction in the
synthesis of iodothyronines and may inhibit thyroid hormone secretion.
Propranolol.  Propranolol is a drug used in the treatment of hypertension, angina, and other cardiovascular
disorders as well as for the symptomatic treatment of thyrotoxicosis.  Although the basis for its use in
treatment of thyrotoxicosis is to counteract the cardiovascular symptoms of the disorder, the drug is also an
inhibitor of iodothyronine deiodination (Meier and Burger 1996).  The effect is unrelated to its activity as a
β-adrenergic receptor antagonist, as both the L- and D-isomer (devoid of β-receptor antagonist activity)
inhibit the deiodination of T4.  The mechanism for this action is not understood. 
Dexamethasone.  Although the corticosteroids exert multiple effects on the physiological regulation of
thyroid hormone release (e.g., decreased TSH release from the pituitary), these agents also have
appreciable activity as inhibitors of iodothyronine deiodinase and can decrease the metabolic clearance of
iodothyronines (Meier and Burger 1996).
Iodinated Drugs.  A variety of iodine-containing drugs have been shown to inhibit iodothyronine
deiodination and thereby decrease the metabolic clearance of iodothyronines.  These include the
antiarrhythmic agent, amiodarone (previously discussed), and several radiographic contrast agents used for
cholecystography such as iopanoic acid, sodium ipodae, and tyropanoate (Meier and Burger 1996).
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to iodine than will most persons
exposed to the same level of iodine in the environment.  Reasons may include genetic makeup, age, health
and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These parameters
result in reduced detoxification or excretion of iodine, or compromised function of organs affected by
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iodine.  Populations who are at greater risk due to their unusually high exposure to iodine are discussed in
Section 6.7, Populations With Potentially High Exposures.
People who consume diets deficient in iodine may be more vulnerable to the toxic effects of exposure to
radioiodine.  At very low intakes, representing iodine deficiency (e.g., 20 µg/day), uptake of iodide into
the thyroid gland is increased (Delange and Ermans 1996).  This response is mediated by TSH, which
stimulates iodide transport and iodothyronine production in the thyroid gland (see Section 3.5.1).  If
exposure to radioiodine was to occur in an individual who is iodine-deficient, a larger fraction of the
absorbed radioiodine may be taken up by the thyroid gland and a larger radiation dose to the thyroid gland
may be received.  Iodine deficiency has been suggested to be a possible contributing factor to the increase
in thyroid cancer incidence observed in Belarus after the Chernobyl reactor accident (Gembicki et al.
1997).
People who have multinodular goiter or thyroid gland adenomas can have foci of thyroid gland tissues that
produce and secrete thyroid hormone autonomously from control of the gland by TSH.  The mechanisms
for thyroid tissue autonomy appear to involve clonal expansion of follicle cells that have a modified TSH
receptor or receptor coupling mechanism (Corvilain et al. 2000).  Autonomous nodules can give rise to
hyperthyroidism (e.g., toxic nodular goiter, toxic adenoma).  Iodine deficiency and goiter appear to be risk
factors in the development of autonomous nodules (Aghini-Lombardi et al. 1999).  People who have the
autonomous nodules appear to be more vulnerable to iodide-induced hyperthyroidism (Braverman and
Roti 1996; Ermans and Camus 1972).  This may, in part, explain the increased incidence of
hyperthyroidism that sometimes accompanies the introduction of iodide supplements into the diet of
iodine-deficient populations (Connolly 1971b; Corvilain et al. 1998; Delange et al. 1999).  In experimental
studies, supplemental doses of  75–150 µg I/day for 1–2 weeks have induced hyperthyroidism in euthyroid
patients who had autonomous thyroid adenoma (Livadas et al. 1977).  Patients with certain types of
thyroid autoimmunity may be more susceptible to developing hyperthyroidism when exposed to excess
iodine (Braverman and Roti 1996; Braverman et al. 1971a).
Populations with diets that are deficient in selenium may be more susceptible to iodine toxicity.  Selenium
is a cofactor in the iodothyronine deiodinases that are important for the synthesis of the thyroid hormone,
T3, in extrathyroidal tissues.  Iodine deficiency, in conjunction with selenium deficiency, has been
associated with goiter and cretinism, a developmental impairment related to prenatal hypothyroidism
(Goyens et al. 1987; Vanderpas et al. 1990).  In this state, in which the thyroid gland is responding to a
deficiency in T3 production by increasing iodide transport and iodination activity in the thyroid gland,
infants and children (as well as adults) may experience a higher thyroid uptake of absorbed iodine and
possibly a higher radiation dose to the thyroid when exposed to radioiodine.
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3.11 METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of
exposure to iodine.  However, because some of the treatments discussed may be experimental and
unproven, this section should not be used as a guide for treatment of exposures to iodine.  When specific
exposures have occurred, poison control centers and medical toxicologists should be consulted for medical
advice.  The following text provides specific information about treatment following exposures to iodine:
Braverman LE, Utiger RD.  2000.  Werner and Ingbar's the thyroid:  A fundamental and clinical text. 
Philadelphia, PA:  Lippincott-Raven.
Treatment of toxicity from exposure to excess iodine is directed at lowering exposure and, if clinical
hypothyroidism or hyperthyroidism persists, correcting the thyroid dysfunction.  Treatment of clinical
hypothyroidism includes the administration of thyroid hormone.  Treatment of hyperthyroidism involves
administering thyroid hormone synthesis inhibitors.
Treatment of toxicity from exposure to radioiodine is also directed at lowering thyroid gland uptakes of
absorbed iodine, for example, by administration of potassium iodide.  If the exposure produces persistent
hypothyroidism or hyperthyroidism, the treatment strategies for the clinical abnormalities are the same as
those for exposure for nonradioactive iodine.
3.11.1 Reducing Peak Absorption Following Exposure
No information was located on methods to reduce peak absorption following exposure.  Mitigation of toxic
effects following exposure to radioiodine is directed at reducing the uptake of absorbed iodine in the
thyroid gland (see Section 3.11.2).
3.11.2 Reducing Body Burden
Approximately 90% of the iodine in the human body is contained in the thyroid gland.  The thyroid gland
is also the major toxicity target of radioiodine.  Therefore, methods for reducing the uptake and
accumulation of radioiodine in the thyroid gland can reduce the radioiodine body burden, the absorbed
radiation dose to the thyroid gland and body, and the toxic effects of exposure to radioiodine.  Iodine
uptake into the thyroid gland is highly sensitive to the iodide intake.  At very high intakes of iodine,
representing an intake excess (e.g., >1 mg/day), iodine uptake into the thyroid gland decreases, primarily
as a result of decreased iodothyronine synthesis (Wolff-Chaikoff effect) and iodide transport into the gland
(Nagataki and Yokoyama 1996; Saller et al. 1998).  A single oral dose of 30 mg iodide (as sodium iodide)
decreases the 24-hour thyroid uptake of radioiodine by approximately 90% in healthy adults (Ramsden et
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al. 1967; Sternthal et al. 1980).  The inhibition of uptake was sustained with repeated oral doses of sodium
iodide for 12 days, with complete recovery to control (presodium iodide) uptake levels within 6 weeks
after the last sodium iodide dose (Sternthal et al. 1980), or within 8 days after a single dose (Ramsden et al.
1967).  Repeated oral doses of 1.5–2.0 mg iodide/m3 of surface area produced an 80% decrease in thyroid
uptake of radioiodine in children (Saxena et al. 1962).  Inhibition of radioiodine uptake by the thyroid
gland that occurs when large doses of iodide are administered results in more rapid urinary excretion of
radioiodine and decreased iodine body burden (Ramsden et al. 1967).  The administration of iodide as
prophylaxis for reducing thyroid uptake of radioiodine after accidental releases of radioiodine has been
recommended by the FDA and NCRP (FDA 1978; NCRP 1977).
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
The mechanisms of action of excess iodine in producing goiter, hypothyroidism, hyperthyroidism, or
thyroiditis involve direct interactions between iodide and physiological elements involved in thyroid
hormone synthesis and release, and iodine transport.  Therefore, the principal strategy for reducing toxic
effects is to decrease iodine intake or uptake into the thyroid gland (see Section 3.11.2).  Numerous cases
of reversal of iodine-induced hypothyroidism or hyperthyroidism after reduction of iodide intake have
been reported and are described in this profile (see Section 3.2.2.2, Endocrine Effects).  The principal
clinical strategy for managing permanent hypothyroidism is the administration of T4 (Brent and Larsen
2000).  The principal clinical strategy for managing permanent hyperthyroidism is the administration of
agents that inhibit iodination of thyroglobulin, such as propylthiouracil or methimazole, or that inhibit
thyroid uptake of iodine, such as perchlorate or destruction of the thyroid gland with radiation.  The latter
is usually accomplished by administering a cytotoxic dose of 131I.  β-Adrenergic antagonists are also used
to manage some of the symptoms of thyrotoxicosis (Cooper 2000).
The sulfhydryl compound, amifostine, has been found to reduce the toxic effects of high exposures to 131I
in patients who undergo ablative therapy with 131I for thyroid cancers (Bohuslavizki et al. 1996, 1998a,
1998b, 1999).  The mechanism for the protective effect appears to be accumulation of amifostine in the
salivary gland and scavenging of free radicals formed as a result of interactions of ionizing radiation from
131I with tissues.
3.12 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate
information on the health effects of iodine is available.  Where adequate information is not available,
ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the initiation
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of a program of research designed to determine the health effects (and techniques for developing methods
to determine such health effects) of iodine.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of Iodine
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
iodine are summarized in Figures 3-14 and 3-15.  The purpose of this figure is to illustrate the existing
information concerning the health effects of iodine.  Each dot in the figure indicates that one or more
studies provide information associated with that particular effect.  The dot does not necessarily imply
anything about the quality of the study or studies, nor should missing information in this figure be
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying
Substance-Specific Data Needs Related to Toxicological Profiles (ATSDR 1989), is substance-specific
information necessary to conduct comprehensive public health assessments.  Generally, ATSDR defines a
data gap more broadly as any substance-specific information missing from the scientific literature.
3.12.2 Identification of Data Needs
Acute-Duration Exposure.    The primary effect of acute exposures to excess iodine in humans is
hypothyroidism.  This effect has been studied extensively in experimental studies of humans and is also
well documented in the clinical case literature.  Reported NOAELs for iodine-induced hypothyroidism in
humans vary widely for reasons that are not completely understood.  Acute exposures to excess iodine
produce allergic reactions in people.  The mechanisms for sensitivity and the reactions are not completely
understood.
The effects of acute exposures to radioiodine (primarily 131I) have been extensively studied in humans.  An
enormous amount of epidemiological and case literature derives from the clinical use of 131I in diagnostic
procedures and in treatment of thyroid gland enlargement and thyrotoxicosis.  Epidemiology studies have
also examined health effects resulting from accidental environmental exposures due to nuclear bomb
detonations (e.g., Marshall Islands) and releases from nuclear power plants (e.g., Chernobyl).  These
studies collectively and convincingly identify the thyroid gland as the primary target of radioiodine.  Other 
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Figure 3-14.  Existing Information on Health Effects of Stable Iodine
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Figure 3-15.  Existing Information on Health Effects of Radioactive Iodine
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tissues that are either near the thyroid gland, such as the parathyroid gland, or that accumulate iodine, such
as the salivary gland, also are affected by exposures to 131I; however, these effects occur at absorbed
radiation doses that are clearly cytotoxic to the thyroid gland.  Breast tissue expresses NIS and appears
capable of accumulating 131I and transferring it to mammary milk; therefore, it is a potential target of 131I. 
However, epidemiology studies reported to date have not found a significant risk of breast cancer even
after cytoxic exposures to 131I.
Intermediate-Duration Exposure.    The primary effect of intermediate-duration exposures to excess
iodine in humans is hypothyroidism.  This effect has been studied extensively in humans and is well
documented in the clinical case literature.  Reported LOAELs for iodine-induced hypothyroidism in
euthyroid humans, without goiter, fall within a reasonably narrow range, and are higher than those for
people who are iodine deficient, suggesting a higher sensitivity in these subjects.  The mechanisms for this
are not completely understood.  Intermediate-duration exposure has also been shown to induce
hyperthyroidism in people who have nontoxic goiter.  Here again, the mechanisms are not completely
understood, although clonal expansion of autonomous follicle cells and autoimmunity are suspected
contributors.  Intermediate-duration exposures to excess iodine produce allergic reactions in people.  The
mechanisms for sensitivity and the reactions are not completely understood.
Chronic-Duration Exposure and Cancer.    Epidemiological studies and clinical case literature
identify the thyroid gland as the principal target of chronic exposure to excess iodine.  Goiter,
hypothyroidism, hyperthyroidism, and/or thyroid autoimmunity are the main outcomes of chronic
exposure to excess iodine.  Which effect occurs appears to be related to the pre-existing iodine intake (e.g.,
deficient or replete) and the presence or absence of possibly pre-existing autoimmunity and/or thyroid
gland enlargement (or nodularity).  
Genotoxicity.    Stable iodine has been tested for genotoxicity in a variety of eukaryotic cell systems and
has been found to be without mutagenic activity.  The genotoxicity of radioactive iodine (131I) has been
extensively studied in clinical studies of patients who received 131I for therapy of thyroid cancer and
thyrotoxicosis and in people who were exposed to radioiodine from nuclear power plant accidents (e.g.,
Chernobyl).
Reproductive Toxicity.    Several studies of reproductive effects of exposures to 131I have been
reported.  These studies indicate that relatively high exposures to radioiodine (i.e., that are cytotoxic to the
thyroid gland) can produce impairment of testicular function.  The mechanism for this is not understood,
but the observation of these effects suggests a possible exposure of the testes to 131I.  The testis is not
presently known to express NIS; however, studies of the uptake of radioiodine in testes were not located.
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Developmental Toxicity.    Developmental toxicity of iodine and radioiodine related to effects on the
fetal/neonatal thyroid gland has been well documented in the clinical case literature.  The primary effect is
congenital hypothyroidism and associated sequelae. 
Immunotoxicity.    The epidemiological and clinical case literature has identified thyroid autoimmunity
and allergic reactions as the primary immunologic effects of exposure to excess iodine.  Thyroid
autoimmunity is an extremely important mechanism of thyroid gland disease.  The mechanisms by which
iodine induces thyroid autoimmunity are not completely understood.  The production of antibodies to
highly iodinated thyroglobulin has been proposed as a possible contributor.
Neurotoxicity.    The primary target of iodine toxicity is the thyroid gland.  A large amount of clinical
literature exists on the  neurological sequelae of thyroid gland disorders.
Epidemiological and Human Dosimetry Studies.    The epidemiological literature on iodine- and
radioiodine-related health effects is very substantial and provides information on exposures associated with
the primary effect, thyroid gland dysfunction.  There remain certain complications in the interpretation of
the major epidemiology studies of environmental exposures to iodine and radioiodine.  These relate to the
magnitude of the contribution of iodine deficiency and autoimmunity in the observed thyroid gland
outcomes (e.g., hypothyroidism, hyperthyroidism, thyroid gland nodularity, and cancers).
Studies of human dosimetry of 131I are extensive, in large part, because of the extensive use of 131I in
diagnostic and treatment procedures that require highly certain estimates of the radiation dose delivered to
the thyroid gland.  The clinical information has been incorporated into reconstructions of thyroid doses
experienced by the general public.
Biomarkers of Exposure and Effect.    
Exposure.  The use of urinary iodide for assessing steady state iodine intakes is well substantiated in the
clinical and epidemiological literature and is supported by toxicokinetics studies in humans.  Similarly, the
use of external scintillation spectrometry to estimate radioiodine doses to the thyroid gland also has a
substantial clinical history.
Effect.  The clinical literature on thyroid gland disorders extensively documents the major biomarkers of
thyroid gland dysfunction that are relevant to iodine toxicity.
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Absorption, Distribution, Metabolism, and Excretion.    The toxicokinetics of iodine in humans
has been substantially explored and characterized in experimental studies and clinical cases.  Radioiodine
toxicity is most likely in tissues that can transport and accumulate iodide.  Studies of the expression of NIS
and factors that alter expression of NIS can further advance our understanding of which tissues are at risk
and what factors, including genetic factors, might affect sensitivity to radioiodine in humans.
Comparative Toxicokinetics.    The extensive information on the toxicokinetics of iodine in humans
makes extrapolations from animals less important in assessing the health effects of iodine in humans. 
Studies of interindividual variability in humans are valuable for identifying sensitive subpopulations.
Methods for Reducing Toxic Effects.    The principal method for preventing the toxic effects of
radioiodine is dosing with stable iodine, which decreases the thyroid gland uptake of radioiodine and the
absorbed radiation dose to the gland.  The mechanistic basis and effectiveness of this approach is well
established from experimental and clinical studies.
Children’s Susceptibility.    Higher susceptibility of the fetus and infants to iodine and radioiodine
toxicity is substantiated by the epidemiological and clinical case literatures.  The toxicokinetic basis for the
susceptibility of infants and children to iodine exposure is understood.  Uncertainties in assessing the
potential health effect of iodine exposures are largely related to estimating exposures, in particular, the
pathways by which environmental releases result in radioiodine uptake into the fetal or infant thyroid
gland (see Section 6.8.1).
Child health data needs relating to exposure are discussed in 6.8.1 Identification of Data Needs: Exposures
of Children.
3.12.3 Ongoing Studies
Ongoing studies pertaining to iodine have been identified and are shown in Table 3-9.
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Table 3-9.  Ongoing Studies on Health Effects of Radioactive Iodine
Investigator Affiliation Title Sponsor





Brent, GA University of California,
Los Angeles
Regulation of the sodium/iodine
symporter in breast
NCI
Burek, CL John Hopkins University Immunotoxic effects of iodine NIH—National Institute of
Diabetes and Digestive and
Kidney Diseases
Burek, CL John Hopkins University Nod h2h4 mice as a sentinel model for
autoimmune thyroid
NIEHS
Carrasco, N Yeshiva University Characterization of the thyroid Na
+/I-symporter
NIH—National Institute of
Diabetes and Digestive and
Kidney Diseases
Degroot, LJ University of Chicago Pathogenesis and therapy of
autoimmune thyroid disease
NIH—National Institute of
Diabetes and Digestive and
Kidney Diseases
Kong, Y-CM Wayne State University T cell recognition—repertoire in
autoimmune thyroiditis
NIH—National Institute of
Diabetes and Digestive and
Kidney Diseases
Naylor, EW Neo Gen Screening, Inc. Simplified population screening for adult
hypothyroidism
NIH—National Institute of
Diabetes and Digestive and
Kidney Diseases
Refetoff, SS University of Chicago Regulation and mechanisms of hormone
action
NIH—National Institute of
Diabetes and Digestive and
Kidney Diseases
Refetoff, SS University of Chicago Screening for inherited thyroid defects NCRR
Sgouros, G Sloan-Kettering Institute
for Cancer
Modeling and dosimetry for radiolabeled
antibody therapy
NCI
St Germain, DL Dartmouth College Regulation of thyroid hormone
metabolism
NIH—National Institute of
Diabetes and Digestive and
Kidney Diseases
St Germain, DL Dartmouth College The role of the Type 3 deiodinase in
development
NIH—National Institute of
Diabetes and Digestive and
Kidney Diseases






Diabetes and Digestive and
Kidney Diseases
Source:  CRISP 2001; National Institutes of Health; Central Repository of Incidents, Solutions, and Problems 
NCI = National Cancer Institute; NCRR = National Center for Research Resources; NIEHS = National Institute of Environmental
Health Sciences; NIH = National Institute of Health/National Institute of General Medical Sciences
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4.  CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION
4.1 CHEMICAL IDENTITY
Iodine is a nonmetallic element belonging to the halogen family in Group VIIA of the periodic table. 
Iodine is found in nature as iodide (i.e., I-) in brines or in molecular compounds with other elements (e.g.,
iodate or IO3 -).  The chemical information for elemental iodine and some of its compounds is listed in
Table 4-1.  Radioactive isotopes of iodine (e.g., see Section 4.2) are an additional cause of concern with
regard to human health (see Chapter 3). 
4.2 PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES
The physical properties of iodine and selected iodine compounds are listed in Table 4-2.  The percent
occurrence of iodine isotopes and radiological properties of iodine isotopes is listed in Table 4-3.
Iodine can exist in several oxidation states: -1, 0, +1, +3, +5, and +7.  Under normal environmental
conditions, the -1, 0, and +5 oxidation states are the most important.  There are 36 isotopes of iodine
having masses between 108 and 143 (Chu et al. 1999); 14 of these yield significant radiation.  The only
naturally-occurring isotopes of iodine are 127I and 129I, which are stable and radioactive, respectively. 
Isotopes of mass less than 127 are produced in particle accelerators, while those >127 are formed in
neutron generators such as nuclear reactors and atomic bombs.  A total of 72% of uranium fissions and
75% of plutonium fissions leads directly or by beta decay of precursors, to iodine isotopes.  For example,
2.89% of 235U and 3.86% of 239Pu fission atoms lead to the formation of a series of isobar 131 isotopes,
including 131In, 131Sn, 131Sb, 131Te, 131I, and 131Xe.  Each isotope can be formed as an initial fission product
and, once formed, each isotope decays by beta-ray emission to the right on the sequence, through 131I, and
ending with stable 131Xe.  The process can be displayed as:
 
The same process occurs for 129I (t½=1.6x107 years) and includes mass 129 isobars beginning with 129Cd
and ending with 129Xe.  Iodine isotopes above 127I decay by emitting beta and gamma radiation, whose
combined energies are unique to each iodine isotope.  131I, for example, decays by beta particle emission,
and 0.96 MeV of energy is shared between the beta particle and the gamma ray.  At least seven possible
beta/gamma combinations occur.  In 90.4% of the decays, a 0.61 MeV beta particle is emitted.  The
remaining excess energy is emitted as either a 0.364 MeV gamma ray for 85.3% of the time, or a pair of








































Table 4-1.  Chemical Identity of Iodine and Iodine Compounds
Property Iodine Hydrogen iodide Sodium iodide Potassium iodide Methyl iodide Cesium iodide
Chemical formula I2 HI INa IK CH3I CsI





















Trade names None None None None Halon 10001 No data
Identification numbers
CAS registry 7553-56-2 10034-85-2 7681-82-5 7681-11-0 74-88-4 7789-17-5
NIOSH RTECS NN1575000 MW3760000 WB6475000 TT2975000 PA9450000 No data
EPA hazardous waste None None None None U138 None









None None UN 2644 Poison/IMO
6.1
None
HSDB 34 2155 750 5040 1336 None
NCI 42355 None None 77362 9366 None







































Table 4-1.  Chemical Identity of Iodine and Iodine Compounds (continued)
Property Potassium iodate Sodium periodate Calcium iodide Copper (I) iodide Povidone iodine































Trade names None None None None None
Identification numbers
CAS registry 7758-05-6 7790-28-5 10102-68-8 7681-65-4 25655-41-8
NIOSH RTECS NN1350000 None None None TR1579600
EPA hazardous waste None None None None None
OHM/TADS None None None None None
DOT/UN/NA/IMO shipping None None None None
HSDB 1231 None None 271 6831
NCI None None None 26245
STCC None None None None None
Source:  HSDB 2001; Lide 2000
CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North America/International Maritime Dangerous Goods
Code; EPA = Environmental Protection Agency; HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; RTECS = Registry of Toxic Effects of Chemical
Substances; STCC = Standard Transportation Commercial Code
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Table 4-2.  Physical and Chemical Properties of Iodine and Iodine Compoundsa
Property Iodine Hydrogen iodide Sodium iodide Potassium iodide
Molecular weight, g/mole 253.809a 127.91a 149.89a 166.02a
Color Bluish-blacka Colorlessa White Colorless or whitea
Physical state Solid; scales or
platesa




Melting point 113.60 ECa -50.8 ECa 651 ECa 680 ECa
Boiling point 185.24 ECa -35.1 ECa 1,304 ECd 1,323 ECd
Density, g/cm3 (25 EC) 4.93a 5.23a 3.67a 3.12a
Odor Characteristica No data Odorlessa No data
Odor threshold:
Water No data No data No data No data
Air No data No data No data No data
Solubility (25 EC):
Water 330 mg/La 2,340 g/L (10 EC)a 2,000 g/La 1,429 g/La
Organic solvents(s) 141 g/kg
benzenea 
Solublea 500 g/L alcohola 13 g/L acetonea
Partition coefficients:
Log Kow 2.49b No data No data No data
Log Koc No data No data No data No data
Vapor pressure (25 EC) 0.305 mm Hga 5,940 mm Hgc 1 mm Hg
(767 EC)c
No data
Henry’s law constant No data No data No data No data
Autoignition temperature No data No data No data No data
Flashpoint No data No data No data No data
Flammability limits No data Non-flammable No data No data
Explosive limits No data No data No data No data
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Table 4-2.  Physical and Chemical Properties of Iodine and Iodine Compoundsa
(continued)
Property Methyl iodide Cesium iodide Potassium iodate
Sodium
periodate
Molecular weight, g/mole 141.94a 259.81a 214.02a 213.892d
Color Colorlessa Colorlessd Whitea Whited
Physical state Liquida Solid; crystals, or
powdera
Solid, crystalsa Solid; crystalsd
Melting point -66.5 ECa 621 ECa 560 ECa Decomposes
~300 EC
Boiling point 42.5 ECa ca. 1,280 ECa No data No data
Density, g/cm3 (25 EC) 2.28 (20 EC)a 4.5a 3.98c 3.86d
Odor Pungent, ether-
likec
No data No data No data
Odor threshold:
Water No data No data No data No data




Misciblea 9.16 g/100 gc Solubled
Organic solvents(s) Misciblea Soluble in
alcohol; insoluble
in acetonea
No data No data
Partition coefficients:
Log Kow 1.51c No data No data No data
Log Koc No data No data No data No data
Vapor pressure (25 EC) 405 mm Hg No data No data No data
Henry’s law constant 0.00526 atm-cu
m/mole
No data No data No data
Autoignition temperature No data No data No data No data
Flashpoint No data No data No data No data
Flammability limits No data No data No data No data
Explosive limits No data No data No data No data
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Table 4-2.  Physical and Chemical Properties of Iodine and Iodine Compounds
(continued)
Property Calcium iodide Copper (I) iodide Povidone iodine
Molecular weight, g/mole 293.89a 190.45a 364.95c
Color Yellowa Red-browna Yellow-brownc





Melting point 740 EC 588–606 ECa 300 ECe
Boiling point 1,100 EC ~1,290 ECa No data
Density, g/cm3 (25 EC) 5.63a
Odor No data No data Slight characteristicc 
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility (25 EC)
Water Very solublea 80 mg/L (18 EC)c Solublec




Log Kow No data No data No data
Log Koc No data No data No data
Vapor pressure No data No data No data
Henry’s law constant No data No data No data
Autoignition temperature No data No data No data
Flashpoint No data No data No data
Flammability limits No data No data No data
Explosive limits No data No data No data
Source:  Chemfinder 2001, unless otherwise specified.
aBudavari et al. 1998
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Table 4-3.  Percent Natural Occurrence and Radioactive Properties 














123I 15715-08-9 – 1.08 (97.0%) 158.97 13.3 hours 1.92x106




125I 14158-31-7 – ECb 35.5 59.4 days 1.76x104




127I 7553-56-2 <100 – – stable –








































Source:  Chu et al. 1999
aNot all gamma and beta energies are included in summary; see Chu et al. (1999) for a complete listing
bEC = electron capture decay
cActivity = (NA ln2)/(Mw t½)
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131I 131Xe (stable) + β− (0.61 MeV; 85.3%) +  γ (0.36 MeV)
+ β− (0.61 MeV; 5.1%) + γ (0.284 MeV) + γ (0.080 MeV)
+ β− (0.81 MeV; 0.6%) +  γ (0.16 MeV)
+ β− (0.47 MeV; 0.3%) +  γ (0.50 MeV)
+ β− (0.47 MeV; 0.2%) +  γ (0.33 MeV) + γ (0.2 MeV)
+ β− (0.33 MeV; 6.9%) +  γ (0.64 MeV)
+ β− (0.25 MeV; 1.6%) +  γ (0.72 MeV)
Isotopic masses of iodine <127 can be produced using a beam of high energy protons generated using a 
linear accelerator.  Proton beams tuned at fixed energies up to 30 MeV produce isotopes, such as 123I, by
interaction of the proton beam with a high atomic weight target.
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1 PRODUCTION
Iodine, a halogen, occurs in low concentrations in nature in the form of iodides mainly in sea water,
although there are a number of major sources iodine including the underground waters from certain deep-
well boring and mineral springs (i.e., brines) and natural deposits of sodium nitrate ore (i.e., caliche) found
in the northern part of Chile.  Only a few marine organisms contain iodine in relatively large quantities
including seaweeds, sponges, and corals.  The different production processes for recovering iodine are
based on the raw materials used.  About 65% of the iodine consumed in the world comes from brines
processed in Japan, the United States, and the former Soviet Union.  The primary production process for
recovery of iodine from brines is the blow-out process.  The blow-out process for brines can be divided
into brine clean-up, iodide oxidation followed by air blowing and recovery, and iodine finishing.  In 2000,
iodine was recovered from brines by the blow-out process by three companies operating in Oklahoma,
which accounted for 100% of the U.S. elemental iodine production.  These three companies are IOCHEM
Corporation (Dewey County, Oklahoma), North American Brine Chemicals (Dover, Oklahoma), and
Woodward Iodine Corporation (Woodward County, Oklahoma).  Production of iodine in the United States
has remained steady ranging from 1,270 to 1,620 metric tons between the years 1996 and 1999
(Lauterbach et al. 1995; USGS 1998, 2001).
After World War II, the U.S. government began stockpiling iodine for defense applications.  By 1968, the
DOD had acquired 3,700 metric tons of iodine.  In 1992, Congress determined that the stockpile was
unnecessary, reduced the stockpile goal to zero, and authorized the sale of all excess material.  As of
September 30th, 2000, the uncommitted inventory of stockpile-grade iodine was 1,782 metric tons (USGS
1998, 2001).
The only naturally occurring isotopes of iodine are 127I and 129I, which are stable and radioactive,
respectively.  Other radioactive iodine isotopes (e.g., 131I) do not occur in nature; they are the direct result
of anthropogenic activity.  As discussed in Chapter 4, 129I and 131I are produced by nuclear fission.  Nearly
all of the 129I and 131I generated in the United States is present in spent nuclear reactor fuel rods.  These fuel
rods are currently located at commercial reactor facilities or at Department of Energy (DOE) facilities
across the United States.  The cumulative yield of 129I is about 1% of all fission products.  Thus, 129I
represents only a very small fraction of the total fission product inventory in the nuclear fuel cycle.  A
limited amount of 123I, 125I, and 131I will be produced for industrial, scientific, and medicinal applications by
International Isotopes Inc. (Denton, Texas) using a linear accelerator (DOE 1996d; International Isotopes
2001; USGS 1998). 
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5.2 IMPORT/EXPORT
In 1999, 62% of the apparent consumption of iodine in the United States (5,650 metric tons) was imported. 
Of the 5,430 metric tons of iodine imported in 1999, approximately 64% was imported from Chile, 27%
from Japan, and 9% from Russia.  Exports of iodine have decreased from 2,410, 2,760, and 2,790 metric
tons in 1996, 1997, and 1998, respectively, to 1,130 metric tons in 1999 (USGS 1998, 2001). 
5.3 USE
End uses for iodine in 1996 were estimated from a United States Geological Survey (USGS) canvass of
consumers as follows (by percentage): sanitation (39%); pharmaceutical (24%); heat stabilizers (13%);
catalyst (9%); animal feed (7%); and other (8%).  Other smaller uses included inks and colorants,
photographic chemicals, laboratory reagents, production of batteries, high-purity metals, motor fuels, and
lubricants.  Hydrogen iodide (i.e., HI) is used in the manufacture of hydroiodic acid and organic iodo
compounds, and to remove iodine from iodo compounds.  Potassium iodide (i.e., KI) is used in animal
feeds, catalysts, photographic chemicals, for sanitation, and for treatment of poisoning with radioactive
materials resulting from nuclear accidents.  Sodium iodide (i.e., NaI) is used in photography and for the
production of organic chemicals.  Methyl iodide (i.e., CH3I) is used as a methylation agent in organic
synthesis, in microscopy, as an embedding material for examining diatoms, and in testing for pyridine. 
Potassium iodate (i.e., KIO3) is used in salt iodization, an oxidizing agent in analytical chemistry, and as a
maturing agent and dough conditioner (Lauterbach and Ober 1995; USGS 1998). 
Radioactive iodine has been used successfully for the treatment of cancer of the thyroid.  The radioactive
isotope 123I is considered the agent of choice for brain, thyroid, and renal imaging and uptake
measurements.  125I is used as a cancer therapeutic, and as a brain, blood, and metabolic function
diagnostic.  131I is used as a brain, pulmonary, and thyroid diagnostic (Lauterbach 1995; USGS 1998).
5.4 DISPOSAL
Most nonradioactive iodine minerals, iodine compounds, and iodine-containing materials do not require
special disposal or handling requirements.  However, some chemical forms may be classified as hazardous
materials if the compound is chemically reactive, flammable, or toxic.  Care should be taken to read and
understand all of the hazards, precautions, and safety procedures for each specific chemical form.  In
addition, all federal, state, and local laws and regulations should be investigated and subsequently followed
with regard to disposal and handling of the specific chemical form of the iodine compound or material.
Radioactive iodine does require special disposal and handling requirements and is regulated by the Nuclear
Regulatory Commission.  Radioactive waste-containing radioactive iodine can be grouped into three
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categories: low-level waste (LLW); high-level waste (HLW) and spent nuclear fuel; and mixed waste.  As
defined by the Nuclear Waste Policy Act, high-level radioactive waste is “the highly radioactive material
resulting from the reprocessing of spent nuclear fuel, including liquid waste produced directly in
reprocessing and any solid material derived from such liquid waste that contains fission products in
sufficient concentration.”  However, most classifications of HLW also include spent nuclear fuel.  Most
HLW was generated from the production of plutonium.  A small fraction is related to the recovery of
enriched uranium from naval reactor fuel.  This waste typically contains highly radioactive, short-lived
high activity fission by-products as well as other long-lived isotopes, hazardous chemicals, and toxic
heavy metals.  Radioiodine contamination is only a small fraction of the activity of HLW.  Liquid HLW is
typically stored in large underground tanks of either stainless steel or carbon steel depending on whether
they are acid or alkaline solutions.  There are about 100 million gallons of high-level liquid waste stored in
underground tanks in Washington, South Carolina, Idaho, and New York.  These tanks contain a variety of
radioactive liquids, solids, and sludges.  Some of the liquid wastes have been solidified into glass, ceramic
slag, salt cakes, and sludges (DOE 1996a; Murray 1994).
Spent nuclear fuels, such as fuel elements and irradiated targets used in nuclear reactors, are currently
disposed of at the commercial nuclear power plants and DOE facilities where they were produced.  Spent
fuel is highly radioactive due to the large concentration of fission products and must be stored in special
water-cooled pools that shield and cool the material.  Most of the radioactive iodine remains trapped in the
spent fuel rod matrix and is never released.  Roughly all DOE spent fuel, about 3,000 metric tons, is stored
at four sites: Hanford, Savannah River, Idaho National Engineering Laboratory, and West Valley, New
York.  Commercial reactors have generated more than 30,000 metric tons of spent fuel.  The spent fuel
from these facilities is stored at the more than 100 commercial nuclear reactor sites around the United
States.  Since spent commercial nuclear reactor fuel is placed in on-site storage while awaiting off-site
disposal, the only isotope of iodine remaining in the fuel matrix when it leaves the generating facility will
be 129I.  The establishment of an HLW and spent fuel repository for both DOE and commercial waste is
currently under evaluation at Yucca Flats, Nevada.  It is not projected to be in operation until after the year
2010 (DOE 1996b, 2001d; Eisenbud 1987; Murray 1994).
Mixed waste contains both radioactive and chemically hazardous materials such as toxic, corrosive,
flammable, or explosive materials.  The radioactive component may be either HLW or LLW.  All liquid
HLW is mixed waste, usually in the presence of organic solvents or heavy metals in addition to radioactive
components.  Disposal of mixed wastes is regulated by the EPA under the Resource Conservation and
Recovery Act (RCRA) and by the National Regulatory Commission under the Atomic Energy Act.  The
EPA and National Regulatory Commission have developed special procedures on how to handle and
dispose of this special category.  The DOE operates an incinerator in Oak Ridge, Tennessee, which burns
mixed hazardous radioactive wastes (DOE 1996a). 
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Low-level waste is all radioactive waste that cannot be classified as HLW, spent fuel, or mixed waste. 
Low-level does not necessarily mean low radioactivity or low environmental hazards.  However, the bulk
of LLW has relatively little radioactivity and practically no transuranic elements.  Thus, LLW usually does
not require shielding from radioactivity or heat removal equipment.  Most LLW is acceptable for near
surface land disposal.  LLW types that may be contaminated with 129I include both wet and dry wastes. 
Examples of the physical form of LLW are spent ion exchange resins, filter sludges, filter cartridges,
evaporator bottoms, compactible trash, noncompactible trash, irradiated components, ashes produced from
the incineration of combustible material, contaminated detergents or solvents, organic liquids, and
discarded contaminated equipment or tools.  Of the LLW generated today, approximately 64% of the
volume and 70% of the radioactivity are generated as a result of nuclear power plant activities or
supporting fuel cycle operations.  Other sources of LLW are industrial, academic, government, and
medical.  Radioiodine contamination accounts for only a small fraction of the activity of LLW.  LLW
typically is packaged in drums or boxes and buried in shallow pits or trenches.  Approximately 3 million
cubic meters of LLW generated in the United States have been disposed of this way.  LLW from DOE
sources is currently disposed of at several DOE facilities across the United States.  Only three sites accept
non-DOE LLW, Barnwell, South Carolina; Richland, Washington; and Envirocare of Utah, Inc. (Clive,
Utah).  Over half of the LLW in the eastern United States is disposed of at the Barnwell site.  As required
by the Federal LLRW (Low Level Radioactive Waste) Policy Act in 1980 and the 1985 amendments,
states or interstate compacts are required to build facilities to contain LLW generated from sources within
their boundaries.  However, other than Barnwell, South Carolina; Richland, Washington; and Clive, Utah
sites, no other facility in the United States is currently accepting LLW from non-DOE sources.  Currently,
many generators store LLW on-site until additional facilities can be constructed in the future (DOE 1996a;
Eisenbud 1987; Envirocare 2001; Murray 1994). 
Decay on-site is one method chosen in the medical community to handle their low level radioiodine waste. 
Contaminated clothing, food trays, linen, materials used to clean patients’ rooms, furniture, and telephones
are quarantined until levels of radioiodine are sufficiently low.  A period of 10 half-lives may be adequate
to reduce the radioactivity to safe levels to permit reuse of the materials without controls.
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6.  POTENTIAL FOR HUMAN EXPOSURE
6.1 OVERVIEW
Stable iodine has been identified in at least 8, iodine-129 (129I) in at least 2, and iodine-131 (131I) in at least
6 of the 1,585 hazardous waste sites that have been proposed for inclusion on the EPA National Priorities
List (NPL) (HazDat 2001).  However, the number of sites evaluated for iodine, 129I, and 131I is not known. 
The frequency of these sites can be seen in Figures 6-1, 6-2, and 6-3, respectively.  All of these sites are
located within the United States.
Iodine is a naturally occurring constituent of the earth’s crust and is the least abundant of the halogen
elements (Straub et al. 1966).  The stable isotope iodine, 127I, is ubiquitous throughout the earth’s surface. 
The concentration of 127I in the earth’s crust is approximately 0.5 ppm; in the oceans, the concentration is
45–60 µg/L, and in the atmosphere, the concentration ranges from 10 to 20 ng/m3.  Concentrations of
iodine in the environment throughout the United States vary depending on the proximity to the seacoast
and the soil type.  The concentration of iodine in bedrock varies between 0.5 and 380 ppm, depending on
whether the rock is igneous or sedimentary.
Iodine exists in many chemical forms (e.g., molecular iodine, iodide, iodate, periodate) and can undergo
oxidation-reduction as well as microbial alkylation (mostly methyl iodide).  Iodine has nine radioisotopes,
of which 125I, 129I, and 131I are commonly encountered in acute or chronic exposures to human populations,
due either to the life-times of the radioisotope in the environment, their production, and/or their utilization
in industry, medicine, and research.  
129I is the only naturally occurring iodine radioisotope.  It is produced as a fission product of uranium and
thorium in soils and oceans, and is also formed in reactions of xenon with high energy particles in the
upper atmosphere and reactions of neutrons with 128Te and 130Te (Soldat 1976).  129I has a half-life of
1.6x107 years and decays through β emission; 129I has a mass/decay rate equivalency of 1 g 129I=6.55 MBq
(177 microcuries) (Robkin and Shleien 1995).  129I/127I ratios from natural production of 129I should be
3x10-14 in the environment, but with the introduction of 129I from nuclear weapons testing and nuclear
energy activities, the ratio is now 10-8 (Ballad et al. 1978).  The estimated global inventory of 129I is
approximately 9,600 Ci (5.43x107 g), of which 9,200 Ci (5.2x107 g) is associated with igneous activity
(DOE 1994).
125I and 131I are produced in the fission of uranium and plutonium by neutron bombardment in reactors
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Figure 6-3.  Frequency of NPL Sites with Iodine 131 Contamination
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capture (EC) emitting a 35.5 keV gamma-ray and K-shell x-rays (27.4 keV, 112%; 31.4 keV, 24%).  The
specific activity of 125I is 67.7 TBq/g or 18,277 Ci/g.  The half-life of 131I is 8.02 days and decays through
β emission; 131I has a specific activity of 457 TBq/g or 123,429 Ci/g.  Unlike 129I, 125I and 131I do not have
long residency times in the environment due to their short half-lives and, thus, do not pose risks associated
with an accumulation in the environment.  However, in acute exposures to 125I and 131I, there is the
potential for significant radiation to the thyroid.
Releases of iodine into the environment occur from both natural sources and human activity.  The natural
sources include volatilization of iodine from the oceans, weathering of rock, and volcanic activity (Cohen
1985; Whitehead 1984).  Sources of iodine from human activities include release of radioiodine from
nuclear weapons testing and nuclear fuel reprocessing, waste stream effluent from municipal plants, and
combustion of waste and fossil fuels (Likhtarev et al. 1993; Moran et al. 1999; NAS 1974; NCRP 1983;
Stetar et al. 1993).
Iodine enters the atmosphere mainly through volatilization of methyl iodide and, to a lesser extent,
molecular iodine from the ocean surface.  129I is introduced naturally through the conversion of xenon-129
to 129I through the interaction with high energy particles in the upper atmosphere.  131I was released through
weapons production/utilization, nuclear fuel reprocessing, and energy production (AEC 1974; Likhtarev et
al. 1993; Marter 1993; Moran et al. 1999; NCRP 1983; Robkin and Sheien 1995).  In the atmosphere,
iodine undergoes extensive photochemical changes and can exist as gaseous inorganic, gaseous organic, or
particulate forms.  These forms have an average residency time in the atmosphere of 10, 18, and 14 days,
respectively (Whitehead 1984).
The gaseous inorganic and particulate forms of iodine are precipitated from the atmosphere through wet
(rain, sleet, and snow) and dry (gravitational settling and wind turbulence) deposition processes
(Whitehead 1984).  Alkyl iodides, such as methyl iodide, have a low susceptibility to both wet and dry
deposition.  The deposition of iodine will depend on particle size and concentration, wind turbulence, and
the chemical form of iodine.  If precipitation occurs over land, iodine will be deposited onto plant surfaces
or soil surfaces, or into surface waters.  The average retention time of iodine on plant surfaces is
7.5–14 days due to weathering (AEC 1974; Heinemann and Vogt 1980; Kirchner 1994).  Retention of
iodine in the soil is influenced by a number of factors, including soil pH, soil moistness, porosity of soil,
and composition of organic and inorganic (e.g., aluminum and iron oxides) components (Sheppard et al.
1995; Whitehead 1984).  Approximately 1% of iodine received through atmosphere-to-soil deposition is
returned through volatilization of molecular iodine and methyl iodide; the remaining iodine is eventually
returned to the oceans through surface water and groundwater (NRC 1979; Whitehead 1984).  The average
residency time of iodine in the soil at 0.3- and 1-meter depths has been suggested to be 80 and 800 years,
with only 1–3% of deposited iodine migrating to the 1-meter depth (DOE 1986).  
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Transport of iodine through surface water and groundwater is not greatly retarded by the soil, rock, and
sediments over or through which these waters flow (NRC 1981).  The concentration of iodine in river
water ranges between 0.1 and 18 µg/L, which parallels the concentration of iodine in rainwater of
0.1–15 µg/L (NRC 1979).  In groundwater, the mean concentration is 1 µg/L (Yuita 1994a).  The
concentration of iodine in river water often increases downstream of urban areas due to the discharge of
waste streams from municipal treatment facilities.  This is especially true for 131I that enters sewage streams
from patients undergoing radioiodine therapies (Tubiana 1982; UNSCEAR 2000).  Slightly elevated
concentrations of 129I have been observed in surface water and groundwater near nuclear fuel reprocessing
facilities (Beals and Hayes 1995; DOE 1994).
Iodine has been shown to bioaccumulate in many seawater and freshwater aquatic plants (Poston 1986). 
Freshwater plants (e.g., algae) contain 10-5% by weight of iodine, whereas marine plants (algae) contain
10-3% by weight (NCRP 1983).  In freshwater fish, iodine concentrations in tissues range from 0.003 to
0.81 ppm, which gives concentration ratios (fish/water) of 0.9–810.  In marine fish, the iodine
concentrations range between 0.023 and 0.11 ppm, yielding concentration ratios of between 10 and
20 (Poston 1986).  In terrestrial plants, iodine can be taken up through the roots, mainly as iodide and to a
lesser extent, as iodate or iodine (Burte et al. 1991; Whitehead 1984).  The average iodine concentration in
terrestrial plants is 0.42 µg/g.  The uptake is dependent on soil conditions and the use of fertilizers
(Moiseyev et al. 1984).  Distribution of iodine and iodide varies throughout the plant (Voigt et al. 1988). 
The uptake of iodine into terrestrial plants in combination with deposition of iodine onto the surfaces of
plants plays an important role in the transfer of iodine through the soil-plant-cow-milk pathway.  The
efficiency through which iodine is transferred through this pathway is important in ascertaining the risk of
radioiodine exposures in the general human population from continuous or accidental releases of 131I and
129I, especially in children (AEC 1974; Soldat 1976; Tubiana 1982; Voigt et al. 1989).
The iodine content of food has been studied extensively, with intakes of iodine typically ranging from
0.064 to 0.379 mg/day (FDA 1974; Pennington et al. 1984, 1986).  The major sources of iodine intake
from food in a typical U.S. diet are added salt and food additives, followed by meat and meat products,
milk and milk products, and green/yellow vegetables (FDA 1974).  Other foods that can provide a high
amount of iodine in the diet include seaweed, marine shellfish, and marine fish.
It is estimated that the intake of iodine through inhalation is 4x10-5 g/year (NRC 1979).  The average
intake of iodine from drinking water, assuming an average iodine concentration of 3 µg/L, is estimated to
be 1.5x10-3 g/year (NRC 1979).  If the average intake of iodine from food is assumed to be the
recommended dietary allowance (RDA) for iodine of 150 mg/day, then the yearly intake of iodine would
be approximately 55 g.  Thus, the largest source of iodine in the average U.S. diet comes from food intake. 
The intake of iodine through food consumption can be increased greatly in diets high in marine fish
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(-800 µg/kg wet weight), shellfish (-800 µg/kg), and seaweed-based products (0.8–4.5 g/kg dry weight)
(FDA 1974).
Currently, the intake of 129I and 131I by the general population through inhalation, drinking water, and food
intake does not pose any significant risk, due to the extremely low levels of 129I and 131I in the general
environment.  However, there are certain populations of individuals who are at risk to potential exposures
to high levels of iodine or acute/chronic levels of radioiodine.  Individuals undergoing specific diagnostic
or therapeutic procedures or receiving certain types of medications can significantly increase whole-body
and thyroid burdens of iodine and 131I (FDA 1989b; Tubiana 1982).  Family members, especially children,
of patients undergoing 131I therapies can experience exposure to both the radioisotope and the radiation
emitted from 131I (Barrington et al. 1999; Jacobson et al. 1978).  Likewise, medical personnel working
with, or in proximity to, 131I can also have elevated whole-body and thyroid burdens of this radioisotope
and are at risk to exposure to the photon radiation emitted from 131I (Blum and Liuzzi 1967; Mountford and
O’Doherty 1999; Tubiana 1982).  Workers in nuclear power plants or nuclear fuel reprocessing facilities
are at risk for potentially high acute exposures of 129I and 131I (Bhat et al. 1973; Raghavendran et al. 1978). 
Laboratory workers who are involved in the iodination of chemicals or biologics with 125I/131I or the use of
these radioiodinated materials also show increased thyroid burdens of these radioisotopes (Bogdanove and
Strash 1975; de Groot 1979; Dunn and Dunscombe 1981; Jönsson and Mattsson 1998; Kivinitty et al.
1984; Krzesniak et al. 1979; Kwok and Hilditch 1982; Pomroy 1979).
6.2 RELEASES TO THE ENVIRONMENT
Iodine, 129I, and 131I have been identified in 8, 2, and 6, respectively, of 1,585 current or former NPL
hazardous waste sites within a variety of environmental media (air, leachate, and groundwater) collected at
these sites (HazDat 2001).
Releases of iodine and its radioisotopes into the environment occur from natural sources and from human
activity (Figures 6-4 and 6-5).  The emphasis of the discussion of iodine release into the atmosphere will
focus on atmospheric (air), water (marine and surface waters), and soils which are major compartments in
the geochemical cycling of iodine (Figures 6-4 and 6-5).  Throughout this chapter, the units used to
express concentration or intake of iodine and its radioisotopes are the same units reported by the authors. 
In some cases, values are expressed in mass units, while in other cases, the values are expressed as
activities (either in Bq or Ci).  For 129I, the mass/decay rate equivalencies is 1 g 129I = 6.55 MBq
(177 microcuries) (Robkin and Shleien 1995).  For 131I, the specific activity of this radioisotope is
457 TBq/g or 123,429 Ci/g.  For 125I, the specific activity is 67.7 TBq/g or 18,277 Ci/g.
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6.2.1 Air
Iodine, 129I, and 131I have been identified in 2, 1, and 6 air samples, respectively, collected from the
1,585 NPL hazardous waste sites where it was detected in some environmental media (HazDat 2001).
The introduction of iodine into the atmosphere is derived from both natural and human activities
(Figures 6-4 and 6-5), amounting to approximately 4x107 kg within the total global atmosphere at an
average concentration of 10–20 ng/m3 (Whitehead 1984).  The predominant source of iodine in the
atmosphere is obtained from the transfer of iodine from the ocean to the surrounding atmosphere (FDA
1974).  Evaporation of sea spray is one pathway through which iodine can enter the atmosphere. 
However, a high ratio (ca. 1,000) of iodine to chlorine measured in the atmosphere and rainwater in
comparison to that found for seawater strongly suggests that other, more important pathways are
responsible for the transfer of iodine from oceans and the surrounding atmosphere.  These could include
the photochemical or ozone-induced oxidation of iodide to elemental iodine (NCRP 1983; Whitehead
1984).  Indeed, the concentration of ozone near the ocean surface could account for upwards of
6–12x107 kg of iodine released yearly into the atmosphere from the world’s oceans.  Yet, the concentration
of iodine at the ocean’s surface is too low to support this iodide oxidation mechanism as a major
contributor to the transfer of iodine into the atmosphere.  Instead, it has been suggested that the formation
of methyl iodide and other alkyl iodides from the biological metabolism of iodine/iodide may, in fact, play
a major role in the annual transfer of approximately 1.3–2.0x109 kg of iodine from the ocean into the
atmosphere (NRC 1981; Rasmussen et al. 1982; Whitehead 1984).  Under this mechanism, the methyl
iodide that is transferred into the atmosphere can undergo photolytic dissociation into methyl and I
radicals, with the resultant formation of elemental iodine and other forms of inorganic iodine (HI, HOI,
INO2, IONO2, OIO, etc.) (Chameides and Davis 1980; Cox et al. 1999; Vogt et al. 1999).  Other sources of
iodine introduction into the atmosphere from the ocean include the release of particulate forms of iodine
(IO3-), iodine-bearing particulates, and/or organically-bound iodine into the marine atmosphere with an
airborne concentration ranging from 2 to 4 ng/m3 (NCRP 1983; Vogt et al. 1999; Whitehead 1984).
The transfer of iodine from land surface(s) into the atmosphere also occurs, but to a much lesser extent
than what is observed for the transfer of iodine between the ocean and atmospheric compartments
(Figures 6-4 and 6-5).  It is estimated that 1.6x106 kg/year of iodine is transferred into the atmosphere from
surface soils and from the terrestrial biosphere, with an average airborne concentration of iodine ranging
from 3 to 49 ng/m3 as both the gaseous and particulate forms of organic and inorganic iodine (NRC 1981;
Whitehead 1984).  Iodine is transferred into the atmosphere from land sources through processes such as
volatilization of iodine from soil and suspension of soil.  For example, it is estimated that approximately
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Figure 6-4.  Geochemical Cycle of Triad Elements (I, Br, Cl)
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Figure 6-5.  An Outline of the Movement of Iodine in the Environment*
Source:  Whitehead 1984
*1 = deposition in rainfall; 2 = dry deposition (including absorption by plant leaves); 3 = volatilization; 4 = suspension of
dust; 5 = suspension of marine aerosols; 6 = uptake by plant roots; 7 = decomposition of plant residues;
8 = consumption of food; 9 = decomposition of animal excreta and residues; 10 = run-off; 11 = irrigation; 12 = non-
specific adsorption/desorption; 14 = immobilization/mineralisation involving soil organic matter; 15 = leaching;
16 = weathering; 17 = combustion of fossil fuels
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(Muramatsu and Yoshida 1995).  Like the atmosphere over the ocean compartment, iodine is found in the
gaseous form ranging from 3 to 45 ng/m3 versus 0.5–6.9 ng/m3 bound to particulates (Whitehead 1984). 
The ratios of gaseous to particulate forms of iodine (2–5) and inorganic to organic forms of iodine (0.1–2)
vary, depending on location (Whitehead 1984).
A natural radioisotope of iodine, 129I, is also introduced into the atmosphere.  Sources of 129I include
interaction of 129Xe with high energy particles in the upper atmosphere and, to a lesser extent, spontaneous
fission and the reaction of neutrons with 128Te (tellurium-128) and 130Te (tellurium-130) (NCRP 1983). 
This leads to a natural abundance of 129I that varies between 10-12 and 10-15 atoms per atom of the stable
isotope of iodine, 127I (Soldat 1976).  This amounts to approximately 80 kg of 129I in the surface
environment (e.g., oceans, atmosphere, land) with 5x10-4 kg in the atmosphere (Moran et al. 1999). 
Because 129I has a half-life of 1.6x107 years, the introduction of this radioisotope into the atmosphere, and
the environment as a whole, is cumulative from the standpoint of assessing human exposures.
Introduction of iodine and its radioisotopes can occur as a consequence of energy production, nuclear
weapons production/utilization, and agricultural and medicinal/research uses.  For the stable form of iodine
(127I), the introduction of iodine from these manufactured sources is much smaller than that observed for
the introduction of iodine into the atmosphere from natural sources.  However, the introduction of the
radioisotopes of iodine (i.e., 125I, 129I, and 131I) into the atmosphere, and the environment as a whole, is
derived mainly from human activities. 
Combustion of fossil fuels also leads to the introduction of iodine from land-based sources (Figure 6-5). 
The average iodine content of coal is reported to be approximately 4 mg/kg, whereas petroleum contains
iodine at an average concentration of 1 mg/kg (Chameides and Davis 1980).  Based on fossil fuel (e.g.,
coal and petroleum) consumption estimates for 1971 of approximately 2,500 Mtoe/year  (i.e.,
2,500 million tons of oil equivalent per year), this would amount to approximately 4x105 kg of iodine
introduced into the atmosphere for that year (0.1% of the total iodine transferred to and from the
atmosphere) (Bertine and Goldberg 1971; Whitehead 1984).  At the current rate of global coal and
petroleum consumption of approximately 3,000 Mtoe/year, the introduction of iodine into the atmosphere
from this source for the year 2001 would be 5x105 kg per year (IEA 2000; Whitehead 1984).
The production and use of nuclear materials for the generation of electrical energy has also contributed to
the release of iodine and its radioisotopes.  129I is formed in nuclear fission reactions of 235U and 239Pu with
an atomic yield of 0.12% from uranium and 0.5% from plutonium.  The yields of 129I from the fission of
235U and 238Pu are 0.9 and 1.7%, respectively (AEC 1974).  This gives an approximate ratio of 4 for 129I/127I
in the fission of 235U and 238Pu.  Since the nuclear fuel elements are contained in a metal cladding, the
release of 127I and 129I that is produced in the fission reactions does not occur until the fuel is reprocessed. 
For example, it is estimated that the Savannah River fuel reprocessing plant released approximately
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2.8 kg/year of 129I during 1964–1965, but has now fallen below 0.7 kg/year since the 1970s.  This amounts
to a total of 5.7 curies of 129I released during the 1954–1989 operating history of the plant (Marter 1993). 
Releases of 129I from the Hanford Reservation between 1944 and 1995 are estimated to be 1,900 GBq
(290 kg) (Robkin and Sheien 1995).  The releases of another iodine radioisotope, 131I, during the years
1966–1972 was estimated to be 3x105 Bq (8x10-6 Ci)/MW(e)y from fuel reprocessing.  From the Savannah
site, an estimated 2,520 curies of 131I was released from 1954 to 1989 (Marter 1993).  The average releases
of 131I from boiling water reactors (BWR) ranges between 2x10-3 and 5x10-3 Ci/MW(e)y, and for
pressurized water reactors (PWR), the values range from 5x10-5 to 50x10-5 Ci/MW(e)y (NRCC 1980).
Surface testing of nuclear weapons release of 129I into the environment from nuclear explosions of 235U and
239Pu amounted to approximately 30 and 50 µCi per kiloton, respectively.  Thus, it is estimated that
atmospheric testing of nuclear weapons has released approximately 50 kg of 129I into the atmosphere.  The
transport and diffusion of this radioisotope depended on initial height of the nuclear cloud and
meteorological conditions; residency times were <0.5 years in the lower stratosphere and approximately
2 years at medium altitudes.  Diffusion of radioisotopes from higher to lower altitudes then deposited
through either precipitation or dry deposition (NCRP 1983); dry deposition could be as important as
precipitation in surface deposition of iodine (Machta 1963; Straub et al. 1966).  Release of 131I also
occurred during these surface tests of nuclear weapons; however, the 131I that was released into the
environment from these tests has decayed (half-life of 8.02 days) to levels that are no longer of concern in
the environment. 
Accidental releases of iodine and its radioisotopes are also sources of iodine introduction into the
atmosphere.  The 1986 Chernobyl reactor accident has released an estimated 1.3 kg of 129I and
1,200–1,700 Pbq (2.6–3.7 kg) of 131I into the atmosphere (Likhtarev et al. 1993; Moran et al. 1999; Mould
2000).  Other notable accidental releases of 131I include the 1957 Windscale, United Kingdom,
radiochemical plant fire and the Three Mile Island accident that released approximately 700 TBq (1.53 kg)
and 0.6 TBq (1.3 mg) of 131I, respectively (Likhtarev et al. 1993)
6.2.2 Water
Iodine, 129I, and 131I have been identified in 1, 1, and 1 groundwater samples, respectively, and no surface
water samples collected from the 1,585 NPL hazardous waste sites, where it was detected in some
environmental media (HazDat 2001).
Introduction of iodine into surface waters and groundwater occurs predominately through rainwater for
noncoastal land regions and the combination of rainwater and ocean spray in coastal regions (Figures 6-4
and 6-5).  It is estimated that 1.0x1011 g/year of iodine is deposited onto land surfaces, of which
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8.1x1010 g/year enters surface waters and 1.5x1010 enters groundwater (NRC 1981).  The iodine in
rainwater is derived from the transfer of iodine from the oceans to the atmosphere (FDA 1974).
Other natural releases of iodine into surface waters and groundwater include the leaching of iodine from
the weathering of rock and volcanic activity (Figure 6-5).  It is estimated that rocks contribute between
1x109 and 1.6x1010 g/year depending on the iodine content of the rock (0.5–8.8 ppm) (Cohen 1985). 
Volcanic activity can add an estimated 1.2x109 g of iodine per year to the surface environment, where the
greatest contribution to the oceans is due to undersea volcanic activity (Miyake and Tsunogai 1963; NRC
1979).
Municipal waste water treatment plants introduce iodine and 131I into surface waters, predominantly
derived from human waste and the use of 131I in medical treatments.  Iodine is poorly captured within
sludge (2–25%), with the remainder released into surface waters (1.0–16 µg/L) in the waste water stream
(NAS 1974; Stetar et al. 1993).  
Release of radioiodine has occurred as a result of the reprocessing of nuclear fuel.  Release of 129I from
waste water generated by the Idaho National Engineering Laboratory into Snake River Plain aquifer
through deep disposal wells (before February 1984) and unlined disposal ponds (1984–1990) amounted to
approximately 0.56–1.18 curies (DOE 1994).  This release in both shallow and deep groundwater horizons
has been minimized through the recycling of the waste stream and storage of this stream with high-level
radioactive waste.  The Sellafield, United Kingdom and Cape de la Hague, France reprocessing facilities
have cumulatively released 1,440 kg of 129I directly into ocean waters since operations began in the 1960s;
direct releases into the ocean amount to 200 kg/year since 1994 and have been increasing (Moran et al.
1999).
6.2.3 Soil
Iodine, 129I, and 131I have not been identified in soil or sediment samples collected from the 1,585 NPL
hazardous waste sites (HazDat 2001).
The contribution of iodine to soils is derived from natural sources, such as the weathering of rock, decay of
vegetation, iodine received from rainfall, and from human activities (Figures 6-4 and 6-5).  Most soils
contain, on average, approximately 5 mg/kg of iodine worldwide (Whitehead 1984).  It is thought that only
a small proportion of this iodine is derived from the weathering of rock (Fuge 1987; Goldschmidt 1958;
Whitehead 1984), although there is some argument to the contrary (Cohen 1985).  The natural content of
iodine in natural geologic materials is (in ppm): ultramafic igneous (0.06–0.3), basaltic igneous (0.5),
granitic igneous (0.5), shales/clays (212–380), deep sea clays (11–50), limestones (0.4–29), sandstones
(1.7), and coals/ash (1–11) (NAS 1974).  It is expected that the contribution of iodine to soils in regions
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where the bedrock is composed primarily of igneous rock will be much less than that for regions where the
underlying bedrock is composed of sedimentary rock, which has a higher iodine content (Cohen 1985;
NAS 1974; Whitehead 1984).
Wet deposition of iodine from the atmosphere in rain or snowfall contains an average of 2.0 µg iodine/L. 
Assuming an average precipitation rate of 800 mm (32 in) per year, the wet deposition of iodine would
amount to the addition of 16 g iodine/ha"year (Whitehead 1984).  Dry deposition of iodine in a particulate
form or bound to a particulate carrier can add an estimated 9.6 g iodine/ha"year, assuming a deposition rate
of 0.2 cm/second and an average concentration of 15 ng/m3 on particulate iodine (Whitehead 1984). 
However, the iodine that is derived from both the wet and dry deposition will only increase the content of
the soil (to a 15 cm depth) approximately 0.7 ng/g if all the iodine is effectively trapped in the soil
(Whitehead 1984).
Agricultural activities increase iodine in soils through animal excrement and the use of fertilizers/
pesticides (Figure 6-5).  Animal feces can contain up to 10 mg/kg iodine, and urine can contain up to
4 mg/L iodine.  The iodine in sewage sludges and fertilizers used in agriculture can vary between 0.5 and
30 mg/kg.  Most inorganic fertilizers contain <0.5 µg/g iodine, except fertilizers containing Chilean nitrate,
which can provide upwards of 80 µg/g iodine.  Superphosphate and compound fertilizers derived from
rock phosphate can contain up to 26 µg/g iodine (Whitehead 1979).  The use of fertilizers, however, will
not result in an appreciable increase in the iodine content of soil (Whitehead 1984).  Yet, the use of iodine-
containing herbicides, such as ioxynil/ioxynil octanoate (recommended application of 0.5 kg/ha) and the
fungicide benodanil (recommended application of 1.1 kg/ha), can increase iodine content of soil about
0.17 and 0.21 µg/g to a depth of 15 cm, respectively (Whitehead 1979, 1984).
Combustion of coal and petroleum is another source of iodine in soils.  In the combustion of coal and
petroleum, the iodine is introduced to the atmosphere through the flue gases.  A large proportion (-80%)
of the iodine released through the flue gases is deposited onto the surrounding soils by both wet and dry
deposition, adding approximately 4x105 kg iodine/year to soils globally. 
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning
It is estimated that the earth’s surface contains 6.3x1018 g of iodine.  The majority of this iodine is in the
earth’s crust (3.4x1018 g) and in sedimentary rock (2.9x1018 g).  However, this iodine is inaccessible,
except for the small portion that is liberated through weathering processes (-109 g/year) and eventually
enters into the oceans.  The ocean, on the other hand, is the largest compartment of accessible iodine that
can be transferred to other environmental compartments.  The earth’s oceans contain 8.1x1016 g of iodine
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(Figure 6-6) at an average concentration of between 45 and 60 µg/L.  Other environmental compartments
with steady-state levels of iodine include atmosphere (8.8x1010 g), surface soil (4.1x1014 g), subsurface
region (2.5x1013 g), and terrestrial biosphere (3.0x1011 g).  The iodine in the ocean is in equilibrium with
the iodine in ocean sediments (8.0x1017 g), with a net flux of 1.8x1011 g/year.  A net transfer of iodine also
occurs between the ocean surface and the global atmosphere at an average rate of 2.0x1012 g/year, of which
1.9x1012 g/year returns to the ocean through wet/dry deposition processes, and 1.2x1011 g/year is deposited
onto land surfaces.  Of the iodine that is deposited on land, 7.7x1010 g/year is returned to the ocean through
groundwater and river effluents, and 1.6x1010 g/year enters into the terrestrial biosphere, of which
1.4x1010 g/year returns to the soil surface through weathering and decay of vegetation (NRC 1979).
The transfer of iodine between the ocean compartment, atmosphere, and land surfaces is due to the
volatility of iodine in its molecular (I2) and organic (most methyl iodide) forms.  The extent to which
iodine partitions into these compartments, and its residency time, will depend on the chemical form of the
iodine as it enters into a specific compartment, any chemical alterations that the iodine undergoes in that
particular compartment, and the solubility/uptake/retention of the various chemical forms of iodine in the
compartment.  The formation of alkyl iodides (predominantly methyl iodide) and, to a lesser extent,
molecular iodine from biological activity and photochemical reactions on the ocean’s surface, provide for
the transfer of these iodine species into the ocean atmosphere, where they undergo further photochemical
conversions into other gaseous and particulate forms of iodine (Cox et al. 1999; Filistovic and Nedveckait
1998; Vogt et al. 1999; Whitehead 1984).  The relative proportions of iodine as inorganic particulates and
organic gaseous forms is on average 25% for particulates and 40–80% for organic forms as methyl iodide
(Moran et al. 1999).  The residence times for iodine in the atmosphere are 14 days for particulates, 10 days
for inorganic gases (i.e., I2), and 18 days for organic gases (compared to a 9-day residency time for water
vapor), providing for extended global transport and substantial mixing (Moran et al. 1999).
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Figure 6-6.  Diagram of the Global Iodine Cycle at Steady State Showing 
Environmental Compartments, Compartment Inventories in Grams (g), 
Transport Pathways, and Fluxes in Grams per Year (g/year)
Source:  Kocher 1981
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The gaseous and particulate forms of iodine in the atmosphere are deposited onto ocean or land surfaces
through wet and dry deposition.  Gaseous elemental iodine and particulate forms of iodine are susceptible
to wet deposition, whereas methyl iodide has a low susceptibility.  Accordingly, gaseous molecular iodine
and particulate forms of iodine are susceptible to dry deposition; methyl iodide has a low susceptibility
(Whitehead 1984).  
The dry deposition rate is dependent on particle size, wind speed, and turbulence.  Iodine will settle onto
soil and plant surfaces.  Direct deposition of iodine onto plant surfaces is limited to 7.5–14 days, where
particulate iodine is removed from plant surfaces through weathering processes (AEC 1974; Heinemann
and Vogt 1980; Kirchner 1994).  Dry deposition onto plant surfaces is affected by the moistness of the
surface; deposition is approximately 2-fold greater on moist plant surfaces versus dry surfaces (Heinemann
and Vogt 1980).  Also, dry deposition onto plants is affected by the surface area of the plant, as is evident
from the 2-fold increase in iodine deposited on clover versus grasses (Heinemann and Vogt 1980). 
The wet deposition of iodine will be predominantly deposited into soil.  The relative amounts of iodine
initially depositing onto the soil will greatly depend on the density and type of plant cover over the soil. 
Upwards of 90% of elemental iodine vapor can be intercepted by a dense cover of grassland herbage, but
40–70% can typically be expected to be intercepted by a more average density of plant cover (Whitehead
1984).  
Evaporation of iodine from the land surface to the atmosphere is only about 1% of the flux of iodine from
the atmosphere to the land surface (NRC 1979) and iodine is cycled back to the ocean through
groundwater and river effluent (NRC 1979; Whitehead 1984).  However, the overall content of iodine in a
soil is determined by the inputs of iodine into the soil and the ability of the soil to retain iodine (versus
leaching and volatilization), where the main input is from atmospheric deposition, both wet and dry,
followed by degradation of plant material (mostly from adsorbed iodine) (Whitehead 1984).
The low flux of iodine from land surfaces to the atmosphere is due to the retention of iodine within surface
soils, especially in soils rich in organic matter and iron/aluminum oxides (Sheppard et al. 1995).  When the
various chemical forms of iodine enter into the soil, these species are initially retained by their absorbance
onto soil components in equilibrium with their solubility in soil solution.  Isotopic exchange studies
indicate that between 5 and 30% of iodine is exchangeable (Whitehead 1984).  Retention of inorganic and
organic iodine will depend on both nonspecific and specific sorption onto soil components.  Nonspecific
ion-exchange interactions of iodide and iodate anions occur on free hydrous oxides of iron and aluminum;
such exchanges involve electrostatic attractions and are dependent on pH and the concentration of other
anions (Sheppard et al. 1995).  Retention of molecular iodine in soil is thought to be mediated through the
interaction of iodine with thiols and polyphenols present in the organic components of soils (Fawcett and
Kirkwood 1953; Jirousek and Pritchard 1971; Whitehead 1984) and may also involve the
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oxidation/reduction of iodide and free radical reactions (Huang and Lu 1991).  Methyl iodide is sorbed by
soils to a lesser extent than inorganic iodide, but the factors that determine this sorption of methyl iodide to
soils are unclear (Whitehead 1984).
Transport of iodine to lower soil depths is dependent on the porosity and saturation of the soil. 
Macropores formed from roots and earthworm channels allow for rapid transport of iodine into the soil. 
Mobility of iodine into the soil is greatest when the soil is saturated with water.  The drier the soil, the
thinner the water films within the soil, thus limiting the flow rate of water through the soil (Whitehead
1984).
In addition to the aforementioned direct deposition of particulate deposition of iodine onto plant surfaces,
there is also evidence of the uptake of inorganic iodine into the plant through the roots and gaseous iodine
through the leaves (Whitehead 1984).  Iodide is more readily taken up into plant roots than is iodate or
iodine (Burte et al. 1991; Whitehead 1984); the uptake is dependent on soil properties and the use of
fertilizers (Moiseyev et al. 1984).  Molecular iodine can be absorbed through the stomata in the leaves,
whereas methyl iodide and hypoiodous acid are not as readily absorbed (Whitehead 1984).
Both the deposition of particulate iodine onto plant surfaces and the direct uptake of iodine into the plant
factor into the transfer of iodine through the soil-plant-cow-milk pathway.  The level of iodine in feed has
a direct relationship with the level of iodine measured in milk (Tracy et al. 1989; Voigt et al. 1989) and is
dependent on the season, nutritive quality of pastureland, and ambient temperature (Ekman et al. 1967;
Lengemann and Wentworth 1979; Pennington 1990a).  The transfer coefficient for iodine through the total
pathway is approximately 0.003–0.01 for cow and 0.2 for goat, expressed as the fraction of daily intake per
liter milk (d/L) (AEC 1974; Kirchner 1994; Voigt et al. 1988, 1989).
Transfer of iodine in the feed-meat pathway has also been determined in various animals and tissues. 
Transfer factors in whole animals (expressed as the fraction of daily intake per kg [d/kg]) are beef (0.02),
pork (0.09), and chicken (0.004).  The thyroid is the organ with the greatest uptake of iodine (AEC 1974). 
Individual tissue measurements have transfer factors range from 10-4 (kidney) to 10-3 (liver ) to
10-2 (muscle) (Handl and Pfau 1989; Handl et al. 1990).  Transfer factors have also been determined for
feed-chicken eggs (0.03) (AEC 1974).
Iodine can also bioaccumulate to varying extents in aquatic organisms.  Aquatic bioaccumulation factors
for iodine in fresh water are 40 (algae), 5 (invertebrates), and 15 (fish); in salt water, these factors are
4,000–10,000 (algae), 50–100 (invertebrates), and 10–20 (fish) (AEC 1974).  Certain seaweeds and algae
can concentrate iodine to levels as high as 0.8–4.5 g/kg of dried material; these high levels are usually
associated with the relatively high levels of iodine in seawater (50 µg/kg) (FDA 1974).
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6.3.2 Transformation and Degradation
Iodine consists of one stable isotope (127I) and a number of radioisotopes, of which 125I, 129I and 131I are the
most common in environmental and occupational exposures.  The radioisotopes 129I and 131I decay by
β-emission to form 129Xe and 131Xe, respectively, whereas 125I decays by electron capture, emitting gamma
and Te x-rays.  125I and 131I disappear rapidly from the environment due to their short half-lives of 60 and
8.02 days, respectively, and do not undergo long-term accumulation in the environment.  However, the
long physical half-life of 129I (1.57x107 years) means that any release of this radioisotope into the
environment is essentially a permanent addition to the total inventory of iodine in the environment from
the standpoint of assessing human exposures (NCRP 1983).
The chemical reactions of iodine and its radioisotopes within the environment are the same, but the ratios
of the isotopes in these reactions may differ, depending on the relative concentrations of the isotopes in a
particular environment.  127I and its radioisotopes can exist in many forms and oxidation states (iodides
[-1], molecular iodine [0], iodohalides [+1], iodates [+5], and periodates [+7]) (Holland 1963); organic
forms of iodine include methyl iodide, ethyl iodide, isopropyl iodide, and methylene iodide (Vogt et al.
1999).  Thus, “iodine” in the discussion of the chemical reactions of iodine in the environment will be used
to refer to both iodine and its radioisotopes, unless indicated otherwise.
6.3.2.1 Air
The major source of iodine in air is from the evaporation of alkyl iodides (mostly methyl iodide) and, to a
lesser extent, molecular iodine from ocean surfaces (Figures 6-4 and 6-7).  At ordinary pressures and
temperature, methyl iodide and iodine have high vapor pressures and will exist predominately in a free
gaseous form in air.  Both iodine and methyl iodide undergo photochemical reactions to form iodine
radicals (IC), which can then go on to form a number of other iodine species through a complex series of
reaction pathways (Cox et al. 1999; Filistovic and Nedveckait 1998; Vogt et al. 1999); some of these are






























Figure 6-7.  A Simplified Scheme of Iodine Cycling in the Marine Boundary Layer*
Source: Vogt et al.
1999
*Organic iodine compounds are shown in rectangular boxes; temporary iodine reservoir species in the gas and in the aerosol phase are shown in octagons.
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I2 ÷ 2 IC
CH3I ÷ CH3C +IC
IC + HO2 ÷ HI +O2
IC + NO ÷ INO
IC + NO2 ÷ INO2
IC + O3 ÷ IO + O2
IO + NO2 ÷ IONO2
2IO ÷ I2O2
2IO ÷ OIO +IC
The overall photochemical dissociation of CH3I and I2 in the atmosphere results in the steady-state
formation of inorganic iodine species consisting mostly of IONO2 (75%), IO (15%), and HI + HOI (10%)
during the daytime, with only minor changes in these percentages during the night-time, IONO2 (75%),
IO (7%), and HI+HOI (18%) (Filistovic and Nedveckait 1998).
Some of these iodine species (e.g., IO, I2O2) can then go on to react in aerosols or water droplets to form
IO2- and IO3- (Figure 6-7).  Gaseous iodine can also dissolve in water droplets to form iodide or hypoiodate
ions, especially in the presence of alkaline impurities.  Iodine is readily reduced to iodide by hydrogen
sulfide and can be oxidized to free iodine by ozone, hydrogen peroxide, or possibly air and sunlight.  If the
iodine is acidified sufficiently, gaseous hydrogen iodide is liberated (Straub et al. 1966).  Conversely, HI
formed in air can dissolve in water droplets, forming iodide anions that can be oxidized to molecular
iodine.
6.3.2.2 Water
Iodine in water exists as iodide and iodate.  In rainwater, the relative proportion of iodide to iodate is
55:45.  In surface waters, the proportion of iodide to iodate will vary depending on microbial activity and
the release of iodine species from terrestrial sources (De Luca Rebello et al. 1990).  Microbial action
converts iodide to organic forms of iodine, primarily methyl iodide (iodomethane).  The low vapor
pressure and limited solubility in water promote the volatilization of methyl iodide from surface waters to
the surrounding atmosphere.  Likewise, microbial activity and photochemical reactions can lead to the
formation of iodine from iodide or iodate; iodine can evaporate into the atmosphere due to its low vapor
pressure.
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6.3.2.3 Sediment and Soil
Iodine can enter soil as I2, iodide, iodate, or methyl iodide through wet or dry deposition.  Molecular iodine
dissolves in soil water to form iodide or is oxidized to iodate.  Conversely, chemical, and to a lesser extent,
microbial, reduction of iodide or iodate forms molecular iodine that can evaporate from the soil water into
the atmosphere.  Iodine can react with organic components of soil, undergoing iodination reactions with
polyphenols and tyrosine residues (Fawcett and Kirkwood 1953; Jirousek and Pritchard 1971; Whitehead
1984) that may involve the oxidation/reduction of iodide and free radical reactions (Huang and Lu 1991). 
Decreases in pH can alter the proportion of iodide to iodate in soil and water due to the protonation of
iodide to form HI, which can volatilize into the atmosphere.  The relative proportions of iodine species can
also differ in soils under flooded and nonflooded conditions.  The proportions of I2:I-:IO3-:organic iodine
change from 0.045:0.065:0.89:0.016 under the oxidizing nonflooded conditions to
0.007:0.90:0.097:0 under the reducing flooded conditions (Yuita 1994a).
6.3.2.4 Other Media
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
6.4.1 Air
The average global air iodine concentration ranges between 10 and 20 ng/m3 with gaseous iodine usually
exceeding particulate iodine by a factor of 2–6 (Whitehead 1984).  Atmospheric concentrations over land
range from 2 to 14 ng/m3, while atmospheric levels over oceans average between 17 and 52 ng/m3 (NRC
1979).  In an urban air environment, iodine content in air over San Francisco in 1970 ranged between
4.7 and 10 ng/m3 over nine monitoring stations (John et al. 1973).  In remote air environments, for
example the arctic, the iodine concentrations fall dramatically.  Iodine in the arctic stratosphere is
0.27 ng/m3, and is 0.33 ng/m3 at the marine boundary layer (Sheridan and Zoller 1989).  The annual-
average concentration of iodine in Canadian arctic air ranges between 0.43 and 0.96 ng/m3 (Barrie and
Hoff 1985)
Iodine introduction in the form of methyl iodide emission from a municipal waste incineration plant has
been measured at an average of 0.50 µg/m3 in Karlsruhe, Germany (Stieglitz 1995).
Radioiodine releases from nuclear fuel reprocessing facilities have been well documented.  Discharges of
129I from the Hanford Reservation between 1983 and 1992 ranged from 0.02 to 0.6 Ci/year, with a
maximum output of 0.5–0.6 between 1986 and 1988 (DOE 1993).  The average airborne concentrations of
129I onsite ranged from 69–2,000 to 2.2–60 aCi/m3 along the perimeter to 0.13–2.4 aCi/m3 at distant
IODINE 207
6.  POTENTIAL FOR HUMAN EXPOSURE
***DRAFT FOR PUBLIC COMMENT***
monitoring sites (DOE 1993).  At Savannah River, 129I and 131I releases between 1954 and 1989 totaled
5.67 and 2.52 Ci, respectively (DOE 1990). 
The release of radioiodine into the atmosphere from nuclear weapons testing and its deposition onto distant
targets has been measured.  131I that was produced in the above-ground nuclear Test Harry and deposited
(wet) on select New England monitoring sites ranged from 0.2x109 Bq/km in Buffalo to 3.4x109 Bq/km in
Pittsburgh to 6.1x109 Bq/km in Binghamton (Hoecker and Machta 1990).  The emissions of radioiodine
are often associated with particulates.  The amount of 131I associated with particulates increases with the
distance from the source of release.  Upwards of 60% of 131I released into atmosphere is associated with
particulates, based on ground level measurements.  It is assumed that 80–85% of the fallout of 131I is in the
reduced state, 15–20% is present as IO3-, and a few percent or more is present as IO4- (Perkins 1963; Straub
et al. 1966).  The cumulative release of 129I (expressed as Ci) in nuclear weapons testing beginning in 1945
and ending in 1975 has been estimated and is shown in Table 6-1 (NCRP 1983).
6.4.2 Water
The average iodine content in seawater is 40–65 µg/L (NRC 1979).  The iodine content in rainwater
averages between 0.1 and 15 µg/L, and in rainwater over oceans, the iodine content is 1–15 µg/L (NRC
1979).  The iodine content in river water averages between 0.1 and 18 µg/L (NRC 1979).  The
concentration of iodine in river water will be locally influenced by municipal waste water streams.  The
average iodine content in municipal waste water effluent is 4.0 µg/L (range 1.0–16 µg/L) (NAS 1974).  In
groundwater, the average iodine concentration is 1 µg/L (Yuita 1994a).
The iodine content in drinking water typically varies between 0 and 8 µg/kg, with a more nominal range
averaging between 2 and 4 µg/kg.  Concentrations of iodine in drinking water approaching or exceeding
8 µg/kg are usually associated with water that is directly contaminated with sewage or effluent from
sewage discharge sites or from urban run-off (FDA 1974).  For example, the concentration of iodine in the
Potomac River was 4.0 µg/L upstream of Alexandria, but increased to 8.0 µg/L downstream.  Sewage
effluent from Alexandria was believed to be the cause.  Some effluent streams can have iodine
concentrations as high as 1,910 µg/L (FDA 1974).
Seasonal variations in iodine have been measured in Rhode Island precipitation.  The volume-weighted
mean concentration in annual precipitation is 1.71 µg/L, with a concentration range of 0.04–11.3 µg/L. 
The seasonal variations in volume-weighted iodine concentration were 2.14 µg/L during the warm season
and 1.35 µg/L during the cold season (Heaton et al. 1990).
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Table 6-1.  Approximate Releases of 129I from Atmospheric and High Altitude 
Nuclear Weapons Tests








Source:  NCRP 1983
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Radioiodine is released into surface waters through the effluent of municipal sewage treatment plants.  On
an average working day, approximately 24 mCi of 131I is released into the Ohio River, resulting in a
concentration of 0.3 pCi 131I/L downstream from the treatment plant (Sodd et al. 1975).  The concentration
of 131I in water downstream from other municipal treatment plants throughout the United States has also
been determined, ranging from 0 to 83 pCi 131I/L (Prichard et al. 1981).  The 131I that has been measured in
these waters is due to the introduction of 131I into the sewer systems of cities from the excrement of patients
undergoing treatments with this radioisotope. 
The release of 129I into surface waters has also been measured.  It has been estimated that the above-ground
total fission yield of a 207 megaton equivalent of plutonium fission devices contributed approximately
10 Ci of 129I to the environment (NCRP 1983).  Reprocessing of spent fuel could release additional
amounts of 129I into the environment (at most 2 Ci) depending on the amount of fuel that is reprocessed and
the efficiency of gaseous effluent decontamination equipment.  This has resulted in an increase in the ratio
of 129I/127I, which has been changing since 1945 due to release of 129I into environment from nuclear
weapon explosions and nuclear facilities.  These releases range from 10-8–10-7 in the ambient environment
to 10-4–10-3 near some nuclear facilities, as measured in thyroid tissues (NCRP 1983).  The release of 129I
has also resulted in a steady-state inventory of 8.7x1026 atoms (31 Ci or 1.8x105 g) of 129I in the oceans
(AEC 1966).
The average content of 127I and 129I in air over the United States varies between 0.6 and 12.1 ppb
(Table 6-2).  These 129I concentrations did not appear to differ greatly between coastal (e.g., Galveston,
Texas) and interior (e.g., Lafayette, Indiana) measurement sites (Moran et al. 1999).  The measured ratios
of 129I to 127I in air and in precipitation was found to vary, ranging between 2.03 and 27.90 (x10-12) in air
and between 755–12,390 (x10-12) in precipitation (Moran et al. 1999).  These variations in the ratios 
of  129I to 127I may reflect the distances of the various collection sites from the sources of these isotopes
(e.g., distance from coastal regions for 127I and distance from nuclear fuel reprocessing facilities for 129I)
(Moran et al. 1999).
The effect of 129I release from nuclear fuel reprocessing facilities on surface water and groundwater has
been measured.  In 1990–1991, 129I concentrations in the Snake River aquifer at and near the Idaho
National Engineering Laboratory range between 0.6 aCi/L and 3.82 pCi/L, with a mean of 0.81 pCi/L,
which is a change from 1.30 pCi/L measured in 1986.  This change reflects a decrease in the amount of 129I
disposal and changes in disposal techniques (DOE 1994). 
Between January 1993 and June 1994, 129I concentrations measured at 29 sites in and around the Savannah






























Table 6-2.  Concentration of Iodine, Chloride, and 129I/127I Ratio in Air and Precipitation 
as a Function of Location and Collection Time
Air Rain/Snow
Locationa I (ppb) 129I/127I (10-12) 129I/127I (10-12) 129I atoms/L (107) Cl- (ppm)   I/Cl
WL 12/95-2 1.4 12.03 5,756 3.7
WL 12/95-3 0.9 12.45 8,327 3.7 0.2 0.0045
WL 12/95-4 0.6 13.85 12,390 3.7
B 11/95 1.2 7.38 2,027 1.1 1.6 0.0008
CS 8/22/96 6.6 10.39 755 2.3
CS 9/1/96–9/15/96 1.9 4.17 913 2.4 0.3 0.0061
CS 9/15/96–10/15/96 2.5
CS 10/20/96–10/26/96 2.0 1.2 0.0017
CS 10/26/96–11/24/96 1.7 2.03 893 0.7 1.1 0.0015
CS 11/24/96–11/30/96 3.3 1.6 0.0021
CS 12/21/96–1/16/97 2.9 26.80 3,408 4.5
CS 1/20/97–1/30/97 2.5 7.60 2,121 2.5






G 1/96–10/96 1.9 9.44 1,735 1.6






























Table 6-2.  Concentration of Iodine, Chloride, and 129I/127I Ratio in Air and Precipitation 
as a Function of Location and Collection Time (continued)
Air Rain/Snow
Locationa I (ppb) 129I/127I (10-12) 129I/127I (10-12) 129I atoms/L (107) Cl- (ppm)   I/Cl
G 12/6/96–1/6/97 1.7 4.9 0.0003
G 1/7/97–1/16/97 1.2 14.87 3,946 2.3
Ohio snow 1/14/97 0.7 11.10 9,150 3.0
aWL = West Lafayette, IN; B = Bryan, TX; CS = College Station, TX; G = Galveston, TX
Source:  Moran et al. 1999
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6.4.3 Sediment and Soil
The natural occurrence of iodine in igneous and sedimentary rock is approximately 0.2–5.8 ppm,
5–10 times higher in shales rich in organic matter, in soils, and in coals (NAS 1974).  Some references
indicate that these estimates may be low, suggesting instead an average soil content for iodine as high as
5.85 ppm (range: 1.5–13.5 ppm) (NAS 1974).  Indeed, in one survey of iodine content in soils (Table 6-3),
the iodine concentration in common soil types is consistent with the mean of 5.85 ppm (Whitehead 1979). 
This survey also shows the large variation in iodine concentrations as a function of soil type (Whitehead
1979, Table 6-3).  In a study of the iodine concentration of soils in the contiguous United States, the
average iodine concentration in soils was 1.2 µg/g.  This average does not differ between soils measured in
the western United States (west of 96th meridian) (1.2 µg/g) or the eastern United States (1.2 µg/g) (USGS
1984).  Iodine concentration in soils has also been measured as a function of soil depth (Table 6-4),
showing minimal variation in iodine concentration to depths of 12–24 inches (Fuge 1987).  The data in
Table 6-4 also show that soil concentrations were typically higher than the concentration of iodine in the
underlying bedrock.
The iodine content in sewage sludges ranges between 1.0 and 17.1 µg/g dry weight; these values are
similar to those found in soils, with the mean for iodine in sludges generally being lower.  Iodine content
of sludges was not related to size or degree of industrialization of a particular city or town.  Measurements
of iodine in sludge indicate that iodine does not partition strongly into sludges (Whitehead 1979).  131I
content in sludge generated from the Oak Ridge municipal waste water plant averages 0.16 nCi/L.  The
background concentration of 131I content in sludge generated at a municipal sewage treatment in Ann
Arbor, Michigan, was reported to be 1.4 pCi/L, but could rise as high as 15 pCi/L (Fenner and Martin
1997).  These concentrations of 131I in sewage sludge are due to the introduction of 131I into city sewer
systems from the excrement from patients that are treatment therapies that utilize 131I (Stetar et al. 1993)
The soil content of 129I has been compared to 127I and has been found to be generally higher near nuclear
fuel reprocessing facilities than elsewhere.  The 129I/127I ratios near facilities range between 10-4 and 10-3,
whereas more remote locations yield ratios between 10-9 and 10-8 (Robens and Aumann 1988).
6.4.4 Other Environmental Media
Iodine content of aquatic plants varies, depending on whether they are fresh or salt water.  Freshwater
algae contain 10-5% by weight of iodine, whereas marine algae contain 10-3% by weight (NCRP 1983). 
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Table 6-3.  Iodine Content in Specific Soil Types
Soil Concentration of iodine (µg/g dry soil)
Acid igneous rocks and associated till 10.4 (4.4–15.7)a
Till associated with basic igneous rocks 10.9 (3.4–16.3)
Slate, shale, and associated till  9.8 (4.4–27.6)
Sand and sandstone  3.7 (1.7–5.4)
Chalk and limestone  12.3 (7.9–21.8)
Clay  5.2 (2.1–8.9)
River and river terrace, alluvium  3.8 (0.5–7.1)
Marine and estuarine alluvium  19.6 (8.8–36.9)
Peat  46.8 (18.7–46.8)
aAverage iodine concentration with the range of measurements given in the parentheses
Source:  Whitehead 1979
IODINE 214
6.  POTENTIAL FOR HUMAN EXPOSURE
***DRAFT FOR PUBLIC COMMENT***
Table 6-4.  Iodine Content in Missouri Soils as a Function of Depth 
and Parent Material
























































Source:  Fuge 1987
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Epiphytes (plants that have no root systems and acquire their nutrients from the air), such as Spanish moss
in the southern United States, are used to measure long-term exposures of airborne trace elements.  The
concentration of 129I in Spanish moss varies between 0.4 and 4.9 ppm and roughly correlates with
estimated airborne concentrations of 129I (Moran et al. 1999).  In Norway, the iodine in moss averages
3.3 ppm (Schaug et al. 1990).
The average content of iodine in terrestrial plants has been reported to be 0.42 mg/kg worldwide (Yuita
1994a).  In some specific examples, iodine content (mg/kg) has been measured at 0.60–2.6 in beet root
flesh; 0.1–2.4 in cabbage head; and 0.30–1.1 in corn kernel (Sheppard et al. 1993).  The iodine content in
hay has been measured at 0.08 µg/g fresh weight feed (Voigt et al. 1988).  The distributions of I2 in plants,
such as wheat, can vary over the various parts of the plant.  In wheat, iodine concentrations (µg/mg)
change between shoots (0.136), roots (0.206), and total plant (0.153).  For iodide, the distribution
throughout the plant differs as well.  In wheat, the iodide concentrations (µg/mg) are 0.645 in shoots, 0.100
in roots, and 0.261 in plant (Voigt et al. 1988).
The 129I content in deer thyroids has been assessed as a function of proximity to a nuclear fuel processing
facility.  The 129I thyroid concentrations were highest in deer captured near the nuclear fuel reprocessing
plant at the Savannah River Site, South Carolina (1–102 Bq/g thyroid in 6.8% of deer) and Oak Ridge,
Tennessee (0.01–1.0 Bq/g thyroid in 38% of deer).  However, no thyroids from deer in Florida or in west
Tennessee, which are distant from nuclear fuel processing facilities, contained 129I at concentrations above
4 mBq/g thyroid (Van Middlesworth 1993).
Iodine measurements in milk and milk products have yielded the following results (expressed as
µg/100 g): low fat milk (24), skim milk (21), buttermilk (24), chocolate milk (25), plain lowfat yogurt
(33), strawberry lowfat yogurt (17), evaporated milk (37), half-and-half (17), cottage cheese (27),
American cheese (49), cheddar cheese (47), chocolate fast-food milkshake (55), chocolate ice cream (47),
vanilla ice milk (30), ice cream sandwich (51), and chocolate instant pudding (36) (Pennington 1990a).
Measurements of 131I have been monitored in milk through the Environmental Radiation Ambient
Monitoring System (ERAMS) using gamma spectral analysis of milk samples taken from 65 monitoring
sites with at least one located in each U.S. state, Puerto Rico, and the Panama Canal Zone.  The most
recent measurements of 131I in milk samples taken from July–September 1993 through July–September
1997 are below the detection limit at all monitoring sites (see ERD 1993 and ERD 1997 for examples).
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6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Exposure and uptake of iodine and its radioisotopes can be obtained through several routes including
inhalation, transepidermal absorption, dietary intake, use of medications, and medical procedures.  The
uptake, distribution, and effect of these exposures varies depending on the iodine isotope and the
population of interest.  These points are discussed below.
Inhalation Exposures.  Inhalation exposure of the general population to iodine through inhalation
represents an intake pathway.  Normal human respiratory exposure to iodine has been estimated to be
5 µg/day from an atmospheric exposure of 0.7 µg/m3 (FDA 1974).  Uptake of 129I through inhalation is a
minor pathway for human intake of this radioisotope.  It is has been calculated that approximately
4x10-5 g/year of 129I is taken up by the average individual (NRC 1979).
Epidermal Exposures.  Iodine vapor can penetrate through the skin.  Iodine penetration through the
epidermis was measured under controlled conditions in which volunteers were exposed to various
concentrations of 131I in the air (3.1–350x10-10 Ci/L) (Gorodinskii et al. 1979).  Entry of 131I through
inhalation was prevented through the use of a specially designed head mask connected to a clean air supply
line.  Penetration of 131I through the epidermis was monitored by 131I uptake in the thyroid
(3.1–303x10-10 Ci), as measured by a scintillation sensor.  K values were calculated to compare the uptake
of 131I in the thyroid (Am) versus the 131I concentration in the air (C), where K=Am (Ci)/C (Ci/L).  The
K values varied between 0.7 and 2.9,  indicating individual variations in iodine penetration through the
skin and uptake of iodine into the thyroid.  The results of this study also suggest that the value Am after a
4-hour exposure to iodine vapor can be approximated using the relationship Am=3C.  A comparison of the
penetration of iodine through the skin to the penetration of iodine through the lungs in previous work
shows that entrance of iodine through the skin is 1–2% of its entrance through the lungs.
Dietary Intake of Iodine.  The average daily dietary intake of iodine varies considerably, depending on the
diet.  Vought and London found individual daily intakes of iodine to vary from 15 to as high as 1,540 µg
iodine/day, with mean intakes varying from 64 to 379 µg/day (FDA 1974).  The recommended dietary
allowance for iodine is 0.150 mg/day for adults and adolescents (FDA 1989b).
Several studies have attempted to describe the daily intake of iodine as a function of diet and age grouping. 
Hospital diets were measured to have mean iodine intakes of 0.533 mg/day (range 0.274–0.842 mg/day),
0.677 mg/day (range 0.595–0.713 mg/day), and 0.377 mg/day (range 0.246–0.506 mg/day) (Caplan et al.
1976; Pittman et al. 1969).  One nursing home diet had an intake of 1.531 mg/day (Caplan et al. 1976). 
The daily iodine intake in children has also been measured: 8–15 years old (0.450 mg/day) (Trowbridge et
al. 1975), 6-month-old infants (0.359 mg/day, range 0.182–0.576), 2-year-old children (0.435 mg/day,
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range 0.231–0.728), and 15–20-year-old males (0.527 mg/day, range 0.319–0.827) (Pennington et al.
1984).
Dietary iodine intakes have been examined among age groups and were measured to be (in mg/day):
6–11 months old (0.200), 2-year-old children (0.460), 14–16-year-old girls (0.420), 14–16-year-old boys
(0.710), 25–30-year-old women (0.270), 25–30-year-old men (0.520), 60–65-year-old women (0.250), and
60–65-year-old men (0.340) (Pennington et al. 1986).  The average daily iodine intake partitioned by food
category (expressed as µg/day) for men and women in the age group 20–34 years old has also been
reported and is shown in Table 6-5 (FDA 1974)
Drinking Water/Beverages.  Human exposures to iodine through drinking water are typically too low to
provide for significant uptake of iodine.  Surface waters rarely exceed 5.0 µg iodine/L, except where
waters are polluted with municipal waste stream effluent or urban run-off; in these cases, iodine
concentrations can be as high as 8.7 µg/L (FDA 1974).  Some beverages, such as beer and wine, have
iodine contents in the ranges of 43–46 and 8–32 µg/kg, respectively, which could provide a significant
amount of iodine to the diet, depending on their level of daily consumption of these beverages (FDA
1974).
In emergency, camping, or military uses of iodine to disinfect water supplies, iodine concentrations
approach 8–16 mg/L (Zemlyn et al. 1981).  Use of elemental iodine in the disinfecting of water, when
improperly used, can lead to acute iodine toxicity.  Tetraglycine hydroperoxide is more commonly used at
a concentration of 8 mg/L to provide more accurate and reliable delivery of iodine to disinfect drinking
water.  Prolonged (>7 days) use of iodine as a water disinfectant can lead to mild impairment of thyroid
function (Georgitis et al. 1993).  
Food Exposures.  The human diet is the major source of exposure to iodine for the general human
population.  Although marine seafoods typically contain the highest amount of iodine (160–3,200 µg/kg
fresh basis, mean 660±180 µg/kg), they constitute only a small part of the American diet.  The largest
sources of iodine in the human diet come from vegetables (320±100 µg/kg), meat products
(260±70 µg/kg), eggs (260±80 µg/kg), and diary products (130±10 µg/kg) (FDA 1974).  The level of
iodine in vegetables depends upon the type of plant (e.g., spinach has by far the highest content among the
common vegetables) and whether iodine was present in fertilizers.  The content of iodine of eggs and milk
(milk products) depends on the dietary intake of chickens and lactating cows.  Eggs accumulate systemic
iodine; however, systemic levels are controlled by the limit that is placed on the content of iodine in feed
or water (12.5 mg/kg or liter).  Similarly, the content of iodine in milk is dependent upon iodine intake, in
addition to the seasonal climatological variables, level of milk production, and fullness 
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Table 6-5.  Estimated Average Iodine Intake for Adults in the United States
Food Category
Average daily consumption Average daily iodine intake 
Male (g/day) Female (g/day) Male (µg/day) Female (µg/day)
Milk and milk products 397 269 51.6 35.0
Eggs 55 31 14.3 8.1
Meat and meat products 325 192 84.5 49.9
Seafood 14 9 9.2 5.9
Legumes 40 24 – –
Grain and cereal products 12 81 12.2 8.1
Yellow and green vegetables 104 88 33.3 28.2
Other vegetables and fruits 96 56 3.8 2.2
Sugar and sweets 44 35 – –
Beverages (excluding milk) 749 739 3.0 3.0
Estimated salt intake 3.42 3.42 142.0 142.0
Iodine in food as additives – – 100.1 100.1
Total 454.0 382.5
Source:  FDA 1974
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of the mammary gland.  One source of iodine in the cow’s diet is the addition of potassium iodide to feed. 
However, the iodine content of milk varied between regions and even between individual farms.  These
variations were found to be caused, in part, by differences in the use of iodized salt blocks, exposures of
cows to iodine in disinfectants, and the presence of iodine in sanitizers and veterinary medications (FDA
1974).
Food sources of iodine that have caused adverse effects in humans include water, seaweed, ground beef
containing thyroid tissue, foods to which iodine was added as a supplement (iodized water, bread, salt),
and milk that contained iodine resulting from feed supplements and iodophor disinfectants (FDA 1989b). 
For example, iodine in seaweed-based supplements was found to be 0.045–5.0 mg/dose (Norman et al.
1988).  The value of 5.0 mg/dose is approximately 30 times higher than the RDA for iodine and 5 times
higher than the value of 1.0 mg/day, where acute and chronic toxicities for iodine intake begin to be seen
(Pennington 1990).  Outside of these sources of high dietary iodine, the average iodine content in various
food groups (expressed as µg/kg wet weight) are: seafoods (660±180), vegetables (320±100), meat
products (260±70), eggs (260±80), dairy products (130±10), bread and cereals (100±20), and fruits
(40±20) (FDA 1974).
The iodine contained in milk can be readily transferred to milk products, such as cheeses and ice cream. 
Typically, milk has been shown to contain iodine at concentrations ranging from 0.100 to 0.770 mg/L
(Pennington 1988).  Cheeses containing levels as high as 425 µg/kg have been reported (FDA 1974).  The
high concentrations of iodine in milk and in some milk products are thought to be derived from the use of
iodophor disinfectants and sanitizers in the practice of dairy farming and the processing of milk.  As a
topical disinfectant, the concentration of iodine in iodophors is 0.5–1.0% by weight.  Iodophors with an
iodine concentration of 0.001–0.0025% have been used to disinfect equipment and used in teat dips and
udder washings.  Teat dipping can increase the iodine content in milk by an average 174 µg/L (range,
55–353 µg/L).  However, there is evidence that the major contributor to iodine content in milk is feed
supplementation rather than the use of iodophors (FDA 1974).
Processed foods, such as breads, have also been shown to be a source of iodine in the human diet. 
Potassium iodate is used as a conditioner of bread dough by some, but not all, major bakeries.  When used
as a dough conditioner, a concentration of 1–2 µg iodide/g bread is typically obtained.  Iodine content of
fast food, ranging from McDonald’s french fries to a filet-of-fish sandwich, varied between 20 and
84 µg/100 g total product, respectively (FDA 1974).
Food additives can also contribute to human iodine intake; table salt contains cuprous iodide and
potassium iodide, alginic acid, and alginate salts that are used as emulsifiers, and stabilizers and thickeners
which contain upwards of 9 mg/kg iodine, but may only constitute an average intake of 1 µg/person/day
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(FDA 1974).  Iodized salt in the United States provides 0.076 mg iodine/g (0.418 mg per teaspoon) (FDA
1989b).
Distribution of Iodine in Human Tissues.  Iodine concentrations in nonthyroid tissues of recently deceased
individuals obtained from a healthy Chinese population have been assessed using neutron activation
analysis techniques (Hou et al. 1997b).  Typical intake of iodine in the Chinese diet averages between
94 and 169 µg/person/day (Hou et al. 1997a).  The concentrations of iodine in five tissues, plus hair,
averaged over 9–11 individuals and expressed as (ng/g wet weight tissue±1 SD) were: heart (46.6±14.9),
liver (170±34), spleen (26±8.6), lung (33.3±10.6), muscle (23.5±14.3), and hair (927±528) (Hou et al.
1997b).
Exposures Through Medications/Medical Uses of Iodine.  Human exposures to iodine may come from
medications and vitamin supplements containing iodine in varying amounts.  A survey of various
pharmaceuticals found that of those tested, eight contained between 0.251 and 0.375 mg iodine per dose,
with one containing 1.447 mg I/dose (Vought et al. 1972).  The variation of iodine content could be
attributed to the use of erythrosine (2,4,5,7-tetraiodofluorescein) as a red coloration (FDA 1974). 
Erythrosine can be metabolized in the digestive tract to liberate iodide, although the bioavailability of
iodine from erythrosine may be only 2–5% (FDA 1989b).  Some medications directly contain added
potassium iodide or organic iodine compounds.  For example, Lugol’s solution that is used to treat
thyrotoxicosis is a 5% solution of iodine solubilized in 10% potassium iodide.  Other iodine-containing
drugs (most commonly potassium iodide solutions) have been prescribed for their purported expectorant
for action in asthma, bronchitis, cystic fibrosis, and chronic pulmonary obstructive disease; also,
amiodarone is prescribed for heart arrhythmias (FDA 1989b).  Topical application of iodine-containing
medications and dietary supplements can increase iodine in breast milk in lactating women; use of
povidone iodine vaginal gel (50 mg/day for 6 days) increased iodine concentration in breast milk by
3–4 times (FDA 1989b).
Large exposures to iodine can be experienced during certain medical procedures, for example, through the
use of iodinated compounds as contrast agents in radiological imaging procedures.  Iodine in oil is used in
bronchograms, lymphangiograms, and for myelograms, and is excreted slowly, thus predisposing an
individual to imbalances in iodine homoeostasis. 
Radioiodine -131I.  The greatest periods of exposure to 131I (and other radioiodine isotopes derived from
nuclear fission) were during active nuclear testing in the years 1951–1958 and 1961–1962, the large
quantities of fission products released from nuclear accidents such as Three Mile Island and Chernobyl,
and the nuclear processing and waste facilities (e.g., Hanford, Washington; Aiken South Carolina; Idaho
Falls, Idaho).  Human uptake of 131I from environmental sources is largely through ingestion of
contaminated food, with a smaller proportion obtained through inhalation (Straub et al. 1966; Wehmann
IODINE 221
6.  POTENTIAL FOR HUMAN EXPOSURE
***DRAFT FOR PUBLIC COMMENT***
1963).  The distribution of 131I in food depends upon the time the isotope is produced, its presence in the
environment, and the degree of contamination.  Some potential dietary sources of 131I include marine
animals and plants, milk, and leafy vegetables (Straub et al. 1966).
The largest source of 131I in the human diet is cow’s milk.  Approximately 70% of the 131I that is consumed
by a cow is absorbed into the thyroid, with about 1% found in milk (milk-to-plasma ratio of 131I is 2:3)
(Bustad et al. 1964; Lengemann and Comar 1964; Straub et al. 1966).  The transfer of iodine is
bi-directional, and the iodine appears to freely diffuse between mammary gland and plasma (Miller and
Swanson 1963; Straub et al. 1966).  131I exists in both the free inorganic form, as iodide, or bound to
protein in milk.  It has been determined that in cow’s milk, 82–91% of the 131I is in the free inorganic form,
with 4.7–13% bound to protein and <0.1% associated with fat (Glassock 1954; Straub et al. 1966).
The occurrence and concentration of 131I in milk is highly variable, depending on the locale and daily
variations within a specific locale (Pennington 1990a).  Due to meteorological conditions, a large
proportion of 131I from fallout is deposited on the ground through dry deposition processes, with a lesser
amount deposited through wet deposition processes (i.e., precipitation) (Straub et al. 1966).  The highest
concentrations of 131I in milk were observed shortly after atmospheric tests of nuclear weapons and
accidental releases from nuclear reactors or fuel reprocessing facilities (Anderson et al. 1996; Black et al.
1976; Cohn and Gusmano 1963; Kirchner 1994; Martin and Turner 1964; Tracy et al. 1989; Tubiana 1982;
Voigt et al. 1989).  The source of 131I in cow’s milk is derived mainly from the dry and wet deposition (to a
lesser extent uptake into plants from the soil) of 131I onto grasses and other plants that are then consumed
by dairy cows.  A concentration of 1 µCi 131I/kg of 131I in pasture grass yields a 131I concentration of
0.07 µCi 131I/L of milk (Voigt et al. 1989).
In cases of exposure to 131I, the absorbed dose has been estimated in various tissues and whole body for the
ingestion of 1 mCi of 131I.  The values for the absorbed doses (expressed in cGy and based on the
assumption of a 25% uptake of ingested 131I into the thyroid) are: 0.48 (liver), 0.14 (ovary), 0.26 (bone
marrow), 1.4 (gastric mucosa), 0.088 (testis), and 1,300 (thyroid), with a mean whole body dose of
0.71 cGy (Tubiana 1982).
The levels of 131I in domestic and imported foods measured between 1987 and 1992 were found to be
below the detection limit of the gamma-ray spectrometry method (<2 Bq/kg) (Cunningham et al. 1994). 
Detection and quantitation of 129I is difficult due to the low energy of the beta (maximum
energy=0.15 MeV) and gamma rays (0.04 MeV) that are emitted from this isotope.  Concentration of 129I in
thyroid tissues increases the ability to detect this isotope, but further limitation results from the low
specific activity of the radioisotope (0.17 mCi/g) (NCRP 1983).  However, due to the steady-state levels of
129I in the environment, there is a continual exposure of the general human population to this radioisotope
through inhalation and intake through the diet.  It has been estimated (AEC 1974) that a dose of
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approximately 0.2–0.5 mrem/year is delivered to the thyroid of an adult from 129I, depending on diet. 
These estimates include the dose received through the inhalation of 129I.  For an infant, the doses to the
thyroid from 129I intake can vary between 0.15 and 0.4 mrem/year, depending on diet.
6.6 EXPOSURES OF CHILDREN
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in 3.7 Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a larger
skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  The
developing human’s source of nutrition changes with age: from placental nourishment to breast milk or
formula to the diet of older children who eat more of certain types of foods than adults.  A child’s behavior
and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, sometimes
eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children also are
closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Children appear to be more susceptible to the development of thyroid cancers from the irradiation of
thyroid by 131I.  Irradiation of the thyroid from a 1–2 Gy dose in Japanese A-bomb survivors and a 3.3 Gy
dose in Marshall Islanders exposed to fallout results in a high incidence (factor of 2) of thyroid cancers in
children under the age of 10 compared the exposed adult population (Tubiana 1982).  
Of the iodine radioisotopes, 129I poses the least risk to children with respect to thyroid irradiation.  Even at
a high thyroid content of 1 mCi 129I in 1 g of stable iodine, the dose to the thyroid in a 6-month-old infant
would be 0.9 nGy/year as compared to a dose of 7.2 nGy/year in an adult thyroid.  In comparison, 131I can
deliver much higher doses to the thyroid at lower environmental concentrations than those observed for
129I, due to the higher specific activity of 131I (1.24x105 Ci/g; beta particle energies of 0.334 MeV [7.3%]
and 0.606 MeV [89.9%]) versus 129I (177 µCi/g; beta particle energy of 0.154 MeV) (Chu et al. 1999;
Robkin and Schleien 1995).  For example, the annual consumption of milk containing 131I at a
concentration of 1–20 nCi/L would result in a dose to the thyroid in children of between 0.005 and
0.1 cGy/year (Tubiana 1982).  In comparison, similar concentrations of 129I in milk would yield thyroid
dose of between 0.014 and 0.28 pGy/year, based on the specific activities and beta energies listed above. 
Breast milk is also a source of 131I uptake in children.  For example, concentrations of 131I in breast milk
measured in women exposed to nuclear weapons fallout ranged between 0.050 and 0.100 nCi/L, when the
mean body burden of 131I in these women was 0.060 nCi (Cohn and Gusmano 1963).
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Children (both 1 and 10 year olds) appear to have a similar fractional uptake of iodine in the thyroid (i.e.,
approximately 31%) of that found in adults.  For newborns, however, the fractional uptake is
approximately 70% at 2 days after birth, but quickly declines to values accepted for an adult by day 5. 
After the first few weeks, uptake changes very little with age.  Estimated dietary intake of iodine in 1 year
olds is 151 µg/day, and for 10 year olds, it is 184 µg/day.  The percent turnover rates of iodine in the
thyroid does change with age (expressed as d-1) are: 0–4 years old (3.4±0.5), 4–8 years old (2.1±0.5), and
8–12 years old (0.84±0.36); this corresponds to ‘apparent’ half-lives of 20, 33, and 83 days, respectively. 
Iodine concentration in thyroid increases with age (expressed as µg/g): 1 year old (95), 2 years old (130),
4 years old (180), 10 years old (260), 16 years old (320), and adult (400) (Stather and Greenhalgh 1983).
In utero exposures of a human fetus to iodine radioisotopes with high specific activity (e.g., 131I) have been
assessed based on both the maternal intake of iodine radioisotopes and exposure to external radiation
generated by these isotopes in the immediate environment.  Iodine and its radioisotopes freely diffuse
across the placenta and, as such, their levels within a fetus and the amniotic fluid will depend greatly on
the concentration of iodine within the mother (Baši… et al. 1988; Dyer and Brill 1972; Etling et al. 1979;
von Zallinger and Tempel 1998).  Before 11 weeks of gestation, the thyroid is still undeveloped and does
not actively take up iodine (Dyer and Brill 1972; von Zallinger and Tempel 1998).  For example, the
percent of iodine that is taken up by the thyroid in comparison to that contained in the total fetal tissues is
quite low at a gestation age of 9–11 weeks (0.0002%), but increases after 11 weeks where the percentage
becomes 0.001% for gestation ages between 13 and 15 weeks, and increases further to 0.002% between
gestation ages of 16 and 22 weeks (Dyer and Brill 1972).  A difference in placental transfer of iodine
between the mother and fetus is also noted as a function of gestation time.  The percentage of 131I activity
found in the fetus compared to the total activity within the mother at 11 weeks was 0.23%, but increased to
2.96% at 22 weeks due to the fact that the concentration of iodine in the fetal thyroid typically exceeds that
of the maternal thyroid by 3–10 times (von Zallinger and Tempel 1998).  Increases in the concentration of
iodine in the fetus and amniotic fluid (6- to 90-fold increases) were observed in women exposed to topical
iodine-containing medications (e.g., vaginal therapy with iodinated polyvinylpyrrolidine) or increased
iodine intake in their diets (Etling et al. 1979).  However, the uptake of iodine (measured by 131I uptake)
into the fetal thyroid (1.08 pCi/g) at a gestation time of 22 weeks is not significantly different from what is
observed for the maternal thyroid (0.82 pCi/g) (Beierwaltes et al. 1963).
Emission of ionizing radiation from iodine radioisotopes can also pose an exposure risk to the human fetus
and the mother in occupations where the mother comes in contact with these isotopes.  For example, fetal
doses in imaging staff performing a whole body scan and/or therapy procedures for thyroid cancer patients
using 131I ranged between 6.7 and 9.0 µSv (Mountford and Steele 1995).  Thus, restrictions on the
exposure of pregnant women are 1.3 mSv to the maternal abdominal surface (corresponding to a 1.0 mSv
dose to the fetus) (Mountford and Steele 1995).
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6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
Occupational Exposures (Medical Personnel, Laboratory Personnel, Personnel at Nuclear Power/
Fabrication/Storage Facilities).  Occupational exposures to airborne iodine can occur when iodine is used
in the regular functions of the workplace.  OSHA has set a limit for airborne iodine concentrations in the
workplace of 0.1 ppm.  Exposures of workers to concentrations at or in excess of the OSHA limit can often
occur.  For example, at a plant that processes photo-polymer plates, most workers were exposed to an
average concentration of iodine of 0.005 ppm, but were exposed to concentrations of 0.122–0.146 ppm
when they were in the immediate proximity of the iodine holding tank or iodine applicator (Kim et al.
1981). 
Workers in the nuclear industry, especially in nuclear fuel reprocessing facilities, have the potential for
chronic thyroid burdens of 131I in addition to acute exposures from accidental releases.  For example, in
Indian workers, the dose from chronic 131I exposures was found to be as high as 47.4–68.1 rem for thyroid
and 0.024–0.047 rem for whole body (Raghavendran et al. 1978).  In an acute exposure to 131I in a steam
leak at a nuclear power plant, the mean thyroid burden of 131I in the exposed workers was 1.32 µCi on the
third day after the exposure; the 131I burden decreased exponentially, falling below 0.027 µCi on the 38th
day (Bhat et al. 1973).
Internal contamination of medical personnel by 131I can be a problem, especially under conditions where
the release of iodine as a vapor can occur (Eadie et al. 1980; Luckett and Stotler 1980).  Thyroid burdens
of 131I in medical personnel can typically average around 2,400 pCi (ranges of 35–18,131 pCi) (Blum and
Liuzzi 1967).  Personnel working with 131I could potentially receive up to 5 nCi per mCi handled.  This
means that persons handling therapeutic doses of 131I could have activities of 0.1–1.0 µCi in their thyroids
(Tubiana 1982).  For the application of 131I in nuclear medicine, it has been shown that the radiochemists
and their support staff have a yearly thyroid 131I burden of between 0.5–200 and 0.03–1.5 nCi, respectively
(Jönsson and Mattsson 1998).
External exposures of medical personnel to radiation emitted from radioiodine have been assessed for both
diagnostic and therapeutic applications of 131I and 125I.  The dose rate per unit activity (µSv/h @ MBq) of 131I
has been determined for thyrotoxicosis, thyroid ablation, and thyroid cancer therapies as a function of
distance from the patient.  The dose rate as a function of distance is approximately the same for all three
therapy regimens; 1.43 µSv/h @ MBq at 0.1 meter, 0.18 µSv/h @ MBq at 0.5 meter, and 0.07 µSv/h @ MBq at
1.0 meter (Mountford and O’Doherty 1999).  Surgical implants of 125I seeds in prostate brachytherapy have
the potential for radiation exposures to the radiotherapist.  However, in most instances when the implant
procedure is performed properly, the dose rate is <1 µGy/mCi-hour (Liu and Edwards 1979). 
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Laboratory workers using 125I are at risk for exposures to gamma- and x-rays to the hand.  In a typical
situation where 20 MBq (5 mCi) of 125I from an unshielded source is used weekly (2 hours/week)
throughout a year, a worker would receive a dose of approximately 225 mSv (22.5 rem), 3/10 of the
recommended dose equivalent limit to the hands (de Groot 1979).  Uptake of 125I into the thyroid has also
been shown to occur due to airborne radioiodine released from solutions or spills (Bogdanove and Strash
1975; Dunn and Dunscombe 1981; Krzesniak et al. 1979; Kwok and Hilditch 1982).  Activity levels of
0.013–0.024 and 0.056–0.56 µCi have been measured in the thyroid of a laboratory worker working with
1 and 5 mCi of 125I in the day’s activities, respectively (Kivinitty et al. 1984).  In a more general survey, it
was found that 8% of laboratory technicians working with 125I labeled materials had thyroid burdens of 125I
within 9–90 nCi.  However, 33% of those individuals involved in the direct iodination of biomaterials and
compounds with 125I had thyroid burdens of 9–90 nCi (Pomroy 1979).
Patients Undergoing Medical Treatment Involving Use of Iodinated Compounds.  Patients undergoing
treatment for hyperthyroidism and thyroid carcinoma typically receive between 10 and 150 mCi of 131I
(Beierwaltes 1979).  In addition to the thyroid, other tissue sites in the patient also receive a radiation dose,
albeit a smaller dose.  This is especially important when considering the impact that 131I can have on bone
marrow in a patient undergoing 131I therapy to treat thyroid carcinomas.  During these 131I therapies, the
bone marrow can receive a dose of 1–5 Gy (Tubiana 1982).  This has been shown to lead to a 1%
incidence of leukemia in these patients (Tubiana 1982).
There is also an exposure risk of a patient’s immediate family to both the radiation and elemental 131I that
is emitted from the patient (Barrington et al. 1999).  Patients are allowed to return home after the activity
of 131I within them falls below 30 mCi.  However, this level of 131I activity in a patient can produce an
exposure rate to ionizing radiation of approximately 10 µGy/hour at a distance of 1 meter.  Thus, family
members are also at risk to exposures to 131I that is emitted from the patients.  The dose that a typical
family member receives from a patient at home ranges between 0.17 and 126 µGy/day, as compared to the
natural radiation background of 0.35 µGy/day (Jacobson et al. 1978).  This can result in some family
members exceeding the maximum allowable dose of mSv (1 mrem) per year.  In another study, it was
found that as many as 11% of children exposed to patients undergoing 131I therapy exceeded the 1 mSv
limit (Barrington et al. 1999).  Activities of 131I within the thyroids of family members of patients
undergoing 131I therapy were found to range from the detection limit of the measurement of
92–110,000 pCi, resulting in a dose of 4–1,330 mrem to the thyroid.  Of special concern is the fact that the
131I activity was highest in children (Jacobson et al. 1978). 
A growing number of patients who are undergoing treatment for cancer are using alternative medicines and
nutritional supplements (Cassileth 1999).  It is believed that these alternative medicines and supplements
will help to prevent the onset of a tumor, alleviate specific symptoms that are experienced as a
consequence of their disease or treatment, or aid in the eradication of the tumor.  The self administration of
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some of these alternative medicines and nutritional supplements can result in the intentional (e.g., elevated
iodine intake to prevent breast cancer) or unintentional (e.g., when iodine is a natural component of a
specific alternative medicine) elevation of the daily intake of iodine, especially when patients consume
alternative medicines that contain salt water plants, such as kelp, or those individuals who take
megavitamins or participate in orthomolecular therapy (Cassileth 1999).  The amount of iodine intake will
vary depending on the specific content of iodine in the supplement and the dosage, which could result in
iodine intakes that approach toxic levels (e.g. >6 g/day).  For most cancers, it is unclear what benefit
increased iodine will have for the prognosis of the disease or how it can alter the incidence of a particular
cancer (Cann et al. 2000; Cassileth 1999; Eskin 1970).  However, there is evidence to suggest that elevated
iodine intake, especially for populations where ambient iodine concentrations are low, can help to decrease
the incidence of breast cancer and, in some cases, help to interfere with breast tumorogenesis (Cann et al.
2000; Eskin 1970).
Diseases/Predisposition to Iodine Toxicities.  An increase in the availability of dietary iodine for a
population may also cause difficulty in controlling Graves’ disease with antithyroid drugs, decrease the
remission rates for those on antithyroid medication, and increase the dose of radioiodine required to induce
euthyroidism (FDA 1989b).  In the general population, between 0.2 and 33.3% of individuals develop
goiter in response to excess iodine consumption, whereas an increase in the incidence of sensitivity or
acute reactions was observed in <30% of individuals in the general population (FDA 1989b).
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate
information on the health effects of iodine is available.  Where adequate information is not available,
ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the initiation
of a program of research designed to determine the health effects (and techniques for developing methods
to determine such health effects) of iodine. 
 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
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6.8.1 Identification of Data Needs
Physical and Chemical Properties.    Adequate pertinent data on the physical and chemical
properties of iodine and its radioisotopes and compounds are available in the literature.
Production, Import/Export, Use, Release, and Disposal.    Since iodine is not covered under
SARA, Title III, manufacturers and users are not required to report releases to the EPA.  There is a lack of
data on the release and disposal of iodine.  There is a relatively good database on the release of radioiodine
(Beals and Hayes 1995; DOE 1990, 1994; NCRP 1983; Patton and Cooper 1993), but only limited
information is available on disposal and inventories of radioiodine in disposal sites (DOE 1994).
Environmental Fate.    The major source of iodine on terrestrial surfaces originates from the
volatilization of iodine from the ocean surface.  Adequate information is available pertaining to the
chemical species and reactions that take place at and above the ocean surface that are responsible for the
production of volatile forms of iodine (Cox et al. 1999; Filistovic and Nedveckait 1998; Vogt et al. 1999;
Whitehead 1984).  Further work is needed to examine the organisms and microbial metabolic processes
that are responsible to the formation of alkyl iodides, as well as the exact contribution of alkyl iodides,
molecular iodine, and spray to the introduction of iodine into the atmosphere.  There is a good body of
literature on the photochemical reactions of iodine, both in the gaseous phase and in/on particulates or
water droplets (Cox et al. 1999; Filistovic and Nedveckait 1998; Moran et al. 1999; Vogt et al. 1999;
Whitehead 1984).  The factors that are responsible for the retention of iodine in soil have also been
examined extensively (Fawcett and Kirkwood 1953; Jirousek and Pritchard 1971; Sheppard et al. 1995;
Whitehead 1984).  However, more work is needed to characterize the interactions of iodine with organic
components, especially with respect to the mechanisms of the binding and release of iodine from these
organic components.  The environmental fate of 129I and 131I has been examined extensively (AEC 1974;
DOE 1978a, 1986; NRC 1979, 1981).
Bioavailability from Environmental Media.    Adequate pertinent data for intake of iodine and
radioiodine from inhalation, drinking water, and food intake are available (DOE 1993; NCRP 1983; NRC
1979; Whitehead 1984).  
 
Food Chain Bioaccumulation.    Concentrations of iodine in freshwater and marine fish have been
determined (Poston 1986).  Concentrations of iodine in aquatic plants have also been ascertained (NCRP
1983).  Although aquatic plants and fish concentrate iodine in their tissues, there is little evidence for
bioaccumulation of iodine in the food chain.  Iodine and radioiodine concentrations have been measured in
foods, especially in the context of milk and the transfer of radioiodine through the soil-plant-cow-milk
pathway (AEC 1974; Kirchner 1994; Tracy et al. 1989; Voigt et al. 1988, 1989).  Although some
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information is available, more information is needed on the uptake of iodine from the soil into plants
(Burte et al. 1991; Moiseyev et al. 1984; Whitehead 1984).
Exposure Levels in Environmental Media.    Adequate pertinent data are available for current
exposure of iodine in air, rainwater, surface water, groundwater, and soil (FDA 1974; Moran et al. 1999;
NRC 1979; Whitehead 1984; Yuita 1994a).  
Exposure Levels in Humans.    A good database exists for exposure levels of the general population
to iodine and its radioisotopes in various food types and drinking water (Allegrini et al. 1983; Bruhn et al.
1983; Dellavalle and Barbano 1984; Kidd et al. 1974; Pennington et al. 1986), including exposure levels in
milk (Pennington 1988).  Information for the average daily intakes of iodine based on diet and age
groupings is available (Caplan et al. 1976; Pennington et al. 1984, 1986).  Information on occupational
exposures is available, especially for exposure of medical personnel to 131I and laboratory workers to 125I
(Blum and Liuzzi 1967; Bogdanove and Strash 1975; de Groot 1979; Dunn and Dunscombe 1981; 
Krzesniak et al. 1979; Kwok and Hilditch 1982; Mountford and O’Doherty 1999; Pomroy 1979; Tubiana
1982).  Data exist for distribution of iodine in human and fetal tissues, but more information is needed
(Dyer and Brill 1972; Hou et al. 1997b; von Zallinger and Tempel 1998).
Exposures of Children.    A good database exists for exposure levels of children to iodine and its
radioisotopes in various environmental exposure pathways, including food types, drinking water, and
especially milk and milk products (Cohn and Gusmano 1963; FDA 1974, 1989; Soldat 1976; Stather and
Greenhalgh 1983; Tubiana 1982).  Information for the average daily intakes of iodine for children based
on age groupings is available (Pennington et al. 1984, 1986; Trowbridge et al. 1975).  Information on in
utero exposures to iodine and its radioisotopes is available (Baši… et al. 1988; Beierwaltes et al. 1963; Dyer
and Brill 1972; Etling et al. 1979; Mountford and Steele 1995; von Zallinger and Tempel 1998).  There is
also some information on the exposure of children to 131I, and the radiation that it emits, that occurs when
children are in contact with, or in the vicinity of, individuals undergoing 131I treatment (Barrington et al.
1999; Jacobson et al. 1978).  However, more information is needed to adequately assess the risk of
children to this exposure.  Also, there will be a need to develop biomarkers to assess the low level
exposures of children to 129I.  Improvements in analytical methods have provided an ability to detect the
low concentrations of 129I in tissues and, thus, given us an opportunity to reliably assess low level
exposures of 129I in children and adults.  Yet, the development of biomarkers, such as the identification of
DNA mutations that would be specifically formed as a consequence of 129I exposure in a cell to monitor the
possible biological effects of these low level exposures, have been lacking.
Child health data needs relating to susceptibility are discussed in 3.12.2 Identification of Data Needs:
Children’s Susceptibility.
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Exposure Registries.    No exposure registries for iodine were located.  This substance is not currently
one of the compounds for which a subregistry has been established in the National Exposure Registry. 
Iodine will be considered in the future when chemical selection is made for subregistries to be established. 
The information that is amassed in the National Exposure Registry facilitates the epidemiological research
needed to assess adverse health outcomes that may be related to exposure to this substance.
6.8.2 Ongoing Studies
Two studies are currently underway (FEDRIP 2000) to study the interaction of iodine with differing soil
components and the effect of iodine intake on the underlying mechanisms contributing to autoimmune
thyroiditis.  In the first study, Dr. R.L. Jones, at the Department of Natural Resources and Environmental
Sciences, University of Illinois, Urbana, Illinois, is conducting a study of iodine in Illinois soils.  The
objective of this work is to determine the concentrations of iodine in a group of selected surface soils so
that estimates of iodine concentrations can be made for major soil areas in Illinois.  Analysis of soils as a
function of depth and soil type will identify proportions of iodine in organic matter, and iron and
aluminum fractions with the objective of identify whether differences occur between soils because of
differences in soil development and genesis.
In another study, conducted by Dr. Carol L. Burek at Johns Hopkins University, Baltimore, Maryland,
work is underway to determine whether increased intake of iodine contributes to an increase in the
incidence of autoimmune thyroiditis (AT).  The researchers intend to show that increases in iodine intake
lead to an increased level of a highly iodinated form of thyroglobulin protein.  It is thought that this highly
iodinated form of thyroglobulin can act as an auto-immunogen and may be responsible for the T-cell
mediated auto-immune response that is targeted against the thyroid gland.  Using the NOD mouse model,
the researchers will examine whether increased doses of iodine lead to an increase in the incidence of AT
in these mice.  Once this is established, the researchers will examine whether this increased incidence in
AT is accompanied by an increase in the levels of highly iodinated thyroglobulin protein and increased
activity of T-cells against this potential auto-immunogen.
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7.  ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring iodine, its radioisotopes, its metabolites, and other biomarkers of exposure
and effect to iodine.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the
intention is to identify well-established methods that are used as the standard methods of analysis.  Many
of the analytical methods used to for environmental samples are the methods approved by federal agencies
and organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). 
Other methods presented in this chapter are those that are approved by a trade association such as the
Association of Official Analytical Chemists (AOAC) and the American Public Health Association
(APHA).  Additionally, analytical methods are included that modify previously used methods to lower
detection limits, and/or improve accuracy and precision.
7.1 BIOLOGICAL MATERIALS
Entry of iodine and its radioisotopes into the human body can be gained through ingestion, inhalation, or
penetration through skin (IAEA 1988; NCRP 1985).  The quantities of iodine within the body can be
assessed through the use of bioassays that are comprised of either in vivo measurements and/or in vitro
measurements.  In vivo measurements can be obtained through techniques that directly quantitate
internally-deposited iodine using, for example, thyroid or whole body counters.  These in vivo
measurement techniques are commonly used to measure body burdens of iodine radioisotopes, but cannot
be used to assess the stable isotope of iodine.  Instead, in vitro measurements provide an estimate of
internally deposited iodine (both the stable and radioactive isotopes), utilizing techniques that measure
iodine in body fluids, feces, or other human samples (Gautier 1983).  Examples of these analytical
techniques are given in NCRP Report No. 87 (1987) and are also listed in Table 7-1.
7.1.1 Internal Iodine Measurements
In vivo measurement techniques are the most direct and widely used approach for assessing the burden of
iodine radioisotopes within the body.  The in vivo measurement of these radioisotopes within the body is
performed with various radiation detectors and associated electronic devices that are collectively known as
in vivo thyroid monitors or whole body counters, depending on the body site of interest.  These radiation
detectors commonly utilize sodium iodide (NaI), hyperpure germanium, and organic liquid scintillation

























Table 7-1.  Analytical Methods for Determining Iodine in Biological Samples
Sample matrix Preparation method
Analytical
method Sample detection limit Percent recovery Reference
Urine Sample purified on Dowex
1x8 resin column; dried
resin fused with NaOH/
KNO3, dissolved in water;
dry 0.5 mL aliquot on
polythene sheet;
irradiated, dissolved in
water with iodine carrier;
extracted with trioctyl-
amine/xylene; back





0.01 µg/L 94% Ohno 1971
Urine Sample digested in chloric
acid; arsenious acid added








96–97% Benotti and Benotti
1963; Benotti et al.
1965
Thyroid Powdered or fresh tissue
digested with H2SO4;








No data Ballad et al. 1976,
Boulos et al. 1973,
Oliver et al. 1982






























Table 7-1.  Analytical Methods for Determining Iodine in Environmental Samples (continued)
Sample matrix Preparation method
Analytical













No data Hou et al. 1997b
Tissues Aqueous NaOH and
Na2S2O5 added to tissue
homogenates; ashed;
residue dissolved in water
and then injected into an
HPLC for the separation of
components on a two-
column system followed by












reagent, digested in CrO3,






Feces Dried; pulverized; digested
in HNO3/HF; treated with
HCl/HNO3
ICP-AES 0.1 µg/mL 88–90% Que Hee and Boyle
1988
Feces Dried; pulverized; digested
in chloric acid; arsenious






per sample (20–30 mg
sample size)
97–101% Benotti and Benotti
1963, Benotti et al.
1965
Table 7-1.  Analytical Methods for Determining Iodine in Environmental Samples (continued)
Sample matrix Preparation method
Analytical





































0.5 µg/L 97.6–102.4% Verma et al. 1992
Milk, yogurt,
cream
Sample incubated in two
parts (v:v) methanol;
filtered; 4 mL filtrated
passed through Sep-Pak
C18 cartridge; final 2 mL of
eluate filtered; 100 µL




25 µg/L  92–114% Chadha and Lawrence
1990
Bread Bread is dried; ground;
treated with 2N Na2CO3
plus 1% KclO3; dried;
incinerated; dissolved;




0.05 µg/g No data Sachs et al. 1972
As-Ce catalytic spectrophotometry = arsenious-ceric ion catalytic spectrophotometry; HPLC = high performance liquid chromatography; ICP-AES = inductively
coupled plasma-atomic emission spectrometry; INAA = instrument neutron activated analysis; UV = ultraviolet/visible
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The gamma-ray and x-ray photopeaks that are commonly used in the detection and quantitation of these
iodine radioisotopes are the 28 keV (0.0665 photons/transition) gamma-ray and/or the Kα1 (27.5 keV,
0.739 photons/transition), Kα2 (27.2 keV, 0.397 photons/transition), Kβ1 (31.0 keV, 0.140 photons/
transition), and Kβ2 (31.7 keV, 0.043 photons/transition) x-rays for 125I, and the 364 keV gamma-ray for 131I
(Jönsson and Mattsson 1998; Landon et al. 1980; Palmer et al. 1976).  The third iodine radioisotope that is
commonly encountered in the environment, 129I, is difficult to quantitate using in vivo monitoring and
scanning techniques due to its low specific activity (0.17 mCi/g), low abundance in the environment, and
low energy β- (150 keV) and gamma (40 keV) radiation (NCRP 1983).
Because approximately 20–30% of the iodine that enters the body is taken up by the thyroid gland, in vivo
thyroid monitoring is preferably and reliably used for assessing 125I and 131I burdens in exposed individuals
(Bartolini et al. 1988; Bhat et al. 1973; Blum and Liuzzi 1967; Jacobson et al. 1978; Jönsson and Mattsson
1998; Landon et al. 1980; Mandó and Poggi 1988; Nishiyama et al. 1980; Palmer et al. 1976; Plato et al.
1976; Pomroy 1979).  As such, in vivo thyroid scanning techniques are routinely used to assess thyroid
burdens of 125I and 131I in individuals with occupational exposures to these radioisotopes; for example,
medical personnel, laboratory technicians, nuclear medicine staff, radiochemists, and personnel involved
with nuclear fuel processing.  The relatively low attenuation of the gamma rays emitted from 131I by most
tissues allows for whole body and thyroid scanning techniques to be utilized in quantitating this iodine
radioisotope within an individual (Berg et al. 1987; Nishiyama et al. 1980).  Attenuation of lower energy
gamma-ray and x-ray emissions for 125I through tissues is greater than what is observed for the higher
energy 131I gamma-ray.  However, the position and close proximity of the thyroid at the base and surface of
the neck helps to minimize the effect that attenuation can have on the detection and quantitation of 125I in
the thyroid, as compared to deeper tissues.
Many configurations of the thyroid and whole body counter and scanning methods have been utilized for
monitoring and quantitating thyroid iodine radioisotope burdens, ranging from unshielded single-crystal
field detectors to shielded, multi-detector scanning detectors (IAEA 1962, 1970, 1972, 1976, 1985; NCRP
1987; Palmer et al. 1976; Plato et al. 1976).  The minimum detectable activity of these devices is typically
around 30–300 pCi for thyroid monitoring and approximately 2 nCi for whole body scanners (Nishiyama
et al. 1980; Palmer et al. 1976; Plato et al. 1976).  Where appropriate, shielding of the room that houses the
thyroid or whole body counter can be used to increase the detection sensitivity of the equipment by
minimizing background radiation.  To further insure that internalized iodine radioisotopes are accurately
measured, removal of external contamination with radioactive iodine or other gamma-emitting
radioisotopes on the clothing or skin of the individual to be scanned is recommended (Palmer et al. 1976). 
Also, in vitro measurements of iodine (see Section 7.1.2) can be used in conjunction with in vivo thyroid
monitoring when assessing individuals working with iodine radioisotopes, especially in the assessment of
individuals who have experienced accidental or routine exposures to iodine radioisotopes (Bhat et al. 1973;
Nishiyama et al. 1980).
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Calibration of thyroid and whole body counts is achieved through the use of tissue-equivalent phantoms. 
These phantoms are constructed to mimic the shape and density of the anatomical structure using tissue
equivalent materials such as water-filled canisters or masonite (Bhat et al. 1973; Jönsson and Mattsson
1998; Landon et al. 1980; Nishiyama et al. 1980; Palmer et al. 1976; Plato et al. 1976).  An example of a
neck phantom is a polyethylene or Lucite cylindrical container filled with water to approximate the
dimensions and density of the neck (Jönsson and Mattsson 1998; Landon et al. 1980; Palmer et al. 1976;
Plato et al. 1976).  Radioiodine standards are measured either as point sources along the phantom or, more
typically, dissolved within two water-filled polyethylene or glass tubes (1–2.5 cm in diameter by 5–7 cm
in length) that are set at an appropriate distance apart to approximate the positioning of the two lobes of the
thyroid glands in the base of the neck.  The dimensions of the Lucite and polyethylene neck phantoms are
varied to more accurately mimic the actual ranges of adult and children’s neck sizes (Palmer et al. 1976;
Plato et al. 1976; Pomroy 1979).  Other types of modified thyroid-neck phantom models and whole body
phantoms have been used to calibrate radioiodine measurements as well (Nishiyama et al. 1980). 
Comparisons of the actual counting rates obtained from the phantom and the known activity of the
radioiodine standards are used to determine the efficiency of the counting technique and, thus, provide the
basis for calibration.
Assessment of short- and long-term retention of iodine radioisotopes must take into account the turnover
rate for radioiodine within the human body.  For 125I, the mean effective half-life within the body is
37–39 days (Bartolini et al. 1988; Landon et al. 1980); for 131I, the mean effective half-life is 5–7.6 days
(Bhat et al. 1973).  These values are much less than the actual biological half-life of iodine (127I) in the
body of 96–138 days (Bartolini et al. 1988; Landon et al. 1980), due to the relatively short physical half-
lives of these radioisotopes.  For acute and chronic exposures to radioiodine, the estimates of radioiodine
retention are best calculated from results of multiple thyroid or whole-body measurements.  This is
because of individual variability in thyroid uptake rates, excretion rates, and uncertainties in determining
uptake of radioiodine through inhalation, ingestion, and the skin (Landon et al. 1980; Mandó and Poggi
1988).  However, direct comparisons between laboratories of body burdens and clearance rates for specific
radioisotopes can be complicated by the differing whole body measurement techniques, calibration
methods, and methods used to account for normal background radiation counts that are utilized within the
different laboratories.   
7.1.2 External Measurements
In vitro analyses of iodine are routinely performed in situations where in vivo analyses cannot be obtained
or in support of an in vivo monitoring program.  Urine is the preferred sample for in vitro analyses of
iodine, although other sample types, such as feces, tissue, blood, serum, and hair, also can be used on a
more limited basis with good detection sensitivities that are typically on the order of <1 µg per sample
(NAS 1974).  Urine provides for an analysis of soluble iodine, fecal analysis can be used to assess the
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fraction of ingested iodine not absorbed by the gut, and tissue is used to assess whole or regional body
burdens of iodine (NCRP 1987).
The in vitro analysis of the stable isotope of iodine, 127I, in commonly acquired human samples (e.g., urine,
tissue, feces) is performed by a number of methods that have the selectivity and/or sensitivity to measure
iodine in biological matrices (Table 7-1).  These methods include arsenious-ceric ion catalytic
spectrophotometry, instrumental neutron activation analysis (INAA), inductively coupled plasma atomic
emission spectrometry (ICP-AES), and high performance liquid chromatography/ultra-violet-visible
detection techniques (Andersson and Forsman 1997; Barker 1948; Benotti and Benotti 1963; Benotti et al.
1965; Cornelis et al. 1975; EPA 1986; Hou et al. 1997b; Ohno 1971; Que Hee and Boyle 1988).  The
INAA and ICP-AES methods offer the greatest sensitivity for the detection of iodine in human samples
(Table 7-1).  An example of an application of INAA to the measurement of iodine in urine involves a
prepurification of the urine sample to remove interfering ions, such as bromide, upon activation by
neutrons (photopeaks are 0.45 MeV for 128I and 0.55 MeV for 82Br).  The urine sample is first passed over
Dowex 1X8 anion exchange resin, and then followed by the fusion of the washed and dried resin with
NaOH/HNO3.  The fusion residue is dissolved in water with a 0.5 mL aliquot transferred to a polyethylene
sheet and dried.  The sample is then irradiated with neutrons, dissolved in a solution containing a iodide
carrier, extracted with trioctylamine/xylene, back extracted first with 1 M sodium nitrate to remove
bromine and then back extracted into 1 N ammonia.  From here, the iodine is precipitated as silver iodide,
filtered, and analyzed by gamma spectrometry (Ohno 1971).
For the in vitro analysis of the iodine radioisotopes, 125I and 131I, in human samples, there are a number of
the analytical methods that can measure these radioisotopes directly in the samples without the
requirement for an extensive sample preparation procedure (Table 7-2), as has been demonstrated for other
radioisotopes (Gautier 1983).  In the radiochemical analysis of radioiodine in urine, a 24-hour urine
collection (approximately 2 L) is obtained followed by the transfer of a 1 L aliquot to a Marinelli beaker
for counting in a gamma ray spectrometer.  This simple procedure offers high recoveries of 98% and the
minimum detection sensitivity 100 pCi/L that is required to evaluate individuals for exposures to 125I and
131I.  Similar methods can also used for the analysis of these iodine radioisotopes in tissues, feces, blood,

























Table 7-2.  Analytical Methods for Determining Radioiodine in Biological Samples
Sample matrix Preparation method Analytical method Sample detection limit
Percent
recovery Reference




100 pCi/L (131I) 98% Gautier 1983
Thyroid 129I counted directly in thyroid tissue X-ray spectrometry
with HP Ge detector
0.04 pCi/g (129I) No data Van Middlesworth
1993
Thyroid Powdered or fresh tissue digested
with H2SO4; iodide converted to Al2I6;





45 pg/g (129I) No data Boulos et al. 1973,
Oliver et al. 1982
Thyroid and
other tissues
Tissue sample were lyophiized and
ground; pyrolyzed in O2/N2 stream;
iodine absorbed onto charcoal; iodine
liberated from charcoal by heating;
isolated by distillation on cooled glass
and then neutron irradiated
INAA with Ge(Li)
γ-spectrometry
18–74 fCi/g (129I) 85% (thyroid)
50–60% (other
tissues)
Handl et al. 1990
Saliva Saliva samples obtained and directly
counted
Scintillation counter 1.26–36.5 nCi/mL
(range of measured
values) (125I)
No data Nishizawa et al.
1985
Feces Sample directly counted in detector γ-spectrometry with
NaI detector
0.14 nCi/L (131I) No data Lipsztein et al. 1991
Cow’s milk Sample (50–100 mL) directly counted
in iron shielded gamma spectrometer
γ-spectrometry with
NaI detector
4–100 pCi/L (range of
measured values) (131I)
No data Ekman et al. 1967
Cow’s milk Conversion of iodine to iodide;
concentrated on anion exchange




0.3 pCi/L (129I) 58% raw milk,
80% pasteurized
milk; with 30 mg
iodine carrier
Gabay et al. 1974





0.05 pCi/g (131I) No data Cunningham et al.
1989, 1994
HP = high purity; INAA = instrument neutron activation analysis
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For the quantitation of 129I, more sensitive methods are required than those described above for 125I and 131I
(Table 7-2).  One approach utilizes the transmutation of the 129I isotope to another isotope that can be
quantitated using mass spectrometric techniques.  For example, neutron activation of iodine extracted from
thyroid tissues, followed by noble gas mass spectrometry analysis of the resulting xenon isotopes, has been
used to measure 129I and the 129I/127I ratio in these tissues (Boulos et al. 1973).  This procedure uses the
measurement of 126Xe, 128Xe, and 130Xe isotopes that are formed in the decay of the iodine isotopes, 126I,
128I, and 130I, to determine the amount 129I and 127I in tissue extracts (see below).
127I(n,γ)128I  6  128Xe   (β-, half-life = 25 minutes)
127I(n,2n)126I  6  126Xe   (β-, half-life = 13 days)
129I(n,γ)130I  6  130Xe   (β-, half-life = 12.4 hours)
127I(n,γ)128I(n,γ)129I(n,γ)130I  6  130Xe   (β-, half-life = 12.4 hours)
Both the ratio of  130Xe/128Xe and 130Xe/126Xe will be proportional to the ratio of  129I/127I in the extract.  The
method is able to provide a detection sensitivity that is sufficient to measure 129I as low as 45 pg/g tissue
and/or a ratio of 129I/127I of 10-10.  In those cases where INAA methods cannot be applied due to a large
sample set size, availability of an appropriate reactor, the short half-life of the isotope of interest (e.g., 130I),
or the cost of activation, there are other techniques available to enhance the detection sensitivity for the 129I
isotope (Gabay et al. 1974).  For example, preconcentration of 129I using anion exchange methods in
addition to purifying the sample of interfering materials has been used successfully to analyze samples
containing low amounts of 129I (Gabay et al. 1974, Table 7-2).  Also, inductively coupled plasma-mass
spectrometry (ICP-MS) methods have been used to quantitate iodine in biological samples using differing
sample preparation methods, including Schöniger combustion and extraction methods, providing limits of
detection (50 and 0.3 ng/g, respectively) that are appropriate for performing trace analysis of iodine in a
large number of environmental and biological samples (Gélinas et al. 1998).
Accuracy of in vivo and in vitro measurements of iodine and its radioisotopes is determined through the
use of standard, certified solutions or radioactive sources with known concentrations or activities of iodine. 
National Institute of Standards and Technology (NIST) traceable standards for 125I and 127I can be obtained
through a number of commercial sources.  The primary source of certified iodine radioisotope standards is
the NIST.  Standard reference materials (SRM) for 129I (SRM 4401LZ, 30MBq [0.8 mCi]) and 131I
(SRM 4949C, 17 kBq [0.45 µCi]) are available from NIST.  SRMs are also available for 127I
measurements, including SRM 909 (serum), SRM 1486 (bone meal), SRM 1548 (mixed diet), SRM 1549
(nonfat milk powder), SRM 1846 (infant formula), and SRM 2383 (baby food).
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7.2 ENVIRONMENTAL SAMPLES
There are two common approaches for measuring iodine radioisotopes in the environment.  Iodine
radioisotopes can either be measured directly in the field (in situ) using portable survey instruments or
samples can be procured from the field and returned to the laboratory for quantitation of iodine.  However,
quantitation of the stable iodine isotope in environmental samples is generally conducted in the laboratory.
 
7.2.1 Field Measurements of Iodine
In situ measurement techniques are extremely useful for the rapid characterization of radionuclide
contamination in the environment, such as soils, sediments, and vegetation, or when monitoring personnel
for exposure to radionuclides.  The measurement of gamma-ray-emitting radionuclides in the environment
is conducted with portable survey instruments such as Gieger-Mueller detectors, sodium iodide
scintillation detectors, and gamma-ray spectrometers.  However, the use of gamma-spectrometers in field
survey equipment is preferred for measuring 131I in the field because of its selectivity and sensitivity (EML
1997).  The energy and penetrance of the gamma-rays that are emitted during the decay of 131I provides an
advantage for assessing the level of iodine both on and below the surface using portable field survey
instruments such as the gamma-ray spectrometer (EML 1997).  These gamma-ray spectrometers are
equipped with a high purity germanium detector that is able to resolve the 364 keV gamma-ray emitted
from 131I from the gamma-rays emitted from other radionuclides; for example ,40K (NRC 1997).  The
concentration and distribution of 131I that have been detected in the field will need to be determined by
laboratory-based analyses of soil samples procured from the survey area.
7.2.2 Laboratory Analysis of Environmental Samples
Analytical methods for quantifying iodine and iodine radioisotopes in environmental samples (e.g., air,
water, soil, biota, and food) are summarized in Tables 7-3 (127I) and 7-4 (125I, 129I, and 131I).  The methods
that are commonly used in the analysis of 127I are based on instrument-based analytical techniques, such as
spectrophotometry, electrochemistry, INAA, mass spectrometry (MS), and some colorimetric techniques. 
The analysis of 125I, 129I, and 131I can be determined either as total mass or total activity, depending on the
analytical technique that is used.  Typically, radiochemical methods of analysis employing gamma-ray
spectrometry and β-γ coincidence scintillation techniques are used to quantitate 125I and 131I in
environmental samples.  However, more sensitive analytical techniques, such as INAA and MS, are
typically required to analyze 129I in environmental samples (Lindstrom et al. 1991; Stephenson and
Motycka 1994).  Neutron activation and mass spectrometric methods are especially useful, since the

























Table 7-3.  Analytical Methods for Determining Iodine in Environmental Samples
Sample







Aerosols collected using an Anderson
cascade impactor; iodine separated from
filters by ignition and adborbed onto
charcoal; extracted from charcoal using
NaOH solution; acidified; extracted into
CCl4 as iodine; back extracted into dilute
H2SO4 and precipitated as PdI2, then
neutron irradiated





No data Tsukada et al. 1991
Air (ambient) A known volume of air is passed through a
multistage filter assembly; filters extracted
in a heated NaOH/Na2SO3 solution
containing 129I- as an internal standard;
filtered; acidified; iodide precipitated as
AgI; filtered; precipitate dissolved in
aqueous NH3 and analyzed
IDMS 0.02–0.024 ng/m3
(for an average air
volume of 70 m3)




A known volume of air is drawn into a glass
tube containing 150 mg of charcoal; iodine
extracted into 0.01 M Na2CO3 using an









CaO added to sample; filtered; sodium
acetate/acetic acid then bromine water
added; excess bromine with sodium
formate removed; KI and H2SO4, titrate
added with phenylarsine oxide or sodium
thiosulfate using starch indicator





Water Sample acidified with HCl; oxidized with
H2O2 or KMnO4; treated with NaSO3 to
remove excess oxidant; titrated with KIO3




























Table 7-3.  Analytical Methods for Determining Iodine in Environmental Samples (continued)
Sample







Ascorbic acid (2%) added to sample;
5 minute stand; reacted with acidified
NaNO2; evolved iodine extracted into
xylene and analyzed at the emission
intensity for iodine of 178.28 nm




Sample reacted with acidified NaNO2;
evolved iodine extracted into xylene; back
extracted into 0.5 % aqueous ascorbic acid
and analyzed at the emission intensity for
iodine of 178.28 nm




Samples divided and  spiked with 129I- or
129IO3-; oxidized with UV or HNO3/H2O2
(total I), or concentrated/purified on an
anion exchange column (I-, IO3-; anionic
organoiodine); samples are then reduced
with Na2SO3 and precipitated as AgI






No data Reifenhäuser and
Heumann 1990
Drinking water Sample separated on a Dionex AS12
analytical HPLC column; the eluted iodate
reacted with acidified bromide in post-
column reaction to form tribromide that is
detected at 267 nm
HPLC with UV
detection




Tap water Sample acidified to 0.1 mN nitric acid +
Hg+2 (as Hg(NO3)2) added to 300 µg/L;














0.1 µg/L 100% Jones et al. 1982
Fresh water
(iodate)
Iodine-iodide is removed from sample
through extraction into chloroform as ion-
pair with tetraphenylarsonium cation
As-Ce catalytic
spectrophotometry
0.1 µg/L -100% (at 2 µg/L
iodate)
Jones et al. 1982
Table 7-3.  Analytical Methods for Determining Iodine in Environmental Samples (continued)
Sample





























Fresh water One liter sample is acidified with nitric acid;




0.20 µg/L No data Salbu et al. 1975
Drinking water
(total iodine)
K2CO3 added to sample; centrifuged to
remove precipitated alkaline earth metals;
iodine measured by addition of nitric acid,
NaCl, NH4Fe(SO4)2 and KSCN
Spectrophotometry 0.2 µg/L 90–108% Moxon 1984
Drinking water
(free iodide)
K2CO3 added to sample; centrifuged to
remove precipitated alkaline earth metals;
iodide measured by addition of reduced
amounts of nitric acid, NaCl, NH4Fe(SO4)2,
and KSCN
Spectrophotometry 0.4 µg/L 89–109% Moxon 1984
Fresh and sea
waters
Samples directly injected onto a weakly
anionic ion-exchange column for iodide
analysis; iodate measured through








Sample (neat or diluted) were treated with
HClO4, acetone, and KMnO4; KMnO4
reduced with oxalic acid, then treated with
NaS2O3/chromic acid followed by extraction
into benzene containing p-dichlorobenzene
as an internal standard
GC-ECD 0.1 µg/L No data Maros et al. 1989
Sea water Sample acidified with acetic acid; bromine
vapor dissolved into sample; excess








Iodide in sample precipitated with AgNO3;
precipitate dissolved in acetic acid
saturated with Br2; filtered; filtrate reduced
in volume; then reacted with starch solution
and CdI2
Spectrophotometry 0.025 µg/L 99% (at 10 µg/L
iodine)
Tsunogai 1971
Table 7-3.  Analytical Methods for Determining Iodine in Environmental Samples (continued)
Sample































Iodide in sample precipitated with AgNO3;
iodate in fitrate is reduced to iodide with
NaSO3/H2SO4, acetic acid saturated with
Br2 added; filtered; filtrate reduced in
volume; reacted with starch solution and
CdI2
Spectrophotometry 0.025 µg/L No data Tsunogai 1971
Sea water Sample filtered and concentrated/purified
on an AG1X4 anion exchange column; I-,
IO3-, and organic iodine were isolated
preferentially isolated; neutron irradiated;
iodide carrier added; treated with NaNO2 in
HNO3; extracted into CCl4; back extracted
into a KHSO3 solution and counted
INAA using Ge(Li)
γ-spectrometry
0.2 µg/L 99.5% (post-
irradiation
recovery)
Hou et al. 1999
Sea water and
brackish water*
Sample treated with CaO; iodide oxidized
with Br2 in acetate buffer; excess Br2
removed with sodium formate; iodate
converted to iodine and titrated with









Sample is acidified with HCl; iodide
converted to iodine with KNO2 and
extracted into CCl4; absorbance of iodine-









500 µL of sample diluted to 50 ml with
water plus NaNO2 solution; measured












Sample treated with 14 N H2SO4 plus 3 M
H2O2; extracted with CCl4; back into
0.1 mM NaS2O3; then iodine/methylene
blue ion pair extracted into 1,2-dichloro-
ethane
Spectrophotometry 10 µg/L 68% (at 0.4 mM
iodine)
Koh et al. 1988
Table 7-3.  Analytical Methods for Determining Iodine in Environmental Samples (continued)
Sample





























Groundwater Metals chelated with EDTA and iodate is
directly measured; iodide can be indirectly
measured through conversion to iodate by
treatment with chlorine water
Single-sweep
polarography
0.005 µg/L No data Whitnack 1975
Soil Sample dried; sieved (7 mm diameter),
ground; sieved (2 mm diameter); extracted
with 2 N NaOH; arsenious acid added then
submitted for automated analysis
As-Ce catalytic
spectrophotometry




Sample dried and pulverized; mixed with
V2O5 and pyrohydrolyzed; evolved iodine




0.05 µg/g (0.5 g
sample size)
75–90% Rae and Malik 1996
Coal and fly
ash
<250 mg samples dried; irradiated with





No data Germani et al. 1980
Vegetation Sample prepared by microwave digestion
using HNO3/H2O2; treated with Na2S2O3 or
ascorbic acid solution to convert iodate to
iodide  
ICP-MS 100 pg/g 96–104% Kerl et al. 1996
As-Ce catalytic spectrophotometry = arsenious-ceric ion catalytic spectrophotometry; GC-ECD = gas chromatography-electron capture detection;  HPLC = high
performance liquid chromatography; ICP-AES = inductively coupled plasma-atomic emission spectrometry; ICP-MS = inductively coupled plasma-mass

























Table 7-4.  Analytical Methods for Determining Radioiodine in Environmental Samples
Sample matrix Preparation method Analytical method Sample detection limit Percent recovery Reference
Air (occupational) Air samples drawn into a
regulated, constant-flow air
sampler for personnel
monitoring at a flow rate of 2
L/minute for several periods of
2–7 minutes; air-borne iodine
was trapped in a charcoal
sampling tube, then counted
Scintillation counter
with NaI detector




Air drawn through a 25 mm
cellulose nitrate/acetate filter at
a constant flow rate of





No data Eadie et al. 1980
Aerosols (ambient) Aerosols were collected using
an Anderson cascade impactor;
filters removed from impactor
and then neutron irradiated
INAA with Ge γ-ray
detector
0.24–0.26 aCi/m3 (range
of measured values) (129I)
No data Tsukada et al.
1991
Water Add iodide carrier and NaOCl to
4 L sample; stir; add
NH2OH@HCl and NaHSO3; stir;
filter; extract through anion
exchange resin; elute iodide
with NaOCl; treat with HNO3;
extract with toluene and
aqueous NH2OH@HCl, back
extract with aqueous NaHSO3;
precipitate iodide as CuI
γ-spectrometry with
Ge detector
<1 pCi/L (131I) No data ASTM 1994
Drinking water Iodate carrier added to sample
and iodate  reduced to iodide
with NaSO3; iodide precipitated
with AgNO3; AgI dissolved and






























Table 7-4.  Analytical Methods for Determining Radioiodine in Environmental Samples (continued)
Sample matrix Preparation method Analytical method Sample detection limit Percent recovery Reference
Drinking water Iodate carrier and tartaric acid
are added to sample, HNO3
added and sample distilled into
NaOH solution; distillate
acidified with H2SO4 and
oxidized with NaNO2; extracted





0.1 pCi/L (131I) No data Krieger 1976
Fresh water Conversion of iodine to iodide;
concentrated on anion
exchange resin; extracted with
CCl4, water, then toluene
Liquid scintillation
counter
0.3 pCi/L (129I) 74% with 30 mg
iodine carrier
Gabay et al. 1974
Fresh water Iodide carrier added to sample;
treated with HCl and sodium
metabisulfite; iodide
conentrated on a strong anion
exchange resin with iodine






30 pCi/L (125I) No data Howe and Bowlt
1991
River water Sample directly analyzed or
concentrated on an anion
exchange resin; eluted with
nitric acid; analyzed, using
indium as an internal standard
ICP-MS 0.5  pCi/L (129I) No data Beals and Hayes
1995; Beals et al.
1992
Table 7-4.  Analytical Methods for Determining Radioiodine in Environmental Samples (continued)

























Aqueous sample Sample concentrated on a
Dowex 1x8 anion exchange
resin; resin pyrolyzed; iodine
adsorbed onto activated
charcoal; iodine removed by
heating charcoal; neutron
irradiated; iodine carrier added;
iodine extracted into xylene;
iodide precipitated with silver
INAA with Ge(Li)
detector
3.8 fCi/L (129I) 50% Anderson 1978
Water Iodide carrier was added to
samples; treated with sodium
hypochlorite, purified; reduced
to isolate iodine and iodine
precipitated as AgI; AgI was
mixed with either a niobium or
ultrapure silver metal binder and
dried onto stainless-steel
sample holders for analysis
AMS <0.3 pg/g (129I) No data DOE 1994; Elmore
and Phillips 1987;
Elmore et al. 1980
Water and waste
water
Direct count of sample γ-spectrometry with
Ge/Li detector









No data (131I) No data Sodd et al. 1975
Treated sewage
(influent/effluent)
Sample counted directly or first
concentrated on anion
exchange column after
reduction of iodine to iodide in




180 pCi/L (direct count),
0.35 pCi/L (concentrated)
(131I)
No data Prichard et al.
1981
Table 7-4.  Analytical Methods for Determining Radioiodine in Environmental Samples (continued)



























Sample dried; iodine extracted
through combustion of soil in
oxygen; iodine trapped onto
charcoal after passage over
hydrated manganese dioxide
(HMD); neutron irradiated; Br




5 aCi/g (129I) No data Lindstrom et al.
1991; Lutz et al.
1984
Vegetables Sample lyophilized; Na2CO3,
NaCl, and 131I (internal
standard) added; dried and
ashed; treated with MnO2 and
evolved iodine trapped in 0.1%
NaHSO3 containing iodide
carrier 
ICP-MS 1.4 pg/g (0.24 fCi/g)(129I) 88% Cox et al. 1992
Plants Plant samples were lyophiized
and ground; 125I added as
internal standard; sample was
pyrolyzed in O2/N2 stream;
iodine absorbed onto charcoal;
iodine liberated from charcoal
by heating; isolated by




18–74 fCi/g (129I) 50–60% Handl et al. 1990
AMS = accelerator mass spectrometry; ICP-MS = inductively coupled plasma-mass spectrometry; INAA = instrumental neutron activation analysis
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(Muramatsu et al. 1985).  For example, the mass spectrometry techniques that are utilized to measure
iodine in samples, such as neutron activation-noble gas mass spectrometry or accelerator mass
spectrometry, provide the ability to resolve the 127I and 129I isotopes in the quantitation step and also have
the required sensitivity range to measure ratios of 10-10–10-7 for 129I/127I in most environmental and
biological samples (Gramlich and Murphy 1989; Schmidt et al. 1998).
The analysis of 127I in air is based on the quantitation of this isotope of iodine in its gaseous form (I2) or
within aerosols or particulates, either separately or combined (Dams et al. 1970; Gäbler and Heumann
1993; Kim et al. 1981; Sheridan and Zoller 1989; Tsukada et al. 1991).  The concentration of gaseous
iodine in air can be determined by passing a known volume of air through a tube containing activated
charcoal, followed by extraction of the iodine from the charcoal and analysis by a number of techniques,
including ion chromatography (Kim et al. 1981).  Both the gaseous and particulate forms of iodine can be
simultaneously assessed by passing a specified volume of air through a filtering device containing a series
of filters with differing pore sizes and coatings (Gäbler and Heumann 1993; Tsukada et al. 1991).  Both
gaseous and particulate forms of iodine are trapped on the various filter stages, depending on the type of
coating and pore size of the filter stage after a calibrated amount of air is pulled through the filters.  For the
analysis of 127I on the filters, the filter is solvent extracted and the extracted iodine is analyzed by INAA
(Sheridan and Zoller 1989; Tsukada et al. 1991), nondestructive neutron activation analysis (Dams et al.
1970), and isotope dilution mass spectrometry (Gäbler and Heumann 1993).  Analysis of airborne 125I, 129I,
and 131I can also be performed using the filtering techniques described above, followed by a direct
measurement by beta- or gamma-ray counting of these radioisotopes on the filter or within activated
charcoal (Eadie et al. 1980; Luckett and Stotler 1980) or quantitated with more sensitive techniques (129I)
such as INAA (Tsukada et al. 1991).  
For the analysis of iodine in water, there is a broad array of sample preparation and detection
methodologies that are available (see Tables 7-3 and 7-4).  A number of methods can directly quantitate
iodine or its radioactive isotopes within a water sample using spectrophotometric, ion-selective electrodes,
INAA, ICP-MS, polarography, or radiochemical techniques with minimal sample preparation and good
detection sensitivities (0.1–2.0 µg/L for 127I, < 2 pCi/L for 131I) (ASTM 1995, 1998, Beals and Hayes 1995;
Beals et al. 1992; Butler and Gershey 1984; Jones et al. 1982; Prichard et al. 1981; Salbu et al. 1975; Sodd
et al. 1975; Stephenson and Motycka 1994; Whitnack 1975).  Some analytical methods provide for the
analysis of total iodine in the sample as well as the various iodine species in water (e.g., I-, I2, IO3-, and
organic iodine) (Reifenhäuser and Heumann 1990; Wong and Cheng 1998).  However, poor or
inconsistent recovery of some iodine species (e.g., I- and IO3-) during the ion exchange stage of the sample
preparation, which is due to both irreversible binding of these iodine species to some ion exchange resins
and interference from dissolved organic carbon, often can limit the accuracy of these methods for
determining iodine species in aqueous samples (Stephenson and Motycka 1994).
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One of the more commonly used assays for analyzing iodine at µg/L concentrations in water can be done
directly using the catalytic spectrophotometric method.  In the assay, iodine acts as a catalyst in the
reduction of the ceric ions [Ce(IV)] by arsenous ions [As(III)]:
I-
 2Ce(IV) + As(III)      ÷     2Ce(III) + As(V)
In the absence of iodine, the reaction is very slow (-35 hours), but is on the order of minutes in the
presence of iodine.  The changes in the reaction rate, as followed by the decay in the Ce(IV) absorbance at
either 420 or 366 nm, are inversely proportional to the iodine concentration in the sample (Jones et al.
1982; Lauber 1975; Truesdale and Smith 1975).  This assay has been developed into an automated process
offering the advantage of large sample batch analyses (Truesdale and Smith 1975).
However, like many of the methods that are used to quantitate iodine, a number of interferences can affect
the measurement of iodine by the catalytic spectrophotometric method, including background coloration,
turbidity, and compounds, such as Fe(II), that are capable of reducing Ce(IV) (Jones et al. 1982; Truesdale
and Smith 1975).  Thus, methods have been developed that purify iodine by first extracting iodine into an
organic solvent and then back extracting the iodine into an appropriate aqueous solution for As–Ce
catalytic spectrophotometric analysis (Jones et al. 1982; Whitehead 1979).  Likewise, for most methods,
there is often a need to preconcentrate, redox convert the various iodine species (e.g., I-, I2, IO3-), and/or
isolate iodine or its radioisotopes from the sample in order to improve sensitivity or remove interfering
species, as is illustrated in Tables 7-3 and 7-4.  Newer techniques have been developed to improve the
separate quantitation of iodine species.  An example is the use of ICP-MS to quantitate iodide directly in
the samples after filtering, whereas iodine is quantitated as a vapor that is evolved from the sample
following treatment of the sample with potassium nitrite in sulfuric acid.  This approach provides a
detection limit of 0.04 µg/mL and recoveries of 86.5–118.6% (Anderson et al. 1996)
The quantity of iodine and its radioisotopes in soil, sediments, minerals, vegetation, and biota is
determined using detection methods similar to those described above (Tables 7-3 and 7-4).  Analysis of
iodine in samples by spectrophotometry, electrochemistry, and MS requires some form of sample
digestion, either treatment in acid or pyrolysis.  For most methods,  sample concentration or purification is
required to remove interfering species and/or improve detection sensitivity.  
In the quantitation of 129I in soil, mineral, and biological samples by the INAA method, improvements to
the INAA method for determining 129I have been developed to minimize the possible interferences that can
occur from 133Cs(n,α)130I, 127I(3n,γ)130I, 235U(n,f)129I as well as neutron capture by 128Te and 130Te.  The
presence of bromine within a particular sample also can interfere with the quantitation of 129I due to the
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higher activity of 82Br, the small difference in the photopeak maxima for 129I (0.45 MeV) and 82Br
(0.55 MeV) and chemical similarities for I and Br (Ohno 1971; Rook et al. 1975).  Most of these
interferences have been eliminated through the use of preirradiation separation step that involves the
combustion of iodine from biological materials followed by the collection of iodine on activated charcoal
(Rook et al. 1975).  A postirradiation step also has been developed using a electromagnetic mass separator
with a hot cathode arc ion chamber source to separate and collect sample components within a specific
mass range onto a aluminum foil for subsequent quantitation by a β-γ coincidence analysis system (Rook
et al. 1975).
The detection limits, accuracy, and precision of any analytical methodology are important parameters in
determining the appropriateness of a method to quantitate a specific analyte at the desired level of
sensitivity within a particular matrix.  The Lower Limit of Detection (LLD) has been adopted to refer to
the intrinsic detection capability of a measurement procedure (sampling through data reduction and
reporting) to aid in determining which method is best suited for the required sample quantitation (EML
1997; NRC 1984).  Several factors influence the LLD, including background counting-rates, size or
concentration of sample, detector sensitivity, recovery of desired analyte during sample isolation and
purification, level of interfering contaminants, and, particularly, counting time.  Because of these variables,
the LLDs between laboratories, utilizing the same or similar measurement procedures, will vary.
The accuracy of a measurement technique in determining the quantity of a particular analyte in
environmental samples is greatly dependent on the reliability of the calibrating technique.  Thus, the
availability of standard, certified radiation sources with known concentrations of iodine and its
radioisotopes are required in order to insure the reliability of the calibration methods and accuracy of
iodine measurements in environmental samples.  NIST traceable standards for 127I can be obtained through
a number of commercial sources.  The primary source of certified iodine radioisotope standards is the
NIST.  Standard reference materials for 129I (SRM 4401LZ, 30 MBq [0.8 mCi]) and 131I (SRM 4949C,
17 kBq [0.45 µCi]) are available from NIST.  SRMs are also available for 127I measurements, including
SRM 1515 (apple leaves), SRM 1547 (peach leaves), SRM 1566 (oyster tissue), SRM 1572 (citrus leaves),
SRM 1573 (tomato leaves), SRM 1575 (pine needles), SRM 1577 (bovine liver), SRM 1632 (coal),
SRM 1633 (fly ash), SRM 1643 (water), SRM 2704 (sediment), and SRM 2709 (soil).
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate
information on the health effects of iodine is available.  Where adequate information is not available,
ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the initiation
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of a program of research designed to determine the health effects (and techniques for developing methods
to determine such health effects) of iodine. 
 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
7.3.1 Identification of Data Needs
Methods for Determining Biomarkers of Exposure and Effect.    Analytical methods with
satisfactory sensitivity and precision are available to determine the levels of iodine and its radioisotopes in
human tissues and body fluids.
Exposure.  Analytical methods with satisfactory sensitivity and precision are available to determine the
exposure levels of iodine and its radioisotopes in human tissues and body fluids.
Effect.  Analytical methods with satisfactory sensitivity and precision are available to determine the levels
of effect for iodine and its radioisotopes in human tissues and body fluids.
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media.    Analytical methods with the required sensitivity and accuracy are available for quantitating
iodine, both total and isotopic, in environmental matrices (Tables 7-3 and 7-4).  Knowledge of the levels of
iodine in various environmental media, along with appropriate modeling (see Chapters 2 and 4), can be
used to evaluate potential human exposures through inhalation and ingestion pathways.
Whether in the environment or in the human body, iodine radioisotopes will undergo radioactive decay to
form a series compounds that are also radioactive (see Chapter 3).  Current analytical methods, such as
mass spectrometry, have the necessary resolution and sensitivity to detect and quantitate these decay
products. 
7.3.2 Ongoing Studies
Current research studies, as provided by a search of the Federal Research in Progress (FEDRIP) database,
are looking at improvements in the resolution and sensitivity of gamma ray scintillation spectrometers
through the development of innovative scintillating materials.  In the work proposed in the research grant
entitled “Ultra-Compact Cesium Iodide - Mercuric Iodide Gamma-Ray Scintillation Spectrometer” (B.E.
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Patti, Principal Investigator), the investigators are working with CsI/HgI scintillation pairs to develop a
room temperature gamma-spectrometer after having some preliminary success with the detection of the
660 keV gamma-ray from 137Cs (4.58% FWHM) (FEDRIP 2000).  In another study entitled “Bismuth
Iodide Crystal Growth” (L.A. Boatner, Principal Investigator), the investigators are working on developing
techniques for growing bismuth iodide crystals for room temperature radiation detectors and testing these
crystals for their efficiency and energy resolution characteristics (FEDRIP 2000).
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8.  REGULATIONS AND ADVISORIES
The international, national, and state regulations and guidelines regarding stable iodine in air, water, and
other media are summarized in Table 8-1.  The regulations regarding radioactive iodine are summarized in
Tables 8-2 and 8-3.
No MRLs were derived for inhalation exposure to stable or radioactive iodine.  Oral MRLs of 0.01
mg/kg/day were derived for both acute- and chronic-duration exposures.  No oral MRL was derived for
intermediate-duration exposure.
The EPA has not classified iodine for human carcinogenicity, nor has the EPA derived reference
concentrations (RfCs) or reference doses (RfDs) for stable or radioactive iodine (IRIS 2000).  
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Table 8-1.  Regulations and Guidelines Applicable to Stable Iodine
Agency Description Information References
INTERNATIONAL
Guidelines:















0.1 ppm OSHA 2001a
29CFR1926.55






category for iodine production
Effluent reduction
attainable by the







FDA Drug products containing certain
active ingredients offered over-














Food additives permitted for





Total amount for foods
labeled without reference to
age or physiological state
225 µg
IODINE 257
8.  REGULATIONS AND ADVISORIES
***DRAFT FOR PUBLIC COMMENT***
Table 8-1.  Regulations and Guidelines Applicable to Stable Iodine (continued)
Agency Description Information References
NATIONAL (cont.)
FDA (cont.) Food additives permitted for






Children under 4 years of
age
Adults and children 4 or




















5.0 µg FDA 2001a




Nutritional quality guidelines FDA 2000f
RDIa











iodide, sodium iodate, sodium
iodide, and thymol iodide
Recognized as safe










List of products and processes
using specially denatured
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Table 8-1.  Regulations and Guidelines Applicable to Stable Iodine (continued)
Agency Description Information References
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NATIONAL (cont.)
USC List II chemical—regulated by
the Attorney General as a
chemical used in manufacturing







Alaska PEL (ceiling) 0.1 ppm BNA 2001h
California Airborne contaminant BNA 2001h
HAP BNA 2001h
Hawaii Air contaminant BNA 2001h







Michigan Occupational air contaminant
—maximum allowable
concentrations
0.1 ppm BNA 2001h
Limits for air contaminants BNA 2001h
PEL (ceiling) 0.1 ppm
Montana Occupational air contaminant BNA 2001h
TLV 0.1 ppm
New Hampshire Regulated toxic air pollutant BNA 2001h
OEL 1 mg/m3





New York Exposure limits BNA 2001h
PEL (ceiling) 0.1 ppm
Oregon Air contaminant
PEL (8-hour TWA) 0.1 ppm BNA 2001h
Texas Airborne contaminant BNA 2001h
Vermont Hazardous air contaminant BNA 2001h
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Agency Description Information References
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STATE (cont.)
Vermont Hazardous air contaminants that








Washington Toxic air pollutant and
acceptable source impact levels




Maine Drinking water guideline—iodide
ion
340 µg/L HSDB 2001
Rhode Island Water resources—toxic pollutant BNA 2001h
c. Food No data
d. Other
California Hazardous substance list BNA 2001h
Florida Toxic substance in the
workplace
BNA 2001h
Massachusetts Oil and hazardous material list BNA 2001h




aRDI for adults and children 4 or more years of age
b100 calories, based on 2,000 calorie intake as a daily standard
AAC = acceptable ambient concentrations; ACGIH = American Conference of Governmental Industrial Hygienists;
ATF = Alcohol, Tobacco, and Firearms; BPT = best practicable control technology; BNA = Bureau of National Affairs;
CFR = Code of Federal Regulations; EL = emissions level; EPA = Environmental Protection Agency; FDA = Food and
Drug Administration; HAP = hazardous air pollutant; HSDB = Hazardous Substances Data Bank; IARC = International
Agency for Research on Cancer; IDLH = immediately dangerous to life and health; NIOSH = National Institute of
Occupational Safety and Health; OEL = occupational exposure limit; OSHA = Occupational Safety and Health
Administration; PEL = permissible exposure limit; RDI = recommended daily intake; REL = relative exposure limit;
STEL = short term exposure limit; TLV = threshold limit value; TWA = time weighted average; USC = United States
Code
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Table 8-2.  Regulations and Guidelines Applicable to Radioactive Iodine
Agency Description Information References
INTERNATIONAL
Guidelines:






Lens of the eye
Skinc
Hands and feet
20 mSv per year, averaged










Lens of the eye
Skinc
Hands and feet










Averaged over 5 years
Annual equivalent dose to
Lens of the eye
Skin
Hands and feet
Embryo-fetus exposures once 
the pregnancy is known
Monthly equivalent dose














NIOSH REL No data
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Table 8-2.  Regulations and Guidelines Applicable to Radioactive Iodine
(continued)
Agency Description Information References
NATIONAL (cont.)






















































































OSHA PEL (8-hour TWA) No data
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NATIONAL (cont.)
b. Water
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Table 8-2.  Regulations and Guidelines Applicable to Radioactive Iodine
(continued)
Agency Description Information References
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NATIONAL (cont.)

















Sources of radiation used for
food inspection—sealed units
producing radiation (125I)















DOE Radiation standards—DAC for
controlling radiation exposure to
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Table 8-2.  Regulations and Guidelines Applicable to Radioactive Iodine
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NATIONAL (cont.)
DOE Radiation standards—DAC for



















Values for establishing sealed
radioactive source accountability









DOT General requirements for
shipments and packagings—A1
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Table 8-2.  Regulations and Guidelines Applicable to Radioactive Iodine
(continued)
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NATIONAL (cont.)















EPA Annual possession quantities for
environmental compliance





















































Release limits for containmentg BNA 2001e
129I 100 Ci 40CFR191,
Appendix A
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Table 8-2.  Regulations and Guidelines Applicable to Radioactive Iodine
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Agency Description Information References
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NATIONAL (cont.)
EPA Carcinogenicity slope factorsh EPA 1997g
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Table 8-2.  Regulations and Guidelines Applicable to Radioactive Iodine
(continued)
Agency Description Information References






Equivalent dose annual limits
 for tissues and organs
Lens of eye
Skin, hands, and feet
50 mSv














Equivalent dose limits for 
tissues and organsk
Lens of eye
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Table 8-2.  Regulations and Guidelines Applicable to Radioactive Iodine
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Agency Description Information References
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NATIONAL (cont.)





























Individual monitoring BNA 2001a
131I 1 Ci 10CFR20.2206
Laboratory testing and use BNA 2001b
125I and 131I #10 µCi 10CFR32.71
Packaging and transportation of
radioactive material


















































consideration of the need for an
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Table 8-2.  Regulations and Guidelines Applicable to Radioactive Iodine
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NATIONAL (cont.)
NRC Standards for protection against
radiation—quantities of licensed

















































c. Food No data
d. Other
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Table 8-2.  Regulations and Guidelines Applicable to Radioactive Iodine
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STATE (cont.)





















consideration of the need for an



























Kansas Licensing of sources of radiation
—Schedule B; exempt quantities
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STATE (cont.)





























aThe limits apply to the sum of the relevant doses from external exposure in the specified period and the 50-year
committed dose (to age 70 years for children) from intakes in the same period.
bWith the further provision that the effective dose should not exceed 50 mSv in any single year.  Additional restrictions
apply to the occupational exposure of pregnant women.
cThe limitation on the effective dose provides sufficient protection for the skin against stochastic effects.  An additional
limit is needed for localized exposures in order to prevent deterministic effects.
dIn special circumstances, a higher value of effective dose could be allowed in a single year, provided that the average
over 5 years does not exceed 1 mSv per year.
eDerived intervention levels (DIL) are concentrations of radioactivity in food whose consumption would deliver a
committed effective dose equivalent equal to the most limiting of the protection action guides (PAGs) developed by
FDA (1998).
fClass D: approximate length of retention in the pulmonary region is less than 10 days.
gRelease limit per 1,000 metric tons of heavy metal or other unit of waste.
hRadioactive slope factors calculated by EPA’s Office of Radiation and Indoor Air (ORIA).  Slope factors are central
estimates in a linear model of the age-averaged, lifetime attributable radiation cancer incidence (fatal and nonfatal
cancer) risk per unit of activity ingested, expressed as risk per picocurie (pCi).
iInhalation slope factors are central estimates in a linear model of the age-average, lifetime attributable radiation cancer
incidence (fatal and nonfatal cancer) risk per unit of activity inhaled, expressed as risk per picocurie (pCi).
jExternal slope factors are central estimates of the lifetime attributable radiation cancer incidence risk for each year of
exposure to external radiation from photon-emitting radionuclides distributed uniformly in a thick layer of soil,
expressed as risk/year per pCi per gram of soil.
kSum of external and internal exposures but excluding doses from natural sources.
lColumn 1: gas concentration
mColumn 2: liquid and solid concentration
ACGIH = American Conference of Governmental Industrial Hygienists; ALI = annual limits on intake; BNA = Bureau of
National Affairs; CFR = Code of Federal Regulations; DAC = derived air concentrations; DOE = Department of Energy;
DOT = Department of Transportation; EPA = Environmental Protection Agency; FDA = Food and Drug Administration;
IARC = International Agency for Research on Cancer; ICRP = International Commission on Radiological Protection;
mSv = millisievert; NIOSH = National Institute of Occupational Safety and Health; NCRP = National Council on
Radiation Protection; NRC = Nuclear Regulatory Commission; OSHA = Occupational Safety and Health
Administration; PAG = protective action guide; PEL = permissible exposure limit; REL = relative exposure limit;
TLV = threshold limit value; TWA = time-weighted average
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nuclide Half-life f1c e(50) e(50) e(50)
120I 1.35/hour 1.0 1.0x10-10 1.9x10-10 3.4x10-10
120mI 0.883/hour 1.0 8.7x10-11 1.4x10-10 2.1x10-10
121I 2.12/hour 1.0 2.8x10-11 3.9x10-11 8.2x10-11
123I 13.2/hour 1.0 7.6x10-11 1.1x10-10 2.1x10-10
124I 4.18/day 1.0 4.5x10-9 6.3x10-9 1.3x10-8
125I 60.1/day 1.0 5.3x10-9 7.3x10-9 1.5x10-8
126I 13.0/day 1.0 1.0x10-8 1.4x10-8 2.9x10-8
128I 0.416/hour 1.0 1.4x10-11 2.2x10-11 4.6x10-11
129I 1.57x107/year 1.0 3.7x10-8 5.1x10-8 1.1x10-7
130I 12.4/hour 1.0 6.9x10-10 9.6x10-10 2.0x10-9
131I 8.04/day 1.0 7.6x10-9 1.1x10-8 2.2x10-8
132I 2.30/hour 1.0 9.6x10-11 2.0x10-10 2.9x10-10
132mI 1.39/hour 1.0 8.1x10-11 1.1x10-10 2.2x10-10
133I 20.8/hour 1.0 1.5x10-9 2.1x10-9 4.3x10-9
134I 0.876/hour 1.0 4.8x10-11 7.9x10-11 1.1x10-10
135I 6.61/hour 1.0 3.3x10-10 4.6x10-10 9.3x10-10
aICRP (1994)
bICRP (1994) calculated inhalation dose coefficients for particles with AMAD of 1 or 5 µm.
CFractional absorption factor used by ICRP (1994, Annexes E and F) to calculate effective dose coefficients.
ALI = annual limits on intake; AMAD = activity median average diameters; Ci = curies
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Absorbed Dose, Chemical—The amount of a substance that is either absorbed into the body or placed in
contact with the skin.  For oral or inhalation routes, this is normally the product of the intake quantity and
the uptake fraction divided by the body weight and, if appropriate, the time, expressed as mg/kg for a
single intake or mg/kg/day for multiple intakes.  For dermal exposure, this is the amount of material
applied to the skin, and is normally divided by the body mass and expressed as mg/kg.  
Absorbed Dose, Radiation—The mean energy imparted to the irradiated medium, per unit mass, by
ionizing radiation.  Units:  rad (rad), gray (Gy).
Absorbed Fraction—A term used in internal dosimetry.  It is that fraction of the photon energy (emitted
within a specified volume of material) which is absorbed by the volume.  The absorbed fraction depends
on the source distribution, the photon energy, and the size, shape and composition of the volume.
Absorption—The process by which a chemical penetrates the exchange boundaries of an organism after
contact, or the process by which radiation imparts some or all of its energy to any material through which
it passes.
Absorption Coefficient—Fractional absorption of the energy of an unscattered beam of x- or gamma-
radiation per unit thickness (linear absorption coefficient), per unit mass (mass absorption coefficient), or
per atom (atomic absorption coefficient) of absorber, due to transfer of energy to the absorber.  The total
absorption coefficient is the sum of individual energy absorption processes (see Compton Effect,
Photoelectric Effect, and Pair Production).
Absorption Coefficient, Linear—A factor expressing the fraction of a beam of x- or gamma radiation
absorbed in a unit thickness of material.  In the expression I=Ioe-µx, Io is the initial intensity, I the intensity
of the beam after passage through a thickness of the material x, and µ is the linear absorption coefficient.
Absorption Coefficient, Mass—The linear absorption coefficient per cm divided by the density of the
absorber in grams per cubic centimeter.  It is frequently expressed as µ/ρ, where µ is the linear absorption
coefficient and ρ the absorber density.
Absorption Ratio, Differential—Ratio of concentration of a nuclide in a given organ or tissue to the
concentration that would be obtained if the same administered quantity of this nuclide were uniformly
distributed throughout the body.
Activation—The process of making a material radioactive by bombardment with neutrons or protons.
Activity—The number of radioactive nuclear transformations occurring in a material per unit time (see
Curie, Becquerel).  The term for activity per unit mass is specific activity.
Activity Median Aerodynamic Diameter (AMAD)—The diameter of a unit-density sphere with the same
terminal settling velocity in air as that of the aerosol particle whose activity is the median for the entire size
distribution of the aerosol.
Acute Exposure, Chemical—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Acute Exposure, Radiation—The absorption of a relatively large amount of radiation (or intake of a
radioactive material) over a short period of time.
Acute Radiation Syndrome—The symptoms which taken together characterize a person suffering from the
effects of intense radiation.  The effects occur within hours or days.
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Ad libitum—Available in excess and freely accessible. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit surface area or per
unit weight of organic carbon of a specific particle size in the soil or sediment to the concentration of the
chemical in solution at equilibrium.
Adsorption Ratio (Kd)—See Distribution Coefficient
Alpha Particle—A positively charged particle ejected spontaneously from the nuclei of some radioactive
elements.  It is identical to a helium nucleus, i.e., 2 neutrons and two protons, with a mass number of 4 and
an electrostatic charge of +2.
Alpha Track—The track of ionized atoms (pattern of ionization) left in a medium by an alpha particle that
has traveled through the medium.
Annihilation (Positron-Electron)—An interaction between a positive and a negative electron in which they
both disappear; their rest mass, being converted into electromagnetic radiation (called annihilation
radiation) with two 0.51 MeV gamma photons emitted at an angle of 180E to each other.
Atom—The smallest particle of an element that cannot be divided or broken up by chemical means.  It
consists of a central core called the nucleus, which contains protons and neutrons and an outer shell of
electrons.
Atomic Mass (u)—The mass of a neutral atom of a nuclide, usually expressed in terms of "atomic mass
units."  The "atomic mass unit" is one-twelfth the mass of one neutral atom of carbon-12; equivalent to
1.6604x10-24 g.
Atomic Number—The number of protons in the nucleus of an atom.  The "effective atomic number" is
calculated from the composition and atomic numbers of a compound or mixture.  An element of this
atomic number would interact with photons in the same way as the compound or mixture.  (Symbol: Z).
Atomic Mass Number—See Mass Number.
Atomic Weight—The weighted mean of the masses of the neutral isotopes of an element expressed in
atomic mass units.
Attenuation—A process by which a beam from a source of radiation is reduced in intensity by absorption
and scattering when passing through some material.
Attenuation Coefficient—The fractional reduction in the intensity of a beam of radiation as it passes
through an absorbing medium.  It may be expressed as reduction per unit distance, per unit mass thickness,
or per atom, and is called the linear, mass, or atomic attenuation coefficient, respectively.
Auger Effect—The emission of an electron from the extranuclear portion of an excited atom when the
atom undergoes a transition to a less excited state.
Background Radiation—The amount of radiation to which a member of the general population is exposed
from natural sources, such as terrestrial radiation from naturally occurring radionuclides in the soil, cosmic
radiation originating from outer space, and naturally occurring radionuclides deposited in the human body. 
Becquerel (Bq)—International System of Units unit of activity and equals that quantity of radioactive
material in which one transformation (disintegration) occurs per second (see Units).
Beta Particle—An electron that is emitted from the nucleus of an atom during one type of radioactive
transformation.  A beta particle has a mass and charge equal in magnitude to that of the electron.  The
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charge may be either +1 or -1.  Beta particles with +1 charges are called positrons (symbolized β+), and
beta particles with -1 charges are called negatrons (symbolized β-).
Biological Half-time—The time required for a biological system, such as that of a human, to eliminate by
natural process half of the amount of a substance (such as a chemical substance, either stable or
radioactive) that has entered it.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms at a
specific time or during a discrete time period of exposure divided by the concentration in the surrounding
water at the same time or during the same period.
Biologic Effectiveness of Radiation—See Relative Biological Effectiveness.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples.  They have
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Body Burden, Chemical—The total amount of a chemical found in an animal or human body.
Body Burden, Radioactivity—The amount of radioactive material found in an animal or human body.
Bone Seeker—Any compound or ion which migrates in the body and preferentially deposits into bone.
Branching—The occurrence of two or more modes by which a radionuclide can undergo radioactive
decay.  For example, 214Bi can undergo alpha or beta minus decay, 64Cu can undergo beta minus, beta plus,
or electron capture decay.  An individual atom of a nuclide exhibiting branching disintegrates by one mode
only.  The fraction disintegrating by a particular mode is the "branching fraction" for that mode.  The
"branching ratio" is the ratio of two specified branching fractions (also called multiple disintegration).
Bremsstrahlung—X rays that are produced when a charged particle accelerates (speeds up, slows down, or
changes direction) in the strong field of a nucleus.
Buildup Factor—The ratio of the radiation intensity, including both primary and scattered radiation, to the
intensity of the primary (unscattered) radiation.
Cancer Effect Level (CEL)—The lowest dose of chemical or radiation in a study, or group of studies, that
produces significant increases in the incidence of cancer (or tumors) between the exposed population and
its appropriate control.
Capture, Electron—A mode of radioactive decay involving the capture of an orbital electron by its
nucleus.  Capture from a particular electron shell, e.g., K or L shells, is designated as "K-electron capture"
or "L-electron capture."
Capture, K-Electron—Electron capture from the K shell by the nucleus of the atom.  Also loosely used to
designate any orbital electron capture process.
Carcinogen—A chemical or radiation that is capable of inducing cancer.
Carcinoma—Malignant neoplasm composed of epithelial cells, regardless of their derivation.
Case-Control Study—A type of epidemiological study which examines the relationship between a
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research but are not actual research studies.
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Cataract—A clouding of the crystalline lens of the eye which obstructs the passage of light.
Ceiling Value—A concentration of a substance that should not be exceeded, even temporarily.
Charged Particle—A nuclear particle, atom, or molecule carrying a positive or negative charge.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed
group.
Collective dose—The sum of the individual doses received in a given period of time by a specified
population from exposure to a specified source of radiation.  Collective dose is expressed in units such as
man-rem and person-sievert.
Compton Effect—An attenuation process observed for x- or gamma radiation in which an incident photon
interacts with an orbital electron of an atom to produce a recoil electron and a scattered photon whose
energy is less than the incident photon.
Containment—The confinement of a chemical or radioactive substance in such a way that it is prevented
from being dispersed from its container or into the environment, or is released only at a specified rate.
Contamination—Deposition of a stable or radioactive substance in any place where it is not desired.
Cosmic Rays—High-energy particulate and electromagnetic radiations which originate outside the earth's
atmosphere.
Count (Radiation Measurements)—The external indication of a radiation-measuring device designed to
enumerate ionizing events.  It refers to a single detected event. The term “count rate” refers to the total
number registered in a given period of time.  The term is sometimes erroneously used to designate a
disintegration, ionizing event, or voltage pulse.
Counter, Gas-flow Proportional (GPC)—β-particles are detected by ionization of the counter gas which 
results in an electrical impulse at an anode wire. If a sufficient amount of radiostrontium  is present and the
ionization efficiency is calibrated, the quantity of radiostrontium can be determined.
Counter, Geiger-Mueller (GM counter)—Highly sensitive, gas-filled radiation-measuring device to detect
(count) individual photons or particulate radiation.
Counter, Scintillation—The combination of phosphor, photomultiplier tube, and associated circuits for
counting light emissions produced in the phosphors by ionizing radiation.  Scintillation counters generally
are more sensitive than GM counters for gamma radiation.
Counting, Cerenkov—Relatively energetic β-particles pass through a transparent medium of high
refractive index and a highly-directional, bluish-white light ("Cerenkov" light) is emitted.  This light is
detected using liquid scintillation counting equipment. 
Cross-sectional Study—A type of epidemiological study of a group or groups which examines the
relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Curie (Ci)—A unit of radioactivity.  One curie equals that quantity of radioactive material in which there
are 3.7x1010 nuclear transformations per second.  The activity of 1 gram of radium is approximately 1 Ci.
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Attocurie (aCi)—One-thousandth of a femtocurie (3.7x10-8 disintegrations per second).
Femtocurie (fCi)—One-billionth of a microcurie (3.7x10-5 disintegrations per second).
Megacurie (MCi)—One million curies (3.7x1016 disintegrations per sec).
Microcurie (µCi)—One-millionth of a curie (3.7x104 disintegrations per sec).
Millicurie (mCi)—One-thousandth of a curie (3.7x107 disintegrations per sec).
Nanocurie (nCi)—One-billionth of a curie (3.7x101 disintegrations per sec).
Picocurie (pCi)—One-millionth of a microcurie (3.7x10-2 disintegrations per second.
Daughter Products—See Progeny and Decay Product
Decay, Radioactive—Transformation of the nucleus of an unstable nuclide by spontaneous emission of
charged particles and/or photons (see Disintegration).
Decay Chain or Decay Series—A sequence of radioactive decays (transformations) beginning with one
nucleus.  The initial nucleus, the parent, decays into a daughter or progeny nucleus that differs from the
first by whatever particles were emitted during the decay.  If further decays take place, the subsequent
nuclei are also usually called daughters or progeny.  Sometimes, to distinguish the sequence, the daughter
of the first daughter is called the granddaughter, etc.
Decay Constant (λ)—The fraction of the number of atoms of a radioactive nuclide which decay in unit
time (see Disintegration Constant).
Decay Product, Daughter Product, Progeny—A new nuclide formed as a result of radioactive decay.  A
nuclide resulting from the radioactive transformation of a radionuclide, formed either directly or as the
result of successive transformations in a radioactive series.  A decay product (daughter product or progeny)
may be either radioactive or stable.
Delta Ray—Electron removed from an atom during the process of ionization (also called secondary
electron).  Delta rays cause a track of ionizations along their path.
Depleted uranium (DU)—Uranium having a percentage of 235U smaller than the 0.7% found in natural
uranium.  It is obtained as a by-product from 235U enrichment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical or radiation prior to conception (either parent), during prenatal development,
or postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any
point in the life span of the organism.
Disintegration Constant—Synonymous with decay constant.  The fraction of the number of atoms of a
radioactive material that decays per unit time (see Decay Constant.)
Disintegration, Nuclear—A spontaneous nuclear transformation (radioactivity) characterized by the
emission of energy and/or mass from the nucleus.  When large numbers of nuclei are involved, the process
is characterized by a definite half-life (see Transformation, Nuclear).
Distribution Coefficient (Kd)—Describes the distribution of a chemical between the solid and aqueous
phase at thermodynamic equilibrium, is given as follows:






where [C]s is the concentration of the chemical associated with the solid phase in units of (mg)/(kg solid),
and [C]w is the concentration of the chemical in the aqueous phase in units of (mg)/(L solution).  As the
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Dose—A general term denoting the quantity of a substance, radiation, or energy absorbed.  For special
purposes it must be appropriately qualified.  If unqualified, it refers to radiation absorbed dose.
Absorbed Dose—The energy imparted to matter by ionizing radiation per unit mass of irradiated
material at the place of interest.  The unit of absorbed dose is the rad.  One rad equals 100 ergs per
gram.  In SI units, the absorbed dose is the gray which is 1 J/kg (see Rad).
Cumulative Dose (Radiation)—The total dose resulting from repeated or continuous exposures to
radiation.
Dose Assessment—An estimate of the radiation dose to an individual or a population group usually
by means of predictive modeling techniques, sometimes supplemented by the results of
measurement.
Dose Equivalent (DE)—A quantity used in radiation safety practice to account for the relative
biological effectiveness of the several types of radiation.  It expresses all radiations on a common
scale for calculating the effective absorbed dose.  It is defined as the product of the absorbed dose in
rad and certain modifying factors.  (The unit of dose equivalent is the rem.  In SI units, the dose
equivalent is the sievert, which equals 100 rem.)
Dose, Radiation—The amount of energy imparted to matter by ionizing radiation per unit mass of
the matter, usually expressed as the unit rad, or in SI units, the gray.  100 rad'1 gray (Gy) (see
Absorbed Dose).
Maximum Permissible Dose Equivalent (MPD)—The greatest dose equivalent that a person or
specified part thereof shall be allowed to receive in a given period of time.
Median Lethal Dose (MLD)—Dose of radiation required to kill, within a specified period (usually
30 days), 50% of the individuals in a large group of animals or organisms.  Also called the LD50, or
LD50/30 if for 30 days..
Threshold Dose—The minimum absorbed dose that will produce a detectable degree of any given
effect.
Tissue Dose—Absorbed dose received by tissue in the region of interest, expressed in rad (see Dose,
Gray, and Rad).
Dose, Fractionation—A method of administering therapeutic radiation in which relatively small doses are
given daily or at longer intervals.
Dose, Protraction—A method of administering therapeutic radiation by delivering it continuously over a
relatively long period at a low dose rate.
Dose Rate—Absorbed dose delivered per unit time.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a toxicant
and the incidence of the adverse effects.
Dosimetry—Quantification of radiation doses to cells, tissues, organs, individuals or populations resulting
from specified exposures.
Early Effects (of radiation exposure)—Effects that appear within 60 days of an acute exposure.
Electron—A stable elementary particle having an electric charge equal to ±1.60210x10-19 C (Coulombs)
and a rest mass equal to 9.1091x10-31 kg.  A positron is a positively charged "electron" (see Positron).
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Electron Volt—A unit of energy equivalent to the energy gained by an electron in passing through a
potential difference of one volt.  Larger multiple units of the electron volt are frequently used:  keV for
thousand or kilo electron volts; MeV for million or mega electron volts (eV).  1 eV=1.6x10-12 erg.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to a
chemical; the distinguishing feature between the two terms is the stage of development during which the
insult occurred.  The terms, as used here, include malformations and variations, altered growth, and in
utero death.
Energy—Capacity for doing work.  "Potential energy" is the energy inherent in a mass because of its
spatial relation to other masses.  "Kinetic energy" is the energy possessed by a mass because of its motion
(SI unit: joules):
Binding Energy (Electron)—The amount of energy that must be expended to remove an electron
from an atom.
Binding Energy (Nuclear)—The energy represented by the difference in mass between the sum of
the component parts and the actual mass of the nucleus.  It represents the amount of energy that must
be expended to break a nucleus into its component neutrons and protons.
Excitation Energy—The energy required to change a system from its ground state to an excited state. 
Each different excited state has a different excitation energy.
Ionizing Energy—The energy required to knock an electron out of an atom.  The average energy lost
by electrons or beta particles in producing an ion pair in air or in soft tissue is about 34 eV.
Radiant Energy—The energy of electromagnetic radiation, such as radio waves, visible light, x and
gamma rays.
Enriched Material—Material in which the relative amount of one or more isotopes of a constituent has
been increased.
Enriched Uranium—Uranium in which the abundance of the 235U isotope is increased above normal.
Enrichment, Isotopic—An isotopic separation process by which the relative abundances of the isotopes of
a given element are altered, thus producing a form of the element that has been enriched in one or more
isotopes and depleted in others.  In uranium enrichment, the percentage of uranium-235 in natural uranium
can be increased from 0.7% to >90% in a gaseous diffusion process based on the different thermal
velocities of the constituents of natural uranium (234U, 235U, 238U) in the molecular form UF6.  
EPA Health Advisory—An estimate of acceptable drinking water levels for a chemical substance based on
health effects information.  A health advisory is not a legally enforceable federal standard, but serves as
technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Equilibrium, Radioactive—In a radioactive series, the state which prevails when the ratios between the
activities of two or more successive members of the series remains constant.
Secular Equilibrium—If a parent element has a very much longer half-life than the daughters (so
there is not appreciable change in its amount in the time interval required for later products to attain
equilibrium) then, after equilibrium is reached, equal numbers of atoms of all members of the series
disintegrate in unit time.  This condition is never exactly attained, but is essentially established in
such a case as 226Ra and its transformation series to stable 206Pb.  The half-life of 226Ra is about 1,600
years; of 222Rn, approximately 3.82 days, and of each of the subsequent members, a few minutes. 
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After about a month, essentially the equilibrium amount of radon is present; then (and for a long
time) all members of the series disintegrate the same number of atoms per unit time.  At this time, the
activity of the daughter is equal to the activity of the parent.
Transient Equilibrium—If the half-life of the parent is short enough so the quantity present
decreases appreciably during the period under consideration, but is still longer than that of
successive members of the series, a stage of equilibrium will be reached after which all members of
the series decrease in activity exponentially with the period of the parent.  At this time, the ratio of
the parent activity to the daughter activity is constant.
Equilibrium, Electron—The condition in a radiation field where the energy of the electrons entering a
volume equals the energy of the  electrons leaving that volume.
Equilibrium Fraction (F)—In radon-radon daughter equilibrium, the parents and daughters have equal
radioactivity, that is, as many decay into a specific nuclide as decay out.  However, if fresh radon is
continually entering a volume of air or if daughters are lost by processes other than radioactive decay, e.g.,
plate out or migration out of the volume, a disequilibrium develops.  The equilibrium fraction is a measure
of the degree of equilibrium/disequilibrium.  The equilibrium fraction is used to estimate working levels
based on measurement of radon only.  For radon, 1 working-level concentration is defined at 100 pCi of
radon in equilibrium with its 4 successive progeny in 1 liter of air.  Thus, 100 pCi/L radon at 50%
equilibrium is 0.5 WL.
Excitation—The addition of energy to a system, thereby transferring it from its ground state to an excited
state.  Excitation of a nucleus, an atom, or a molecule can result from absorption of photons or from
inelastic collisions with other particles.  The excited state of an atom is an unstable or metastable state and
will return to ground state by radiation of the excess energy.
Exposure (Chemical)—Contact of an organism with a chemical or physical agent.  Exposure is quantified
as the amount of the agent available at the exchange boundaries of the organism (e.g., skin, lungs, gut) and
available for absorption.
Exposure (Radiation)—Being exposed to ionizing radiation or to a radioactive material.  A measure of the
ionization produced in air by x or gamma radiation; the sum of the electric charges on all ions of one sign
produced in air when all electrons liberated by photons in a volume of air are completely stopped in air
(dQ), divided by the mass of the air in the volume (dm). The unit of exposure in air is the roentgen, or
coulomb per kilogram (SI units). One roentgen is equal to 2.58x10-4 coulomb per kilogram (C/kg).
Fission, Nuclear—A nuclear transformation characterized by the splitting of a nucleus into at least two
other nuclei and several neutrons, and is accompanied by the release of a relatively large amount of
energy.
Gamma Ray, Penetrating—Short wavelength electromagnetic radiation of nuclear origin.
Genetic Effect of Radiation—Inheritable change, chiefly mutations, produced by the absorption of
ionizing radiation by germ cells.  Genetic effects have not been observed in any human population exposed
at any dose level.
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic or carcinogenic event because of specific
alteration of the molecular structure of the genome.
Gray (Gy)—SI unit of absorbed dose, 1 J/kg.  One gray equals 100 rad (see Units).
Half-life, Radioactive—Time required for a radioactive substance to lose 50% of its activity by decay. 
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Effective Half&time ' Biological half&time x Radioactive half&life
Biological half&time % Radioactive half&life
Half-life, Effective—See Half-Time, Effective.
Half-time, Biological—Time required for an organ, tissue, or the whole body to eliminate one-half of any
absorbed substance by regular processes of elimination.  This is the same for both stable and radioactive
isotopes of a particular element, and is sometimes referred to as half-time, symbolized as tbiol or Tb.
Half-time, Effective—Time required for a radioactive element in an organ, tissue, or the whole body to be
diminished 50% as a result of the combined action of radioactive decay and biological elimination,
symbolized as Te or Teff.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.
Immunological Effects—Functional changes in the immune response.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.  Literally, “in
glass.”
In Vivo—Occurring within the living organism.  Literally, “in life.”
Intensity—Amount of energy per unit time passing through a unit area perpendicular to the line of
propagation at the point in question.
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the
Toxicological Profiles.
Internal Conversion—Process in which a gamma ray knocks an electron out of the same atom from which
the gamma ray was emitted.  The ratio of the number of internal conversion electrons to the number of
gamma quanta emitted in the de-excitation of the nucleus is called the "conversion ratio."
Ion—Atomic particle, atom or chemical radical bearing a net electrical charge, either negative or positive.
Ion Pair—Two particles of opposite charge, usually referring to the electron and positive atomic or
molecular residue resulting after the interaction of ionizing radiation with the orbital electrons of atoms.
Ionization—The process by which a neutral atom or molecule acquires a positive or negative charge.
Primary Ionization—(1) In collision theory:  the ionization produced by the primary particles as
contrasted to the "total ionization" which includes the "secondary ionization" produced by delta
rays.  (2) In counter tubes:  the total ionization produced by incident radiation without gas
amplification.
Specific Ionization—Number of ion pairs per unit length of path of ionizing radiation in a
medium; e.g., per centimeter of air or per micrometer of tissue.
Total Ionization—The total electric charge of one sign on the ions produced by radiation in the
process of losing its kinetic energy.  For a given gas, the total ionization is closely proportional to
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the initial ionization and is nearly independent of the nature of the ionizing radiation.  It is
frequently used as a measure of absorption of radiation energy.
Ionization Density—Number of ion pairs per unit volume.
Ionization Path (Track)—The trail of ion pairs produced by an ionizing particle in its passage through
matter.
Ionizing Radiation—Any radiation capable of knocking electrons out of atoms and producing ions. 
Examples: alpha, beta, gamma and x rays, and neutrons.
Isobars—Nuclides having the same mass number but different atomic numbers.
Isomers—Nuclides having the same number of neutrons and protons but capable of existing, for a
measurable time, in different quantum states with different energies and radioactive properties.  Commonly
the isomer of higher energy decays to one with lower energy by the process of isomeric transition.
Isotopes—Nuclides having the same number of protons in their nuclei, and hence the same atomic number,
but differing in the number of neutrons, and therefore in the mass number.  Identical chemical properties
exist in isotopes of a particular element.  The term should not be used as a synonym for nuclide because
isotopes refer specifically to different nuclei of the same element.
Stable Isotope—A nonradioactive isotope of an element.
Kerma (k)—A measure of the kinetic energy transferred from gamma rays or neutrons to a unit mass of
absorbing medium in the initial collision between the radiation and the absorber atoms.  The SI unit is J/kg. 
The special name of this unit is the rad (traditional system of units) or Gray (SI).
Joule—The S.I. unit for work and energy.  It is equal to the work done by raising a mass of one newton
through a distance of one meter (J = Nm), which corresponds to about 0.7 ft-pound.
Labeled Compound—A compound containing one or more radioactive atoms intentionally added to its
structure.  By observations of radioactivity or isotopic composition, this compound or its fragments may be
followed through physical, chemical, or biological processes.
Late Effects (of radiation exposure)—Effects which appear 60 days or more following an acute exposure.
LD50/30—The dose of a chemical or radiation expected to cause 50% mortality in those exposed within
30 days. For radiation, this is about 350 rad (3.5 gray) received by humans over a short period of time.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported to
have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for a
specific length of time is expected to cause death in 50% of a defined experimental animal population
within a specified time, usually 30 days.
Lethal Dose(L0) (LDL0)—The lowest dose of a chemical introduced by a route other than inhalation that is
expected to have caused death in humans or animals within a specified time, usually 30 days.
Lethal Dose(50) (LD50)—The dose of a chemical which has been calculated to cause death in 50% of a
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical is
expected to cause death in 50% of a defined experimental animal population.
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Linear Energy Transfer (LET)—A measure of the energy that a charged particle transfers to a material per
unit path length. 
Low-LET—Energy transfer characteristic of light charged particles such as electrons produced
by x and gamma rays where the distance between ionizing events is large on the scale of a
cellular nucleus.
High-LET—Energy transfer characteristic of heavy charged particles such as protons and alpha
particles where the distance between ionizing events is small on the scale of a cellular nucleus.
Average LET—The energy of a charged particle divided by the length of the path over which it
deposits all its energy in a material.  
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest dose of chemical in a study, or group of
studies, that produces statistically or biologically significant increases in frequency or severity of adverse
effects between the exposed population and its appropriate control.
Lung Clearance Class (fast, F; medium, M; slow, S)—A classification scheme for inhaled material
according to its rate of clearance from the pulmonary region of the lungs to the blood and the
gastrointestinal tract.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the lymph
nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Mass Numbers (A)—The number of nucleons (protons and neutrons) in the nucleus of an atom.
Minimal Risk Level—An estimate of daily human exposure to a substance that is likely to be without an
appreciable risk of adverse noncancerous effects over a specified duration of exposure.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific
population.
Mutagen—A substance that causes changes (mutations) in the genetic material in a cell.  Mutations can
lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a
substance.
Neutrino (ν)—A neutral particle of infinitesimally small rest mass emitted during beta plus or beta minus
decay.  This particle accounts for conservation of energy in beta plus and beta minus decays.  It plays no
role in damage from radiation.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a substance at which there were no
statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Nuclear reactor—A power plant that heats water by using nuclear reactions instead of burning coal, oil, or
natural gas.  All of these sources of energy simply heat water and use the steam which is produced to turn
turbines that make electricity or propel a ship.
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Nucleon—Common name for a constituent particle of the nucleus.  Applied to a proton or neutron.
Nuclide—A species of atom characterized by the constitution of its nucleus.  The nuclear constitution is
specified by the number of protons (Z), number of neutrons (N), and energy content; or, alternatively, by
the atomic number (Z), mass number A'(N+Z), and atomic mass.  To be regarded as a distinct nuclide, the
atom must be capable of existing for a measurable time.  Thus, nuclear isomers are separate nuclides,
whereas promptly decaying excited nuclear states and unstable intermediates in nuclear reactions are not
so considered.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical in
n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances
and a disease or condition) which represents the best estimate of relative risk (risk as a ratio of the
incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who
were not exposed to the risk factor).  An odds ratio of greater than 1 is considered to indicate greater risk
of disease in the exposed group compared to the unexposed.
Pair Production—An absorption process for x- and gamma radiation in which the incident photon is
absorbed in the vicinity of the nucleus of the absorbing atom, with subsequent production of an electron
and positron pair (see annihilation).  This reaction can only occur for incident photon energies exceeding
1.02 MeV.
Parent—A radionuclide which, upon disintegration, yields a new nuclide, either directly or as a later
member of a radioactive series.
Permissible Exposure Limit (PEL)—A maximum allowable atmospheric level of a substance in workplace
air averaged over an 8-hour shift.
Pharmacokinetics—The science of quantitatively predicting the fate (disposition) of an exogenous
substance in an organism. Utilizing computational techniques, it provides the means of studying the
absorption, distribution, metabolism and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models: data-based
and physiologically-based.  A data-based model divides the animal system into a series of compartments
which, in general, do not represent real, identifiable anatomic regions of the body whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically-based dose-response
model which quantitatively describes the relationship between target tissue dose and toxic end points. 
These models advance the importance of physiologically based models in that they clearly describe the
biological effect (response) produced by the system following exposure to an exogenous substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—A model comprising a series of compartments
representing organs or tissue groups with realistic weights and blood flows.  These models require a
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates and, possibly membrane permeabilities.  The models also utilize biochemical information
such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also called
biologically based tissue dosimetry models.
Photon—A quantum of electromagnetic energy (E) whose value is the product of its frequency (ν) in hertz
and Planck's constant (h).  The equation is:  E = hν.
IODINE 427
10.  GLOSSARY
***DRAFT FOR PUBLIC COMMENT***
Photoelectric Effect—An attenuation process observed for x and gamma radiation in which an incident
photon interacts with a tightly bound inner orbital electron of an atom delivering all of its energy to knock
the electron out of the atom.  The incident photon disappears in the process.
Positron—A positively charged electron.
Potential, Ionization—The energy expressed as electron volts (eV) necessary to separate one electron from
an atom, resulting in the formation of an ion pair.
Power, Stopping—A measure of the ability of a material to absorb energy from an ionizing particle
passing through it; the greater the stopping power, the greater the energy absorbing ability (see Linear
Energy Transfer).
Progeny—The decay product or products resulting after a radioactive decay or a series of radioactive
decays.  The progeny can also be radioactive, and the chain continues until a stable nuclide is formed.
Proton—Elementary nuclear particle with a positive electric charge equal numerically to the charge of the
electron and a rest mass of 1.007 mass units.
Quality—A term describing the distribution of the energy deposited by a particle along its track; radiations
that produce different densities of ionization per unit intensity are said to have different "qualities."
Quality Factor (Q)—The linear-energy-transfer-dependent factor by which absorbed doses are multiplied
to obtain (for radiation protection purposes) a quantity that expresses - on a common scale for all ionizing
radiation - the approximate biological effectiveness of the absorbed dose.
Rad—The unit of absorbed dose equal to 100 ergs per gram, or 0.01 joule per kilogram (0.01 Gy)  in any
medium (see Absorbed Dose).
Radiation—The emission and propagation of energy through space or through a material medium in the
form of waves (e.g., the emission and propagation of electromagnetic waves, or of sound and elastic
waves).  The term radiation or radiant energy, when unqualified, usually refers to electromagnetic
radiation.  Such radiation commonly is classified according to frequency, as microwaves, infrared, visible
(light), ultraviolet, and x and gamma rays (see Photon.) and, by extension, corpuscular emission, such as
alpha and beta radiation, neutrons, or rays of mixed or unknown type, as cosmic radiation.
Radiation, Annihilation—Photons produced when an electron and a positron unite and cease to exist.  The
annihilation of a positron-electron pair results in the production of two photons, each of 0.51 MeV energy.
Radiation, Background—See Background Radiation.
Radiation, Characteristic (Discrete)—Radiation originating from an excited atom after removal of an
electron from an atom.  The wavelength of the emitted radiation is specific, depending only on the element
and particular energy levels involved.
Radiation, External—Radiation from a source outside the body.
Radiation, Internal—Radiation from a source within the body (as a result of deposition of radionuclides in
body tissues).
Radiation, Ionizing—Any electromagnetic or particulate radiation capable of producing ions, directly or
indirectly, in its passage through matter (see Radiation).
Radiation, Monoenergetic—Radiation of a given type in which all particles or photons originate with and
have the same energy.
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Radiation, Scattered—Radiation which during its passage through a substance, has been deviated in
direction.  It may also have been modified by a decrease in energy.
Radiation, Secondary—A particle or ray that is produced when the primary radiation interacts with a
material, and which has sufficient energy to produce its own ionization, such as bremsstrahlung or
electrons knocked from atomic orbitals with enough energy to then produce ionization (see Delta Rays).
Radioactive Material—Material containing radioactive atoms.
Radioactivity—Spontaneous nuclear transformations that result in the formation of new elements.  These
transformations are accomplished by emission of alpha or beta particles from the nucleus or by the capture
of an orbital electron.  Each of these reactions may or may not be accompanied by a gamma photon.
Radioactivity, Artificial—Man-made radioactivity produced by particle bombardment or nuclear fission,
as opposed to naturally occurring radioactivity.
Radioactivity, Induced—Radioactivity produced in a substance after bombardment with neutrons or other
particles.  The resulting activity is "natural radioactivity" if formed by nuclear reactions occurring in nature
and "artificial radioactivity" if the reactions are caused by man.
Radioactivity, Natural—The property of radioactivity exhibited by more than 50 naturally occurring
radionuclides.
Radioisotope—An unstable or radioactive isotope of an element that decays or disintegrates
spontaneously, emitting radiation.  Approximately 5,000 natural and artificial radioisotopes have been
identified.
Radionuclide—Any radioactive isotope of any element.
Radiosensitivity—Relative susceptibility of cells, tissues, organs, organisms, or any living substance to the
injurious action of radiation.  Radiosensitivity and its antonym, radioresistance, are currently used in a
comparative sense, rather than in an absolute one.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the NOAEL (from animal and human
studies) by a consistent application of uncertainty factors that reflect various types of data used to estimate
RfDs and an additional modifying factor, which is based on a professional judgment of the entire database
on the chemical.  The RfDs are not applicable to non-threshold effects such as cancer.
Relative Biological Effectiveness (RBE)—The RBE is a factor used to compare the biological
effectiveness of absorbed radiation doses (i.e., rad) due to different types of ionizing radiation.  More
specifically, it is the experimentally determined ratio of an absorbed dose of a radiation in question to the
absorbed dose of a reference radiation (typically 60Co gamma rays or 200 keV x rays) required to produce
an identical biological effect in a particular experimental organism or tissue (see Quality Factor).
Rem—A unit of dose equivalent that is used in the regulatory, administrative, and engineering design
aspects of radiation safety practice.  The dose equivalent in rem is numerically equal to the absorbed dose
in rad multiplied by the quality factor (1 rem is equal to 0.01 sievert).
Rep—Roentgen equivalent, physical: A former unit of ionizing radiation equivalent to the dosage of
93 ergs absorbed per gram of tissue (93 erg/gm=0.93 rad).
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
CERCLA.  Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount
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established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act.  Quantities are
measured over a 24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior,
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of this
system.
Roentgen (R)—A unit of exposure (in air) to ionizing radiation.  It is the amount of x or gamma rays
required to produce ions carrying 1 electrostatic unit of electrical charge in 1 cubic centimeter of dry air
under standard conditions.  Named after William Roentgen, a German scientist who discovered x rays in
1895.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed at
some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
Self-Absorption—Absorption of radiation (emitted by radioactive atoms) by the material in which the
atoms are located; in particular, the absorption of radiation within a sample being assayed.
Short-Term Exposure Limit (STEL)—The maximum concentration to which workers can be exposed for
up to 15 min continually.  No more than four excursions are allowed per day, and there must be at least
60 min between exposure periods.  The daily TLV-TWA may not be exceeded.
SI Units—The International System of Units as defined by the General Conference of Weights and
Measures in 1960.  These units are generally based on the meter/kilogram/second units, with special
quantities for radiation including the becquerel, gray, and sievert.
Sickness, Acute Radiation (Syndrome)—The complex symptoms and signs characterizing the condition
resulting from excessive exposure of the whole body (or large part) to ionizing radiation.  The earliest of
these symptoms are nausea, fatigue, vomiting, and diarrhea, and may be followed by loss of hair
(epilation), hemorrhage, inflammation of the mouth and throat, and general loss of energy.  In severe cases,
where the radiation dose is relatively high (over several hundred rad or several gray), death may occur
within two to four weeks.  Those who survive six weeks after exposure of a single high dose of radiation
may generally be expected to recover.
Sievert (Sv)—The SI unit of any of the quantities expressed as dose equivalent.  The dose equivalent in
sieverts is equal to the absorbed dose, in gray, multiplied by the quality factor (1 sievert equals 100 rem). 
Specific-activity—Radioactivity per unit mass of material containing a radionuclide, expressed, for
example, as Ci/gram or Bq/gram.
Specific Energy—The actual energy per unit mass deposited per unit volume in a small target, such as the
cell or cell nucleus, as the result of one or more energy-depositing events.  This is a stochastic quantity as
opposed to the average value over a large number of instance (i.e., the absorbed dose).
Standard Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected number of
deaths in a specific standard population.
Stopping Power—The average rate of energy loss of a charged particle per unit thickness of a material or
per unit mass of material traversed.
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Surface-seeking Radionuclide—A bone-seeking internal emitter that is deposited and remains on the bone
surface for a long period of time, although it may eventually diffuse into the bone mineral.  This contrasts
with a volume seeker, which deposits more uniformly throughout the bone volume.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited
exposure to those assumed over a lifetime of exposure to a chemical.
Target Theory (Hit Theory)—A theory explaining some biological effects of radiation on the basis that
ionization, occurring in a discrete volume (the target) within the cell, directly causes a lesion which
subsequently results in a physiological response to the damage at that location.  One, two, or more "hits"
(ionizing events within the target) may be necessary to elicit the response.
Teratogen—A chemical that causes birth defects.
Threshold Limit Value (TLV)—The maximum concentration of a substance to which most workers can be
exposed without adverse effect.  TLV is a term used exclusively by the ACGIH.  Other terms used to
express the same concept are the MAC (Maximum Allowable Concentration) and PEL (Permissible
Exposure Limits).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek.
Toxic Dose (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, which is
expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The study of the absorption, distribution and elimination of toxic compounds in the living
organism.
Toxicosis—A diseased condition resulting from poisoning.
Transformation, Nuclear—The process by which a nuclide is transformed into a different nuclide by
absorbing or emitting particulate or electromagnetic radiation.
Transition, Isomeric—The process by which a nuclide decays to an isomeric nuclide (i.e., one of the same
mass number and atomic number) of lower quantum energy.  Isomeric transitions (often abbreviated I.T.)
proceed by gamma ray and/or internal conversion electron emission.
Tritium—The hydrogen isotope with one proton and two neutrons in the nucleus (Symbol: 3H).  It is
radioactive and has a physical half-life of 12.3 years.
Unattached Fraction—That fraction of the radon daughters, usually 218Po and 214Po, which has not yet
attached to a dust particle or to water vapor.  As a free atom, it has a high probability of being exhaled and
not retained within the lung.  It is the attached fraction which is primarily retained.
Uncertainty Factor (UF)—A factor used in operationally deriving the RfD from experimental data.  UFs
are intended to account for (1) the variation in sensitivity among the members of the human population, (2)
the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using LOAEL data
rather than NOAEL data.  Usually each of these factors is set equal to 10.
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Units, Radiological—
Units Equivalents
Becquerel* (Bq) 1 disintegration per second = 2.7x10-11 Ci
Curie (Ci) 3.7x1010 disintegrations per second = 3.7x1010 Bq
Gray* (Gy) 1 J/kg = 100 rad
Rad (rad) 100 erg/g = 0.01 Gy
Rem (rem) 0.01 sievert
Sievert* (Sv) 100 rem
*International Units, designated (SI)
Working Level (WL)—Any combination of short-lived radon daughters in 1 liter of air that will result in
the ultimate emission of 1.3x105 MeV of potential alpha energy.
Working Level Month (WLM)—A unit of exposure to radon daughters corresponding to the product of
the radon daughter concentration in Working Level (WL) and the exposure time in nominal months
(1 nominal month = 170 hours).  Inhalation of air with a concentration of 1 WL of radon daughters for 170
working hours results in an exposure of 1 WLM.
X rays—Penetrating electromagnetic radiations whose wave lengths are very much shorter than those of
visible light.  They are usually produced by bombarding a metallic target with fast electrons in a high
vacuum.  X rays (called characteristic x rays) are also produced when an orbital electron falls from a high
energy level to a low energy level.
Zero-Threshold Linear Hypothesis—The assumption that a dose-response curve derived from data in the
high dose and high dose-rate ranges may be extrapolated through the low dose and low dose range to zero,
implying that, theoretically, any amount of radiation will cause some damage.

IODINE A-1
***DRAFT FOR PUBLIC COMMENT***
APPENDIX A
ATSDR MINIMAL RISK LEVEL AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C.
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L.
99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly
with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances
most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological
profiles for each substance included on the priority list of hazardous substances; and assure the initiation of
a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given
route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance that is
likely to be without appreciable risk of adverse noncancer health effects over a specified duration of
exposure.  MRLs are based on noncancer health effects only and are not based on a consideration of cancer
effects.  These substance-specific estimates, which are intended to serve as screening levels, are used by
ATSDR health assessors to identify contaminants and potential health effects that may be of concern at
hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or action
levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach.  They are below levels that might cause adverse health effects in the people most sensitive to
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently,
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level above
the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
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elderly, nutritionally or immunologically  compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons
may be particularly sensitive.  Thus, the resulting MRL may be as much as a hundredfold below levels that
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology, expert panel peer reviews, and agencywide MRL Workgroup reviews, with
participation from other federal agencies and comments from the public.  They are subject to change as
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in
the most recent toxicological profiles supersede previously published levels.  For additional information
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease
Registry, 1600 Clifton Road, Mailstop E-29, Atlanta, Georgia 30333.
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MINIMAL RISK LEVEL WORKSHEET
Chemical Name: Iodine (sodium iodide, potassium iodide)
CAS Number: 7553-56-2 (7681-82-5, 7681-11-0)
Date: July 20, 2001
Profile Status: Draft 3 Pre Public
Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute   [ ] Intermediate   [ ] Chronic
Graph Key: 6
Species: Human
Minimal Risk Level: 0.01  [X] mg/kg/day   [ ] ppm
The administered doses of iodide (as sodium iodide) were 250, 500, or 1,500 µg I/day for 14 days (Paul et
al. 1988); or 500, 1,500, or 4,500 µg I/day (Gardner et al. 1988).  The pre-existing dietary iodide intakes
were estimated from the reported 24-hour urinary iodide excretion rate, which was 200 µg/day (Paul et al.
1988) or 300 µg I/day (Gardner et al. 1988).  The total intake of iodide was estimated as the sum of the
administered iodide and the estimated dietary intake: 450, 700, or 1,700 µg/day (Paul et al. 1988); or 300,
800, 1,800, or 4,800 µg/day (Gardner et al. 1988).  The estimated dosages on a per kg body weight (70 kg)
were: 0.0064, 0.010, or 0.024 mg/kg/day (Paul et al. 1988); or 0.011, 0.026, or 0.069 mg/kg/day (Gardner
et al. 1988).
In protecting public health ATSDR recommends using the conservative lower end of this calculated
NOAEL range, 0.01 mg/kg/day, to derive an acute-duration MRL of 0.01 mg/kg/day. 
Reference:  Gardner DF, Centor RM, Utiger RD.  1988.  Effects of low dose oral iodide supplementation
on thyroid function in normal men.  Clin Endocrinol 28:283-288; Paul T, Meyers B, Witorsch RJ, et al. 
1988.  The effect of small increases in dietary iodine on thyroid function in euthyroid subjects. 
Metabolism 37(2):121-124.
Experimental design:  Healthy euthyroid adults (9 males, 9 females) who had no history of thyroid disease
or detectable antithyroid antibodies received daily oral doses of 250, 500, or 1,500 µg I/day as sodium
iodide for 14 days (Paul et al. 1988).  Based on 24-hour urinary excretion of iodide prior to the iodide
supplement, the background iodine intake was estimated to be approximately 200 µg/day; thus, the total
iodide intake was approximately 450, 700, or 1,700 µg I/day (approximately 0.0064, 0.01, or
0.024 mg/kg/day, assuming a 70-kg body weight). 
Ten healthy, euthyroid, adult males received daily oral doses of 500, 1,500, or 4,500 µg I/day (as sodium
iodide) for 14 days (Gardner et al. 1988).  Based on 24-hour urinary excretion of iodide prior to the iodide
supplement of 250–320 µg/day, the total estimated intakes were 800, 1,800, or 4,800 µg/day or
approximately 0.011, 0.026, or 0.069 mg/kg/day.
Effects noted in study and corresponding doses:  In the Paul et al. (1988) study, subjects who received
1,700 µg/day (0.024 mg/kg/day) had significantly depressed (5–10%) serum concentrations of TT4, FT4,
and TT3 compared to pretreatment levels, and serum TSH concentrations were significantly elevated (47%)
compared to pretreatment values.  Hormone levels were within the normal range during treatment.  In this
same study, nine females received daily doses of 250 or 500 µg I/day for 14 days (total intake was
approximately 450 or 700 µg/day [0.0064 or 0.010 mg/kg/day]) and there were no significant changes in
serum hormone concentrations. 
In the Gardner et al. (1988) study, there were no effects on serum thyroid hormone or TSH concentrations
at the 800 µg/day intake (0.011 mg/kg/day); however, intakes of 1,800 or 4,800 µg I/day (0.026 or
0.064 mg/kg/day) produced small (10%), but significant, transient decreases in serum TT4 and FT4
concentrations and an increase (48%) in serum TSH concentration, relative to the pretreatment values. 
Dose and end point used for MRL derivation:  0.01 mg/kg/day; reversible subclinical hypothyroidism.
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[X] NOAEL   [ ] LOAEL
Uncertainty Factors used in MRL derivation:
[ ]  10 for use of a LOAEL
[ ]  10 for extrapolation from animals to humans
[ ]  10 for human variability
Although the acute NOAEL is derived from acute studies of healthy adults, supporting studies indicate that
the NOAEL would be applicable to children and elderly adults (Boyages et al. 1989; Chow et al. 1991). 
On this basis, an uncertainty factor is not needed to adjust the NOAEL to account for human variability in
sensitivity.  In the Chow et al. (1991) study, 30 healthy elderly adult females, without evidence of thyroid
peroxidase antibodies (TPA), received daily doses of 500 µg I/day (as potassium iodide) for 14 or 28 days. 
Serum concentrations of FT4 were significantly decreased and serum TSH concentrations were
significantly elevated in the women who received the iodide supplements, relative to a placebo control
group.  On average, the magnitude of the changes did not produce clinically significant depression in
thyroid hormone levels; however, five subjects had serum TSH concentrations that exceeded 5 mU/L.  The
subjects had a lower dietary iodine intake than those in the Gardner et al. (1988) study; approximately
72–100 µg/day, based on urinary iodide measurements.  Therefore, the total iodide intake was
approximately 600 µg/day (0.0086 mg/kg/day). 
In the Boyages et al. (1989) study, thyroid status was compared in groups of children, ages 7–15 years,
who resided in two areas of China where drinking water iodide concentrations were either 462 µg/L
(n=120) or 54 µg/L (n=51) (Boyages et al. 1989; Li et al. 1987).  Although the subjects were all euthyroid
with normal values for serum thyroid hormones and TSH concentrations, TSH concentrations were
significantly higher in the high iodine group.  The high iodide group had a 65% prevalence of goiter and a
15% prevalence of Grade 2 goiter compared to 15% for goiter and 0% for Grade 2 goiter in the low iodine
group.  Urinary iodine was 1,236 µg I/g creatinine in the high iodine group and 428 µg I/g creatinine in the
low iodine group.  Assuming a body weight of 40 kg and lean body mass of 85% of body weight, the
above urinary iodine/creatinine ratios are approximately equivalent to iodine excretion rates, or steady-
state ingestion rates of 1,150 µg/day (0.029 mg/kg/day) and 400 µg/day (0.01 mg/kg/day) in the high and
low iodide groups, respectively. 
The MRL is higher than the National Research Council Recommended Dietary Allowance of 150 µg/day
(0.0021 mg/kg/day for a 70-kg adult), with additional allowances of 25 µg/day (0.0025 mg/kg/day) and
50 µg/day (0.0029 mg/kg/day) during pregnancy and lactation, respectively (NRC 1989).   
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No; however, urinary
iodide levels were converted to estimates of iodine intakes.  Steady-state baseline dietary intakes of iodide
were assumed to be equivalent to the reported 24-hour urinary iodine excretion rates.  This assumption is
consistent with information available on the toxicokinetics of iodide that indicates nearly complete
absorption of ingested iodide and that urinary excretion accounts for >97% of the absorbed dose (see
Sections 3.4.1.2 and 3.4.4.2).  The assumption is also supported by studies in which 24-hour urinary iodide
was measured before and after supplementation (Kahaly et al. 1998; Konno et al. 1993b).  For example,
31 patients received oral supplements of 382 µg I/day for 6 months.  Prior to the supplementation, the
mean 24-hour urinary iodide excretion rate was 36 µg/day (range, 13–69 ), whereas, after 6 months of
iodide supplementation, the mean 24-hour urinary iodide excretion rate was 415 µg/day (Kahaly et al.
1998).  The difference between these two values, 379 µg/day, is nearly identical to the supplemental dose
of 382 µg/day.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  NA
Was a conversion used from intermittent to continuous exposure?  No.
Other additional studies or pertinent information that lend support to this MRL:  Two other acute studies
reported NOAELs and LOAELs of 0.3 and 1.0 mg/kg/day, respectively (Robison et al. 1998, 1999), which
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are substantially higher than those from the Paul et al. (1988) and Gardner et al. (1988) studies.  These
suggest that doses much higher than the MRL can be tolerated in some people without producing thyroid
gland suppression. 
Agency Contact (Chemical Manager):  John Risher, Ph.D.
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MINIMAL RISK LEVEL WORKSHEET
Chemical Name: Iodine (sodium iodide, potassium iodide)
CAS Number: 7553-56-2 (7681-82-5, 7681-11-0)
Date: July 20, 2001
Profile Status: Draft 3 Pre Public
Route: [ ] Inhalation   [X] Oral
Duration: [  ] Acute   [ ] Intermediate   [X] Chronic
Graph Key: 29
Species: Human
Minimal Risk Level: 0.01  [X] mg/kg/day   [ ] ppm
Iodine intakes estimated from urinary iodine levels (see below) were 400 and 1,150 µg/day.  These
correspond to 0.010 or 0.029 mg/kg/day for a 40-kg child of age 11 years.
Reference:  Boyages SC, Bloot AM, Maberly GF, et al.  1989.  Thyroid autoimmunity in endemic goitre
caused by excessive iodine intake.  Clin Endocrinol 31:452-465; Li W, Qu C, Jia G, et al.  1987.  Endemic
goitre in Central China caused by excessive iodine intake.  Lancet, August 1:257-258.
Experimental design:  Thyroid status was compared in groups of children, ages 7–15 years, who resided in
two areas of China where drinking water iodide concentrations were either 462 µg/L (n=120) or 54 µg/L
(N=51) (Boyages et al. 1989; Li et al. 1987).  Urinary iodine was 1,236 µg I/g creatinine in the high iodine
group and 428 µg I/g creatinine in the low iodine group.  Assuming a body weight of 40 kg and lean body
mass of 85% of body weight, the above urinary iodine/creatinine ratios are approximately equivalent to
iodine excretion rates, or steady state ingestion rates of 1,150 (29 µg/kg/day) and 400 µg/day
(10 µg/kg/day) in the high and low iodide groups, respectively. 
Effects noted in study and corresponding doses:  Although the subjects were all euthyroid with normal
values for serum thyroid hormones and TSH concentrations, TSH concentrations were significantly higher
(33%) in the high iodine group.  The high iodide group had a 65% prevalence of goiter and a 15%
prevalence of Grade 2 goiter compared to 15% for goiter and 0% for Grade 2 goiter in the low iodine
group.  
Dose and end point used for MRL derivation:  0.01 mg/kg/day; subclinical hypothyroidism with thryoid
gland enlargement.
[X] NOAEL   [ ] LOAEL
Uncertainty Factors used in MRL derivation:
[ ]  10 for use of a LOAEL
[ ]  10 for extrapolation from animals to humans
[ ]  10 for human variability
An uncertainty factor is not needed to adjust the NOAEL to account for human variability in sensitivity
because the NOAEL is based on a sensitive end point in children, a sensitive subpopulation.  Supporting
studies indicate that the NOAEL would be applicable to elderly adults who may represent another sensitive
subpopulation (Chow et al. 1991; Szabolcs et al. 1997).  In the Chow et al. (1991) study, 30 healthy elderly
adult females, without evidence of thyroid peroxidase antibodies (TPA), received daily doses of 500 µg
I/day (as potassium iodide) for 14 or 28 days.  Serum concentrations of FT4 were significantly decreased
and serum TSH concentrations were significantly elevated in the women who received the iodide
supplements, relative to a placebo control group.  On average, the magnitude of the changes did not
produce clinically significant depression in thyroid hormone levels; however, five subjects had serum TSH
concentrations that exceeded 5 mU/L.  The pre-existing dietary iodine intake was approximately
IODINE A-7
APPENDIX A
***DRAFT FOR PUBLIC COMMENT***
72–100 µg/day, based on urinary iodide measurements.  Therefore, the total iodide intake was
approximately 600 µg/day (0.0086 mg/kg/day). 
Szabolcs et al. (1997) studied a group of elderly nursing home residents in the Carpathian Basin and
revealed a prevalence of hypothyroidism that increased with increasing iodine intake.  Subjects were from
one of three regions where, based on reported urinary iodine levels of 72, 100, or 513 µg I/g creatinine, the
iodine intakes were approximately 117, 163, or 834 µg/day (0.0017, 0.0023, or 0.012 mg/kg/day for low,
n=119; moderate, n=135; or high intake, n=92, respectively).  The prevalence of elevated serum TSH
concentrations together with serum FT4 concentrations below the normal range, was 0.95, 1.5, and 7.6% in
the low, moderate, and high iodine groups, respectively.  If a prevalence of abnormal thyroid hormone
levels of less than 5% is considered a NOAEL, this study supports a NOAEL in elderly adults that is
slightly below 0.012 mg/kg/day.  Linear interpolation of the dose-prevalence data reported above yields an
estimate of a 5% prevalence at an iodine intake of approximately 0.008 mg/kg/day.
The MRL is higher than the National Research Council Recommended Dietary Allowance of 150 µg/day
(0.0021 mg/kg/day for a 70-kg adult), with additional allowances of 25 µg/day (0.0025 mg/kg/day) and
50 µg/day (0.0029 mg/kg/day) during pregnancy and lactation, respectively (NRC 1989). 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No; however, urinary
iodide levels were converted to estimates of iodine intakes.  Urinary iodide:creatinine ratios were
converted to estimated iodide intake as follows assuming a constant relationship between urinary
creatinine excretion rate and lean body mass.  The rate of creatinine excretion (e.g., UCr, g creatinine/day)
was calculated from the relationship between lean body mass (LBM) and Ucr:
LBM U Cr= ⋅ +0 0272 858. & .
where the constants 0.0272 and 8.58 are the weighted arithmetic mean of estimates of these variables from
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LBM BW females= ⋅085. ,
LBM BW males= ⋅088. ,
where BW is the reported body weight for children of age 11 years (40 kg) (EPA 1997).  Iodide intake was
calculated as:
IntakeI U I Cr UCr= ⋅/ &
where UI/Cr is the urinary iodide:creatine ratio (µg I/g creatine).  This approach yields relationships
between 24-hour urinary iodide excretion rates and the urinary iodide:creatine ratios that are in reasonable
agreement with observation (Konno et al. 1993b).  The approach is consistent with information available
on the toxicokinetics of iodide that indicates nearly complete absorption of ingested iodide and that urinary
excretion accounts for >97% of the absorbed dose (see Sections 3.4.1.2 and 3.4.4.2). 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  NA
Was a conversion used from intermittent to continuous exposure?   No.
Other additional studies or pertinent information that lend support to this MRL:  One other study of elderly
adults supports the MRL as being protective of this population.  Thyroid status was compared in
423 residents (ages 66–70 years) of Jutland, Denmark who had iodine intakes of 40–60 µg/day
(0.7 µg/kg/day) and 100 residents of Iceland who had intakes of 300–350 µg/day (5 µg/kg/day) (Laurberg
et al. 1998).  Subjects from the high iodine intake region had a significantly higher prevalence (18%) of
serum TSH levels above the high end of the normal range (>4 mU/L) compared to subjects from the low
iodine region (3.8%).  The prevalence of serum TSH concentrations above 10 mU/L was 4.0% in the high
iodine region and 0.9% in the low iodine region.  Females in both regions had a significantly higher
prevalence of elevated TSH concentrations than males.  Serum concentrations of T4 were not depressed,
even in subjects with TSH concentrations that exceeded 10 mU/L.  Thus, although the subjects appeared to
be euthyroid, the higher iodine intakes were associated with a subclinical suppression of the thyroid gland
as indicated by a high prevalence of elevated serum TSH concentrations.  
Agency Contact (Chemical Manager):  John Risher, Ph.D.
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This chapter of the profile is a health effects summary written in non-technical language.  Its intended
audience is the general public especially people living in the vicinity of a hazardous waste site or chemical
release.  If the Public Health Statement were removed from the rest of the document, it would still
communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern.  The topics
are written in a question and answer format.  The answer to each question includes a sentence that will
direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides an overview of the nature, manufacture, uses, general population exposures, and
health effects of the substance under review.  This overview is followed by a discussion of the most critical
health effects.  The discussion of health effects is based on evaluations of existing toxicologic,
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive,
weight-of-evidence discussions for human health end points by addressing the following questions.
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order they appear within the Discussion of Health Effects by
Route of Exposure section, by route (inhalation, oral, dermal) and within route by effect.  Human data are
presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  In vitro
data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in
this chapter.  If data are located in the scientific literature, a table of genotoxicity information is included.
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer potency
or perform cancer risk assessments.  Minimal risk levels (MRLs) for noncancer end points (if derived) and
the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for
inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic).  These
MRLs are not meant to support regulatory action; but to acquaint health professionals with exposure levels
at which adverse health effects are not expected to occur in humans.  They should help physicians and
public health officials determine the safety of a community living near a chemical emission, given the
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concentration of a contaminant in air or the estimated daily dose in water.  MRLs are based largely on
toxicological studies in animals and on reports of human occupational exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2,
"Relevance to Public Health," contains basic information known about the substance.  Other sections such
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a modified
version of the risk assessment methodology the Environmental Protection Agency (EPA) provides (Barnes
and Dourson 1988) to determine reference doses for lifetime exposure (RfDs).  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement,
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR cannot
make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all
potential systemic, neurological, and developmental effects.  If this information and reliable quantitative
data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species
(when information from multiple species is available) with the highest NOAEL that does not exceed any
adverse effect levels.  When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL)
can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed.  Additional
uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations
(people who are most susceptible to the health effects caused by the substance) and for interspecies
variability (extrapolation from animals to humans).  In deriving an MRL, these individual uncertainty
factors are multiplied together.  The product is then divided into the inhalation concentration or oral
dosage selected from the study.  Uncertainty factors used in developing a substance-specific MRL are
provided in the footnotes of the LSE Tables.
Chapter 3
Health Effects
Tables and Figures for Levels of Significant Exposure (LSE)
Tables (3-1, 3-2, and 3-3) and figures (3-1 and 3-2) are used to summarize health effects and illustrate
graphically levels of exposure associated with those effects.  These levels cover health effects observed at
increasing dose concentrations and durations, differences in response by species, minimal risk levels
(MRLs) to humans for noncancer end points, and EPA's estimated range associated with an upper- bound
individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a
quick review of the health effects and to locate data for a specific exposure scenario.  The LSE tables and
figures should always be used in conjunction with the text.  All entries in these tables and figures represent
studies that provide reliable, quantitative estimates of No-Observed-Adverse- Effect Levels (NOAELs),
Lowest-Observed-Adverse-Effect Levels (LOAELs), or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.
LEGEND
See LSE Table 3-1
(1) Route of Exposure One of the first considerations when reviewing the toxicity of a substance using
these tables and figures should be the relevant and appropriate route of exposure.  When sufficient
data exists, three LSE tables and two LSE figures are presented in the document.  The three LSE
tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE
Table 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation (LSE Figure 3-1)
and oral (LSE Figure 3-2) routes.  Not all substances will have data on each route of exposure and
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will not therefore have all five of the tables and figures.  In the case of radionuclide profiles, there
are separate LSE tables, by route of exposure, for toxicity of stable isotopes and radioactive
isotopes; for radioactive isotopes, there may be an LSE table for a fourth route, external exposure.
(2) Exposure Period Three exposure periods - acute (less than 15 days), intermediate (15–364 days), and
chronic (365 days or more) are presented within each relevant route of exposure.  In this example, an
inhalation study of intermediate exposure duration is reported.  For quick reference to health effects
occurring from a known length of exposure, locate the applicable exposure period within the LSE
table and figure.
(3) Health Effect The major categories of health effects included in LSE tables and figures are death,
systemic, immunological, neurological, developmental, reproductive, and cancer.  NOAELs and
LOAELs can be reported in the tables and figures for all effects but cancer.  Systemic effects are
further defined in the "System" column of the LSE table (see key number 18).
(4) Key to Figure Each key number in the LSE table links study information to one or more data points
using the same key number in the corresponding LSE figure.  In this example, the study represented
by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the 2
"18r" data points in Figure 3-1).
(5) Species The test species, whether animal or human, are identified in this column.  Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 3.4,
"Toxicokinetics," contains any available information on comparative toxicokinetics.  Although
NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to
derive an MRL.
(6) Exposure Frequency/Duration The duration of the study and the weekly and daily exposure regimen
are provided in this column.  This permits comparison of NOAELs and LOAELs from different
studies.  In this case (key number 18), rats were exposed to 1,1,2,2-tetrachloroethane via inhalation
for 6 hours per day, 5 days per week, for 3 weeks.  For a more complete review of the dosing
regimen refer to the appropriate sections of the text or the original reference paper, i.e., Nitschke et
al. 1981.
(7) System This column further defines the systemic effects.  These systems include: respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. 
"Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. 
In the example of key number 18, 1 systemic effect (respiratory) was investigated.
(8) NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which no
harmful effects were seen in the organ system studied.  Key number 18 reports a NOAEL of 3 ppm
for the respiratory system which was used to derive an intermediate exposure, inhalation MRL of
0.005 ppm (see footnote "b").
(9) LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the study
that caused a harmful health effect.  LOAELs have been classified into "Less Serious" and "Serious"
effects.  These distinctions help readers identify the levels of exposure at which adverse health
effects first appear and the gradation of effects with increasing dose.  A brief description of the
specific end point used to quantify the adverse effect accompanies the LOAEL.  The respiratory
effect reported in key number 18 (hyperplasia) is a Less serious LOAEL of 10 ppm.  MRLs are not
derived from Serious LOAELs.
(10) Reference The complete reference citation is given in Chapter 9 of the profile.
(11) CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of
carcinogenesis in experimental or epidemiologic studies.  CELs are always considered serious
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effects.  The LSE tables and figures do not contain NOAELs for cancer, but the text may report
doses not causing measurable cancer increases.
(12) Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found in
the footnotes.  Footnote "b" indicates the NOAEL of 3 ppm in key number 18 was used to derive an
MRL of 0.005 ppm.
LEGEND
See Figure 3-1
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period The same exposure periods appear as in the LSE table.  In this example, health
effects observed within the intermediate and chronic exposure periods are illustrated.
(14) Health Effect These are the categories of health effects for which reliable quantitative data exists. 
The same health effects appear in the LSE table.
(15) Levels of Exposure concentrations or doses for each health effect in the LSE tables are graphically
displayed in the LSE figures.  Exposure concentration or dose is measured on the log scale "y" axis. 
Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in mg/kg/day.
(16) NOAEL In this example, 18r NOAEL is the critical end point for which an intermediate inhalation
exposure MRL is based.  As you can see from the LSE figure key, the open-circle symbol indicates
to a NOAEL for the test species-rat.  The key number 18 corresponds to the entry in the LSE table. 
The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see
entry 18 in the Table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table).
(17) CEL Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived.  The diamond
symbol refers to a Cancer Effect Level for the test species-mouse.  The number 38 corresponds to
the entry in the LSE table.
(18) Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the
upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer
dose response curve at low dose levels (q1*).































ReferenceLess serious (ppm) Serious (ppm)
2 6 INTERMEDIATE EXPOSURE
5 6 7 8 9 10
3 6 Systemic 9 9 9 9 9 9
4 6 18 Rat 13 wk
5 d/wk
6 hr/d










Wong et al. 1982
39 Rat 89–104 wk
5 d/wk
6 hr/d
10 (CEL, lung tumors,
nasal tumors)
NTP 1982
40 Mouse 79–103 wk
5 d/wk
6 hr/d
10 (CEL, lung tumors,
hemangiosarcomas)
NTP 1982
a The number corresponds to entries in Figure 3-1.
12 6
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5 x 10-3 ppm; dose adjusted for intermittent exposure and divided by
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APPENDIX C
ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ADI Acceptable Daily Intake
ADME Absorption, Distribution, Metabolism, and Excretion
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT Best Available Technology
BCF bioconcentration factor
BEI Biological Exposure Index
BSC Board of Scientific Counselors
C Centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL Cancer Effect Level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CNS central nervous system
CPSC Consumer Products Safety Commission
CWA Clean Water Act
d day
Derm dermal
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMCO North America/International Maritime Dangerous Goods Code
DWEL Drinking Water Exposure Level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
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FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection







GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
hr hour
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank 
IDLH Immediately Dangerous to Life and Health
IARC International Agency for Research on Cancer
ILO International Labor Organization
in inch




Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LCLo lethal concentration, low
LC50 lethal concentration, 50% kill
LDLo lethal dose, low
LD50 lethal dose, 50% kill
LT50 lethal time, 50% kill
LOAEL lowest-observed-adverse-effect level
LSE Levels of Significant Exposure
m meter
MA trans,trans-muconic acid
MAL Maximum Allowable Level
mCi millicurie
MCL Maximum Contaminant Level





mm Hg millimeters of mercury
mmol millimole
mo month
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
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NCE normochromatic erythrocytes
NCI National Cancer Institute
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System
NFPA National Fire Protection Association
ng nanogram
NLM National Library of Medicine
nm nanometer
NHANES National Health and Nutrition Examination Survey
nmol nanomole
NOAEL no-observed-adverse-effect level
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH Polycyclic Aromatic Hydrocarbon
PBPD Physiologically Based Pharmacodynamic 
PBPK Physiologically Based Pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
PID photo ionization detector
pg picogram
pmol picomole
PHS Public Health Service
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS Pretreatment Standards for New Sources




RTECS Registry of Toxic Effects of Chemical Substances
RQ Reportable Quantity
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
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sec second
SIC Standard Industrial Classification
SIM selected ion monitoring
SMCL Secondary Maximum Contaminant Level
SMR standard mortality ratio
SNARL Suggested No Adverse Response Level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC Total Organic Compound
TPQ Threshold Planning Quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act




VOC Volatile Organic Compound
yr year
WHO World Health Organization
wk week
> greater than
> greater than or equal to
= equal to
< less than








q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
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APPENDIX D
OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY, AND BIOLOGY
Understanding the basic concepts in radiation physics, chemistry, and biology is important to the
evaluation and interpretation of radiation-induced adverse health effects and to the derivation of radiation
protection principles.  This appendix presents a brief overview of the areas of radiation physics, chemistry,
and biology and is based to a large extent on the reviews of Mettler and Moseley (1985), Hobbs and
McClellan (1986), Eichholz (1982), Hendee (1973), Cember (1996), and Early et al. (1979).
D.1 RADIONUCLIDES AND RADIOACTIVITY
The substances we call elements are composed of atoms.  Atoms in turn are made up of neutrons, protons
and electrons: neutrons and protons in the nucleus and electrons in a cloud of orbits around the nucleus. 
Nuclide is the general term referring to any nucleus along with its orbital electrons.  The nuclide is charac-
terized by the composition of its nucleus and hence by the number of protons and neutrons in the nucleus. 
All atoms of an element have the same number of protons (this is given by the atomic number) but may
have different numbers of neutrons (this is reflected by the atomic mass numbers or atomic weight of the
element).  Atoms with different atomic mass but the same atomic numbers are referred to as isotopes of an
element.
The numerical combination of protons and neutrons in most nuclides is such that the nucleus is quantum
mechanically stable and the atom is said to be stable, i.e., not radioactive; however, if there are too few or
too many neutrons, the nucleus is unstable and the atom is said to be radioactive.  Unstable nuclides
undergo radioactive transformation, a process in which a neutron or proton converts into the other and a
beta particle is emitted, or else an alpha particle is emitted.  Each type of decay is typically accompanied
by the emission of gamma rays.  These unstable atoms are called radionuclides; their emissions are called
ionizing radiation; and the whole property is called radioactivity.  Transformation or decay results in the
formation of new nuclides some of which may themselves be radionuclides, while others are stable
nuclides.  This series of transformations is called the decay chain of the radionuclide.  The first
radionuclide in the chain is called the parent; the subsequent products of the transformation are called
progeny, daughters, or decay products.
In general there are two classifications of radioactivity and radionuclides:  natural and artificial (man-
made).  Naturally-occurring radioactive material (NORM) exists in nature and no additional energy is
necessary to place them in an unstable state.  Natural radioactivity is the property of some naturally
occurring, usually heavy elements, that are heavier than lead.  Radionuclides, such as radium and uranium,
primarily emit alpha particles.  Some lighter elements such as carbon-14 and tritium (hydrogen-3)
primarily emit beta particles as they transform to a more stable atom.  Natural radioactive atoms heavier
than lead cannot attain a stable nucleus heavier than lead.  Everyone is exposed to background radiation
from naturally-occurring radionuclides throughout life.  This background radiation is the major source of
radiation exposure to man and arises from several sources.  The natural background exposures are
frequently used as a standard of comparison for exposures to various artificial sources of ionizing
radiation.
Artificial radioactive atoms are produced either as a by-product of fission of uranium or plutonium atoms
in a nuclear reactor or by bombarding stable atoms with particles, such as neutrons or protons, directed at
the stable atoms with high velocity.  These artificially produced radioactive elements usually decay by
emission of particles, such as positive or negative beta particles and one or more high energy photons
(gamma rays).  Unstable (radioactive) atoms of any element can be produced.
Both naturally occurring and artificial radioisotopes find application in medicine, industrial products, and
consumer products.  Some specific radioisotopes, called fall-out, are still found in the environment as a
result of nuclear weapons use or testing.
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D.2 RADIOACTIVE DECAY
D.2.1 Principles of Radioactive Decay
The stability of an atom is the result of the balance of the forces of the various components of the nucleus. 
An atom that is unstable (radionuclide) will release energy (decay) in various ways and transform to stable
atoms or to other radioactive species called daughters, often with the release of ionizing radiation.  If there
are either too many or too few neutrons for a given number of protons, the resulting nucleus may undergo
transformation.  For some elements, a chain of daughter decay products may be produced until stable
atoms are formed.  Radionuclides can be characterized by the type and energy of the radiation emitted, the
rate of decay, and the mode of decay.  The mode of decay indicates how a parent compound undergoes
transformation.  Radiations considered here are primarily of nuclear origin, i.e., they arise from nuclear
excitation, usually caused by the capture of charged or uncharged nucleons by a nucleus, or by the
radioactive decay or transformation of an unstable nuclide.  The type of radiation may be categorized as
charged or uncharged particles, protons, and fission products) or electromagnetic radiation (gamma rays
and x rays).  Table D-1 summarizes the basic characteristics of the more common types of radiation
encountered.
D.2.2 Half-Life and Activity
For any given radionuclide, the rate of decay is a first-order process that is constant, regardless of the
radioactive atoms present and is characteristic for each radionuclide.  The process of decay is a series of
random events; temperature, pressure, or chemical combinations do not effect the rate of decay.  While it
may not be possible to predict exactly which atom is going to undergo transformation at any given time, it
is possible to predict, on average, the fraction of the radioactive atoms that will transform during any
interval of time.
The activity is a measure of the quantity of radioactive material.  For these radioactive materials it is
customary to describe the activity as the number of disintegrations (transformations) per unit time.  The
unit of activity is the curie (Ci), which was originally related to the activity of one gram of radium, but is
now defined as that quantity of radioactive material in which there are:
1 curie (Ci) = 3.7x1010 disintegrations (transformations)/second (dps) or 2.22x1012 disintegrations
(transformations)/minute (dpm).
The SI unit of activity is the becquerel (Bq); 1 Bq = that quantity of radioactive material in which there is
1 transformation/second.  Since activity is proportional to the number of atoms of the radioactive material,
the quantity of any radioactive material is usually expressed in curies, regardless of its purity or
concentration.  The transformation of radioactive nuclei is a random process, and the number of
transformations is directly proportional to the number of radioactive atoms present.  For any pure
radioactive substance, the rate of decay is usually described by its radiological half-life, TR, i.e., the time it
takes for a specified source material to decay to half its initial activity.  The specific activity is an indirect
measure of the rate of decay, and is defined as the activity per unit mass or per unit volume. The higher the
specific activity of a radioisotope, the faster it is decaying.
The activity of a radionuclide at time t may be calculated by:
A = Aoe-0.693t/Trad
where A is the activity in dps or curies or becquerels, Ao is the activity at time zero, t is the time at which
measured, and Trad is the radiological half-life of the radionuclide (Trad and t must be in the same units of
time).  The time when the activity of a sample of radioactivity becomes one-half its original value is the
radioactive half-life and is expressed in any suitable unit of time.
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Radiation Rest massa Charge Air Solid Comments
Alpha (α) 4.00 amu +2 4–10 MeV 5–10 cm 25–80 µm Identical to ionized
He nucleus
Negatron (β–) 5.48x10-4 amu;
0.51 MeV
–1 0–4 Mev 0–10 m 0–1 cm Identical to electron
Positron (β+) 5.48x10-4 amu;
0.51 Mev
+1 0-4 Mev 0–10 m 0–1 cm Identical to electron




0 0–15 MeV b b Free half-life:  16
min






– 0 10 keV–3 MeV b b Photon from nuclear
transformation
a The rest mass (in amu) has an energy equivalent in MeV that is obtained using the equation E=mc2, where 1 amu = 932 MeV.
b Path lengths are not applicable to x- and gamma rays since their intensities decrease exponentially; path lengths in solid tissue
are variable, depending on particle energy, electron density of material, and other factors.
   amu = atomic mass unit; e.m.  = electromagnetic; MeV = MegaElectron Volts
The specific activity is a measure of activity, and is fined as the activity per unit mass or per unit volume.
This activity is usually expressed in curies per gram and may be calculated by
curies/gram   = 1.3x108 / (Trad) (atomic weight)     or  
 
[3.577 x 105 x  mass(g)] / [Trad  x   atomic weight]
where Trad is the radiological half-life in days.
In the case of radioactive materials contained in living organisms, an additional consideration is made for
the reduction in observed activity due to regular processes of elimination of the respective chemical or
biochemical substance from the organism.  This introduces a rate constant called the biological half-life
(Tbiol) which is the time required for biological processes to eliminate one-half of the activity.  This time is
virtually the same for both stable and radioactive isotopes of any given element.
Under such conditions the time required for a radioactive element to be halved as a result of the combined
action of radioactive decay and biological elimination is the effective clearance half-time:
Teff = (Tbiol x Trad) / (Tbiol + Trad).
Table D-2 presents representative effective half-lives of particular interest.
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Table D-2.  Half-Lives of Some Radionuclides in Adult Body Organs
Half-lifea
Radionuclide Critical organ Physical Biological Effective
Uranium-238 Kidney 4,460,000,000 y 4 d 4 d
Hydrogen-3b
(Tritium)
Whole body 12.3 y 10 d 10 d
Iodine-131 Thyroid 8 d 80 d 7.3 d
Strontium-90 Bone 28 y 50 y 18 y
Plutonium-239 Bone surface 24,400 y 50 y 50 y
Lung 24,400 y 500 d 500 d
Cobalt-60 Whole body 5.3 y 99.5 d 95 d
Iron-55 Spleen 2.7 y 600 d 388 d
Iron-59 Spleen 45.1 d 600 d 42 d
Manganese-54 Liver 303 d 25 d 23 d
Cesium-137 Whole body 30 y 70 d 70 d
ad = days, y = years
bMixed in body water as tritiated water
D.2.3 Interaction of Radiation with Matter
Both ionizing and nonionizing radiation will interact with materials; that is, radiation will lose kinetic
energy to any solid, liquid or gas through which it passes by a variety of mechanisms.  The transfer of
energy to a medium by either electromagnetic or particulate radiation may be sufficient to cause formation
of ions.  This process is called ionization.  Compared to other types of radiation that may be absorbed, such
as ultraviolet radiation, ionizing radiation deposits a relatively large amount of energy into a small volume.
The method by which incident radiation interacts with the medium to cause ionization may be direct or
indirect.  Electromagnetic radiations (x rays and gamma photons) are indirectly ionizing; that is, they give
up their energy in various interactions with cellular molecules, and the energy is then utilized to produce a
fast-moving charged particle such as an electron.  It is the electron that then may react with a target
molecule.  This particle is called a “primary ionizing particle.  Charged particles, in contrast, strike the
tissue or medium and directly react with target molecules, such as oxygen or water.  These particulate
radiations are directly ionizing radiations.  Examples of directly ionizing particles include alpha and beta
particles.  Indirectly ionizing radiations are always more penetrating than directly ionizing particulate
radiations.
Mass, charge, and velocity of a particle all affect the rate at which ionization occurs.  The higher the
charge of the particle and the lower the velocity, the greater the propensity to cause ionization.  Heavy,
highly charged particles, such as alpha particles, lose energy rapidly with distance and, therefore, do not
penetrate deeply.  The result of these interaction processes is a gradual slowing down of any incident
particle until it is brought to rest or "stopped" at the end of its range.
D.2.4 Characteristics of Emitted Radiation
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D.2.4.1  Alpha Emission.    In alpha emission, an alpha particle consisting of two protons and two
neutrons is emitted with a resulting decrease in the atomic mass number by four and reduction of the
atomic number of two, thereby changing the parent to a different element.  The alpha particle is identical to
a helium nucleus consisting of two neutrons and two protons.  It results from the radioactive decay of some
heavy elements such as uranium, plutonium, radium, thorium, and radon.  All alpha particles emitted by a
given radioisotope have the same energy.  Most of the alpha particles that are likely to be found have
energies in the range of about 4 to 8 MeV, depending on the isotope from which they came.
The alpha particle has an electrical charge of +2.  Because of this double positive charge and their size,
alpha particles have great ionizing power and, thus, lose their kinetic energy quickly.  This results in very
little penetrating power.  In fact, an alpha particle cannot penetrate a sheet of paper.  The range of an alpha
particle (the distance the charged particle travels from the point of origin to its resting point) is about 4 cm
in air, which decreases considerably to a few micrometers in tissue.  These properties cause alpha emitters
to be hazardous only if there is internal contamination (i.e., if the radionuclide is inside the body).
D.2.4.2  Beta Emission.      A beta particle (&) is a high-velocity electron ejected from a disintegrating
nucleus.  The particle may be either a negatively charged electron, termed a negatron (&-) or a positively
charged electron, termed a positron (&+).  Although the precise definition of "beta emission" refers to both
&- and &+, common usage of the term generally applies only to the negative particle, as distinguished from
the positron emission, which refers to the &+ particle.
D.2.4.2.1  Beta Negative Emission.    Beta particle (&-) emission is another process by which a
radionuclide, with a neutron excess achieves stability.  Beta particle emission decreases the number of
neutrons by one and increases the number of protons by one, while the atomic mass number remains
unchanged.1  This transformation results in the formation of a different element.  The energy spectrum of
beta particle emission ranges from a certain maximum down to zero with the mean energy of the spectrum
being about one-third of the maximum.  The range in tissue is much less.  Beta negative emitting
radionuclides can cause injury to the skin and superficial body tissues, but mostly present an internal
contamination hazard.
D.2.4.2.2  Positron Emission.    In cases in which there are too many protons in the nucleus, positron
emission may occur.  In this case a proton may be thought of as being converted into a neutron, and a
positron (&+) is emitted.1  This increases the number of neutrons by one, decreases the number of protons
by one, and again leaves the atomic mass number unchanged.  The gamma radiation resulting from the
annihilation (see glossary) of the positron makes all positron emitting isotopes more of an external
radiation hazard than pure & emitters of equal energy.
D.2.4.2.3  Gamma Emission.    Radioactive decay by alpha, beta, or positron emission, or electron
capture often leaves some of the energy resulting from these changes in the nucleus.  As a result, the
nucleus is raised to an excited level.  None of these excited nuclei can remain in this high-energy state. 
Nuclei release this energy returning to ground state or to the lowest possible stable energy level.  The
energy released is in the form of gamma radiation (high energy photons) and has an energy equal to the
change in the energy state of the nucleus.  Gamma and x rays behave similarly but differ in their origin;
gamma emissions originate in the nucleus while x rays originate in the orbital electron structure or from
rapidly changing the velocity of an electron (e.g., as occurs when shielding high energy beta particles or
stopping the electron beam in an x ray tube).
D.3 ESTIMATION OF ENERGY DEPOSITION IN HUMAN TISSUES
Two forms of potential radiation exposures can result: internal and external.  The term exposure denotes
physical interaction of the radiation emitted from the radioactive material with cells and tissues of the
human body.  An exposure can be "acute" or "chronic" depending on how long an individual or organ is
exposed to the radiation.  Internal exposures occur when radionuclides, which have entered the body (e.g.,
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through the inhalation, ingestion, or dermal pathways), undergo radioactive decay resulting in the
deposition of energy to internal organs.  External exposures occur when radiation enters the body directly
from sources located outside the body, such as radiation emitters from radionuclides on ground surfaces,
dissolved in water, or dispersed in the air.  In general, external exposures are from material emitting
gamma radiation, which readily penetrate the skin and internal organs.  Beta and alpha radiation from
external sources are far less penetrating and deposit their energy primarily on the skin's outer layer. 
Consequently, their contribution to the absorbed dose of the total body dose, compared to that deposited by
gamma rays, may be negligible.
Characterizing the radiation dose to persons as a result of exposure to radiation is a complex issue.  It is
difficult to:  (1) measure internally the amount of energy actually transferred to an organic material and to
correlate any observed effects with this energy deposition; and (2) account for and predict secondary
processes, such as collision effects or biologically triggered effects, that are an indirect consequence of the
primary interaction event.
D.3.1 Dose/Exposure  Units
D.3.1.1  Roentgen.    The roentgen (R) is a unit of x or gamma-ray exposure and is a measured by the
amount of ionization caused in air by gamma or x radiation.  One roentgen produces 2.58x10-4 coulomb
per kilogram of air.  In the case of gamma radiation, over the commonly encountered range of photon
energy, the energy deposition in tissue for a dose of 1 R is about 0.0096 joules (J) /kg of tissue.
D.3.1.2  Absorbed Dose and Absorbed Dose Rate.    The absorbed dose is defined as the energy
imparted by the incident radiation to a unit mass of the tissue or organ.  The unit of absorbed dose is the
rad; 1 rad = 100 erg/gram = 0.01 J/kg in any medium.  An exposure of 1 R results in a dose to soft tissue of
approximately 0.01 J/kg.  The SI unit is the gray which is equivalent to 100 rad or 1 J/kg.  Internal and
external exposures from radiation sources are not usually instantaneous but are distributed over extended
periods of time.  The resulting rate of change of the absorbed dose to a small volume of mass is referred to
as the absorbed dose rate in units of rad/unit time.
D.3.1.3  Working Levels and Working Level Months.    Working level (WL) is a measure of the
atmospheric concentration of radon and its short-lived progeny.  One WL is defined as any combination of
short-lived radon daughters (through polonium-214), per liter of air, that will result in the emission of
1.3x105 MeV of alpha energy.  An activity concentration of 100 pCi radon-222/L of air, in equilibrium
with its daughters, corresponds approximately to a potential alpha-energy concentration of 1 WL.  The WL
unit can also be used for thoron daughters.  In this case, 1.3x105 MeV of alpha energy (1 WL) is released
by the thoron daughters in equilibrium with 7.5 pCi thoron/L.  The potential alpha energy exposure of
miners is commonly expressed in the unit Working Level Month (WLM).  One WLM corresponds to
exposure to a concentration of 1 WL for the reference period of 170 hours, or more generally
WLM = concentration (WL) x exposure time (months)  (one “month” = 170 working hours).
D.3.2 Dosimetry Models
Dosimetry models are used to estimate the dose from internally deposited to radioactive substances.  The
models for internal dosimetry consider the amount of radionuclides entering the body, the factors affecting
their movement or transport through the body, distribution and retention of radionuclides in the body, and
the energy deposited in organs and tissues from the radiation that is emitted during spontaneous decay
processes.  The dose pattern for radioactive materials in the body may be strongly influenced by the route
of entry of the material.  For industrial workers, inhalation of radioactive particles with pulmonary
deposition and puncture wounds with subcutaneous deposition have been the most frequent.  The general
population has been exposed via ingestion and inhalation of low levels of naturally occurring radionuclides
as well as radionuclides from nuclear weapons testing.
The models for external dosimetry consider only the photon doses to organs of individuals who are
immersed in air or are exposed to a contaminated object.  
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D.3.2.1  Ingestion.    Ingestion of radioactive materials is most likely to occur from contaminated
foodstuffs or water or eventual ingestion of inhaled compounds initially deposited in the lung.  Ingestion of
radioactive material may result in toxic effects as a result of either absorption of the radionuclide or
irradiation of the gastrointestinal tract during passage through the tract, or a combination of both.  The
fraction of a radioactive material absorbed from the gastrointestinal tract is variable, depending on the
specific element, the physical and chemical form of the material ingested, and the diet, as well as some
other metabolic and physiological factors.  The absorption of some elements is influenced by age, usually
with higher absorption in the very young.
D.3.2.2  Inhalation.    The inhalation route of exposure has long been recognized as being a major portal
of entry for both nonradioactive and radioactive materials.  The deposition of particles within  the lung is
largely dependent upon the size of the particles being inhaled.  After the particle is deposited, the retention
will depend upon the physical and chemical properties of the dust and the physiological status of the lung. 
The retention of the particle in the lung depends on the location of deposition, in addition to the physical
and chemical properties of the particles.  The converse of pulmonary retention is pulmonary clearance. 
There are three distinct mechanisms of clearance which operate simultaneously.  Ciliary clearance acts
only in the upper respiratory tract.  The second and third mechanisms act mainly in the deep respiratory
tract.  These are phagocytosis and absorption.  Phagocytosis is the engulfing of foreign bodies by alveolar
macrophages and their subsequent removal either up the ciliary "escalator" or by entrance into the
lymphatic system.  Some inhaled soluble particles are absorbed into the blood and translocated to other
organs and tissues.
D.3.3 Internal Emitters
An internal emitter is a radionuclide that is inside the body.  The absorbed dose from internally deposited
radioisotopes depends on the energy absorbed per unit tissue by the irradiated tissue.  For a radioisotope
distributed uniformly throughout an infinitely large medium, the concentration of absorbed energy must be
equal to the concentration of energy emitted by the isotope.  An infinitely large medium may be
approximated by a tissue mass whose dimensions exceed the range of the particle.  All alpha and most beta
radiation will be absorbed in the organ (or tissue) of reference.  Gamma-emitting isotope emissions are
penetrating radiation, and a substantial fraction of gamma energy may be absorbed in tissue.  The dose to
an organ or tissue is a function of the effective retention half-time, the energy released in the tissue, the
amount of radioactivity initially introduced, and the mass of the organ or tissue.
D.4 BIOLOGICAL EFFECTS OF RADIATION
When biological material is exposed to ionizing radiation, a chain of cellular events occurs as the ionizing
particle passes through the biological material.  A number of theories have been proposed to describe the
interaction of radiation with biologically important molecules in cells and to explain the resulting damage
to biological systems from those interactions.  Many factors may modify the response of a living organism
to a given dose of radiation.  Factors related to the exposure include the dose rate, the energy of the
radiation, and the temporal pattern of the exposure.  Biological considerations include factors such as
species, age, sex, and the portion of the body exposed.  Several excellent reviews of the biological effects
of radiation have been published, and the reader is referred to these for a more in-depth discussion
(Brodsky 1996; Hobbs and McClellan 1986; ICRP 1984; Mettler and Moseley 1985; Rubin and Casarett
1968).
D.4.1 Radiation Effects at the Cellular Level
According to Mettler and Moseley (1985), at acute doses up to 10 rad (100 mGy), single strand breaks in
DNA may be produced.  These single strand breaks may be repaired rapidly.  With doses in the range of
50–500 rad (0.5–5 Gy), irreparable double-stranded DNA breaks are likely, resulting in cellular
reproductive death after one or more divisions of the irradiated parent cell.  At large doses of radiation,
usually greater than 500 rad (5 Gy), direct cell death before division (interphase death) may occur from the
direct interaction of free-radicals with essentially cellular macromolecules.  Morphological changes at the
cellular level, the severity of which are dose-dependent, may also be observed.
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The sensitivity of various cell types varies.  According to the Bergonie-Tribondeau law, the sensitivity of
cell lines is directly proportional to their mitotic rate and inversely proportional to the degree of
differentiation (Mettler and Moseley 1985).  Rubin and Casarett (1968) devised a classification system that
categorized cells according to type, function, and mitotic activity.  The categories range from the most
sensitive type, "vegetative intermitotic cells, " found in the stem cells of the bone marrow and the
gastrointestinal tract, to the least sensitive cell type, "fixed postmitotic cells," found in striated muscles or
long-lived neural tissues.
Cellular changes may result in cell death, which if extensive, may produce irreversible damage to an organ
or tissue or may result in the death of the individual.  If the cell recovers, altered metabolism and function
may still occur, which may be repaired or may result in the manifestation of clinical symptoms.  These
changes may also be expressed at a later time as tumors or cellular mutations, which may result in
abnormal tissue.
D.4.2 Radiation Effects at the Organ Level
In most organs and tissues the injury and the underlying mechanism for that injury are complex and may
involve a combination of events.  The extent and severity of this tissue injury are dependent upon the
radiosensitivity of the various cell types in that organ system.  Rubin and Casarett (1968) describe and
schematically display the events following radiation in several organ system types.  These include:  a rapid
renewal system, such as the gastrointestinal mucosa; a slow renewal system, such as the pulmonary
epithelium; and a nonrenewal system, such as neural or muscle tissue.  In the rapid renewal system, organ
injury results from the direct destruction of highly radiosensitive cells, such as the stem cells in the bone
marrow.  Injury may also result from constriction of the microcirculation and from edema and
inflammation of the basement membrane, designated as the histohematic barrier (HHB), which may
progress to fibrosis.  In slow renewal and nonrenewal systems, the radiation may have little effect on the
parenchymal cells, but ultimate parenchymal atrophy and death over several months result from HHB
fibrosis and occlusion of the microcirculation.
D.4.3 Low Level Radiation Effects
Cancer is the major latent harmful effect produced by ionizing radiation and the one that most people
exposed to radiation are concerned about.  The ability of alpha, beta, and gamma radiation to produce
cancer in virtually every tissue and organ in laboratory animals has been well-demonstrated.  The
development of cancer is not an immediate effect.  Radiation-induced leukemia has the shortest latent
period at 2 years, while other radiation induced cancers have latent periods >20 years. The mechanism by
which cancer is induced in living cells is complex and is a topic of  intense study.  Exposure to ionizing
radiation can produce cancer at any site within the body; however, some sites appear to be more common
than others, such as the breast, lung, stomach, and thyroid.  
DNA is a major target molecule during exposure to ionizing radiation.  Other macromolecules, such as
lipids and proteins, are also at risk of damage when exposed to ionizing radiation.  The genotoxicity of
ionizing radiation is an area of intense study, as damage to the DNA is ultimately responsible for many of
the adverse toxicological effects ascribed to ionizing radiation, including cancer.  Damage to genetic
material is basic to developmental or teratogenic effects, as well.  However, for effects other than cancer,
there is little evidence of human effects at low levels of exposure.
D.5 UNITS IN RADIATION PROTECTION AND REGULATION
D.5.1  Dose Equivalent and Dose Equivalent Rate
Dose equivalent or rem is a special radiation protection quantity that is used, for administrative and
radiation safety purposes only, to express the absorbed dose in a manner which considers the difference in
biological effectiveness of various kinds of ionizing radiation.  The ICRU has defined the dose equivalent,
H, as the product of the absorbed dose, D, and the quality factor, Q, at the point of interest in biological
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tissue.  This relationship is expressed as H = D x Q.  The dose equivalent concept is applicable only to
doses that are not great enough to produce biomedical effects. 
The quality factor is a dimensionless quantity that depends in part on the stopping power for charged
particles, and it accounts for the differences in biological effectiveness found among the types of radiation. 
Originally relative biological effectiveness (RBE) was used rather than Q to define the quantity, rem,
which was of use in risk assessment.  The generally accepted values for quality factors for various
radiation types are provided in Table D-3.  The dose equivalent rate is the time rate of change of the dose
equivalent to organs and tissues and is expressed as rem/unit time or sievert/unit time.
Table D-3.  Quality Factors (Q) and Absorbed Dose Equivalencies
Type of radiation Quality factor (Q)
Absorbed dose equal to a unit dose
equivalent*
X, gamma, or beta radiation 1 1
Alpha particles, multiple-charged
particles, fission fragments and
heavy particles of unknown charge
20 0.05
Neutrons of unknown energy 10 0.1
High-energy protons 10 0.1
*Absorbed dose in rad equal to 1 rem or the absorbed dose in gray equal to 1 sievert.
Source: USNRC.  1999.  Standards for the protection against radiation, table 1004(b).1.  10 CFR 20.1004.  U.S. Nuclear
Regulatory Commission, Washington, D.C. 
D.5.2  Relative Biological Effectiveness
RBE is used to denote the experimentally determined ratio of the absorbed dose from one radiation type to
the absorbed dose of a reference radiation required to produce an identical biologic effect under the same
conditions.  Gamma rays from cobalt-60 and 200–250 keV x-rays have been used as reference standards. 
The term RBE has been widely used in experimental radiobiology, and the term quality factor used in
calculations of dose equivalents for radiation safety purposes (ICRP 1977; NCRP 1971; UNSCEAR 1982). 
RBE applies only to a specific biological end point, in a specific exposure, under specific conditions to a
specific species.  There are no generally accepted values of RBE.
D.5.3  Effective Dose Equivalent and Effective Dose Equivalent Rate
The absorbed dose is usually defined as the mean absorbed dose within an organ or tissue.  This represents
a simplification of the actual problem.  Normally when an individual ingests or inhales a radionuclide or is
exposed to external radiation that enters the body (gamma), the dose is not uniform throughout the whole
body.  The simplifying assumption is that the detriment will be the same whether the body is uniformly or
non-uniformly irradiated.  In an attempt to compare detriment from absorbed dose of a limited portion of
the body with the detriment from total body dose, the ICRP (1977) has derived a concept of effective dose
equivalent.  The effective dose equivalent, HE, is
HE = (the sum of) Wt Ht
where Ht is the dose equivalent in the tissue, Wt is the weighting factor, which represents the estimated
proportion of the stochastic risk resulting from tissue, T, to the stochastic risk when the whole body is
uniformly irradiated for occupational exposures under certain conditions (ICRP 1977).  Weighting factors
for selected tissues are listed in Table D-4.
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The ICRU (1980), ICRP (1984), and NCRP (1985) now recommend that the rad, roentgen, curie, and rem
be replaced by the SI units:  gray (Gy), Coulomb per kilogram (C/kg), Becquerel (Bq), and sievert (Sv),
respectively.  The relationship between the customary units and the international system of units (SI) for
radiological quantities is shown in Table D-5.
Table D-4.  Weighting Factors for Calculating Effective Dose 
Equivalent for Selected Tissues
Weighting factor
Tissue ICRP60 NCRP115/ ICRP60 NRC
Bladder 0.040 0.05 –
Bone marrow 0.143 0.12 0.12
Bone surface 0.009 0.01 0.03
Breast 0.050 0.05 0.15
Colon 0.141 0.12 –
Liver 0.022 0.05 –
Lung 0.111 0.12 0.12
Esophagus 0.034 0.05 –
Ovary 0.020 0.05 –
Skin 0.006 0.01 –
Stomach 0.139 0.12 –
Thyroid 0.021 0.05 0.03
Gonads 0.183 0.20 0.25
subtotal 0.969 1 0.70
Remainder 0.031 0.05 0.30
ICRP60 = International Commission on Radiological Protection, 1990 Recommendations of the ICRP; 
NCRP115 = National Council on Radiation Protection and Measurements.  1993.  Risk Estimates for Radiation Protection,
Report 115.  Bethesda, Maryland;  NRC = Nuclear Regulatory Commission.
NRC = Nuclear Regulatory Commission, Title 10, Code of Federal Regulations, Part 20
IODINE D-11
APPENDIX D
***DRAFT FOR PUBLIC COMMENT***
Table D-5.  Comparison of Common and SI Units for Radiation Quantities
Quantity
Customary
units Definition SI units Definition
Activity (A) curie (Ci) 3.7x1010
transformations s-1
becquerel (Bq) s-1




rad per second 
(rad s-1)
10-2 Jkg-1s-1 gray per second 
(Gy s-1)
Jkg-1 s-1

















Jkg-1 = Joules per kilogram; Jkg-1s-1 = Joules per kilogram per second; Jm-1 = Joules per meter; s-1 = per second
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